Rank	NCT Number	Title	Acronym	Status	Study Results	Conditions	Interventions	Outcome Measures	Sponsor/Collaborators	Gender	Age	Phases	Enrollment	Funded Bys	Study Type	Study Designs	Other IDs	Start Date	Primary Completion Date	Completion Date	First Posted	Results First Posted	Last Update Posted	Locations	Study Documents	URL
1	NCT04334291	International COVID19 Clinical Evaluation Registry,	HOPE COVID 19	Recruiting	No Results Available	COVID 19	Combination Product: Observational (registry)	Death|In hospital stay.|Heart failure|Renal failure|Respiratory Insufficiency.|Upper respiratory tract involvement|Pneumonia|Sepsis|Systemic inflammatory response Syndrome.|Clinically relevant bleeding|Other complications.	IVAN J NUÑEZ GIL|St Carlos Hospital, Madrid, Spain	All	Child, Adult, Older Adult		2500	Other	Observational	Observational Model: Cohort|Time Perspective: Cross-Sectional	20/241-E|EUPAS34399	March 23, 2020	May 1, 2020	May 5, 2020	April 6, 2020		April 6, 2020	Hospital Lclinico San Carlos, Madrid, Spain		https://ClinicalTrials.gov/show/NCT04334291
2	NCT04338126	Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients	TCInpatient	Not yet recruiting	No Results Available	COVID19	Drug: Tranexamic acid|Drug: Placebo oral tablet	Admission to Intensive Care Unit	University of Alabama at Birmingham	All	19 Years and older   (Adult, Older Adult)	Phase 2	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	TXACOVID2	April 15, 2020	October 15, 2020	December 15, 2020	April 8, 2020		April 8, 2020	University of Alabama at Birmingham, Birmingham, Alabama, United States		https://ClinicalTrials.gov/show/NCT04338126
3	NCT04338906	Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19	CLOCC	Not yet recruiting	No Results Available	COVID	Drug: Camostat Mesilate|Drug: Placebo|Drug: Hydroxychloroquine	Not hospitalized|Time to improvement of 2 categories from admission on a 7-point ordinal scale|Proportion of participants in each group with normalization of fever|Proportion of participants in each group with oxygen saturation > 94% on room air for >24h|Time to fever normalization (if febrile at baseline)|Time to first negative SARS-CoV-2 PCR in NP swap (if pos. at baseline)|Time to first negative SARS-CoV-2 PCR in lower respiratory tract specimens (sputum, bronchoalveolar lavage, tracheal aspirate) (if positive at baseline)|Duration of oxygen therapy|Proportion of participants in each group with need for mechanical ventilation|Duration of hospitalization|All cause mortality	Heinrich-Heine University, Duesseldorf|Universitätsklinikum Hamburg-Eppendorf|University Hospital, Frankfurt|St. Georg Hospital Leipzig, Germany|Hospital Schwabing Munich, Germany|Missioklinik, Wuerzburg, Germany	All	18 Years and older   (Adult, Older Adult)	Phase 4	334	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CLOCC-2020	June 1, 2020	June 1, 2021	December 31, 2021	April 8, 2020		April 8, 2020			https://ClinicalTrials.gov/show/NCT04338906
4	NCT04328272	Effectiveness of Hydroxychloroquine in Covid-19 Patients	Covid	Not yet recruiting	No Results Available	COVID19	Drug: Hydroxychloroquine 200 Mg Oral Tablet|Drug: Azithromycin 500Mg Oral Tablet|Dietary Supplement: Glucose tablets	National Early Warning Score equal to zero|C-reactive proteins|Lymphocyte Count|d-dimers	Prof. Dr. Umar Farooq|Ayub Medical College, Abbottabad	All	18 Years to 50 Years   (Adult)	Phase 3	75	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	Ath/ct101/22/3	March 28, 2020	May 28, 2020	June 28, 2020	March 31, 2020		April 2, 2020	Ayub Teaching Institution, Abbottābād, K.p.k, Pakistan		https://ClinicalTrials.gov/show/NCT04328272
5	NCT04343092	Ivermectin Adjuvant to Hydroxychloroquin in COVID19 Patients		Not yet recruiting	No Results Available	COVID 19	Drug: Ivermectine|Drug: Hydroxychloroquine Sulfate|Drug: Placebos	Number of cured patients|Number of participants with treatment-related adverse events	University of Baghdad	All	18 Years and older   (Adult, Older Adult)	Phase 1	50	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	PRO20040001	April 8, 2020	August 1, 2020	August 1, 2020	April 13, 2020		April 13, 2020			https://ClinicalTrials.gov/show/NCT04343092
6	NCT04335188	COVID-19 Registry Rhineland-Palatinate (Germany)		Recruiting	No Results Available	COVID	Other: Prospective oberservational registry	Chest x-ray|Chest CT|Supportive care - ICU|Supportive care - oxygen therapy|Supportive care - ventilation|Medication|Therapeutic strategies|Lab parameters|Intra-hospital complications|Vital status at discharge	IHF GmbH - Institut für Herzinfarktforschung|Ministerium für Soziales, Arbeit, Gesundheit und Demografie des Landes Rheinland-Pfalz	All	Child, Adult, Older Adult		4000	Other	Observational	Observational Model: Other|Time Perspective: Prospective	COVID-19 Registry	April 6, 2020	July 31, 2021	September 30, 2021	April 6, 2020		April 8, 2020	Klinikum der Stadt Ludwigshafen am Rhein GmbH, Klinik für Herzchirurgie, Ludwigshafen, RLP, Germany		https://ClinicalTrials.gov/show/NCT04335188
7	NCT04338945	Impact of Pandemic COVID-19 on Surgical Specialities Residents in Italy		Enrolling by invitation	No Results Available	COVID	Behavioral: COVID-surgRES questionaire	Measure of the impact of COVID Emergency on surgical specialist training programs|Measure of impact of COVID Emergency on wellness of residents	Ospedale Policlinico San Martino	All	18 Years and older   (Adult, Older Adult)		1200	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	COVID-ItaliansurgRES-SPIGC	March 15, 2020	April 15, 2020	May 1, 2020	April 8, 2020		April 10, 2020	U.O.C. Chirurgia Generale Universitaria "V. Bonomo", Bari, Italy|Ospedale Perrino Asl Brindisi, Brindisi, Italy|Dipartimento di scienze mediche e chirurgiche, Università di Catanzaro, Catanzaro, Italy|Ospedale Policlinico San Martino, Genova, Italy|Azienda Ospedaliera San Camillo-Forlanini, Roma, Italy|IRCCS Fondazione Policlinico Universitario Agostino Gemelli, Roma, Italy|Ospedale Cristo re, Roma, Italy		https://ClinicalTrials.gov/show/NCT04338945
8	NCT04338828	Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED	NO COV-ED	Not yet recruiting	No Results Available	COVID19	Drug: Nitric Oxide Gas|Other: Inhaled Supplemental Oxygen	Rates of return visits to the ED|Inpatient hospitalizations required|Rates of intubation|Rates of mortality	Massachusetts General Hospital|Department of Anesthesia, Critical Care and Pain Medicine (DACCPM), Massachusetts General Hospital	All	18 Years and older   (Adult, Older Adult)	Phase 2	260	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	2019P00XXXX	April 2020	April 2021	April 2022	April 8, 2020		April 8, 2020	Massachusetts General Hospital, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT04338828
9	NCT04338360	Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19		Available	No Results Available	COVID19	Biological: COVID-19 convalescent plasma		Mayo Clinic	All	18 Years and older   (Adult, Older Adult)			Other	Expanded Access:Intermediate-size Population		20-003312				April 8, 2020		April 8, 2020	Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic Health System in Albert Lea, Albert Lea, Minnesota, United States|Mayo Clinic Health System in Austin, Austin, Minnesota, United States|Mayo Clinic Health System in Cannon Falls, Cannon Falls, Minnesota, United States|Mayo Clinic Health System in Lake City, Lake City, Minnesota, United States|Mayo Clinic Health System in Mankato, Mankato, Minnesota, United States|Mayo Clinic Health System in Owatonna, Owatonna, Minnesota, United States|Mayo Clinic Health System in Red Wing, Red Wing, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|Mayo Clinic Health System - Eau Claire, Eau Claire, Wisconsin, United States|Mayo Clinic Health System - Franciscan Healthcare, La Crosse, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT04338360
10	NCT04343794	Using Biovitals® Sentinel to Monitor Disease Progression in Subjects Quarantined for Suspected COVID-19		Not yet recruiting	No Results Available	COVID19	Device: BIOVITALS	Time to diagnosis of COVID-19 by RT-PCR in subjects|Compliance to complete the study|Sensitivity and specificity of Biovitals® Sentinel|Cross infection rate within the family cluster|Length of hospital stay of positive subjects|Length of ICU stay of positive patients|National Early Warning Score 2 rating of positive patients|Viral load of positive patients|Worsening of comorbidities|Mortality	The University of Hong Kong	All	18 Years and older   (Adult, Older Adult)	Not Applicable	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	COVID19_Biovitals_Protocol_1	April 1, 2020	December 31, 2021	January 31, 2022	April 13, 2020		April 13, 2020			https://ClinicalTrials.gov/show/NCT04343794
11	NCT04334252	Descriptive Study Regarding Ambulant Screening During COVID-19 Pandemia		Not yet recruiting	No Results Available	COVID 19	Other: Questionnaire	Prevalence of symptoms|Prevalence of positive Sars CoV-2 PCR|Prevalence of positive radiological findings|Prediction of symptoms	Jessa Hospital	All	18 Years and older   (Adult, Older Adult)		5000	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	JessaH_COVID19_prescreening	April 17, 2020	December 20, 2022	December 20, 2023	April 6, 2020		April 9, 2020			https://ClinicalTrials.gov/show/NCT04334252
12	NCT04335097	Sensor Based Vital Signs Monitoring of Covid 19 Patients During Home Isolation	HSC19	Not yet recruiting	No Results Available	COVID 19	Device: Biosensors	Stop home isolation|NEWS score|Clinic at hospitalization|Symptoms developed|Relative/peers evaluation of the patient|Serious of symptoms at admittance hospital	Lars Wik|University of Stavanger|Oslo University Hospital|Norwegian Telemedicine|Basque Country University	All	18 Years and older   (Adult, Older Adult)	Not Applicable	214	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	127157	April 7, 2020	April 8, 2021	December 20, 2025	April 6, 2020		April 6, 2020			https://ClinicalTrials.gov/show/NCT04335097
13	NCT04341207	Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients	ONCOVID	Recruiting	No Results Available	Cancer & COVID 19	Drug: Hydroxychloroquine|Drug: Azithromycin	Prevalence and the 3-months incidence of SARS-CoV-2 in cancer patients|Covid-19 disease-specific mortality rate in cancer patients treated by hydroxychloroquine and azithromycin	Gustave Roussy, Cancer Campus, Grand Paris	All	18 Years and older   (Adult, Older Adult)	Phase 2	1000	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-001250-21|2020/3078	April 3, 2020	April 2022	April 2022	April 10, 2020		April 10, 2020	Gustave Roussy, Villejuif, Val De Marne, France		https://ClinicalTrials.gov/show/NCT04341207
14	NCT04341506	Non-contact ECG Sensor System for COVID19		Not yet recruiting	No Results Available	COVID-19	Device: Non-contact ECG	ECG changes associated with COVID-19	Northwestern Medicine	All	18 Years and older   (Adult, Older Adult)		100	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	20-0407	April 15, 2020	July 15, 2020	September 15, 2020	April 10, 2020		April 10, 2020			https://ClinicalTrials.gov/show/NCT04341506
15	NCT04343261	CONVALESCENT PLASMA IN THE TREATMENT OF COVID 19		Not yet recruiting	No Results Available	SARS-CoV-2|COVID|Coronavirus	Biological: Convalescent Plasma	Mortality|Viral Load|Serum Antibody Titers	Saint Francis Care	All	18 Years to 90 Years   (Adult, Older Adult)	Phase 2	15	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SFH-20-23	April 10, 2020	December 1, 2020	April 1, 2021	April 13, 2020		April 13, 2020	Trinity Health Of New England, Hartford, Connecticut, United States		https://ClinicalTrials.gov/show/NCT04343261
16	NCT04339608	Max COVID19- Study		Recruiting	No Results Available	COVID-19		COVID-19 positive case	Max Healthcare Insititute Limited	All	18 Years and older   (Adult, Older Adult)		10000	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	Covid-19/MHC/2020	April 2, 2020	May 30, 2020	June 30, 2020	April 9, 2020		April 9, 2020	Max Super Speciality Hospital, A Unit of Devki Devi Foundation, New Delhi, Delhi, India		https://ClinicalTrials.gov/show/NCT04339608
17	NCT04342884	COVID-19 Community Research Partnership		Not yet recruiting	No Results Available	Coronavirus|COVID		Seroprevalence of SARS-CoV-2 infection in the general population of North Carolina|Seroprevalence of SARS-CoV-2 infection among health care workers of North Carolina|Cumulative incidence of SARS-CoV-2 infection|Monthly incidence of SARS-CoV-2 infection|Stratified incidence of SARS-CoV-2 infection by age group|Stratified incidence of SARS-CoV-2 infection by sex|Stratified incidence of SARS-CoV-2 by season|Stratified incidence of SARS-CoV-2 infection by geographic area (zip code)|Stratified incidence of SARS-CoV-2 infection by preexisting comorbidities|Stratified incidence of SARS-CoV-2 infection by COVID-2 contacts|Stratified incidence of SARS-CoV-2 infection by use of personal protective equipment (PPE) by health workers|Relative risk of SARS-CoV-2 infection by age group|Relative risk of SARS-CoV-2 infection by sex|Relative risk of SARS-CoV-2 infection by season|Relative risk of SARS-CoV-2 infection by geographic area (zip code)|Relative risk of SARS-CoV-2 infection by preexisting comorbidities|Relative risk of SARS-CoV-2 infection by COVID-2 contacts|Relative risk of SARS-CoV-2 infection by use of PPE by health workers|Incidence of sequelae	Wake Forest University Health Sciences	All	Child, Adult, Older Adult		150000	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	IRB00064912	April 2020	December 2021	December 2021	April 13, 2020		April 13, 2020	Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States		https://ClinicalTrials.gov/show/NCT04342884
18	NCT04329611	ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease		Not yet recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine	Composite of hospitalization, invasive mechanical ventilation or death within 30 days|mortality|Symptom duration|Disposition at 30 days defined as recovered, ongoing symptoms but not hospitalized, hospitalized, or deceased.	Dr. Michael Hill|University of Calgary	All	18 Years and older   (Adult, Older Adult)	Phase 3	1660	Other	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	ABCOV-01 version 1.1	April 15, 2020	July 31, 2020	August 31, 2020	April 1, 2020		April 7, 2020	University of Calgary/Foothills Medical Centre, Calgary, Alberta, Canada		https://ClinicalTrials.gov/show/NCT04329611
19	NCT04338074	TXA and Corona Virus 2019 (COVID19) in Outpatients	TCOutpatient	Not yet recruiting	No Results Available	COVID-19	Drug: Tranexamic acid tablets|Drug: Placebo oral tablet	Hospitalization	University of Alabama at Birmingham	All	19 Years and older   (Adult, Older Adult)	Phase 2	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	TXACOVID1	April 15, 2020	October 15, 2020	October 30, 2020	April 8, 2020		April 8, 2020	University of Alabama at Birmingham, Birmingham, Alabama, United States		https://ClinicalTrials.gov/show/NCT04338074
20	NCT04343742	Determination of the Effectiveness of Oral Chlorine Dioxide in the Treatment of COVID 19		Recruiting	No Results Available	COVID-19	Drug: chlorine dioxide 3000 ppm	negative testing of covid19	Genesis Foundation	All	Child, Adult, Older Adult		20	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	Genesis AKCOVID- FG-1	April 1, 2020	April 7, 2020	June 1, 2020	April 13, 2020		April 13, 2020	San Carlos Hospital, Bogota, Cundinamarca, Colombia		https://ClinicalTrials.gov/show/NCT04343742
21	NCT04343183	Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection		Not yet recruiting	No Results Available	COVID-19	Device: Hyperbaric Oxygen Therapy	Decrease incidence of intubation by 30% or greater|Decrease renal injury	Ochsner Health System	All	18 Years and older   (Adult, Older Adult)	Not Applicable	48	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	STUDY00001051	April 2020	June 2020	June 2020	April 13, 2020		April 13, 2020	Ochsner Medical Center, New Orleans, Louisiana, United States		https://ClinicalTrials.gov/show/NCT04343183
22	NCT04333550	Application of Desferal to Treat COVID-19		Recruiting	No Results Available	COVID-19	Drug: Deferoxamine	Mortality rate|change in patients clinical manifestation|change in patients PaO2|Length of hospitalization|C-reactive protein|lymphocyte count|length of intensive care unit stay	Kermanshah University of Medical Sciences	All	3 Years to 99 Years   (Child, Adult, Older Adult)	Phase 1|Phase 2	50	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	1398.1224	April 2020	September 2020	March 2021	April 3, 2020		April 6, 2020	Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran, Kermanshah, Iran, Islamic Republic of		https://ClinicalTrials.gov/show/NCT04333550
23	NCT04342663	A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection	STOP COVID	Not yet recruiting	No Results Available	COVID 19|Coronavirus	Drug: Fluvoxamine|Drug: Placebo	Time to clinical worsening|clinical deterioration on a Likert-type scale (1-6)|clinical deterioration measured by number of days|Symptomatic severity on a likert scale (0-10 where 0= none and 10=very severe)	Washington University School of Medicine	All	18 Years and older   (Adult, Older Adult)	Phase 2	152	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	202004023	April 10, 2020	June 1, 2020	July 1, 2020	April 13, 2020		April 13, 2020	BJC, Belleville, Illinois, United States|Washington University School of Medicine, Saint Louis, Missouri, United States		https://ClinicalTrials.gov/show/NCT04342663
24	NCT04336904	Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19		Active, not recruiting	No Results Available	COVID-19	Drug: Favipiravir|Other: Placebo	Time from randomization to clinical recovery|Time from randomization to negativity in RT-PCR nucleic acid test|Incidence of deterioration/aggravation of pneumonia|Time from randomization to resolution of pyrexia|Time from randomization to relief of cough|Time from randomization to relief of dyspnoea|Rate of auxiliary oxygen therapy|ICU admission rate|Mortality	Giuliano Rizzardini|ASST Fatebenefratelli Sacco	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 3	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	HS216C17-PHASE III	March 25, 2020	July 2020	July 2020	April 7, 2020		April 8, 2020	Asst Fatebenefratelli Sacco, Milano, Italy		https://ClinicalTrials.gov/show/NCT04336904
25	NCT04321993	Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients		Not yet recruiting	No Results Available	COVID-19	Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine sulfate|Drug: Baricitinib (janus kinase inhibitor)|Drug: Sarilumab (anti-IL-6 receptor)	Clinical status of subject at day 15 (on a 7 point ordinal scale).|Status on an ordinal scale assessed daily while hospitalized and on days 15 and 29 and 180.|Length of time to clinical improvement|Number of participants with normal pulmonary function and normal O2 saturation on days 11, 15 and 29|Number of participants that developed Acute Respiratory Distress Syndrome (ARDS) after treatment|Length of time to clinical progression|Cause of death (if applicable)|Sequential Organ Failure Assessment (SOFA) score, daily while hospitalized and on days 15 and 29. (Initial, highest, deltas and mean)|Length of time to normalization of fever|Length of time to normalization of oxygen saturation|Duration of supplemental oxygen (if applicable)|Duration of mechanical ventilation (if applicable)|Duration of hospitalization|Adverse events	Lisa Barrett|Nova Scotia Health Authority|Dalhousie University	All	18 Years and older   (Adult, Older Adult)	Phase 2	1000	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SAIL-004	April 2020	February 2021	July 2021	March 26, 2020		April 7, 2020	Nova Scotia Health Authority, Halifax, Nova Scotia, Canada		https://ClinicalTrials.gov/show/NCT04321993
26	NCT04333407	Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.	C-19-ACS	Recruiting	No Results Available	COVID-19	Drug: Aspirin 75mg|Drug: Clopidogrel 75mg|Drug: Rivaroxaban 2.5 MG|Drug: Atorvastatin 40mg|Drug: Omeprazole 20mg	All-cause mortality at 30 days after admission|Absolute change in serum troponin from admission to peak value|Discharge Rate|Intubation Rate	Imperial College London	All	18 Years to 85 Years   (Adult, Older Adult)	Not Applicable	3170	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20HH5868	April 3, 2020	March 30, 2021	March 30, 2021	April 3, 2020		April 9, 2020	Charing Cross Hospital, London, United Kingdom		https://ClinicalTrials.gov/show/NCT04333407
27	NCT04333732	CROWN CORONATION: Chloroquine RepurpOsing to healthWorkers for Novel CORONAvirus mitigaTION	CROWN CORONA	Not yet recruiting	No Results Available	COVID 19	Drug: Low-dose chloroquine/hydroxychloroquine|Drug: Mid dose chloroquine or hydroxychloroquine|Drug: High does chloroquine or hydroxychloroquine|Drug: Placebo	Symptomatic COVID-19|Peak severity of COVID-19 over the study period	Washington University School of Medicine	All	18 Years and older   (Adult, Older Adult)	Phase 2	55000	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention	202004xxx	April 2020	February 2021	February 2021	April 3, 2020		April 3, 2020	Washington University School of Medicine, Saint Louis, Missouri, United States|Melbourne Medical School, Melbourne, Victoria, Australia|Population Health Resarch Institute, Hamilton, Ontario, Canada|University of Toronto, Toronto, Ontario, Canada|St James's Hospital, Dublin, Leinster, Ireland|Wits RHI, University of the Witwatersrand, Johannesburg, Gauteng, South Africa|University College London, London, United Kingdom		https://ClinicalTrials.gov/show/NCT04333732
28	NCT04321421	Hyperimmune Plasma for Critical Patients With COVID-19	COV19-PLASMA	Active, not recruiting	No Results Available	COVID-19	Other: hyperimmune plasma	death|time to extubation|length of intensive care unit stay|time to CPAP weaning|viral load|immune response	Foundation IRCCS San Matteo Hospital|OSPEDALE CARLO POMA ASST MANTOVA|OSPEDALE MAGGIORE LODI|OSPEDALE ASST CREMONA	All	18 Years and older   (Adult, Older Adult)	Not Applicable	49	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRCCSSanMatteoH	March 17, 2020	May 31, 2020	May 31, 2020	March 25, 2020		March 25, 2020	Catherine Klersy, Pavia, PV, Italy		https://ClinicalTrials.gov/show/NCT04321421
29	NCT04331509	COVID-19 Symptom Tracker		Recruiting	No Results Available	COVID-19	Other: No Intervention	Physical health symptoms|Lack of physical health symptoms|Fever	King's College London|Zoe Global Limited|Massachusetts General Hospital|Harvard School of Public Health|Stanford University	All	18 Years and older   (Adult, Older Adult)		10000000	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	COVID-19 Symptom tracker	March 23, 2020	March 23, 2022	March 23, 2022	April 2, 2020		April 7, 2020	Massachusetts General Hospital, Boston, Massachusetts, United States|King's College London, London, United Kingdom		https://ClinicalTrials.gov/show/NCT04331509
30	NCT04323514	Use of Ascorbic Acid in Patients With COVID 19		Recruiting	No Results Available	Hospitalized Patients With Covid-19 Pneumonia	Dietary Supplement: Vitamin C	In-hospital mortality|PCR levels|Lactate clearance|Hospital stay|Symptoms|Positive swab|Tomography imaging	University of Palermo	All	Child, Adult, Older Adult	Not Applicable	500	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	3143	March 13, 2020	March 13, 2021	March 13, 2021	March 26, 2020		March 26, 2020	A.R.N.A.S. Civico - Di Cristina - Benfratelli, Palermo, Italy	Study Protocol, Statistical Analysis Plan, and Informed Consent Form, https://ClinicalTrials.gov/ProvidedDocs/14/NCT04323514/Prot_SAP_ICF_000.pdf	https://ClinicalTrials.gov/show/NCT04323514
31	NCT04342637	COVID-19 Endoscopy Survey	COVID-19 Endo	Not yet recruiting	No Results Available	COVID-19	Other: Practice details	Effect of GI societies recommendations on prevention of SARS-CoV-2 infection|To measure the percentage change in performed endoscopic procedure in response to COVID-19|Effect of COVID-19 precautions on procedure time|Effect of COVID-19 precautions on time of disinfection|Effect of COVID-19 precautions on procedure success|Effect of COVID-19 precautions on complications|Effect of COVID-19 precautions on working time|Effect of COVID-19 precautions on staff number	Al-Azhar University	All	30 Years to 70 Years   (Adult, Older Adult)		40	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	WES-2	April 10, 2020	October 10, 2020	December 10, 2020	April 13, 2020		April 13, 2020	Kings County Hospital Center, Brooklyn, NY, USA, Albertson, New York, United States|Faculty of Medicine, Zagazig University, Zagazig, Sharkia, Egypt|Al-Azhar Univerisity, Cairo, Egypt|Ahvaz Imam hospital, Ahvaz, Iran, Islamic Republic of		https://ClinicalTrials.gov/show/NCT04342637
32	NCT04291053	The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19		Not yet recruiting	No Results Available	COVID-19	Drug: Huaier Granule	Mortality rate|Clinical status assessed according to the official guideline|The differences in oxygen intake methods|Duration (days) of supplemental oxygenation|Duration (days) of mechanical ventilation|The mean PaO2/FiO2|Length of hospital stay (days)|Length of ICU stay (days)|Pulmonary function	Tongji Hospital	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 2|Phase 3	550	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TJ-IRB20200205	April 1, 2020	August 1, 2020	September 1, 2020	March 2, 2020		March 17, 2020			https://ClinicalTrials.gov/show/NCT04291053
33	NCT04336462	Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19	COVID-19	Recruiting	No Results Available	COVID-19	Device: oxyhydrogen|Device: Oxygen	Recovery time|Clinical Symptom Remission time|fever duration|Leicester cough questionaire (LCQ)|minimum oxygen|Negative conversion rate|white blood cell(WBC)|Red blood cells(RBC)|Hemoglobin(Hb )|Platelets(PLT)|Lymphocyte count|The percentage of lymphocyte|neutrophils|C-reactive protein (CRP)|Myocardial enzyme|liver function|Renal function|Muscle enzyme	Shanghai Asclepius Meditec Inc.|Shanghai Public Health Clinical Center|Henan Provincial People's Hospital|Shenzhen Third People's Hospital|The First People's Hospital of Yunnan|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Shanghai 6th People's Hospital|Guangdong Provincial Hospital of Traditional Chinese Medicine	All	18 Years to 85 Years   (Adult, Older Adult)	Not Applicable	100	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	JT202002LZ	February 15, 2020	February 21, 2020	August 1, 2020	April 7, 2020		April 7, 2020	First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China		https://ClinicalTrials.gov/show/NCT04336462
34	NCT04343144	CORIMUNO19-NIVO: TRIAL EVALUATING EFFICACY and SAFETY OF NIVOLUMAB (OPDIVO®) IN PATIENTS WITH COVID-19 INFECTION, NESTED IN THE CORIMUNO-19 COHORT	CORIMUNO-NIVO	Not yet recruiting	No Results Available	COVID19- Infection With SARS-CoV-2 Virus	Drug: Nivolumab Injection	Time to clinical improvement|Overall survival|Cumulative incidence of ICU admission|Length of hospital stay|Positive nasal PCR|Incidence of adverse events|Incidence of grade 3-4 adverse events|WHO scale	Assistance Publique - Hôpitaux de Paris	All	18 Years and older   (Adult, Older Adult)	Phase 2	92	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	APHP200389-5	April 15, 2020	July 31, 2020	September 30, 2020	April 13, 2020		April 13, 2020	Pneumologie hôpital Tenon, Paris, France		https://ClinicalTrials.gov/show/NCT04343144
35	NCT04337190	Impact of Angiotensin II Receptor Blockers Treatment in Patients With COVID 19 (COVID-ARA2)	COVID-ARA2	Recruiting	No Results Available	COVID|Acute Respiratory Distress Syndrome	Biological: blood sampling	ACE2 level change over time|ACE2 activity over time|Mortality at day 28|ARDS severity|Duration of mechanical ventilation|Need for prone positionning|Need for extracorporeal membran oxygenation|Use of paralytic agents|Need for renal replacement therapy|Need for vasoactive drugs (norepinephrine, dobutamine,epinephrine)|Sequential Organ Failure Assessment (SOFA) score|Number of session(s) of prone positionning|Duration of extracorporeal membran oxygenation treatment|Type of vasoactive drugs|Duration of vasoactive treatment	University Hospital, Angers	All	18 Years and older   (Adult, Older Adult)		100	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	COVID-ARA2	April 3, 2020	October 6, 2020	December 6, 2020	April 7, 2020		April 10, 2020	University Hospital Angers, Angers, France		https://ClinicalTrials.gov/show/NCT04337190
36	NCT04324489	DAS181 for Severe COVID-19: Compassionate Use		Recruiting	No Results Available	COVID-19	Drug: DAS181	Improved clinical status|Return to room air|SARS-CoV-2 RNA|Discharge|Death	Renmin Hospital of Wuhan University|Ansun Biopharma, Inc.	All	18 Years to 70 Years   (Adult, Older Adult)	Not Applicable	4	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DAS181-SARS-CoV-2	March 6, 2020	April 25, 2020	April 30, 2020	March 27, 2020		April 2, 2020	Renmin Hospital of Wuhan University, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04324489
37	NCT04343755	Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection		Not yet recruiting	No Results Available	COVID-19	Biological: Convalescent Plasma	For patients hospitalized for COVID-19 but not intubated|Primary objective for patients with COVID-19 already intubated|Duration of hospitalization|Duration of mechanical ventilation|Time to symptoms resolution|Overall survival|Rate of virologic clearance by nasopharyngeal swab at day 10|Impact of donor titers level on efficacy|Impact of donor titers level on safety|Recipient Anti-SARS-CoV2 titer assessment on days 0 (pre-infusion),3,10,30, 60	Hackensack Meridian Health	All	18 Years and older   (Adult, Older Adult)	Phase 2	55	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro2020-0375	April 2020	April 2021	April 2021	April 13, 2020		April 13, 2020			https://ClinicalTrials.gov/show/NCT04343755
38	NCT04333420	Open-label, Randomized Study of IFX-1 in Patients With Severe COVID-19 Pneumonia	PANAMO	Recruiting	No Results Available	COVID-19 Pneumonia	Drug: Best supportive Care (BSC) + IFX-1|Drug: Best supportive care only	Change in PaO2/FiO2|Patients achieving early response	InflaRx GmbH	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	130	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IFX-1-P2.9	March 31, 2020	October 31, 2020	December 31, 2020	April 3, 2020		April 7, 2020	University Amsterdam, Amsterdam, Netherlands		https://ClinicalTrials.gov/show/NCT04333420
39	NCT04336774	CAPTION AI to Minimize Risk of COVID Exposure	CAPTION AI	Not yet recruiting	No Results Available	COVID-19	Device: Caption AI	Percent of patient echos that are not interpretable|Percent of patient echos that provide an automated (AI) LVEF (left ventricular ejection fraction)|Time to acquire images as measured by time stamps|Percent of agreement between AI calculate LVEF and LVEF read by physician	Duke University|Caption Health, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	500	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	pro00105212	April 2020	November 1, 2020	November 9, 2020	April 7, 2020		April 7, 2020	Duke University Medical Center, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT04336774
40	NCT04335123	Study of Open Label Losartan in COVID-19		Recruiting	No Results Available	COVID-19	Drug: Losartan	Number of participants with treatment-related adverse events as assessed by protocol definition of AE|Number of days on supplemental oxygen in respiratory failure due to COVID-19|Incidence of mechanical ventilation use|Days on mechanical ventilation|Incidence of non-invasive positive pressure ventilation or heated high flow nasal cannula use|Days on non-invasive positive pressure ventilation or high flow nasal cannula|Incidence of transfer to ICU from non-ICU hospital bed|ICU length of stay (days)|30-day mortality rate|Hospital length of stay (days)|Cumulative incidence of severe adverse events|Cumulative incidence of adverse events|Change from baseline in oxygenation|Incidence of medications with possible antiviral activity (hydroxychloroquine, lopinavir/ritonavir, ribavirin or remdesivir) or adjunctive therapy use (e.g., tocilizumab)|Incidence (and length in days) of extracorporeal membrane oxygenation use|Incidence (and length in days) of renal replacement therapy use|Intolerance of high dose (50mg) losartan after tolerating 25mg	University of Kansas Medical Center	All	18 Years and older   (Adult, Older Adult)	Phase 1	50	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STUDY00145514	March 25, 2020	September 2020	October 2020	April 6, 2020		April 6, 2020	University of Kansas Medical Center, Kansas City, Kansas, United States		https://ClinicalTrials.gov/show/NCT04335123
41	NCT04323878	Early CPAP in COVID Patients With Respiratory Failure. A Prospective Cohort Study.	EC-COVID-PCS	Not yet recruiting	No Results Available	Early CPAP Ventilation in COVID-19 Patients		Death or need of intubation|30-day mortality	Mario Negri Institute for Pharmacological Research	All	18 Years and older   (Adult, Older Adult)		3000	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	EC-COVID-PCS-Fenice	April 6, 2020	October 5, 2020	November 9, 2020	March 27, 2020		March 31, 2020			https://ClinicalTrials.gov/show/NCT04323878
42	NCT04338100	Point Of Care UltraSonography for Risk-stratification of COVID-19 Patients	POCUSCO	Not yet recruiting	No Results Available	COVID|Coronavirus Infection	Procedure: Follow-up at 14 days	Risk of unfavourable outcome at D14|Risk of unfavourable outcome over time|Risk-stratification threshold values|Adding value of POCUS score to previous risk-stratification clinical rules|POCUS score and patient clinical status at D14|POCUS and CT scan correlation|POCUS versus CT scan risk-stratification performances|POCUS score evolution performances	University Hospital, Angers	All	18 Years and older   (Adult, Older Adult)		300	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	2020-A00782-37	April 6, 2020	December 29, 2020	January 29, 2021	April 8, 2020		April 8, 2020			https://ClinicalTrials.gov/show/NCT04338100
43	NCT04323228	Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19	ONSCOVID19	Not yet recruiting	No Results Available	COVID-19	Dietary Supplement: oral nutrition supplement (ONS) enriched in eicosapentaenoic acid, gamma-linolenic acid and antioxidants|Dietary Supplement: isocaloric/isonutrigenous ONS	Change from baseline score of Nutrition risk screening-2002 (NRS-2002) at end of the trial|Change from baseline Serum ferritin level at end of the trial|Change from baseline serum Interleukin-6 concentration at end of the trial|Change from baseline serum C-reactive protein concentration at end of the trial|Change from baseline serum Tumor necrosis factor-α concentration at end of the trial|Change from baseline serum monocyte chemoattractant protein 1 (MCP-1) at end of the trial|Change from baseline Weight at end of the trial|Height|Change from baseline BMI at end of the trial|Change from baseline mid arm circumference at end of the trial|Change from baseline triceps skin-fold thickness at end of the trial|Change from baseline MAMA at end of the trial|Change from baseline percentage of peripheral O2 saturation at end of the trial|Change from baseline degree of body temperature at end of the trial|Change from baseline count the total leukocyte at end of the trial|Change from baseline differential lymphocytic count at end of the trial|Change from baseline Neutrophil count at end of the trial|Change from baseline neutrophil to lymphocyte ratio at end of the trial	King Saud University	All	18 Years to 65 Years   (Adult, Older Adult)	Phase 4	30	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care	ONS_COVID-19	April 1, 2020	October 1, 2020	October 30, 2020	March 26, 2020		March 27, 2020			https://ClinicalTrials.gov/show/NCT04323228
44	NCT04341870	Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO	CORIMUNO-VIRO	Not yet recruiting	No Results Available	COVID19|SARS-CoV-2 Infection	Drug: Sarilumab|Drug: Azithromycin|Drug: Hydroxychloroquine	Need for ventilation (including invasive and non invasive ventilation), intensive care or death|Early improvement: OMS progression scale <= 5|OMS progression scale|Survival|ICU-free days alive|Ventilation-free days alive|Hospital-free days alive|Oxygen therapy-free days alive|Time to negative viral excretion|Immunophenotyping and multiplex cytokines	Assistance Publique - Hôpitaux de Paris	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 2|Phase 3	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	APHP200375-3	April 2020	April 2020	July 2020	April 10, 2020		April 10, 2020			https://ClinicalTrials.gov/show/NCT04341870
45	NCT04287686	Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19		Withdrawn	No Results Available	COVID-19	Drug: Recombinant human angiotensin-converting enzyme 2 (rhACE2)	Time course of body temperature (fever)|Viral load over time|P/F ratio over time|Sequential organ failure assessment score(SOFA score) over time|Pulmonary Severity Index (PSI)|Image examination of chest over time|Proportion of subjects who progressed to critical illness or death|Time from first dose to conversion to normal or mild pneumonia|T-lymphocyte counts over time|C-reactive protein levels over time|Angiotensin II (Ang II) changes over time|Angiotensin 1-7 (Ang 1-7) changes over time|Angiotensin 1-5 (Ang 1-5) changes over time|Renin changes over time|Aldosterone changes over time|Angiotensin-converting enzyme (ACE) changes over time|Angiotensin-converting enzyme 2 (ACE2) changes over time|Interleukin 6 (IL-6) changes over time|Interleukin 8 (IL-8) changes over time|Soluble tumor necrosis factor receptor type II (sTNFrII) changes over time|Plasminogen activator inhibitor type-1 (PAI-1) changes over time|Von willebrand factor (vWF) changes over time|Tumor necrosis factor-α (TNF-α) changes over time|Soluble receptor for advanced glycation end products (sRAGE) changes over time|Surfactant protein-D (SP-D) changes over time|Angiopoietin-2 changes over time|Frequency of adverse events and severe adverse events	The First Affiliated Hospital of Guangzhou Medical University	All	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	0	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GIRH-APN01	February 2020	April 2020	April 2020	February 27, 2020		March 17, 2020	GCP Office of The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China		https://ClinicalTrials.gov/show/NCT04287686
46	NCT04338698	Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT	PROTECT	Not yet recruiting	No Results Available	COVID 19	Drug: Hydroxychloroquine|Drug: Oseltamivir|Drug: Azithromycin	Laboratory Result|Clinical Outcome	Shehnoor Azhar|Federal Task Force on Science & Technology notified by Government of Pakistan|University of Health Sciences Lahore	All	18 Years and older   (Adult, Older Adult)	Phase 3	500	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment	12(06)/2016-Coord	April 7, 2020	September 1, 2020	November 30, 2020	April 8, 2020		April 10, 2020			https://ClinicalTrials.gov/show/NCT04338698
47	NCT04342689	The Role of Resistant Potato Starch in COVID-19 Infection		Not yet recruiting	No Results Available	COVID-19	Dietary Supplement: Bob's Red Mill|Dietary Supplement: Control - Amioca powder (Amylopectin)	Rates of hospitalization for a COVID-19 related complication|Time to clinical recovery (TTCR)|Symptom Severity Score	Yale University|University of Michigan|University of Minnesota	All	18 Years and older   (Adult, Older Adult)	Not Applicable	1300	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	2000027887	May 1, 2020	October 1, 2020	May 1, 2021	April 13, 2020		April 13, 2020			https://ClinicalTrials.gov/show/NCT04342689
48	NCT04325633	Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection	ENACOVID	Not yet recruiting	No Results Available	COVID-19	Drug: 1: Naproxen|Drug: 2: Standard of care	Mortality all causes at day30|Number of days alive free of mechanical ventilation|Number of days alive outside|Number of days alive outside hospital|Maximal changes in Sofa score|Time to negativation of virus titer in the nasopharyngeal aspirate (NPA)	Assistance Publique - Hôpitaux de Paris	All	18 Years and older   (Adult, Older Adult)	Phase 3	584	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	APHP200387	March 27, 2020	April 27, 2021	June 27, 2021	March 27, 2020		March 27, 2020			https://ClinicalTrials.gov/show/NCT04325633
49	NCT04336956	Covid-19 Pediatric Observatory	PANDOR	Recruiting	No Results Available	COVID-19	Other: hospitalized children with Covid19	Percentage of children with severe or critical form.|Percentage of children requiring intensive care support|Clinical symptoms of children|Biological results of children|CT chest of children|Pulmonary echography|nasopharynx SARScov2 PCR|nasopharynx sarscov2 load|nasopharynx multiplex PCR|number of hospital days	Centre Hospitalier Intercommunal Creteil|ACTIV|GPIP|Société Française de Pédiatrie|GFRUP	All	up to 18 Years   (Child, Adult)		250	Other	Observational	Observational Model: Cohort|Time Perspective: Other	PANDOR	April 7, 2020	June 30, 2021	June 30, 2021	April 7, 2020		April 10, 2020	Centre Hospitalier intercommunal de Creteil, Creteil, France|Assistance Publique Hôpitaux de Paris, Paris, France		https://ClinicalTrials.gov/show/NCT04336956
50	NCT04323332	Traditional Chinese Medicine for Severe COVID-19		Not yet recruiting	No Results Available	COVID-19	Drug: Traditional Chinese Medicine Prescription	Length of hospital stay (days)|Duration (days) of supplemental oxygenation|CT imaging changes|Mortality rate|Time to Clinical Improvement (TTCI)|The pneumonia severity index scores|Time to COVID-19 nucleic acid testing negativity in throat swab|Blood immune cell count|Serum inflammatory markers|Erythrocyte sedimentation rate|Platelet and D-dimer changes|Creatinine changes|Muscle enzymes changes|Usage of antibiotics|Usage of glucocorticoids|Frequency of adverse events	Xiyuan Hospital of China Academy of Chinese Medical Sciences	All	up to 85 Years   (Child, Adult, Older Adult)	Phase 3	50	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020XLA015-1	March 2020	March 2020	April 2020	March 26, 2020		March 26, 2020	Hao Li, Beijing, Beijing, China		https://ClinicalTrials.gov/show/NCT04323332
51	NCT04341168	Clinical and Immunological Characterisation of COVID-19 in Children, Adolescents and Adults		Not yet recruiting	No Results Available	COVID-19|SARS-CoV-2	Other: this study is non- interventional	Clinical course of COVID-19|Analysis of development of antibodies to SARS-CoV-2|Estimation of viral load|Detection of viral coinfections|Measurement of cytokine and chemokine response|Characterisation of virus-host-interaction|Identification of disease patterns in proteome|Analysis of change in lymphocyte subtypes|Analysis of histological changes in severe lung disease|Detection of bacterial coinfections	University Hospital of Cologne|Clinic for Internal Medicine I, University Hospital Cologne, Germany|Institute of Virology, University Hospital Cologne, Germany|Center for Molecular Medicine Cologne (CMMC) Cologne, Germany	All	Child, Adult, Older Adult		160	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	KICC19	April 2020	October 2020	October 2020	April 10, 2020		April 10, 2020	University Hospital Cologne, Cologne, NRW, Germany		https://ClinicalTrials.gov/show/NCT04341168
52	NCT04339660	Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia		Recruiting	No Results Available	COVID-19	Biological: UC-MSCs|Other: Placebo	The immune function (TNF-α 、IL-1β、IL-6、TGF-β、IL-8、PCT、CRP)|Blood oxygen saturation|Rate of mortality within 28-days|Size of lesion area by chest imaging|CD4+ and CD8+ T cells count|Peripheral blood count recovery time|Duration of respiratory symptoms (fever, dry cough, difficulty breathing, etc.)|COVID-19 nucleic acid negative time	Puren Hospital Affiliated to Wuhan University of Science and Technology|Shanghai University|Qingdao Co-orient Watson Biotechnology group co. LTD|Basic Medical Sciences, Chinese Academy of Medical Sciences	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 1|Phase 2	30	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	Pr20200402	February 1, 2020	June 30, 2020	June 30, 2020	April 9, 2020		April 9, 2020	Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04339660
53	NCT04329650	Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia		Not yet recruiting	No Results Available	COVID-19	Drug: Siltuximab|Drug: Methylprednisolone	Proportion of patients requiring ICU admission at any time within the study period.|Days of stay in the ICU during the study period.|Days until resolution of fever defined as body temperature (axillary ≤ 36.6 ° C, oral ≤ 37.2 ° C, or rectal or tympanic ≤ 37.8 ° C) for at least 48 hours, without administration of antipyretics or until hospital discharge.|Proportion of patients with a worsening requirement of supplemental oxygen at 29 days. days.|Days with hypoxemia (SpO2 <93% in ambient air or requiring oxygen supplemental or mechanical ventilation support) at 29 days.|Proportion of patients using mechanical ventilation at 29 days.|Days with use of mechanical ventilation at 29 days.|Days until the start of use of mechanical ventilation, non-invasive ventilation or use of high flow nasal cannula (if the patient have not previously required these interventions at the inclusion of the study) at 29 days.|Days of hospitalization among survivors at 29 days.|Mortality rate from any cause at 29 days.|Proportion of patients with serious adverse events at 29 days.|Proportion of patients with invasive bacterial or fungal infections clinically significant or opportunistic with grade 4 neutropenia (count neutrophil absolute <500 / mm3) at 29 days.|Proportion of patients with invasive bacterial or fungal infections clinically significant or opportunistic at 29 days.|Proportion of patients with grade 2 or higher adverse reactions related to the infusion of the sudy treatments at 29 days.|Proportion of patients with hypersensitivity reactions of grade 2 or higher related to the administration of the study treatments at 29 days.|Proportion of patients with gastrointestinal perforation at 29 days.|Proportion of patients with secondary severe infections confirmed by laboratory or worsening of existing infections at 29 days.|Changes from baseline in plasma leukocyte levels at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma hemoglobin levels at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma platelet at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma creatinine levels at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma total bilirubin levels at days 1, 3, 5, 7 and 9.|Proportion of patients with ALT≥ 3 times ULN (for patients with initial values normal) or> 3 times ULN AND at least 2 times more than the initial value (for patients with abnormal initial values) at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma biomarkers (PCR, lymphocytes, ferritin, d-dimer and LDH) at days 1, 3, 5, 7 and 9.|Changes from baseline in chest Rx at days 1, 3 and 5.	Judit Pich Martínez|Fundacion Clinic per a la Recerca Biomédica	All	18 Years and older   (Adult, Older Adult)	Phase 2	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SILCOR-COVID-19	April 1, 2020	May 20, 2020	May 20, 2020	April 1, 2020		April 13, 2020	Hospital Clínic de Barcelona, Barcelona, Spain		https://ClinicalTrials.gov/show/NCT04329650
54	NCT04340232	Safety and Efficacy of Baricitinib for COVID-19		Not yet recruiting	No Results Available	COVID-19	Drug: Baricitinib	Phase 2: Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Phase 2: Cumulative incidence of serious adverse events (SAEs)|Phase 2: Changes in white blood cell count (CBC) through Day 15|Phase 2: Changes in hemoglobin through Day 15|Phase 2: Changes in platelets through Day 15|Phase 2: Changes in creatinine through Day 15|Phase 2: Changes in glucose through Day 15|Phase 2: Changes in prothrombin time (PT) through Day 15|Phase 2: Changes in total bilirubin through Day 15|Phase 2: Changes in ALT through Day 15|Phase 2: Changes in AST through Day 15|Phase 2: Changes in white blood cell count (CBC) through End of Study (EOS)|Phase 2: Changes in hemoglobin through End of Study (EOS)|Phase 2: Changes in platelets through End of Study (EOS)|Phase 2: Changes in creatinine through End of Study (EOS)|Phase 2: Changes in glucose through End of Study (EOS)|Phase 2: Changes in prothrombin time (PT) though End of Study (EOS)|Phase 2: Changes in total bilirubin through End of Study (EOS)|Phase 2: Changes in ALT through End of Study (EOS)|Phase 2: Changes in AST through End of Study (EOS)|Phase 3: Percentage of patients reporting each severity on an 8-point ordinal scale at Day 15|Phase 2: Change in the 8-point ordinal scale|Phase 2: Change in National Early Warning Score (NEWS)|Phase 3: Change in the 8-point ordinal scale|Phase 3: Change in National Early Warning Score (NEWS)|Phase 3: Time to an improvement of one category using the 8-point ordinal scale|Phase 3: Time to an improvement of two categories using the 8-point ordinal scale|Phase 3: Time to discharge or to a NEWS ≤2 and maintained for 24 hours, whichever occurs first|Phase 3: Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Phase 3: Cumulative incidence of serious adverse events (SAEs)|Phase 3: Duration of hospitalization|Phase 3: Duration of new oxygen use|Phase 3: Duration of new ventilator or ECMO use|Phase 3: Incidence of discontinuation or temporary suspension of drug for any reason|Phase 3: Incidence of new oxygen use|Phase 3: Incidence of new ventilator use|Phase 3: Number of oxygen free days|Phase 3: Number of ventilator or ECMO free days|Phase 3: 14 day mortality rate|Phase 3: 28 day mortality rate|Phase 3: Changes in white blood cell count (CBC) through Day 15|Phase 3: Changes in hemoglobin through Day 15|Phase 3: Changes in platelets through Day 15|Phase 3: Changes in creatinine through Day 15|Phase 3: Changes in glucose through Day 15|Phase 3: Changes in prothrombin time (PT) through Day 15|Phase 3: Changes in total bilirubin through Day 15|Phase 3: Changes in ALT through Day 15|Phase 3: Changes in AST through Day 15|Phase 3: Changes in white blood cell count (CBC) through End of Study (EOS)|Phase 3: Changes in hemoglobin through End of Study (EOS)|Phase 3: Changes in platelets through End of Study (EOS)|Phase 3: Changes in creatinine through End of Study (EOS)|Phase 3: Changes in glucose through End of Study (EOS)|Phase 3: Changes in prothrombin time (PT) though End of Study (EOS)|Phase 3: Changes in total bilirubin through End of Study (EOS)|Phase 3: Changes in ALT through End of Study (EOS)|Phase 3: Changes in AST through End of Study (EOS)	University of Colorado, Denver	All	18 Years to 89 Years   (Adult, Older Adult)	Phase 2|Phase 3	80	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20-0738	April 2020	August 2020	October 2020	April 9, 2020		April 9, 2020	University of Colorado, Denver, Aurora, Colorado, United States		https://ClinicalTrials.gov/show/NCT04340232
55	NCT04306497	Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-19.	CTOROTSADTOC	Recruiting	No Results Available	COVID-19	Drug: TCM prescriptions	The relief / disappearance rate of main symptoms|Chest CT absorption|Virus antigen negative conversion rate|Clinical effective time: the average effective time|The number of severe and critical conversion cases|Incidence of complications|Traditional Chinese Medicine Syndrome Score	Jiangsu Famous Medical Technology Co., Ltd.	All	18 Years to 75 Years   (Adult, Older Adult)		340	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	JSZYJ202001	March 2, 2020	May 2020	May 2020	March 13, 2020		March 17, 2020	Huai'an fourth people's Hospital, Huaian, Jiangsu, China		https://ClinicalTrials.gov/show/NCT04306497
56	NCT04329832	Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19	HAHPS	Recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine|Drug: Azithromycin	COVID Ordinal Outcomes Scale at 14 days|Hospital-free days at 28 days (number of days patient not in hospital)|Ventilator-free days at 28 days (number of days patient not on a ventilator)|ICU-free days at 28 days (number of days patient not in an ICU)|Time to a 1-point decrease in the WHO ordinal recovery score	Intermountain Health Care, Inc.|University of Utah	All	18 Years and older   (Adult, Older Adult)	Phase 2	300	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1051355	March 30, 2020	December 31, 2020	December 31, 2021	April 1, 2020		April 9, 2020	Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States		https://ClinicalTrials.gov/show/NCT04329832
57	NCT04317092	Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)	TOCIVID-19	Recruiting	No Results Available	COVID-19 Pneumonia	Drug: Tocilizumab Injection	One-month mortality rate|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms	National Cancer Institute, Naples	All	Child, Adult, Older Adult	Phase 2	400	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TOCIVID-19|2020-001110-38	March 19, 2020	December 19, 2020	December 19, 2022	March 20, 2020		April 7, 2020	Azienda Ospedaliera "SS. Antonio e Biagio e C. Arrigo" (Dipartimento Internistico SSD Reumatologia), Alessandria, Italy|Ospedale di Busto Arsizio ASST Valle Olona (U.O.C. Malattie Infettive), Busto Arsizio, Italy|A.O.U. Policlinico V. Emanuele (U.O. di Malattie infettive, U.O. di Anestesia e Rianimazione, U.O. di Medicina d'Urgenza), Catania, Italy|AOE Cannizzaro di Catania (U.O. di Malattie Infettive, U.O. di Anestesia e Rianimazione, U.O., Catania, Italy|Ospedale Annunziata Azienda Ospedaliera di Cosenza (U.O.C. Malattie Infettive), Cosenza, Italy|ASST OVEST MILANESE presidi Legnano - Magenta, Magenta, Italy|Azienda Ospedaliero-Universitaria di Modena, Modena, Italy|A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialità Chirurgiche - Struttura Complessa di Anestesia e Rianimazione I), Modena, Italy|A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialità Chirurgiche - Struttura Complessa di Anestesia e Rianimazione II), Modena, Italy|A.O.U. di Modena (Dipartimento Medicine Specialistiche - Struttura Complessa Malattie Infettive), Modena, Italy|Dipartimento Medicine Specialistiche - Struttura Complessa Malattie dell'Apparato Respiratorio, Modena, Italy|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Oncologia), Naples, Italy|National Cancer Institute, Naples, Italy|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Anestesia Rianimazione e terapia intensiva), Naples, Italy|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Malattie Infettive ad indirizzo respiratorio), Naples, Italy|A.O. Ospedali Riuniti Marche Nord - Presidio Ospedaliero San Salvatore di Pesaro (UOC Pronto Soccorso e Medicina d'Urgenza), Pesaro, Italy|Denominazione: UOC di Medicina e Chirurgia d'Accettazione e d'Urgenza dell'Ospedale Santa Maria delle Grazie di Pozzuoli, Pozzuoli, Italy|Ospedale Santa Maria delle Croci, AUSL della Romagna (U.O. Anestesia e Rianimazione), Ravenna, Italy|Grande Ospedale Metropolitano, Reggio Calabria, Reggio Calabria, Italy|Ospedale Infermi, AUSL della Romagna (U.O. Malattie Infettive), Rimini, Italy|Policlinico Gemelli (U.O.C. Dipartimento Scienze di Laboratorio e Infettivologiche), Rome, Italy|ASST Sette Laghi (Dipartimento di Medicina Interna), Varese, Italy|ASST Sette Laghi (Dipartimento Emergenze ed Urgenze), Varese, Italy|ASST Sette Laghi (U.O.C. Anestesia e Rianimazione Neurochirurgica e Generale), Varese, Italy|ASST Sette Laghi (U.O.C. Malattie Infettive e Tropicali), Varese, Italy|A.O.U. Integrata di Verona (Dip. Malattie Infettive), Verona, Italy|Ospedale Magalini (U.O. Malattie Infettive), Villafranca Di Verona, Italy		https://ClinicalTrials.gov/show/NCT04317092
58	NCT04324996	A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19		Recruiting	No Results Available	COVID-19	Biological: NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells	Clinical response|Side effects in the treatment group	Chongqing Public Health Medical Center|Chongqing Sidemu Biotechnology Technology Co.,Ltd.	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	90	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	ChongqingPublicHMC	March 21, 2020	May 31, 2020	September 30, 2020	March 27, 2020		March 27, 2020	Chongqing Public Health Medical Center, Chongqing, China		https://ClinicalTrials.gov/show/NCT04324996
59	NCT04343768	An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial	DIC	Not yet recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir|Drug: Interferon Beta-1A|Drug: Interferon Beta-1B	Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse events	Shahid Beheshti University of Medical Sciences	All	18 Years and older   (Adult, Older Adult)	Phase 4	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Different Interferons in COVID	April 10, 2020	April 20, 2020	April 24, 2020	April 13, 2020		April 13, 2020			https://ClinicalTrials.gov/show/NCT04343768
60	NCT04333355	Safety in Convalescent Plasma Transfusion to COVID-19		Not yet recruiting	No Results Available	COVID-19	Biological: Convalescent Plasma	Side effects|Heart Failure|Pulmonary Edema|Allergic Reaction|Lung infiltrates|Viral load of SARS-CoV-2	Hospital San Jose Tec de Monterrey|Tecnologico de Monterrey	All	18 Years and older   (Adult, Older Adult)	Phase 1	20	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PC-TecSalud Fase I	April 15, 2020	December 20, 2020	April 30, 2021	April 3, 2020		April 3, 2020	Hospital San José, Monterrey, Nuevo Leon, Mexico		https://ClinicalTrials.gov/show/NCT04333355
61	NCT04330586	A Trial of Ciclesonide in Adults With Mild COVID-19		Not yet recruiting	No Results Available	COVID-19	Drug: Ciclesonide Metered Dose Inhaler [Alvesco]|Drug: Hydroxychloroquine	Rate of SARS-CoV-2 eradication at day 14 from study enrollment|Rate of SARS-CoV-2 eradication at day 7 from study enrollment|Time to SARS-CoV-2 eradication (days)|Viral load area-under-the-curve (AUC) reduction versus control|Time to clinical improvement (days)|Proportion of clinical failure	Korea University Guro Hospital	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 2	141	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	KUMC-COVID-19	April 1, 2020	June 30, 2020	September 30, 2020	April 1, 2020		April 1, 2020			https://ClinicalTrials.gov/show/NCT04330586
62	NCT04331171	Epidemiological Observation From a Smartphone Self-monitoring Application for Suspected COVID-19 Patients' Triage	COVID CALL 15	Recruiting	No Results Available	COVID-19	Device: Web application users	To assess of the evolution of the number of calls to Emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/|To assess of the evolution of the proportion of relevant calls to Emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/|To assess the evolution over time of the COVID 19 epidemic|To assess the evolution over space of the COVID 19 epidemic|To assess symptoms|To assess the users population	Weprom|Institut Pasteur|Assistance Publique - Hôpitaux de Paris|DOCAPOST|Direction Générale de l'Offre de Soins	All	18 Years and older   (Adult, Older Adult)		3000000	Other|Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	WP-2020-02	March 17, 2020	March 31, 2020	July 31, 2020	April 2, 2020		April 6, 2020	All French Emergency services, Le Mans, France		https://ClinicalTrials.gov/show/NCT04331171
63	NCT04328012	COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2	COVIDMED	Recruiting	No Results Available	SARS-CoV-2 Infection	Drug: lopinavir/ritonavir|Drug: Hydroxychloroquine Sulfate|Drug: Losartan|Drug: Placebos	National Institute of Allergy and Infectious Diseases COVID-19 Ordinal Severity Scale (NCOSS)|Hospital length of stay (LOS)|Intensive care unit level LOS|Mechanical ventilation|survival	Bassett Healthcare	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	4000	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	1581969	April 6, 2020	January 1, 2021	April 1, 2021	March 31, 2020		April 8, 2020	Bassett Medical Center, Cooperstown, New York, United States		https://ClinicalTrials.gov/show/NCT04328012
64	NCT04328285	Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers	COVIDAXIS	Not yet recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine|Drug: Placebo of Hydroxychloroquine|Drug: Lopinavir and ritonavir|Drug: Placebo of LPV/r Tablets	Occurrence of an symptomatic or asymptomatic SARS-CoV-2 infection among healthcare workers (HCWs)|Evaluation of the occurrence of adverse events in each arm,|Evaluation of the discontinuation rates of the investigational drug in each arm,|Evaluation of the adherence of participants to study drug,|Evaluation of the incidence of symptomatic cases of SARS-CoV-2 infection in each arm,|Evaluation of the incidence of asymptomatic cases of SARS-CoV-2 infection in each arm|Evaluation of the incidence of severe cases of SARS-CoV-2 infection in each arm.|corrected QT interval (ms)	Centre Hospitalier Universitaire de Saint Etienne|Institut Pasteur	All	18 Years and older   (Adult, Older Adult)	Phase 3	1200	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	20PH061|2020-001188-96	April 11, 2020	November 30, 2020	November 30, 2020	March 31, 2020		April 10, 2020	CHU d'Angers, Angers, France|AP-HP - Hôpital Bichat, Paris, France|CHU de Saint-Etienne, Saint-Étienne, France		https://ClinicalTrials.gov/show/NCT04328285
65	NCT04315298	Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19		Recruiting	No Results Available	COVID-19	Drug: Sarilumab|Drug: Placebo	Percent change in C-reactive protein (CRP) levels|Time to improvement (2 points) in clinical status assessment using the 7-point ordinal scale in patients with serum IL-6 levels greater than the upper limit of normal|Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale in severe or critical patients with serum IL-6 levels greater than the upper limit of normal|Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale reporting in severe or critical patients with all IL-6 levels|Time to resolution of fever for at least 48 hours without antipyretics in patients with documented fever|Time to resolution of fever for at least 48 hours without antipyretics by clinical severity|Time to resolution of fever for at least 48 hours without antipyretics by baseline IL-6 levels|Time to improvement in oxygenation for at least 48 hours|Time to improvement in oxygenation for at least 48 hours by clinical severity|Time to improvement in oxygenation for at least 48 hours by baseline IL-6 levels|Time to resolution of fever and improvement in oxygenation for at least 48 hours|Mean change in the 7-point ordinal scale|Percentage of patients in each clinical status category using the 7-point ordinal scale|Time to discharge or to a National Early Warning Score 2 (NEWS2) of ≤2 and maintained for 24 hours|Change from baseline in NEWS2 scoring system|Number of days with fever|Proportion of patients alive, off oxygen|Number of days of resting respiratory rate >24 breaths/min|Number of days with hypoxemia|Number of days of supplemental oxygen use|Time to saturation ≥94% on room air|Number of ventilator free days in the first 28 days|Number of patients requiring initiation of mechanical ventilation|Number of patients requiring non-invasive ventilation|Number of patients requiring the use of high flow nasal cannula|Number of patients admitted into an intensive care unit (ICU)|Number of days of hospitalization among survivors|Number of deaths due to any cause|Change in serum CRP levels|Incidence of serious adverse events|Incidence of Grade 4 neutropenia (ANC <500/mm3)|Incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infection|Incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infection in patients with Grade 4 neutropenia|Incidence of hypersensitivity reactions|Incidence of infusion reactions|Incidence of gastrointestinal perforation|White blood cell count|Hemoglobin levels|Platelet count|Creatinine levels|Total bilirubin level|Alanine aminotransferase (ALT) level|Aspartate aminotransferase (AST) level	Regeneron Pharmaceuticals|Sanofi	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	400	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	6R88-COV-2040	March 18, 2020	March 9, 2021	April 1, 2021	March 19, 2020		April 6, 2020	Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, Santa Monica, California, United States|Regeneron Study Site, Aurora, Colorado, United States|Regeneron Study Site, Denver, Colorado, United States|Regeneron Study Site, New Haven, Connecticut, United States|Regeneron Study Site, Washington, District of Columbia, United States|Regeneron Study Site, Coral Gables, Florida, United States|Regeneron Study Site, Gainesville, Florida, United States|Regeneron Study Site, Orlando, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Decatur, Georgia, United States|Regeneron Study Site, Marietta, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Ann Arbor, Michigan, United States|Regeneron Study Site, Detroit, Michigan, United States|Regeneron Study Site, Rochester, Minnesota, United States|Regeneron Study Site, Edison, New Jersey, United States|Regeneron Study Site, Hackensack, New Jersey, United States|Regeneron Study Site, Livingston, New Jersey, United States|Regeneron Study Site, Morristown, New Jersey, United States|Regeneron Study Site, Neptune, New Jersey, United States|Regeneron Study Site, Newark, New Jersey, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site 1, Bronx, New York, United States|Regeneron Study Site 2, Bronx, New York, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Brooklyn, New York, United States|Regeneron Study Site, Elmhurst, New York, United States|Regeneron Study Facility 2, Manhasset, New York, United States|Regeneron Study Site 1, Manhasset, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site 1, New York, New York, United States|Regeneron Study Site 2, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Stony Brook, New York, United States|Regeneron Study Site, Valhalla, New York, United States|Regeneron Study Site, Tulsa, Oklahoma, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Danville, Pennsylvania, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Scranton, Pennsylvania, United States|Regeneron Study Site, Wilkes-Barre, Pennsylvania, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Murray, Utah, United States|Regeneron Study Site, Falls Church, Virginia, United States|Regeneron Study Site, Everett, Washington, United States|Regeneron Study Site, Renton, Washington, United States		https://ClinicalTrials.gov/show/NCT04315298
66	NCT04275947	The COVID-19 Mobile Health Study (CMHS)	CMHS	Recruiting	No Results Available	COVID-19	Other: nCapp, a cell phone-based auto-diagnosis system	Accuracy of nCapp COVID-19 risk diagnostic model	Chinese Alliance Against Lung Cancer|Shanghai Respiratory Research Institution	All	18 Years to 90 Years   (Adult, Older Adult)		450	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	CAALC-008-CMHS	February 14, 2020	April 30, 2020	May 31, 2020	February 19, 2020		February 19, 2020	Renmin Hospital of Wuhan University, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04275947
67	NCT04299724	Safety and Immunity of Covid-19 aAPC Vaccine		Recruiting	No Results Available	Treat and Prevent Covid-19 Infection	Biological: Pathogen-specific aAPC	Frequency of vaccine events|Frequency of serious vaccine events|Proportion of subjects with positive T cell response|28-day mortality|Duration of mechanical ventilation if applicable|Proportion of patients in each category of the 7-point scale|Proportion of patients with normalized inflammation factors|Clinical improvement based on the 7-point scale if applicable|Lower Murray lung injury score if applicable	Shenzhen Geno-Immune Medical Institute|Shenzhen Third People's Hospital|Shenzhen Second People's Hospital	All	6 Months to 80 Years   (Child, Adult, Older Adult)	Phase 1	100	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GIMI-IRB-20002	February 15, 2020	July 31, 2023	December 31, 2024	March 9, 2020		March 9, 2020	Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China		https://ClinicalTrials.gov/show/NCT04299724
68	NCT04330638	Treatment of COVID-19 Patients With Anti-interleukin Drugs	COV-AID	Recruiting	No Results Available	COVID-19	Other: Usual Care|Drug: Anakinra|Drug: Siltuximab|Drug: Tocilizumab	Time to Clinical Improvement|Time to improvement in oxygenation|Mean change in oxygenation|Number of days with hypoxia|Number of days of supplemental oxygen use|Time to absence fever for more than 48h without antipyretics|Number of days with fever|Time to halving of CRP levels compared to peak value during trial|Time to halving of ferritin levels compared to peak value during trial|Incidence of AEs (Adverse Events)|Incidence of SAEs (Serious Adverse Events)|Duration of hospital stay|Duration of hospital stay in survivors|Mean change in clinical sign score between day 1 and day 7|Mean change in clinical sign score between day 1 and day 15|Time to clinical sign score <6 maintained for 24h|Mean change of SOFA score (Sequential Organ Failure Assessment) between day 1 and day 7|Mean change of SOFA score between day 1 and day 15|Mean change NEWS2 (National Early Warning) score between day 1 and day 7|Mean change NEWS2 score between day 1 and day 15|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-1|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-6|Incidence of nosocomial bacterial or invasive fungal infection|incidence of secondary haemophagocytic lymphohistiocytosis|Incidence of secondary haemophagocytic lymphohistiocytosisscore in relation to serum IL-1|Incidence of secondary haemophagocytic lymphohistiocytosis in relation to serum IL-6|Time to first use of high-flow oxygen devices, non-invasive or invasive mechanical ventilation in non-ventilated patients|Time to first use of salvage systemic steroids in ventilated patients|Number of ventilator free days|Duration of mechanical ventilation in ventilated patients|Duration of ICU stay in patients that enrolled in trial while already on invasive or non-invasive mechanical ventilation|Time to progression to ARDS in ventilated patients|Time to progression to ARDS in ventilated patients according to IL-1|Time to progression to ARDS in ventilated patients according to IL-6|All-cause mortality rate (excluding group that entered during ventilation)|Percentage of patients in clinical status on 6-point Ordinal Scale|Incidence of lung function abnormalities|Incidence of lung fibrosis on chest CT scan|All-cause mortality rate	University Hospital, Ghent|Belgium Health Care Knowledge Centre	All	18 Years and older   (Adult, Older Adult)	Phase 3	342	Other	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	COV-AID	April 2020	September 2020	December 2020	April 1, 2020		April 8, 2020	AZ Sint-Jan Brugge, Brugge, Belgium|University Hospital Saint-Pierre, Brussels, Belgium|Erasmus University Hospital, Brussels, Belgium|University Hospital Saint-Luc, Brussels, Belgium|University Hospital Antwerp, Edegem, Belgium|Ziekenhuis Oost-Limurg, Genk, Belgium|University Hospital Ghent, Gent, Belgium|University Hospital Brussels, Jette, Belgium|University Hospital Liège, Liège, Belgium		https://ClinicalTrials.gov/show/NCT04330638
69	NCT04337996	Dynamic Evaluation of COVID-19 Diagnostic Tests	TRODVID-19	Not yet recruiting	No Results Available	COVID-19	Diagnostic Test: COVID-19 diagnostic test	Positive or negative character of the three tests|sensitivity and specificity of the tests according to the time elapsed since the first symptoms	Tourcoing Hospital	All	18 Years and older   (Adult, Older Adult)	Not Applicable	176	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	RIPH_2020_6	April 2020	July 2020	October 2020	April 8, 2020		April 8, 2020			https://ClinicalTrials.gov/show/NCT04337996
70	NCT04331899	Mild COVID-19 Peginterferon Lambda	COVID-Lambda	Not yet recruiting	No Results Available	COVID-19	Drug: Peginterferon Lambda-1a|Other: Standard of Care Treatment	Duration of Viral shedding of SARS-CoV-2 by qRT-PCR	Stanford University	All	18 Years to 64 Years   (Adult)	Phase 2	120	Other	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	55619	April 15, 2020	May 31, 2021	May 31, 2022	April 2, 2020		April 2, 2020			https://ClinicalTrials.gov/show/NCT04331899
71	NCT04343677	Military COVID-19 Hydroxychloroquine Pre-exposure and Post-exposure Prophylaxis Study		Not yet recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine|Dietary Supplement: Placebo	Incidence|Severity of Disease	United States Department of Defense	All	18 Years and older   (Adult, Older Adult)	Phase 2	1450	U.S. Fed	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention	Pentagon 20-1	April 2020	June 2020	August 2020	April 13, 2020		April 13, 2020	Pentagon, Arlington, Virginia, United States		https://ClinicalTrials.gov/show/NCT04343677
72	NCT04343690	COPING With COVID-19( CWC-19)		Not yet recruiting	No Results Available	COVID-19	Behavioral: Crisis management coaching	Change in stress level as measured by survey|Change wellness as measured by survey	Duke University	All	18 Years and older   (Adult, Older Adult)	Not Applicable	100	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	Pro00105319	April 13, 2020	June 30, 2020	June 30, 2020	April 13, 2020		April 13, 2020	Duke University, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT04343690
73	NCT04337762	Beat COVID-19 - Observational Trial	JUPITER	Recruiting	No Results Available	COVID-19		Health Outcomes	Beat COVID LLC	All	18 Years to 110 Years   (Adult, Older Adult)		100000	Industry	Observational	Observational Model: Case-Control|Time Perspective: Prospective	20200835	April 6, 2020	December 2020	July 2021	April 8, 2020		April 9, 2020	Beat COIVD, LLC, Chicago, Illinois, United States		https://ClinicalTrials.gov/show/NCT04337762
74	NCT04313322	Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells		Recruiting	No Results Available	Use of Stem Cells for COVID-19 Treatment	Biological: WJ-MSCs	Clinical outcome|CT Scan|RT-PCR results	Stem Cells Arabia	All	18 Years and older   (Adult, Older Adult)	Phase 1	5	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	COVID-19	March 16, 2020	June 30, 2020	September 30, 2020	March 18, 2020		March 18, 2020	Stem Cells Arabia, Amman, Jordan		https://ClinicalTrials.gov/show/NCT04313322
75	NCT04304313	A Pilot Study of Sildenafil in COVID-19		Recruiting	No Results Available	COVID-19	Drug: Sildenafil citrate tablets	Rate of disease remission|Rate of entering the critical stage|Time of entering the critical stage|Rate of no fever|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of C-reactive protein (CRP) recovery|Rate of Biochemical criterion (CK, ALT, Mb) recovery|Rate of undetectable viral RNA (continuous twice)|Time for hospitalization|Rate of adverse event	Tongji Hospital	All	18 Years and older   (Adult, Older Adult)	Phase 3	10	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GST-G1	February 9, 2020	March 1, 2020	November 9, 2020	March 11, 2020		March 17, 2020	Department and Institute of Infectious Disease, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04304313
76	NCT04326920	Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC)	SARPAC	Recruiting	No Results Available	COVID-19	Drug: Sargramostim|Other: Control	Improvement in oxygenation at a dose of 250 mcg daily during 5 days improves oxygenation in COVID-19 patients with acute hypoxic respiratory failure|Incidence of AE (Adverse Event)|Incidence of SAEs (Serious Adverse Event)|Clinical Status using 6-point ordinal scale|Clinical Status using Clincal sign score|Clinical Status using SOFA score (Sequential Organ Failure Assessment score),|Clinical Status using NEWS2 score (National Early Warning Score)|incidence of severe or life-threatening bacterial, invasive fungal or opportunistic infection|number of patients requiring initiation of mechanical ventilation|Number of deaths due to any cause at 4 weeks|Number of deaths due to any cause at 20 weeks|number of patients developing features of secondary haemophagocytic lymphohistiocytosis|long term Clinical status defined by 6-point ordinal scale|long term Clinical status defined by chest X-ray|long term Clinical status defined lung function	University Hospital, Ghent|Flanders Institute of Biotechnology	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 4	80	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SARPAC	March 24, 2020	October 31, 2020	December 31, 2020	March 30, 2020		April 2, 2020	AZ Sint Jan Brugge, Brugge, Belgium|University Hospital Ghent, Gent, Belgium		https://ClinicalTrials.gov/show/NCT04326920
77	NCT04332081	Hyperbaric Oxygen for COVID-19 Patients		Recruiting	No Results Available	COVID-19	Device: hyperbaric oxygen therapy (HBOT)	Mortality|Days on invasive mechanical ventilation	NYU Langone Health	All	18 Years and older   (Adult, Older Adult)	Not Applicable	40	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	s20-00399	April 6, 2020	July 2020	July 2020	April 2, 2020		April 9, 2020	NYU Winthrop Hospital, Mineola, New York, United States		https://ClinicalTrials.gov/show/NCT04332081
78	NCT04337541	Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System		Recruiting	No Results Available	COVID-19	Other: Surgical facial mask	Reduction in COVID-19 infection frequency|Antibody-screening	Rigshospitalet, Denmark|Nordsjaellands Hospital|Hvidovre University Hospital|Herlev Hospital|Technical University of Denmark	All	18 Years and older   (Adult, Older Adult)	Not Applicable	6000	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	02/04/2020	April 2, 2020	July 1, 2020	July 1, 2020	April 7, 2020		April 7, 2020	Rigshospitalet, Copenhagen, Denmark		https://ClinicalTrials.gov/show/NCT04337541
79	NCT04338347	CAP-1002 in Severe COVID-19 Disease		Available	No Results Available	COVID-19	Biological: CAP-1002 Allogeneic Cardiosphere-Derived Cells		Capricor Inc.	All	18 Years and older   (Adult, Older Adult)			Industry	Expanded Access:Intermediate-size Population|Treatment IND/Protocol		CAP-1002-COVID-19				April 8, 2020		April 8, 2020	Cedars-Sinai Medical Center, Los Angeles, California, United States		https://ClinicalTrials.gov/show/NCT04338347
80	NCT04340544	Hydroxychloroquine for the Treatment of Mild COVID-19 Disease	COMIHY	Not yet recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine|Drug: Placebo	Difference in time to resolution of clinical signs and symptoms of mild COVID-19 treated with hydroxychloroquine or placebo as assessed by daily self-assessment|Difference between hydroxychloroquine- and placebotreated patients on an ordinal outcome scale until Day 28 (death, admission to intensive care, hospitalization, continuing disease, recovered)|All-cause mortality within 28 days	University Hospital Tuebingen|Robert Bosch Medical Center|Universitätsklinikum Hamburg-Eppendorf|Bernhard Nocht Institute for Tropical Medicine	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 3	2700	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	COMIHY	April 10, 2020	November 30, 2021	September 30, 2022	April 9, 2020		April 9, 2020	Institute for Tropical Medicine, Tübingen, Germany		https://ClinicalTrials.gov/show/NCT04340544
81	NCT04338958	Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation	RuxCoFlam	Not yet recruiting	No Results Available	Covid-19	Drug: Ruxolitinib 10 MG	overall response rate in reversal of hyperinflammation|efficacy of ruxolitinib + standard-of-care (SoC)	Prof. Dr. med. Andreas Hochhaus|University of Jena	All	18 Years and older   (Adult, Older Adult)	Phase 2	200	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RuxCoFlam	May 1, 2020	January 31, 2021	August 31, 2021	April 8, 2020		April 8, 2020	University Hospital Jena, Jena, Germany		https://ClinicalTrials.gov/show/NCT04338958
82	NCT04334512	A Study of Quintuple Therapy to Treat COVID-19 Infection	HAZDpaC	Not yet recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine|Drug: Azithromycin|Dietary Supplement: vitamin C|Dietary Supplement: Vitamin D|Dietary Supplement: Zinc	Successful treatment as determined by Negative Test and resolution of symptoms|Safety of Quintuple Therapy	ProgenaBiome	All	18 Years and older   (Adult, Older Adult)	Phase 2	600	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PRG-044	April 2020	April 2021	July 2021	April 6, 2020		April 13, 2020	ProgenaBiome, Ventura, California, United States		https://ClinicalTrials.gov/show/NCT04334512
83	NCT04327674	The Use of Focused Lung Ultrasound in Patients Suspected of COVID-19		Recruiting	No Results Available	COVID-19		FLUS findings and respiratory failure|FLUS findings and chest x-ray.|FLUS findings and admission to intensive care.|FLUS findings and SAR-CoV-2 PCR-test result.	University of Aarhus	All	18 Years and older   (Adult, Older Adult)		375	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	COVID-FLUS	March 14, 2020	May 15, 2020	May 15, 2020	March 31, 2020		March 31, 2020	Lungemedicinsk Forskningsafdeling. Aarhus University Hospital, Aarhus, Denmark|Regionshospitalet Horsens., Horsens, Denmark		https://ClinicalTrials.gov/show/NCT04327674
84	NCT04341675	Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia	SCOPE	Not yet recruiting	No Results Available	COVID-19	Drug: Sirolimus|Drug: Placebo	Progression to advanced respiratory support	University of Cincinnati	All	18 Years and older   (Adult, Older Adult)	Phase 2	30	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	2020-0337	April 2020	July 2020	September 2020	April 10, 2020		April 10, 2020			https://ClinicalTrials.gov/show/NCT04341675
85	NCT04308317	Tetrandrine Tablets Used in the Treatment of COVID-19	TT-NPC	Enrolling by invitation	No Results Available	Corona Virus Disease 2019,COVID-19	Drug: Tetrandrine	Survival rate|body temperature	Henan Provincial People's Hospital	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 4	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TT-NPC	March 5, 2020	March 1, 2021	May 1, 2021	March 16, 2020		March 16, 2020	Tetrandrine Tablets, Jinhua, Zhejiang, China		https://ClinicalTrials.gov/show/NCT04308317
86	NCT04329923	The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)	PATCH	Recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine Sulfate 400 mg twice a day|Drug: Hydroxychloroquine Sulfate 600 mg twice a day|Drug: Hydroxychloroquine Sulfate 600 mg once a day|Drug: Placebo oral tablet	Median release from quarantine time|Rate of hospital discharge|Rate of infection|Rate of housemate infection|Rate of hospitalization|Cohort 1 adverse event rate|Time to condition appropriate for discharge|Rate of ICU admission|Time to PCR negativity|Cohort 2 adverse events|Scheduled shifts missed|Cohort 3 adverse events	Ravi Amaravadi, MD|University of Pennsylvania	All	18 Years and older   (Adult, Older Adult)	Phase 2	400	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	842838	April 9, 2020	April 1, 2021	December 1, 2021	April 1, 2020		April 13, 2020	University of Pennsylvania, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT04329923
87	NCT04330690	Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial	CATCO	Recruiting	No Results Available	COVID-19	Drug: Lopinavir/ritonavir	Efficacy of Intervention|Time to improvement of one catergory from admission|Subject clinical status|Change in Subject clinical status|Oxygen free days|Incidence of oxygen use|Duration of oxygen use|Incidence of new mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Mortality|Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs)	Sunnybrook Health Sciences Centre|AbbVie	All	6 Months and older   (Child, Adult, Older Adult)	Phase 2	440	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2114	March 18, 2020	March 18, 2022	May 18, 2022	April 1, 2020		April 13, 2020	Vancouver General Hospital, Vancouver Coastal Health, Univeristy of British Columbia, Vancouver, British Columbia, Canada|St Paul's Hospital, Vancouver, British Columbia, Canada|The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada|The Ottawa Hospital - Civic Campus, Ottawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|McGill University Health Centre-Glen Site Royal Victoria Hospital, Montréal, Quebec, Canada|Centre Intégré Universitaire de Santé et de Services Sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada		https://ClinicalTrials.gov/show/NCT04330690
88	NCT04318418	ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19	CODIV-ACE	Not yet recruiting	No Results Available	COVID-19		Severe COVID-19|Death	Neuromed IRCCS	All	Child, Adult, Older Adult		5000	Other	Observational	Observational Model: Case-Control|Time Perspective: Retrospective	DEP_012020	March 23, 2020	April 10, 2020	April 30, 2020	March 24, 2020		March 24, 2020	IRCCS Neuromed, Department of Epidemiology and Prevention, Pozzilli, Italy		https://ClinicalTrials.gov/show/NCT04318418
89	NCT04285801	Critically Ill Patients With COVID-19 in Hong Kong: a Multicentre Observational Cohort Study		Completed	No Results Available	COVID-19		28 day mortality|vasopressor days|days on mechanical ventilation|sequential organ function assessment score|ECMO use|percentage nitric oxide use|percentage free from oxygen supplement	Chinese University of Hong Kong	All	18 Years and older   (Adult, Older Adult)		8	Other	Observational	Observational Model: Case-Only|Time Perspective: Retrospective	2020.059	February 14, 2020	February 25, 2020	February 25, 2020	February 26, 2020		March 10, 2020	Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong		https://ClinicalTrials.gov/show/NCT04285801
90	NCT04333628	Chloroquine for Mild Symptomatic and Asymptomatic COVID-19		Not yet recruiting	No Results Available	COVID-19	Drug: chloroquine|Other: standard care	change in virus duration (viral shedding)|change in the number of patients going from asymptomatic to moderately disease	HaEmek Medical Center, Israel	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	210	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EMC 0045-20	April 2020	April 2021	December 2021	April 3, 2020		April 7, 2020			https://ClinicalTrials.gov/show/NCT04333628
91	NCT04304053	Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention	HCQ4COV19	Recruiting	No Results Available	COVID-19	Drug: Antiviral treatment and prophylaxis|Other: Standard Public Health measures	Effectiveness of chemoprophylaxis assessed by incidence of secondary COVID-19 cases|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3|The mortality rate of subjects at weeks 2|Proportion of participants that drop out of study|Proportion of participants that show non-compliance with study drug	Fundacio Lluita Contra la SIDA|Germans Trias i Pujol Hospital|Department of Health, Generalitat de Catalunya|FUNDACIÓN FLS DE LUCHA CONTRA EL SIDA, LAS ENFERMEDADES INFECCIOSAS Y LA PROMOCIÓN DE LA SALUD Y LA CIENCIA|Laboratorios Gebro Pharma SA|Laboratorios Rubió|Institut Catala de Salut	All	18 Years and older   (Adult, Older Adult)	Phase 3	3040	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	HCQ4COV19|2020-001031-27	March 18, 2020	June 15, 2020	June 15, 2020	March 11, 2020		April 8, 2020	Departament de Salut, Barcelona, Spain		https://ClinicalTrials.gov/show/NCT04304053
92	NCT04319315	Social Media Effect on Knowledge Dissemination During COVID-19 Virus Outbreak		Recruiting	No Results Available	COVID-19	Other: survey	Number of physicians affected by social media measured by online survey designed to measure the influence of social media on medical practice	Assiut University	All	25 Years to 65 Years   (Adult, Older Adult)		400	Other	Observational	Observational Model: Other|Time Perspective: Prospective	AssiutU-3-2020	March 11, 2020	April 1, 2020	April 16, 2020	March 24, 2020		April 7, 2020	Assiut University Hospitals, Assiut, Egypt		https://ClinicalTrials.gov/show/NCT04319315
93	NCT04339426	Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection		Not yet recruiting	No Results Available	Covid19	Drug: Atovaquone/Azithromycin	Virology Cure Rate|Incidence of GI adverse events|Cardiac Toxicity	HonorHealth Research Institute	All	18 Years to 95 Years   (Adult, Older Adult)	Not Applicable	25	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HRI-COVID-19-Anti-Malarial-001	April 2020	October 2020	April 2021	April 9, 2020		April 13, 2020			https://ClinicalTrials.gov/show/NCT04339426
94	NCT04334382	Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19	HyAzOUT	Recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine|Drug: Azithromycin	Hospitalization within 14 days of enrollment|Duration of COVID-19-attributable symptoms|Hospital-free days at 28 days|Ventilator-free days at 28 days|ICU-free days at 28 days	Intermountain Health Care, Inc.|University of Utah|Utah Department of Health	All	45 Years and older   (Adult, Older Adult)	Phase 3	1550	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1051360	April 2, 2020	December 31, 2020	December 31, 2021	April 6, 2020		April 9, 2020	Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States		https://ClinicalTrials.gov/show/NCT04334382
95	NCT04342182	Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study)	ConCoVid-19	Recruiting	No Results Available	COVID-19	Biological: Convalescent plasma	Overall mortality until discharge from the hospital or a maximum of 60 days after admission whichever comes first|Impact of 250ml convP therapy on hospital days|Impact of 250ml convP on weaning from oxygen therapy|Impact of 250ml convP on overall mortality in patients admitted to the ICU within 24 hours after admission|Difference in the effect of convP on mortality in patients with a duration of symptoms less or more the median duration of symptoms in the study population|Impact of 250ml convP therapy on ICU days in patients admitted to the ICU within 24 hours after admission|Impact of plasma therapy on the decrease in SARS-CoV2 shedding from airways	Erasmus Medical Center|Maasstad Hospital	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	426	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	NL73489.078.20	April 1, 2020	July 1, 2020	July 1, 2020	April 10, 2020		April 13, 2020	Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands|Maasstad Ziekenhuis, Rotterdam, Netherlands		https://ClinicalTrials.gov/show/NCT04342182
96	NCT04343001	Coronavirus Response - Active Support for Hospitalised Covid-19 Patients	CRASH-19	Not yet recruiting	No Results Available	Covid-19	Drug: Aspirin|Drug: Losartan|Drug: Simvastatin	Death|Myocardial infarction|Congestive cardiac failure|Severe cardiac arrythmia|Myocarditis|Respiratory failure including ARDS|Viral pneumonitis|Acute renal failure|Sepsis|Stroke|Gastrointestinal bleeding|Receipt of non invasive or mechanical ventilation|Ability to self care at hospital discharge	London School of Hygiene and Tropical Medicine	All	50 Years and older   (Adult, Older Adult)	Phase 3	10000	Other	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-KEP-420	April 2020	April 2021	August 2021	April 13, 2020		April 13, 2020	University College Hospital, Ibadan, Oyo, Nigeria|Shifa Tameer-e-Millat University, Rawalpindi, Pakistan		https://ClinicalTrials.gov/show/NCT04343001
97	NCT04335136	Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19	APN01-COVID-19	Not yet recruiting	No Results Available	COVID-19	Drug: RhACE2 APN01|Drug: Physiological saline solution	Cause of death or invasive mechanical ventilation|LDH level|Mortality|VFD|Time to death	Apeiron Biologics	All	35 Years to 80 Years   (Adult, Older Adult)	Phase 2	200	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	APN01-01-COVID19	April 2020	September 2020	November 2020	April 6, 2020		April 6, 2020	Medizinische Universität Innsbruck, Innsbruck, Austria|Kaiser Franz Josef Spital, 4. Medizinische Abteilung mit Infektions- und Tropenmedizin, Wien, Austria|Medizinische Universität Wien, Wien, Austria|The National University Hospital, Rigshospitalet, Copenhagen, Denmark|Herlev Gentofte Hospital, Herlev, Denmark|Nordsjællands Hospital, Hillerød, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Klinikum rechts der Isar, Technische Universität München, München, Germany		https://ClinicalTrials.gov/show/NCT04335136
98	NCT04331366	Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19	GO2 PEEP	Not yet recruiting	No Results Available	COVID-19	Device: GO2 PEEP MOUTHPIECE	Change in Oxygen Saturation by Pulse Oximetry|Change in Respiratory Rate|Change in Heart Rate|Change in Blood Pressure|Change in Subjective Work of Breathing|Change in Partial Pressure of Oxygen (PaO2)|Change in Partial Pressure of Carbon Dioxide (PaCO2)|Change in pH|Change in Bicarbonate (HCO3)|Change in Oxygen Saturation (O2Sat) by Arterial Blood Gas Test	Emory University	All	18 Years and older   (Adult, Older Adult)	Not Applicable	5	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	STUDY00000381	April 2020	April 2020	April 2020	April 2, 2020		April 2, 2020	Emory University Hospital, Atlanta, Georgia, United States|Emory St. Joseph's Hospital, Atlanta, Georgia, United States		https://ClinicalTrials.gov/show/NCT04331366
99	NCT04331795	Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis	COVIDOSE	Recruiting	No Results Available	COVID-19	Drug: Tocilizumab	Clinical response|Biochemical response|Overall survival|Survival to hospital discharge|Progression of COVID-19 pneumonitis|Rate of non-elective mechanical ventilation|Duration of mechanical ventilation|Time to mechanical ventilation|Rate of vasopressor/inotrope utilization|Duration of vasopressor/inotrope utilization|Time to vasopressor or inotropic utilization|Number of ICU days	University of Chicago	All	18 Years and older   (Adult, Older Adult)	Phase 2	50	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB20-0515	April 4, 2020	July 2020	December 2020	April 2, 2020		April 9, 2020	University of Chicago Medicine, Chicago, Illinois, United States		https://ClinicalTrials.gov/show/NCT04331795
100	NCT04333225	Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers		Enrolling by invitation	No Results Available	COVID-19	Drug: Hydroxychloroquine	Rate of COVID-19 positive conversion|Time-to-first clinical event	Baylor Research Institute	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 2	360	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	020-132	April 3, 2020	July 30, 2020	July 30, 2020	April 3, 2020		April 10, 2020	Baylor University Medical Center, Dallas, Texas, United States		https://ClinicalTrials.gov/show/NCT04333225
101	NCT04335084	A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection	HELPCOVID-19	Not yet recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine|Dietary Supplement: Vitamin C|Dietary Supplement: Vitamin D|Dietary Supplement: Zinc	Prevention of COVID-19 measured by negative testing with RT-PCR|Safety as determined by blood pressure readings|Safety as determined by presence of side effects	ProgenaBiome	All	18 Years and older   (Adult, Older Adult)	Phase 2	600	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	PRG-042	April 2020	April 2021	July 2021	April 6, 2020		April 6, 2020	ProgenaBiome, Ventura, California, United States		https://ClinicalTrials.gov/show/NCT04335084
102	NCT04313023	The Use PUL-042 Inhalation Solution to Prevent COVID-19 in Adults Exposed to SARS-CoV-2		Not yet recruiting	No Results Available	COVID-19	Drug: PUL-042 Inhalation Solution|Drug: Placebo	Prevention of COVID-19	Pulmotect, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 2	200	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	PUL-042-501	April 2020	September 2020	October 2020	March 18, 2020		March 24, 2020			https://ClinicalTrials.gov/show/NCT04313023
103	NCT04307693	Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)		Recruiting	No Results Available	COVID-19	Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine sulfate	Viral load|Viral load change|Time to clinical improvement (TTCI)|Percentage of progression to supplemental oxygen requirement by day 7|Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hours by day 7|Time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission|Rate of switch to Lopinavir/ritonavir or hydroxychloroquine by day 7|adverse effects|Concentration of Lopinavir/ritonavir and hydroxychloroquine	Asan Medical Center	All	16 Years to 99 Years   (Child, Adult, Older Adult)	Phase 2	150	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	S2020-0472-0001	March 11, 2020	May 2020	May 2020	March 13, 2020		March 13, 2020	Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT04307693
104	NCT04323631	Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death		Not yet recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine|Other: The control group will not receive hydroxychloroquine	Number patients developing severe infection or death	Rambam Health Care Campus|Rabin Medical Center	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	1116	Other	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	0154-20-RMB	March 2020	December 2020	December 2020	March 26, 2020		March 26, 2020			https://ClinicalTrials.gov/show/NCT04323631
105	NCT04331834	Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic	PrEP_COVID	Recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine|Drug: Placebos	Confirmed cases of a COVID-19|SARS-CoV-2 seroconversion|Occurrence of any adverse event related with hydroxychloroquine treatment|Incidence of SARS-CoV-2 infection and COVID-19 among healthcare workers|Risk ratio for the different clinical, analytical and microbiological conditions to develop COVID-19|COVID-19 Biobank	Barcelona Institute for Global Health|Hospital Clinic of Barcelona|Laboratorios Rubió	All	18 Years and older   (Adult, Older Adult)	Phase 3	440	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	PrEP_COVID	April 3, 2020	October 3, 2020	October 30, 2020	April 2, 2020		April 7, 2020	ISGlobal, Barcelona, Spain		https://ClinicalTrials.gov/show/NCT04331834
106	NCT04331470	Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19		Recruiting	No Results Available	COVID-19	Drug: Levamisole Pill + Budesonide+Formoterol inhaler|Drug: Lopinavir/Ritonavir + hydoxychloroquine	Clear chest CT-scan|PCR test|Physical statues of patient	Fasa University of Medical Sciences	All	15 Years to 100 Years   (Child, Adult, Older Adult)	Phase 2|Phase 3	30	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	97548	April 4, 2020	April 20, 2020	May 20, 2020	April 2, 2020		April 13, 2020	Vali-Asr Hospital, Fasa, Fars, Iran, Islamic Republic of		https://ClinicalTrials.gov/show/NCT04331470
107	NCT04337216	Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation		Not yet recruiting	No Results Available	COVID-19	Drug: Mavrilimumab	Time to resolution of fever|Change in clinical status|Mortality|Change in CRP|Change in IL-6	Virginia Commonwealth University	All	18 Years and older   (Adult, Older Adult)	Phase 2	10	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HM20019145	April 2020	July 2020	July 2020	April 7, 2020		April 7, 2020	Virginia Commonwealth University, Richmond, Virginia, United States		https://ClinicalTrials.gov/show/NCT04337216
108	NCT04336254	Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients		Recruiting	No Results Available	COVID-19	Biological: allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC)|Other: Intravenous saline injection (Placebo)	TTCI|Lung lesion|Immune function|Time of SARS-CoV-2 clearance|Blood test|SPO2|RR|Body temperature|Side effects in the treatment group|C-reactive protein (mg/L)	Renmin Hospital of Wuhan University|Beijing SH Bio-Tech Corporation, Beijing (CN)|Utooth Biological Technology Co., Ltd. Hubei (CN)	All	18 Years to 65 Years   (Adult, Older Adult)	Phase 1|Phase 2	20	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	2020K-G005|hDPSC-CoVID-2019-02-2020	April 6, 2020	December 31, 2020	March 31, 2021	April 7, 2020		April 7, 2020	Renmin Hospital of Wuhan University (East Campus), Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04336254
109	NCT04292899	Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)		Recruiting	No Results Available	COVID-19	Drug: Remdesivir|Drug: Standard of Care	The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events	Gilead Sciences	All	12 Years and older   (Child, Adult, Older Adult)	Phase 3	2400	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GS-US-540-5773|2020-000841-15	March 6, 2020	May 2020	May 2020	March 3, 2020		April 9, 2020	Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States|Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States|Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States|St Joseph Hospital Eureka, Fortuna, California, United States|Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center,27300 Iris Avenue, Moreno Valley, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Kaiser Permanente Oakland Medical Center, Oakland, California, United States|Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States|The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States|Kaiser Permanente Los Angeles Medical Center,13651 Willard Street, Panorama City, California, United States|Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States|Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States|California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States|Kaiser Permanente-Oakland/San Francisco, 2425 Geary Blvd, San Francisco, California, United States|Providence St. Johns Medical Center, Santa Monica, California, United States|Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States|Stanford Hospital, Stanford, California, United States|University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States|SCL Health St. Joseph Hospital, 1375 East 19th Ave, Denver, Colorado, United States|SCL Health St. Joseph Hospital, Denver, Colorado, United States|SCL Health St. Joseph Hospital, 200 Exempla Circle., Lafayette, Colorado, United States|Yale-New Haven Hospital, New Haven, Connecticut, United States|John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, Hillsborough, New Jersey, United States|RBWJ University Hospital/Newark Beth Israel Medical Center, 1 RWJ Place, New Brunswick, New Jersey, United States|RBWJ University Hospital/Newark Beth Israel Medical Center, 201 Lyons Avenue, Newark, New Jersey, United States|Jacobi Medical Center, Bronx, New York, United States|James J. Peters Veterans Administration Medical Center, Bronx, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Danbury Hospital, Lagrangeville, New York, United States|North Shore University Hospital, 270-05 76th Ave, Manhasset, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States|Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Medical Center-New York Presbyterian Hospital, New York, New York, United States|New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Kaiser Sunnyside Medical Center, Portland, Oregon, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|The Miriam Hospital, Providence, Rhode Island, United States|Prisma Health Richland Hospital, Columbia, South Carolina, United States|The Liver Institute of Methodist Dallas Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States|Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States|University of Utah Health, Salt Lake City, Utah, United States|Maine Medical Center, Arlington, Virginia, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States|VCU Health Medical Center, Richmond, Virginia, United States|Providence Regional Medical Center Everett, Everett, Washington, United States|Providence St. Peter Hospital, Olympia, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Center for Comprehensive Care, Seattle, Washington, United States|MultiCare Deaconess Hospital, Spokane, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|St Joseph Medical Center, Tacoma, Washington, United States|CHU de BORDEAUX, Bordeaux, France|Chu Montpellier, Montpelier Cedex 5, France|CHU de Nantes, Nantes, France|Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Düsseldorf, WA, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany|Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany|Klinik für Hämatologie, Onkologie, Immunologie, München, Germany|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|ASST degli Spedali Civili di Brescia, Brescia, Italy|ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy|UOC Malattie Infettive, IRCCS Ospedale San Raffaele, Milano, Italy|Dipartimento di Malattie Infettive, Malattie Infettive I- Malattie Infettive III, AssT Fatebenefratelli Sacco Ospedale Luigi Sacco, Milano, Italy|UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy|UOC Medicina Di Laboratorio, Azienda Ospedaliera di Padova, Padova PD, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|UOC Malattie Infettive I, Fondazione IRCCS Policlinio San Matteo, Pavia, Italy|Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy|UOC Malattie Infettive ad Alta Intensita di Cure, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma, Italy|Kyungpook National University Hospital, Daegu, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|Leiden University Medical Center, Leiden, Netherlands|Erasmus Medical Centre, Rotterdam, Netherlands|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore|Hospital Principe de Asturias, Alcalá De Henares, Madrid, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Cruces, Bizkaia, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Regional Universitario de Málaga, Málaga, Spain|Hopitaux Universitaires de Genève, Genève 14, Switzerland|Ospedale Regionale di Locarno La Carità, Lugano, Switzerland|Universitätsspital Zürich, Zürich, Switzerland|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom|Royal Lancaster Hospital, Lancaster, United Kingdom|Liverpool University Hospital, Liverpool, United Kingdom|King's College Hospital NHS Trust, London, United Kingdom|University College London, London, United Kingdom|Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Sheffield Teaching Hospitals, Sheffield, United Kingdom		https://ClinicalTrials.gov/show/NCT04292899
110	NCT04332094	Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19	TOCOVID	Recruiting	No Results Available	COVID-19	Drug: Tocilizumab|Drug: Hydroxychloroquine|Drug: Azithromycin	In-hospital mortality|Need for mechanical ventilation in the Intensive Care Unit	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Instituto de Salud Carlos III	All	18 Years and older   (Adult, Older Adult)	Phase 2	276	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IIBSP-COV-2020-23	April 2, 2020	September 2020	October 2020	April 2, 2020		April 7, 2020	Hospital de la Santa Creu i Sant Pau, Barcelona, Spain		https://ClinicalTrials.gov/show/NCT04332094
111	NCT04312997	The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection		Not yet recruiting	No Results Available	COVID-19	Drug: PUL-042 Inhalation Solution|Drug: Placebo	Severity of COVID-19|All cause mortality	Pulmotect, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 2	100	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	PUL-042-502	April 2020	September 2020	October 2020	March 18, 2020		March 24, 2020	Houston Methodist Hospital, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT04312997
112	NCT04334980	Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19		Not yet recruiting	No Results Available	COVID-19	Biological: bacTRL-Spike|Other: Placebo	Frequency of Adverse Events|SARS-CoV-2 Antibodies|Incidence of COVID-19 infection|bacTRL-Spike in stool post-vaccination	Symvivo Corporation	All	19 Years to 55 Years   (Adult)	Phase 1	84	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention	bacTRL-Spike-1	April 30, 2020	August 31, 2021	December 31, 2021	April 6, 2020		April 10, 2020	Vaccine Evaluation Center, BC Children's Research Institute, University of British Columbia., Vancouver, British Columbia, Canada|Canadian Center for Vaccinology Dalhousie University, IWK Health Centre, Halifax, Nova Scotia, Canada		https://ClinicalTrials.gov/show/NCT04334980
113	NCT04276896	Immunity and Safety of Covid-19 Synthetic Minigene Vaccine		Recruiting	No Results Available	Pathogen Infection Covid-19 Infection	Biological: Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs	Clinical improvement based on the 7-point scale|Lower Murray lung injury score|28-day mortality|Duration of mechanical ventilation|Duration of hospitalization|Proportion of patients with negative RT-PCR results|Proportion of patients in each category of the 7-point scale|Proportion of patients with normalized inflammation factors|Frequency of vaccine/CTL Events|Frequency of Serious vaccine/CTL Events	Shenzhen Geno-Immune Medical Institute|Shenzhen Third People's Hospital|Shenzhen Second People's Hospital	All	6 Months to 80 Years   (Child, Adult, Older Adult)	Phase 1|Phase 2	100	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GIMI-IRB-20001	March 24, 2020	July 31, 2023	December 31, 2024	February 19, 2020		March 19, 2020	Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China|Shenzhen Second People's Hospital, Shenzhen, Guangdong, China|Shenzhen Third People's Hospital, Shenzhen, Guangdong, China		https://ClinicalTrials.gov/show/NCT04276896
114	NCT04329572	Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19		Not yet recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin Tablets	Evolution of acute respiratory syndrome, oxygen saturation hemodynamic stability|Viral load|Change in Clinical Condition|Evolution of Acute Respiratory Syndrome|Hospital discharge|Rate of mortality within 28-days	Azidus Brasil|PREVENT SENIOR PRIVATE OPERADORA DE SAÚDE LTDA	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	400	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HIAPRE0320OR	April 3, 2020	May 31, 2020	June 30, 2020	April 1, 2020		April 2, 2020			https://ClinicalTrials.gov/show/NCT04329572
115	NCT04292730	Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment		Recruiting	No Results Available	COVID-19	Drug: Remdesivir|Drug: Standard of Care	The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events	Gilead Sciences	All	12 Years and older   (Child, Adult, Older Adult)	Phase 3	1600	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GS-US-540-5774|2020-000842-32	March 15, 2020	May 2020	May 2020	March 3, 2020		April 9, 2020	Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States|Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States|Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States|St Joseph Hospital Eureka, Fortuna, California, United States|Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center,27300 Iris Avenue, Moreno Valley, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Kaiser Permanente-Oakland/San Francisco, Oakland, California, United States|Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States|The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States|Kaiser Permanente Los Angeles Medical Center,13651 Willard Street, Panorama City, California, United States|Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States|Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States|California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States|Kaiser Permanente-Oakland/San Francisco, 2425 Geary Blvd, San Francisco, California, United States|Providence St. Johns Medical Center, Santa Monica, California, United States|Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States|Stanford Hospital, Stanford, California, United States|University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States|SCL Health St. Joseph Hospital, 1375 East 19th Ave, Denver, Colorado, United States|SCL Health St. Joseph Hospital, Denver, Colorado, United States|SCL Health St. Joseph Hospital, 200 Exempla Circle., Lafayette, Colorado, United States|Yale University, New Haven, Connecticut, United States|Cook County General Hospital, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States|Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Hennepin Healthcare, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States|Hackensack Medical Center, Hackensack, New Jersey, United States|RBWJ University Hospital/Newark Beth Israel Medical Center, Hillsborough, New Jersey, United States|RBWJ University Hospital/Newark Beth Israel Medical Center, 1 RWJ Place, New Brunswick, New Jersey, United States|RBWJ University Hospital/Newark Beth Israel Medical Center, 201 Lyons Avenue, Newark, New Jersey, United States|Jacobi Medical Center, Bronx, New York, United States|James J. Peters Veterans Administration Medical Center, Bronx, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Danbury Hospital, Lagrangeville, New York, United States|North Shore University Hospital, Manhasset, New York, United States|North Shore University Hospital, 270-05 76th Ave, New Hyde Park, New York, United States|Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States|Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Irving Medical Center, New York, New York, United States|Weill Cornell Medical College/NYU Presbyterian Hospital, New York, New York, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Kaiser Sunnyside Medical Center, Portland, Oregon, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|The Miriam Hospital, Providence, Rhode Island, United States|Prisma Health Richland Hospital, Columbia, South Carolina, United States|The Liver Institute of Methodist Dallas Medical Center, Dallas, Texas, United States|UTSW Medical Center, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States|Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States|University of Utah Health, Salt Lake City, Utah, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|VCU Health Medical Center, Richmond, Virginia, United States|Providence Medical Research Center, Everett, Washington, United States|Providence St. Peter Hospital, Olympia, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Center for Comprehensive Care, Seattle, Washington, United States|MultiCare Deaconess Hospital, Spokane, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|St Joseph Medical Center, Tacoma, Washington, United States|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|Chu Montpellier, Montpelier Cedex 5, France|CHU de Nantes, Nantes, France|Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Düsseldorf, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany|Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany|Klinik für Hämatologie, Onkologie, Immunologie, München, Germany|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|ASST degli Spedali Civili di Brescia, Brescia, Italy|ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy|UOC Malattie Infettive, IRCCS Ospedale San Raffaele, Milano, Italy|ASST Fatebenefratelli Sacco, Milano, Italy|UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy|UOC Malattie Infettive e Tropicali, Azienda Ospedaliera di Padova, Padova PD, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|Malattie Infettive I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy|Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma, Italy|Kyungpook National University Hospital, Daegu, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|Leiden University Medical Center, Leiden, Netherlands|Erasmus MC University Hospital, Rotterdam, Netherlands|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Cruces, Bizkaia, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hopitaux Universitaires de Genève, Genève 14, Switzerland|Ospedale Regionale di Locarno La Carità, Lugano, Switzerland|Universitätsspital Zürich, Zürich, Switzerland|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom|Royal Lancaster Hospital, Lancaster, United Kingdom|King's College Hospital NHS Trust, London, United Kingdom|University College London, London, United Kingdom|Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom|Sheffield Teaching Hospitals, Sheffield, United Kingdom		https://ClinicalTrials.gov/show/NCT04292730
116	NCT04312464	Myocardial Damage in COVID-19		Enrolling by invitation	No Results Available	COVID-19|Cardiovascular Diseases	Other: non	The myocardial injury incidence|The risk factors analysis for the death|Clinical characteristics|Clinical course|Cardiovascular comorbidity|Analysis of causes of death	Wuhan Union Hospital, China	All	18 Years and older   (Adult, Older Adult)		500	Other	Observational	Observational Model: Case-Control|Time Perspective: Retrospective	MD-COVID-19	January 1, 2020	March 15, 2020	March 18, 2020	March 18, 2020		March 18, 2020	Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04312464
117	NCT04329507	Non-invasive Detection of Pneumonia in Context of Covid-19 Using Gas Chromatography - Ion Mobility Spectrometry (GC-IMS)		Not yet recruiting	No Results Available	COVID-19|Respiratory Disease	Diagnostic Test: Breath test	To perform a study in patients with clinical features of pneumonia/chest infection to identify a signature of Covid-19 pneumonia in patients exposed to SARS-CoV-2, compared to unexposed patients or those without.|Detection of markers of Covid-19 pneumonia in non-invasive breath samples.|Relationship of this biomarker signature to the presence of SARS-CoV-2 in nasal and throat swabs.|Subsequently, the signature's relationship to other biomarkers of SARS-CoV-2 infection which are currently being explored|In a smaller group of participants, ideally daily non-invasive breath samples will be collected to determine if there are changes between SARS-CoV-2 positive patients and those that are negative until hospital discharge or undue participant burden .	NHS Lothian	All	18 Years and older   (Adult, Older Adult)		200	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	282014	March 25, 2020	March 25, 2020	March 25, 2020	April 1, 2020		April 1, 2020			https://ClinicalTrials.gov/show/NCT04329507
118	NCT04305106	Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT	BEST-RCT	Recruiting	No Results Available	COVID-19 Pneumonia	Drug: Bevacizumab	The time from randomization to clinical improvement	Qilu Hospital of Shandong University|Renmin Hospital of Wuhan University|Ialy Moriggia Pelascini Gravedona Hospital S.p.A|Wuhan University|Jiangbei Union Hospital of Huazhong University of science and technology|Shandong Provincial Chest Hospital	All	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	140	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	QLEmer	March 17, 2020	June 30, 2020	July 31, 2020	March 12, 2020		March 26, 2020	Qilu Hospital of Shandong University, Jinan, Shandong, China		https://ClinicalTrials.gov/show/NCT04305106
119	NCT04315987	NestCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia	HOPE	Not yet recruiting	No Results Available	COVID-19 Pneumonia	Biological: NestCell®	Disappear time of ground-glass shadow in the lungs|Rate of mortality within 28-days|Change of Clinical symptoms including duration of fever and respiratory|Time of nucleic acid turning negative|CD4+ and CD8+ T cell count|Changes of blood oxygen|Side effects in the treatment group	Azidus Brasil|Cellavita Pesquisa Científica Ltda|Hospital Vera Cruz	All	18 Years and older   (Adult, Older Adult)	Phase 1	66	Industry|Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HOPE	April 2020	May 2020	June 2020	March 20, 2020		March 31, 2020	Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil		https://ClinicalTrials.gov/show/NCT04315987
120	NCT04328493	The Vietnam Chloroquine Treatment on COVID-19	VICO	Not yet recruiting	No Results Available	SARS-CoV-2 Infection|COVID-19	Drug: Chloroquine phosphate	Viral clearance time|Lengh of hospital stay|Ventilator free days|Oxygene free days|Time to death|Adverse events|Time to viral PCR negative from rectal swab|fever clearance time|Ordinal outcome scale|Development of ARDS	Oxford University Clinical Research Unit, Vietnam|Ministry of Health, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam|Cu Chi COVID Hospital, Vietnam|Can Gio COVID Hospital, Vietnam|Cho Ray Hospital, Vietnam|National Hospital for Tropical Diseases, Hanoi, Vietnam|Department of Health, Ho Chi Minh city	All	18 Years and older   (Adult, Older Adult)	Phase 2	250	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	COVID	April 1, 2020	April 1, 2021	April 1, 2022	March 31, 2020		March 31, 2020	National Hospital for Tropical Diseases, Hanoi, Vietnam|Can Gio COVID Hospital, Ho Chi Minh City, Vietnam|Cho Ray Hospital, Ho Chi Minh City, Vietnam|Cu Chi COVID Hospital, Ho Chi Minh City, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam		https://ClinicalTrials.gov/show/NCT04328493
121	NCT04320615	A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia	COVACTA	Recruiting	No Results Available	COVID-19 Pneumonia	Drug: Tocilizumab (TCZ)|Drug: Placebo	Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Organ Failure-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ	Hoffmann-La Roche	All	18 Years and older   (Adult, Older Adult)	Phase 3	330	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	WA42380|2020-001154-22	April 3, 2020	August 31, 2021	September 30, 2021	March 25, 2020		April 8, 2020	University of California San Diego, La Jolla, California, United States|eStudySite, La Mesa, California, United States|David Geffen School of Medicine UCLA, Los Angeles, California, United States|Denver Health Medical Center, Denver, Colorado, United States|University of Chicago, Chicago, Illinois, United States|Ochsner Clinic Foundation, Baton Rouge, Louisiana, United States|Baystate Health System, Springfield, Massachusetts, United States|Mayo Clinic - PPDS, Rochester, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|James J Peters Veterans Administration Medical Center - NAVREF, Bronx, New York, United States|New York University Langone Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Baylor University Medical Center; Valdez/ Rhone, Dallas, Texas, United States|Swedish Hospital Medical Center, Seattle, Washington, United States|McMaster University Medical Centre, Hamilton, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Clinical Research Institute of Montreal, Montreal, Quebec, Canada|Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Odense Universitetshospital, Odense C, Denmark|Sjællands Universitetshospital, Roskilde, Roskilde, Denmark|Centre Hospitalier Departemental de Vendee, La Roche Sur Yon, France|Centre Hospitalier et Universitaire de Limoges, Limoges, France|Hôpital de La Croix Rousse, Lyon, France|Hotel Dieu - Nantes, Nantes, France|Hopital de la Pitie Salpetriere, Paris, France|CHRU de Tours, Pharmacie, Tours, France|Universitatsklinikum Dusseldorf, Dusseldorf, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitatsklinikum Schleswig Holstein; Klinik fur Allgemeine Innere Medizin, Kiel, Germany|Uniklinik Köln, Köln, Germany|LMU Klinikum der Universitat Munchen, Munchen, Germany|Azienda Ospedaliera Dei Colli, Napoli, Campania, Italy|Istituto Nazionale Malattie Infettive Lazzaro Spallanzani IRCCS, Roma, Lazio, Italy|ASST Papa Giovanni XXIII; Dipartimento Interaziendale di Farmacia Clinica, Bergamo, Lombardia, Italy|ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco, Milano, Lombardia, Italy|Fondazione IRCCS Policlinico San Matteo di Pavia; S.S. Fisiopatologia Respiratoria, Pavia, Lombardia, Italy|Amphia Ziekenhuis, Breda, Netherlands|St. Antonius Ziekenhuis Nieuwegein, Nieuwegein, Netherlands|Erasmus MC, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Royal Free Hospital, London, United Kingdom|Imperial College London, London, United Kingdom|North Manchester General Hospital, Manchester, United Kingdom|Salford Royal Hospital, Salford, United Kingdom		https://ClinicalTrials.gov/show/NCT04320615
122	NCT04325061	Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19	DEXA-COVID19	Recruiting	No Results Available	Acute Respiratory Distress Syndrome Caused by COVID-19	Drug: Dexamethasone	60-day mortality|Ventilator-free days	Dr. Negrin University Hospital|Li Ka Shing Knowledge Institute|Consorcio Centro de Investigación Biomédica en Red, M.P.	All	18 Years and older   (Adult, Older Adult)	Phase 4	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-001278-31	April 3, 2020	October 30, 2020	October 30, 2020	March 27, 2020		April 9, 2020	ICU, Hospital Universitari Mutua Terrassa, Terrassa, Barcelona, Spain|Hospital Universitario Dr. Negrin, Las Palmas de Gran Canaria, Las Palmas, Spain|Department of Anesthesia, Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain|Intensive Care Unit, Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain|AVI, Hospital Clinic, Barcelona, Spain|Cardiac ICU, Hospital Clinic, Barcelona, Spain|Department of Anesthesia, Hospital Clinic, Barcelona, Spain|Hepatic ICU, Hospital Clínic, Barcelona, Spain|UVIR, Hospital Clinic, Barcelona, Spain|Intensive Care Unit, Hospital General de Ciudad Real, Ciudad Real, Spain|Department of Anesthesia, Hospital Universitario La Princesa, Madrid, Spain|Intensive Care Unit, Hospital Universitario La Princesa, Madrid, Spain|Intensive Care Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Department of Anesthesia, Hospital Universitario La Paz, Madrid, Spain|Intensive Care Unit, Hospital Universitario La Paz, Madrid, Spain|Department of Anesthesia, Hospital Universitario Virgen de Arrixaca, Murcia, Spain|Intensive Care Unit, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Department of Anesthesia, Hospital Unversitario Montecelo, Pontevedra, Spain|Anesthesia, Hospital General Universitario de Valencia, Valencia, Spain|Department of Anesthesia, Hospital Clinico Universitario, Valencia, Spain|Intensive Care Unit, Hospital Clinico Universitario, Valencia, Spain|Department of Anesthesia, Hospital Clínico Universitario, Valladolid, Spain|Anesthesia, Hospital Universitario Río Hortega, Valladolid, Spain|Intensive Care Unit, Hospital Universitario Río Hortega, Valladolid, Spain		https://ClinicalTrials.gov/show/NCT04325061
123	NCT04327531	Evaluation of Covid 19 Knowledge Anxiety and Expectation Levels of Turkish Physicians, Survey Study		Active, not recruiting	No Results Available	COVID-19|Physician-Patient Relations	Behavioral: turkish physicians	Evaluation of covid-19 knowledge level of turkish physicians|what they think about the future	Kanuni Sultan Suleyman Training and Research Hospital	All	25 Years to 55 Years   (Adult)		200	Other	Observational	Observational Model: Ecologic or Community|Time Perspective: Prospective	turkishcovid19	March 26, 2020	April 26, 2020	April 28, 2020	March 31, 2020		April 2, 2020	Pinar Yalcin Bahat, Istanbul, İ̇stanbul, Turkey		https://ClinicalTrials.gov/show/NCT04327531
124	NCT04273529	The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia		Not yet recruiting	No Results Available	COVID-19 Thalidomide	Drug: thalidomide|Drug: placebo	Time to Clinical recoveryTime to Clinical Recovery (TTCR)|All cause mortality|Frequency of respiratory progression|Time to defervescence	First Affiliated Hospital of Wenzhou Medical University|Second Affiliated Hospital of Wenzhou Medical University|Wenzhou Central Hospital	All	18 Years and older   (Adult, Older Adult)	Phase 2	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	20200214-COVID-19-M-T	February 20, 2020	May 30, 2020	June 30, 2020	February 18, 2020		February 21, 2020			https://ClinicalTrials.gov/show/NCT04273529
125	NCT04273581	The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19		Not yet recruiting	No Results Available	COVID-19 Thalidomide	Drug: placebo|Drug: Thalidomide	Time to Clinical Improvement (TTCI)|Clinical status|Time to Hospital Discharge OR NEWS2 (National Early Warning Score 2) of ≤ 2 maintained for 24 hours|All cause mortality|Duration (days) of mechanical ventilation|Duration (days) of extracorporeal membrane oxygenation|Duration (days) of supplemental oxygenation|Length of hospital stay (days)|Time to 2019-nCoV RT-PCR negativity in upper and lower respiratory tract specimens|Change (reduction) in 2019-nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve.|Frequency of serious adverse drug events|Serum TNF-α, IL-1β, IL-2, IL-6, IL-7, IL-10, GSCF, IP10#MCP1, MIP1α and other cytokine expression levels before and after treatment	First Affiliated Hospital of Wenzhou Medical University|Second Affiliated Hospital of Wenzhou Medical University|Wenzhou Central Hospital	All	18 Years and older   (Adult, Older Adult)	Phase 2	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	20200214-COVID-19-S-T	February 18, 2020	April 30, 2020	May 30, 2020	February 18, 2020		February 21, 2020			https://ClinicalTrials.gov/show/NCT04273581
126	NCT04315896	Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial)	HYDRA	Not yet recruiting	No Results Available	COVID-19|Severe Acute Respiratory Syndrome	Drug: Hydroxychloroquine|Drug: Placebo oral tablet	All-cause hospital mortality|Length of hospital stay|Need of mechanical ventilation|Ventilator free days|Grade 3-4 adverse reaction	National Institute of Respiratory Diseases, Mexico|Sanofi	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 3	500	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	HidroxycloroquinaCOVID19	March 23, 2020	October 31, 2020	March 22, 2021	March 20, 2020		March 20, 2020			https://ClinicalTrials.gov/show/NCT04315896
127	NCT04335201	Defibrotide in COVID-19 Pneumonia	DEFI-VID19	Not yet recruiting	No Results Available	Patients With COVID-19 Pneumonia Will Allow to Detect an Absolute Reduction in the Rate of Respiratory-failure	Drug: Defibrotide Injection	to able to reduce the progression of acute respiratory failure|Adverse events|duration of hospitalization|systemic inflammation|overall survival	IRCCS San Raffaele	All	18 Years and older   (Adult, Older Adult)	Phase 2	50	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DEFI-VID19	April 6, 2020	September 30, 2020	December 31, 2020	April 6, 2020		April 6, 2020			https://ClinicalTrials.gov/show/NCT04335201
128	NCT04333862	Assessment of Covid-19 Infection Rates in Healthcare Workers Using a Desynchronization Strategy	Covid-19	Recruiting	No Results Available	SARS-CoV-2		Fraction of healthcare workers infected with SARS-CoV-2|Fraction of healthcare workers with COVID-19|Number of patients infected in the hospital|Development of SARS-CoV2 specific antibody repertoire	University Hospital Inselspital, Berne	All	18 Years and older   (Adult, Older Adult)		500	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	2020-00563	March 19, 2020	June 30, 2020	December 31, 2021	April 3, 2020		April 3, 2020	Guido Beldi, Bern, Switzerland		https://ClinicalTrials.gov/show/NCT04333862
129	NCT04342221	Hydroxychloroquine for COVID-19	COV-HCQ	Recruiting	No Results Available	COVID-19, Hydroxychloroquine Sulfate	Drug: Hydroxychloroquine Sulfate|Drug: Placebo	Effect of HCQ on in vivo viral clearance	University Hospital Tuebingen|Robert Bosch Medical Center|Universitätsklinikum Hamburg-Eppendorf|Bernhard Nocht Institute for Tropical Medicine	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 3	220	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	COV-HCQ|2020-001224-33	March 29, 2020	March 2021	February 2022	April 10, 2020		April 10, 2020	Institute for Tropical Medicine, Tübingen, Germany		https://ClinicalTrials.gov/show/NCT04342221
130	NCT04332107	Azithromycin for COVID-19 Treatment in Outpatients Nationwide	ACTION	Not yet recruiting	No Results Available	COVID-19|SARS-CoV-2	Drug: Azithromycin|Drug: Placebos	Hospitalization|Viral load|Mortality|Adverse events|Positive SARS-CoV-2 test - nasal swab|Positive SARS-CoV-2 test - saliva swab|Positive SARS-CoV-2 test - rectal swab|Genetic macrolide resistance determinants|COVID-19 symptoms|Number of emergency room visits|Number of household members with COVID-19 (confirmed or symptomatic)	University of California, San Francisco	All	18 Years and older   (Adult, Older Adult)	Phase 3	2271	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	20-30504	April 1, 2020	July 30, 2020	July 30, 2021	April 2, 2020		April 8, 2020	University of California San Francisco, San Francisco, California, United States		https://ClinicalTrials.gov/show/NCT04332107
131	NCT04337359	Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness		Available	No Results Available	Severe/Very Severe COVID-19 Illness	Drug: Ruxolitinib		Novartis Pharmaceuticals|Novartis	All	6 Years and older   (Child, Adult, Older Adult)			Industry	Expanded Access:Intermediate-size Population		CINC424A2001M				April 7, 2020		April 7, 2020			https://ClinicalTrials.gov/show/NCT04337359
132	NCT04328441	Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine	BCG-CORONA	Recruiting	No Results Available	COVID-19	Drug: BCG Vaccine|Drug: Placebo	Health Care Workers absenteeism|The cumulative incidence of documented SARS-CoV-2 infection|The number of days of unplanned absenteeism, because of documented SARS-CoV-2 infection|The number of days of absenteeism, because of imposed quarantine as a result of exposure to SARS-CoV-2 infection|The number of days of absenteeism, because of imposed quarantine as a result of having acute respiratory symptoms, fever or documented SARS-CoV-2 infection|The number of days of unplanned absenteeism because of self-reported acute respiratory symptoms|The number of days of self-reported fever (≥38 gr C)|The number of days of self-reported acute respiratory symptoms|The cumulative incidence of self-reported acute respiratory symptoms|The cumulative incidence of death for any reason|The cumulative incidence of death due to documented SARS-CoV-2 infection|The cumulative incidence of Intensive Care Admission for any reason|The cumulative incidence of Intensive Care Admission due to documented SARS-CoV-2 infection|The cumulative incidence of Hospital Admission for any reason|The cumulative incidence of Hospital Admission due to documented SARS-CoV-2 infection|The incidence and magnitude of SARS-CoV-2 antibodies at the end of the study period	UMC Utrecht|Radboud University	All	18 Years and older   (Adult, Older Adult)	Phase 3	1500	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	NL73249.041.20	March 25, 2020	October 25, 2020	December 25, 2020	March 31, 2020		April 3, 2020	Jeroen Bosch ziekenhuis, Den Bosch, Brabant, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Gelderland, Netherlands|Radboud UMC, Nijmegen, Gelderland, Netherlands|Sint Maartenskliniek, Nijmegen, Gelderland, Netherlands|Noordwest Ziekenhuisgroep locatie Alkmaar, Alkmaar, Noord Holland, Netherlands|Hagaziekenhuis, Den Haag, Zuid-Holland, Netherlands|Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands|Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands		https://ClinicalTrials.gov/show/NCT04328441
133	NCT04334044	Treatment of SARS Caused by COVID-19 With Ruxolitinib		Not yet recruiting	No Results Available	COVID-19|Severe Acute Respiratory Syndrome Coronavirus 2	Drug: Ruxolitinib Oral Tablet	Recovery of Pneumonia|Response of C-reactive protein|Response of Ferritin|Response of D-dimer|Rate of ICU admission|Rate of mechanical ventilation|Overall Survival|Toxicity Rate	Grupo Cooperativo de Hemopatías Malignas	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	20	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HAL 345/2020	April 1, 2020	June 1, 2020	June 1, 2020	April 3, 2020		April 3, 2020	Grupo Cooperativo de Hemopatías Malignas, Huixquilucan, Estado De México, Mexico		https://ClinicalTrials.gov/show/NCT04334044
134	NCT04318431	Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children	COVILLE	Not yet recruiting	No Results Available	Covid19	Diagnostic Test: Data collection and rhinopharyngeal swab	Proportion of asymptomatic children or children with mild respiratory symptoms|Confirmed Cov2-SARS cases by age|Confirmed Cov2-SARS cases by symptoms|Viral load|Other respiratory viruses	Centre Hospitalier Intercommunal Creteil|ACTIV	All	6 Months to 15 Years   (Child)	Not Applicable	600	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	COVILLE|2020-A00724-35	April 2020	June 2020	June 2020	March 24, 2020		March 26, 2020	Cabinet du Dr Belaroussi, Boulogne, France|Cabinet du Dr Derkx, Champigny-sur-Marne, France|Cabinet du Dr Coicadan, Chennevières-sur-Marne, France|Cabinet du Dr Corrard, Combs-la-Ville, France|53 Boulevard De La Liberté, Les Lilas, France|157 Avenue du Général Leclerc, Maisons-Alfort, France|Cabinet du Dr Bodin, Montgeron, France|Cabinet du Dr Deberdt, Nogent-sur-Marne, France|Cabinet du Dr Wollner, Nogent-sur-Marne, France|Cabinet du Dr D'acremont, Paris, France|Cabinet du Dr Romain, Paris, France|Cabinet du Dr Turberg-Romain, Paris, France|Cabinet du Dr Michot, Paris, France|Cabinet du Dr Cohen, Saint-Maur-des-Fossés, France|Cabinet de Pédiatrie des Docteurs Ravilly et Bessa, Villejuif, France|13 Villa Beauséjour, Vincennes, France		https://ClinicalTrials.gov/show/NCT04318431
135	NCT04319731	A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure		Not yet recruiting	No Results Available	SARS CoV-2 Infection	Biological: Human Amniotic Fluid	Ventilator Free Days|Duration of supplemental oxygen use|All cause mortality|Systemic inflammation	University of Utah	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	10	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	131618	March 20, 2020	March 20, 2021	March 20, 2021	March 24, 2020		March 24, 2020			https://ClinicalTrials.gov/show/NCT04319731
136	NCT04280588	Fingolimod in COVID-19		Recruiting	No Results Available	Coronavirus Disease (COVID-19)	Drug: Fingolimod 0.5 mg	The change of pneumonia severity on X-ray images	First Affiliated Hospital of Fujian Medical University	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 2	30	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MRCTA, ECFAH of FMU [2020]027	February 22, 2020	July 1, 2020	July 1, 2020	February 21, 2020		February 21, 2020	Wan-Jin Chen, Fuzhou, China		https://ClinicalTrials.gov/show/NCT04280588
137	NCT04329559	COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicentre Observational Study		Recruiting	No Results Available	COVID-19|Liver Cirrhosis		All-cause mortality of COVID-19 patients with liver cirrhosis|Liver-related mortality of COVID-19 patients with liver cirrhosis|Risk factors associated with specific outcomes of COVID-19 patients with liver cirrhosis|Baseline characteristics of COVID-19 patients with liver cirrhosis	Hepatopancreatobiliary Surgery Institute of Gansu Province|Renmin Hospital of Wuhan University|LanZhou University|Minda Hospital Affiliated to Hubei University for Nationalities|Wuhan Union Hospital, China|The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture|Tianjin Second People's Hospital|Sixth People’s Hospital of Shenyang|Guangxi Zhuang Autonomous Region|Shenzhen Third People's Hospital|Ankang Central Hospital|Xingtai People's Hospital|Dalian Sixth People’s Hospital|The Central Hospital of Lishui City|The Affiliated Third Hospital of Jiangsu University|Suizhou Hospital, Hubei University of Medicine	All	18 Years and older   (Adult, Older Adult)		50	Other	Observational	Observational Model: Cohort|Time Perspective: Cross-Sectional	CHESS2002	March 30, 2020	June 29, 2020	June 29, 2021	April 1, 2020		April 1, 2020	Dalian Sixth People's Hospital, Dalian, China|Minda Hospital Affiliated to Hubei University for Nationalities, Enshi, China|The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture, Enshi, China|The First Hospital of Lanzhou University, Lanzhou, China|The Central Hospital of Lishui City, Lishui, China|Guangxi Zhuang Autonomous Region, Nanning, China|The Sixth Peoples Hospital of Shenyang, Shenyang, China|Shenzhen Third People's Hospital, Shenzhen, China|Suizhou Hospital, Hubei University of Medicine, Suizhou, China|Tianjin Second People's Hospital, Tianjin, China|Ankang Central Hospital, Wuhan, China|Renmin Hospital of Wuhan University, Wuhan, China|Wuhan Union Hospital, Wuhan, China|Xingtai People's Hospital, Xingtai, China|The Affiliated Third Hospital of Jiangsu University, Zhenjiang, China		https://ClinicalTrials.gov/show/NCT04329559
138	NCT04343248	A Randomized, Double-Blind, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)		Not yet recruiting	No Results Available	COVID-19|Viral Respiratory Illnesses	Drug: Nitazoxanide|Drug: Placebo	Symptomatic laboratory-confirmed COVID-19|Symptomatic laboratory-confirmed VRI	Romark Laboratories L.C.	All	65 Years to 120 Years   (Older Adult)	Phase 3	300	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention	RM08-3006	April 30, 2020	August 31, 2020	August 31, 2020	April 13, 2020		April 13, 2020			https://ClinicalTrials.gov/show/NCT04343248
139	NCT04340479	The Use of Ultrasound in Establishing COVID-19 Infection as Part of a Trauma Evaluation		Not yet recruiting	No Results Available	COVID|Trauma|Ultrasound	Diagnostic Test: Ultrasound lung imaging as part of FAST+ evaluation	Correlation of FAST+ pulmonary findings with active COVID infection|Description of additional ancillary findings of the FAST+ examination among infected and non-infected patients	University of Colorado, Denver	All	Child, Adult, Older Adult		20	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	20-0751	May 1, 2020	May 1, 2021	May 1, 2021	April 9, 2020		April 10, 2020	Children's Hospital Colorado, Aurora, Colorado, United States		https://ClinicalTrials.gov/show/NCT04340479
140	NCT04318301	Hypertension in Patients Hospitalized With COVID-19	HT-COVID19	Active, not recruiting	No Results Available	COVID-19|Hypertension		Rate of Death|the severity of pneumonia	Zhenhua Zen|Nanfang Hospital of Southern Medical University	All	18 Years to 100 Years   (Adult, Older Adult)		275	Other	Observational	Observational Model: Case-Control|Time Perspective: Retrospective	HT-COVID19	March 21, 2020	March 28, 2020	March 30, 2020	March 23, 2020		April 7, 2020	Hankou Hospital, Hankou, Hubei, China		https://ClinicalTrials.gov/show/NCT04318301
141	NCT04331106	Survey of the Anxiety Associated With the COVID-19 Pandemic	CORA	Recruiting	No Results Available	Anxiety Related to the COVID-19 Pandemic	Diagnostic Test: Online Questionnaire	Characteristics of COVID-19-related anxiety|COVID-19-related anxiety symptoms|Self-efficacy and coping with COVID-19|Consequences of COVID-19 in the last three weeks.|General Illness Attitude|Media reporting|Ultra-brief screening scale for anxiety and depression|Change in characteristics of COVID-19-related anxiety|Change in COVID-19-related anxiety symptoms	Charite University, Berlin, Germany	All	18 Years and older   (Adult, Older Adult)		6000	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	EA1/071/20	March 27, 2020	September 2020	September 2021	April 2, 2020		April 13, 2020	Charité-Universitätsmedizin Berlin - Department of Psychiatry and Psychotherapy, Berlin, Germany		https://ClinicalTrials.gov/show/NCT04331106
142	NCT04336332	Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19		Recruiting	No Results Available	SARS-CoV-2|COVID-19	Combination Product: Hydroxychloroquine Sulfate + Azithromycin|Drug: Hydroxychloroquine Sulfate	Changes in patients viral load|Second evaluation of changes in patients viral load|Symptom questionnaire|Fever assessment|Vital Signs - Body Temperature|Discharge|Recovery|Assessment of agent toxicity|Oropharynx swab sample collections|Blood Sample collections|Viral shedding assessment - nasopharyngeal secretions|Viral shedding assessment - serology|Cytokines in blood	Rutgers, The State University of New Jersey	All	18 Years and older   (Adult, Older Adult)	Phase 2	160	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	002011|Pro2020000712	April 1, 2020	April 30, 2021	April 30, 2021	April 7, 2020		April 13, 2020	Robert Wood Johnson University Hopsital, New Brunswick, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|The University Hospital, Newark, New Jersey, United States		https://ClinicalTrials.gov/show/NCT04336332
143	NCT04334005	Vitamin D on Prevention and Treatment of COVID-19	COVITD-19	Not yet recruiting	No Results Available	Patients Infected With COVID-19	Dietary Supplement: Vitamin D	Composite of cumulative death (i.e. mortality) for all causes and for specific causes.|Necessity of invasive assisted ventilation|Necessity of non-invasive assisted ventilation|Intensive care unit admission|Post-anesthesia care unit admission|Hospital admission|Medical consultation|Home care and isolation time|Bed rest time|symptoms' duration (i.e. cough, fever, nasal congestion, gastrointestinal symptoms, fatigue, anosmia, ageusia, diarrhea or alternative signs of COVID-19)|Subjective perception of recovery	Universidad de Granada	All	40 Years to 70 Years   (Adult, Older Adult)	Not Applicable	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment	COVITD-19	April 10, 2020	June 30, 2020	June 30, 2020	April 3, 2020		April 7, 2020	Universidad de Granada, Granada, Andalucia, Spain|Medicine Faculty, Granada, Spain		https://ClinicalTrials.gov/show/NCT04334005
144	NCT04336384	Impact of Covid-19 in Congenital Heart Disease	COVID-CHD	Recruiting	No Results Available	Congenital Heart Disease|Covid-19		Population characteristics|Clinical course|Cardiovascular complications|Other complications|Number of deaths	University Hospital, Montpellier|Pr. Jean-Benoît THAMBO, Bordeaux (président)|Dr. Céline GRUNENWALD GRONIER, Strasbourg|Dr. Sébastien HASCOET, Le Plessis-Robinson|Dr. Adeline BASQUIN, Rennes|Dr. Nicolas COMBES, Toulouse|Dr. Xavier IRIART, Bordeaux|Dr. Daniela LAUX, Paris|Dr. Magalie LADOUCEUR, Paris|Pr. BERTRAND LEOBON, Toulouse|Pr. Caroline OVAERT, Marseille|Dr. Karine WARIN-FRESSE, Nantes|Alexis BLANC, Montpellier	All	Child, Adult, Older Adult		5000	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	RECHMPL20_0155	March 1, 2020	December 1, 2020	December 30, 2020	April 7, 2020		April 7, 2020	Uh Montpellier, Montpellier, France		https://ClinicalTrials.gov/show/NCT04336384
145	NCT04341688	A Clinical Trial of Gargling Agents in Reducing Intraoral Viral Load in COVID-19 Patients	COVID-19	Not yet recruiting	No Results Available	Intraoral Viral Load in Covid-19 Patients	Drug: Gargle/Mouthwash	Intraoral viral load|Salivary cytokine profile	Aga Khan University|University of Karachi	All	18 Years to 65 Years   (Adult, Older Adult)	Not Applicable	5	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care	2020-Sur-ERC-20	July 1, 2020	December 31, 2020	March 31, 2021	April 10, 2020		April 10, 2020			https://ClinicalTrials.gov/show/NCT04341688
146	NCT04303299	Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine for Treatment of COVID-19 : A Randomized Control Trial	THDMS-COVID-19	Not yet recruiting	No Results Available	SARS-COV-2 Infections|COVID-19	Drug: Oral	SARS-CoV-2 eradication time|Number of patient with Death|Number of patient with Recovery adjusted by initial severity in each arm|Number of day With ventilator dependent adjusted by initial severity in each arm|Number of patient developed Acute Respiratory Distress Syndrome After treatment	Rajavithi Hospital	All	16 Years to 100 Years   (Child, Adult, Older Adult)	Phase 3	320	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TH-DMS-COVID19 study	April 15, 2020	October 31, 2020	November 30, 2020	March 11, 2020		April 10, 2020	Assistant Professor Subsai Kongsaengdao, Bangkok, Thailand		https://ClinicalTrials.gov/show/NCT04303299
147	NCT04330521	Impact of the Coronavirus (COVID-19) on Patients With Cancer		Not yet recruiting	No Results Available	Cancer|COVID-19		Number of participants who fill out the survey and participate in the semi-structured interviews.	Stanford University	All	18 Years to 99 Years   (Adult, Older Adult)		50	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	55596	April 2020	May 2022	May 2022	April 1, 2020		April 1, 2020			https://ClinicalTrials.gov/show/NCT04330521
148	NCT04341116	Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)		Not yet recruiting	No Results Available	Coronavirus Disease 2019 COVID-19	Drug: TJ003234|Drug: Placebo	Proportion (%) of subjects experiencing deterioration in clinical status|Treatment Emergent Adverse Events|Clinical status|Improvement in clinical status|Sequential Organ Failure Assessment (SOFA) score|Change from baseline in PaO2/ FiO2|Length of time to normalization of oxygen saturation|Change from baseline in percentage of subjects requiring mechanical ventilation|Change from baseline in Glucocorticoid use|Mortality rate from any cause|Length of hospitalization|Change from baseline in D-dimer|Serum concentration of TJ003234|Incidence and titer of anti-drug antibodies (ADA)	I-Mab Biopharma Co. Ltd.	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	144	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	TJ003234COV201	April 2020	September 2020	September 2020	April 10, 2020		April 10, 2020	OSF Healthcare Saint Francis Medical Center, Peoria, Illinois, United States|Indiana University Health, Indianapolis, Indiana, United States|Oschner Medical Center, New Orleans, Louisiana, United States		https://ClinicalTrials.gov/show/NCT04341116
149	NCT04332913	Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia	TOSCA	Recruiting	No Results Available	COVID-19 Pneumonia		Percentage of patients with complete recovery defined as fever disappearance and return to normal peripheral oxygen saturation values (SpO2) after 14 days from the end of treatment with tocilizumab.|Percentage of patients achieving a score <3 on the Brescia-COVID respiratory severity scale (BCRSS) after the last tocilizumab administration.|Percentage of patients with partial recovery defined as the disappearance of fever 14 days after the end of treatment with tocilizumab.|Duration of hospitalization|Time to the first negative SARS-CoV-2 negative RT-PCR test|Changes from the baseline in the white blood cell count|Changes from the baseline in the lymphocyte populations (cluster of differentiation (CD)3+CD4+, CD3+CD8+, CD19+, Th17)|Changes from the baseline of c-reactive protein (CRP) values|Changes from the baseline of Ferritin values|Changes from the baseline of BNP values|Changes from the baseline of CK-MB values|Changes from the baseline of Troponin values|Changes from the baseline of LDH values|Changes from the baseline of myoglobulin values|Changes in myocardial ischemia signs at the electrocardiographic trace (YES or NO)|Rate of adverse events report during and after tocilizumab|Mortality (number of Partecipants, cause and timing)|Percentage of patients who develop autoimmune diseases	University of L'Aquila	All	18 Years and older   (Adult, Older Adult)		30	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	0064468/20	April 1, 2020	December 31, 2020	March 31, 2021	April 3, 2020		April 13, 2020	Ospedale San Salvatore, L'Aquila, Italy		https://ClinicalTrials.gov/show/NCT04332913
150	NCT04331600	ChloroQUine As antiviRal treAtmeNT In coroNavirus infEction 2020	QUARANTINE2020	Not yet recruiting	No Results Available	COVID-19	Drug: Chloroquine phosphate|Other: Telemedicine	COVID-19-related hospitalization or all-cause death|Decrease in COVID-19 symptoms|Development of pneumonia|Development of coronavirus infection-related complications	Wroclaw Medical University	All	18 Years and older   (Adult, Older Adult)	Phase 4	400	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	QUARANTINE2020	April 6, 2020	September 30, 2020	December 31, 2020	April 2, 2020		April 2, 2020			https://ClinicalTrials.gov/show/NCT04331600
151	NCT04326790	The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention	GRECCO-19	Not yet recruiting	No Results Available	Corona Virus Disease 19 (Covid 19)	Drug: Colchicine|Drug: Standard treatment	CRP increase to 3 x upper limit of normal|Clinical deterioration in the semiquantitative ordinal scale suggested by the WHO R&D committee|Maximal concentration of cardiac troponin	National and Kapodistrian University of Athens	All	18 Years and older   (Adult, Older Adult)	Phase 2	180	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	906295542	April 6, 2020	August 31, 2020	September 30, 2020	March 30, 2020		April 2, 2020			https://ClinicalTrials.gov/show/NCT04326790
152	NCT04342897	A Study of LY3127804 in Participants With COVID-19		Not yet recruiting	No Results Available	COVID-19|Pneumonia	Drug: LY3127804|Drug: Placebo	Number of Ventilator Free Days|Number of Participants Reporting Each Severity Rating on the National Institute of Allergy and Infectious Diseases (NIAID) Ordinal Assessment|Oxygen Saturation (SpO₂)|Oxygen Flow Rate|Mortality|Length of Hospitalization|Number of Participants with any Serious Adverse Event (SAE)|Number of Participants with any Treatment Emergent Adverse Event (TEAE)	Eli Lilly and Company	All	18 Years and older   (Adult, Older Adult)	Phase 2	200	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	17824|I7W-MC-UDAA	April 18, 2020	July 10, 2020	July 10, 2020	April 13, 2020		April 13, 2020			https://ClinicalTrials.gov/show/NCT04342897
153	NCT04317040	CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment	SAC-COVID	Recruiting	No Results Available	Severe Coronavirus Disease (COVID-19)	Drug: CD24Fc|Drug: Placebo	Improvement of COVID-19 disease status|Conversion rate of clinical status at Day 8|Conversion rate of clinical status at Day 15|Hospital discharge time|All cause of death|Duration of mechanical ventilation|Duration of pressors|Duration of ECMO|Duration of oxygen therapy|Length of hospital stay|Absolute lymphocyte count	OncoImmune, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 3	230	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CD24Fc-007|20200674	April 8, 2020	May 2021	May 2022	March 20, 2020		April 10, 2020	Institute of Human Virology, University of Maryland Baltimore, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT04317040
154	NCT04288102	Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19)		Recruiting	No Results Available	Corona Virus Disease 2019(COVID-19)	Biological: MSCs|Biological: Saline containing 1% Human serum albumin（solution of MSC）	Size of lesion area and severity of pulmonary fibrosis by chest CT|mMRC (Modified Medical Research Council) dyspnea scale|Oxygenation index( PaO2/FiO2)|Duration of oxygen therapy(days)|Duration of hospitalization(days)|Blood oxygen saturation|CD4+ T cell count and cytokine level|Side effects in the MSCs treatment group|6-minute walk test|Maximum vital capacity (VCmax)|Diffusing Capacity (DLCO)	Beijing 302 Hospital|Huoshenshan Hospital|Maternal and Child Health Hospital of Hubei Province|General Hospital of Central Theater Command, Wuhan, China|VCANBIO CELL & GENE ENGINEERING CORP.,LTD, China	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 2	90	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	2020-013-D	March 5, 2020	July 15, 2020	July 31, 2020	February 28, 2020		April 7, 2020	Maternal and Child Hospital of Hubei Province, Wuhan, Hubei, China|Wuhan Huoshenshan Hospital, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04288102
155	NCT04338932	COVID-19 and Deep Venous Thrombosis		Not yet recruiting	No Results Available	COVID-19|Deep Vein Thrombosis (DVT)/Thrombophlebitis		to investigate the prevalence and identify possible risk factors of the occurrence of a DVT in these patients at the ICU.	Jessa Hospital	All	18 Years and older   (Adult, Older Adult)		12	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	JessaH_COVID19_DVT	April 17, 2020	September 30, 2020	December 30, 2020	April 8, 2020		April 8, 2020			https://ClinicalTrials.gov/show/NCT04338932
156	NCT04286503	The Clinical Study of Carrimycin on Treatment Patients With COVID-19		Not yet recruiting	No Results Available	Novel Coronavirus Infectious Disease (COVID-19)	Drug: Carrimycin|Drug: lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate|Drug: basic treatment	Fever to normal time (day)|Pulmonary inflammation resolution time (HRCT) (day)|Negative conversion (%) of 2019-nCOVRNA in gargle (throat swabs) at the end of treatment	Beijing YouAn Hospital|Shenyang Tonglian Group Co., Ltd.|Institute of Medicine and Biotechnology, Chinese Academy of Medical Sciences|Huangshi Central Hospital|Shenyang Pharmaceutical University|First Affiliated Hospital of Chongqing Medical University|The Second Affiliated Hospital of Harbin Medical University|No.2 People's Hospital of Fuyang City|First Affiliated Hospital Bengbu Medical College|Renmin Hospital of Wuhan University|The sixth people's hospital of Shenyang|Nanyang Central Hospital	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 4	520	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BeijingYouan Hospital	February 23, 2020	February 28, 2021	February 28, 2021	February 27, 2020		February 27, 2020		Study Protocol, https://ClinicalTrials.gov/ProvidedDocs/03/NCT04286503/Prot_000.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/03/NCT04286503/ICF_001.pdf	https://ClinicalTrials.gov/show/NCT04286503
157	NCT04342104	NIV and CPAP Failure Predictors in COVID-19 Associated Respiratory Failure		Recruiting	No Results Available	Respiratory Failure|Covid-19	Other: Monitoring for aggravation|Other: Evaluate HACOR score effectivity in this patients	HACOR score efficacy|HACOR score addaptation	Hospital General Universitario Morales Meseguer	All	18 Years and older   (Adult, Older Adult)		100	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	08/04/2020	April 1, 2020	June 1, 2020	July 1, 2020	April 10, 2020		April 13, 2020	Hospital General Universitario Morales Meseguer, Murcia, Spain		https://ClinicalTrials.gov/show/NCT04342104
158	NCT04293692	Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus		Withdrawn	No Results Available	COVID-19	Biological: UC-MSCs|Other: Placebo	Size of lesion area by chest imaging|Blood oxygen saturation|Rate of mortality within 28-days|Sequential organ failure assessment|Side effects in the UC-MSCs treatment group|Electrocardiogram, the changes of ST-T interval mostly|Concentration of C-reactive protein C-reactive protein, immunoglobulin|CD4+ and CD8+ T cells count|Concentration of the blood cytokine (IL-1β, IL-6, IL-8,IL-10,TNF-α)|Concentration of the myocardial enzymes	Puren Hospital Affiliated to Wuhan University of Science and Technology|Wuhan Hamilton Bio-technology Co., Ltd	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	0	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	Pr20200225	February 24, 2020	February 25, 2020	February 25, 2020	March 3, 2020		March 18, 2020	Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04293692
159	NCT04291729	Evaluation of Ganovo （Danoprevir ） Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection		Completed	No Results Available	COVID-19	Drug: Ganovo+ritonavir+/-Interferon nebulization	Rate of composite adverse outcomes|Time to recovery|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no requiring supplemental oxygen|Rate of undetectable New coronavirus pathogen nucleic acid|Rate of mechanical ventilation|Rate of ICU admission|Rate of serious adverse event	The Ninth Hospital of Nanchang|Ascletis Pharmaceuticals Co., Ltd.	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 4	11	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ASC-CTP-NC-01	February 17, 2020	March 19, 2020	March 19, 2020	March 2, 2020		April 13, 2020	The Ninth Hospital of Nanchang, Nanchang, Jiangxi, China		https://ClinicalTrials.gov/show/NCT04291729
160	NCT04339816	Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial	AZIQUINE-ICU	Not yet recruiting	No Results Available	COVID-19|Respiratory Failure	Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Placebo	Proportion of alive patients free off mechanical ventilation|Proportion of patients who avoided the need of mechanical ventilation|ICU LOS|Mortality28|Mortality90	Frantisek Duska, MD, PhD|Masaryk Hospital Usti nad Labem|University Hospital Pilsen|The Faculty Hospital Na Bulovce|St. Anne's University Hospital Brno, Czech Republic|University Hospital, Motol|General University Hospital, Prague|University Hospital Olomouc|Charles University, Czech Republic	All	18 Years and older   (Adult, Older Adult)	Phase 3	240	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	AZIQUINE-ICU-25032020|2020-001456-18	April 20, 2020	December 31, 2021	June 30, 2022	April 9, 2020		April 13, 2020			https://ClinicalTrials.gov/show/NCT04339816
161	NCT04335071	Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)	CORON-ACT	Not yet recruiting	No Results Available	SARS-CoV-2 Infection	Drug: Tocilizumab (TCZ)|Drug: Placebo	Number of patients with ICU admission|Number of patients with intubation|Number of patients with death|Illness severity|Number of patients with clinical improvement|Time to clinical improvement (days)|Duration of hospitalization (days)|Time to ICU admission (days)|Duration of ICU stay|Time to intubation|Duration of mechanical ventilation (days)	University Hospital Inselspital, Berne|Roche Pharma AG	All	30 Years to 80 Years   (Adult, Older Adult)	Phase 2	100	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	2020-00691|2020DR2044	April 2020	October 2020	October 2020	April 6, 2020		April 8, 2020	University Hospital Bern (Inselspital), Bern, Switzerland|Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland|University Hospital Zurich, Zurich, Switzerland		https://ClinicalTrials.gov/show/NCT04335071
162	NCT04342728	COVID-19 Using Ascorbic Acid and Zinc Supplementation	COVIDAtoZ	Enrolling by invitation	No Results Available	COVID|Corona Virus Infection	Dietary Supplement: Ascorbic Acid|Dietary Supplement: Zinc Gluconate|Dietary Supplement: Ascorbic Acid and Zinc Gluconate|Other: Standard of Care	Symptom Reduction|Symptom Resolution: Fever|Symptom Resolution: Cough|Symptom Resolution: Shortness of Breath|Symptom Resolution: Fatigue|Day 5 Symptoms|Hospitalizations|Severity of Symptoms|Adjunctive Medications|Supplementation Side Effects	The Cleveland Clinic	All	18 Years and older   (Adult, Older Adult)	Not Applicable	520	Other	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	IRB 20-361	April 8, 2020	September 30, 2020	April 30, 2021	April 13, 2020		April 13, 2020	Cleveland Clinic, Cleveland, Ohio, United States		https://ClinicalTrials.gov/show/NCT04342728
163	NCT04331054	Protective Role of Inhaled Steroids for Covid-19 Infection	INHASCO	Not yet recruiting	No Results Available	Covid-19 Infection|Hospitalization in Respiratory Disease Department	Drug: 2: Usual practice + SYMBICORT RAPIHALER|Other: 1: Usual practice	Time (in days) to clinical improvement within 30 days after randomization|Mortality rate at D30|Time (in days) from randomization to death|Number of days alive outside ICU within 30 days|Number of days alive free of invasive or non-invasive ventilation within 30 days|Number of days alive with oxygen therapy within 30 days|Maximal oxygen rate within 30 days|Difference between PaO2/FiO2 ratio at randomization and at Day 7 (or at the time of stopping oxygen therapy or discharge if occurs before Day 7)|Number of days alive outside hospital within 30 days|Use of antibiotics for respiratory (proved or suspected) infection within 30 days|Difference between CRP levels at randomization and at Day 7 (or at the time of discharge if occurs before Day 7)|Safety outcomes included events that occurred during treatment, serious adverse events, and premature discontinuation of treatment.	Assistance Publique - Hôpitaux de Paris	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 3	436	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	P 200394|2020-001306-35	April 2020	July 2020	July 2020	April 2, 2020		April 13, 2020	Hôpital Bichat - Service de Pneumologie, Paris, France		https://ClinicalTrials.gov/show/NCT04331054
164	NCT04337346	Evaluation of Covid 19 Anxiety in Endometriosis Patients		Active, not recruiting	No Results Available	Endometriosis|Covid19		Covid 19 Anxiety levels in Endometriosis Patients	Kanuni Sultan Suleyman Training and Research Hospital	Female	18 Years to 45 Years   (Adult)		80	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	endocovid19	April 5, 2020	April 20, 2020	April 25, 2020	April 7, 2020		April 7, 2020	Pinar Yalcin Bahat, Istanbul, İ̇stanbul, Turkey		https://ClinicalTrials.gov/show/NCT04337346
165	NCT04343339	Evolution of Psychoactive Substances Consumption in Connection With COVID-19 Containement	EPILOGUE	Recruiting	No Results Available	Addiction, Substance|COVID-19		Evolution of consumption|health care access	University Hospital, Montpellier	All	18 Years and older   (Adult, Older Adult)		100	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	RECHMPL20_0195	April 8, 2020	July 30, 2020	September 30, 2020	April 13, 2020		April 13, 2020	Uhmontpellier, Montpellier, France		https://ClinicalTrials.gov/show/NCT04343339
166	NCT04330495	Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection		Not yet recruiting	No Results Available	COVID 19|Immunomediated Inflammatory Disease in Treatment With Biological Agents and / or Jak Inhibitors	Drug: Hidroxicloroquina|Drug: Control group	Incidence rate of new COVID-19 cases in both arms|Prevalence of COVID-19 cases in both arms|Mortality rate secondary to COVID-19 cases in both groups|Intensive Care Unit (CU) admission rate secondary to COVID-19 cases in both groups|Adverse events	Instituto de Investigación Marqués de Valdecilla	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 4	800	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention	EnCOVID-HidroxiCLOROQUINA	April 6, 2020	November 6, 2020	November 6, 2020	April 1, 2020		April 13, 2020			https://ClinicalTrials.gov/show/NCT04330495
167	NCT04326075	Early CPAP in COVID Patients With Respiratory Failure.	EC-COVID-RCT	Not yet recruiting	No Results Available	CPAP Ventilation|COVID-19|Emergency Departments	Device: CPAP treatment	Death or need of intubation|30-day mortality	Mario Negri Institute for Pharmacological Research	All	18 Years to 70 Years   (Adult, Older Adult)	Not Applicable	900	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EC-COVID-RCT-Fenice	April 6, 2020	October 5, 2020	November 9, 2020	March 30, 2020		March 31, 2020			https://ClinicalTrials.gov/show/NCT04326075
168	NCT04334850	Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia	MultiCov	Not yet recruiting	No Results Available	Covid19|Pneumonia	Procedure: Combined use of a respiratory broad panel multiplex PCR and procalcitonin|Other: Usual antibiotic treatment	Number of antibiotic free days|Mortality rates|Number of defined daily dose (DDD) per 100 patient-days of broad- and narrow-spectrum antibiotics.|Antibiotics duration at D28|Number of organ-failure free days (based on SOFA)|Incidence rates of bacterial super-infections|Incidence rates of colonization/infection with multidrug resistant bacteria and Clostridium difficile infections|ICU and hospital lengths of stay|Quality of life Quality of life	Assistance Publique - Hôpitaux de Paris|BioMérieux	All	18 Years and older   (Adult, Older Adult)	Not Applicable	194	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	APHP200392|2020-001324-33	April 2020	July 2020	August 2020	April 6, 2020		April 6, 2020	Intensive care department-Hospital Tenon, Paris, France		https://ClinicalTrials.gov/show/NCT04334850
169	NCT04333472	Piclidenoson for Treatment of COVID-19		Not yet recruiting	No Results Available	COVID-19|Coronavirus Infection	Drug: Piclidenoson	Duration of viral shedding in days|Time to clinical recovery (TTCR) in days|Treatment-emergent adverse events (AEs)|Requirement for non-invasive or mechanical ventilation|Length of hospital stay in days|Estimated PaO2/FiO2 ratio on day of discharge|All-cause mortality|Patients reaching undetectable COVID-19 virus levels in respiratory secretions|Duration of symptoms and signs of respiratory infection in days|Need for supportive respiratory management|Viral load|Treatment-emergent serious AEs (SAEs)|AEs leading to withdrawal|Treatment-emergent abnormalities in clinical laboratory parameters	Can-Fite BioPharma|Rabin Medical Center	All	18 Years and older   (Adult, Older Adult)	Phase 2	40	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CAN-COR-1	April 6, 2020	June 6, 2020	July 6, 2020	April 3, 2020		April 3, 2020	Rabin Medical Center, Petah tikva, Israel		https://ClinicalTrials.gov/show/NCT04333472
170	NCT04337320	Evaluation of Postnatal Outcomes of Covid 19 Positive Mothers Newborns		Active, not recruiting	No Results Available	Covid19|Newborn Morbidity	Other: newborns from covid 19 positive mothers	Evaluation of apgar status of newborns from covid 19 positive mothers	Kanuni Sultan Suleyman Training and Research Hospital	All	up to 15 Minutes   (Child)		70	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	covid19pregnancynewborn	April 1, 2020	June 15, 2020	June 20, 2020	April 7, 2020		April 7, 2020	Pinar Yalcin Bahat, Istanbul, İ̇stanbul, Turkey		https://ClinicalTrials.gov/show/NCT04337320
171	NCT04339686	Multicentric Retrospective Observational Study of Thoracic Scanner Performance in COVID Screening.		Not yet recruiting	No Results Available	The Gold Standard for Current SARS CoV2 Detection is RT-PCR	Diagnostic Test: Thoracic CT Scan	Diagnostic performance of chest CT in screening for pulmonary lesions in clinical suspicions of COVID.|Compare the diagnostic performance of chest CT and RT-PCR in COVID 19 at the initial consultation (screening).	Poitiers University Hospital	All	18 Years to 100 Years   (Adult, Older Adult)		56000	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	POWER-COVID_CT	April 2020	September 2020	November 2020	April 9, 2020		April 13, 2020			https://ClinicalTrials.gov/show/NCT04339686
172	NCT04273321	Efficacy and Safety of Corticosteroids in COVID-19		Recruiting	No Results Available	COVID-19|Novel Coronavirus Pneumonia	Drug: Methylprednisolone	the incidence of treatment failure in 14 days|clinical cure incidence in 14 days|the duration of virus change to negative|mortality at day 30|ICU admission rate in 30 days	Beijing Chao Yang Hospital	All	18 Years and older   (Adult, Older Adult)	Not Applicable	400	Other	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Methylprednisolone in COVID-19	February 14, 2020	May 1, 2020	May 30, 2020	February 18, 2020		April 1, 2020	Hubei province hospital of integrated Chinese & Western Medicine, Wuhan, Hubei, China|Yichang first people's Hospital, Yichang, Hubei, China|Beijing YouAn Hospital, Beijing, China|Renmin Hospital of Wuhan University, Wuhan, China|Tianyou Hospital Affiliated to Wuhan University of science and technology, Wuhan, China|Union Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology, Wuhan, China|the first peopel hospital of Xiangyang, Xiangyang, China		https://ClinicalTrials.gov/show/NCT04273321
173	NCT04335305	Checkpoint Blockade in COVID-19 Pandemic	COPERNICO	Not yet recruiting	No Results Available	COVID-19|Pneumonia, Viral	Drug: Tocilizumab|Biological: Pembrolizumab (MK-3475)	Percentage of patients with normalization of SpO2 ≥96%|Proportion of patients with temperature < 37,5 °C armpit.|Proportion of patients discharged from the emergency department and classified as low risk|Change from baseline in organ failure parameters|Proportion of mortality rate|Analysis of the remission of respiratory symptoms|Evaluation of the radiological response|Time to first negative in SARS-CoV-2 RT-PCR test|Change from baseline of ALC (absolute lymphocyte count),white blood cell count and white blood cell differential count|Change from baseline of hemoglobin|Change from baseline of platelets|Change from baseline of activated partial thromboplastin time (aPTT)|Change from baseline of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)|Change from baseline of creatinine|Change from baseline of glucose|Change from baseline of total bilirubin|Change from baseline of albumin|Incidence of adverse events (AEs), incidence of prespecified AEs (safety and tolerability)	MedSIR	All	18 Years and older   (Adult, Older Adult)	Phase 2	24	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MedOPP376	March 30, 2020	May 15, 2020	May 15, 2020	April 6, 2020		April 6, 2020			https://ClinicalTrials.gov/show/NCT04335305
174	NCT04337008	Renin Angiotesnin System - CoronaVirus	SRA-COV	Recruiting	No Results Available	COVID 19	Other: blood draw	overactivity of the renin / aldosterone system	Assistance Publique Hopitaux De Marseille	All	18 Years and older   (Adult, Older Adult)	Not Applicable	50	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	2020-16|2020-A00795-34	April 3, 2020	June 3, 2020	July 31, 2020	April 7, 2020		April 7, 2020	ASSISTANCE PUBLIQUE HÖPITAUX de MARSEILLE, Marseille, France		https://ClinicalTrials.gov/show/NCT04337008
175	NCT04341103	AlloSure Guided Immuno-Optimization for COVID-19: An Early Experience	Al-COVE	Not yet recruiting	No Results Available	Solid Organ Transplant Rejection|COVID-19		Assessing the utility of AlloSure dd-cfDNA to guide clinical immune-optimization for transplant patients with COVID-19	CareDx	All	Child, Adult, Older Adult		500	Industry	Observational	Observational Model: Case-Only|Time Perspective: Prospective	Al-COVE	April 1, 2020	December 1, 2020	March 1, 2021	April 10, 2020		April 10, 2020			https://ClinicalTrials.gov/show/NCT04341103
176	NCT04341285	Early Versus Late ECMO Therapy in COVID-19 Induced ARDS (ECMO-VID)	ECMO-VID	Not yet recruiting	No Results Available	ARDS, Human|COVID-19	Procedure: ECMO Implantation	28 day all cause mortality|90 day all cause mortality|Sepsis-related organ failure assessment score at day 1-14, 28 and 90 days|duration of mechanical ventilation support|Ventilator Associated Pneumonia|Bleeding complications|Acute Renal Failure|Discharge Location	University Hospital Tuebingen|University Hospital Freiburg|RWTH Aachen University|University Hospital Muenster	All	18 Years and older   (Adult, Older Adult)	Not Applicable	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ECMO-VID	June 1, 2020	June 1, 2024	December 1, 2025	April 10, 2020		April 10, 2020	University Hospital Tuebingen, Tuebingen, Germany		https://ClinicalTrials.gov/show/NCT04341285
177	NCT04335786	Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease		Not yet recruiting	No Results Available	Respiratory Distress Syndrome, Adult|SARS-CoV-2	Drug: Valsartan (Diovan)|Drug: Placebo oral tablet	first occurrence of intensive care unit admission, mechanical ventilation or death|Death|Mechanical ventilation|Intensive care unit admission|Occurrence of acute kidney injury	Radboud University	All	18 Years and older   (Adult, Older Adult)	Phase 4	651	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	NL73547.091.20|2020-001320-34	April 2020	July 2020	August 2021	April 6, 2020		April 8, 2020			https://ClinicalTrials.gov/show/NCT04335786
178	NCT04331665	Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia		Not yet recruiting	No Results Available	COVID-19|Pneumonia	Drug: Ruxolitinib	Proportion of patients with COVID-19 pneumonia who become critically ill (defined as requiring mechanical ventilation and/or FiO2 of 60% of more)|Number of adverse events|All cause mortality rate|Average duration of hospital stay	University Health Network, Toronto	All	12 Years and older   (Child, Adult, Older Adult)	Not Applicable	64	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	U-DEPLOY: RUX-COVID|20-5315	April 20, 2020	October 30, 2020	January 31, 2021	April 2, 2020		April 13, 2020	Princess Margaret Cancer Centre, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT04331665
179	NCT04298814	Safety Related Factors of Endotracheal Intubation in Patients With Severe Covid-19 Pneumonia		Not yet recruiting	No Results Available	COVID-19|Endotracheal Intubation	Other: severe covid-19 pneumonia with ET	Success rate of intubation|Infection rate of Anesthesiologist|Extubation time	Tongji Hospital	All	18 Years to 90 Years   (Adult, Older Adult)		120	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	COVEI	March 7, 2020	May 30, 2020	July 30, 2020	March 6, 2020		March 6, 2020			https://ClinicalTrials.gov/show/NCT04298814
180	NCT04278963	Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19		Active, not recruiting	No Results Available	CoVID-19|Chinese Medicine	Drug: YinHu QingWen Decoction|Drug: YinHu QingWen Decoction(low dose)|Other: Chinese medicine treatment|Other: standard western medicine treatment	Mean clinical recovery time (hours)|Time to CoVID-19 RT-PCR negative in upper respiratory tract specimen|Change (reduction) in CoVID-19 viral load in upper respiratory tract specimen as assessed by area under viral load curve.|Time to defervescence (in those with fever at enrolment)|Time to cough reported as mild or absent (in those with cough at enrolment rated severe or moderate)|Time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnea at enrollment rated as severe or moderate)|Frequency of requirement for supplemental oxygen or non-invasive ventilation|Frequency of respiratory progression|Severe case incidence|Proportion of re-hospitalization or admission to ICU|All-cause mortality|Frequency of serious adverse events	China Academy of Chinese Medical Sciences	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	300	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	YHQW-V3.0	February 27, 2020	January 2021	January 2021	February 20, 2020		March 17, 2020	Jingzhou Hospital of Traditional Chinese Medicine, Jingzhou, Hubei, China|Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University, Wuhan, Hubei, China|Xiangyang Hospital of Traditional Chinese Medicine, Xiangyang, Hubei, China		https://ClinicalTrials.gov/show/NCT04278963
181	NCT04335773	COVID-19 in Hospitalised Norwegian Children - Risk Factors, Outcomes and Immunology		Not yet recruiting	No Results Available	Pediatric Respiratory Diseases|COVID|Fatigue Post Viral		Risk Factors|Immunulogical mechanisms|Long term outcome	University Hospital, Akershus|St. Olavs Hospital|Helse Stavanger HF|Haukeland University Hospital|University Hospital of North Norway|Alesund Hospital|Norwegian Institute of Public Health|The University of New South Wales|University of Bristol|Sykehuset Ostfold|Nordlandssykehuset HF|Vestre Viken Hospital Trust|Helse Fonna|Levanger Hospital|Oslo University Hospital|Sykehuset Innlandet HF	All	up to 18 Years   (Child, Adult)		350	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	20/03794	April 1, 2020	December 31, 2030	December 31, 2030	April 6, 2020		April 6, 2020			https://ClinicalTrials.gov/show/NCT04335773
182	NCT04318444	Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)		Not yet recruiting	No Results Available	COVID-19|Corona Virus Infection	Drug: Hydroxychloroquine|Drug: Placebo oral tablet	Number of participants with symptomatic, lab-confirmed COVID-19.	Columbia University	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	1600	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	AAAS9676	March 2020	March 2021	March 2022	March 24, 2020		March 25, 2020	Columbia University Irving Medical Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04318444
183	NCT04341415	Impact of Auricular Vagus Nerve Neuromodulation on COVID-19 Positive Inpatients Outcome	SOS-COVID19	Not yet recruiting	No Results Available	Covid19|SARS-CoV Infection	Procedure: Auricular neuromodulation|Procedure: Control	Comparison of the percentage of clinically improved inpatients between D0 and D14	Fondation Ophtalmologique Adolphe de Rothschild	All	18 Years and older   (Adult, Older Adult)	Not Applicable	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	CRN_2020_8	April 2020	June 2020	June 2020	April 10, 2020		April 10, 2020	Fondation Adolphe de Rothschild, Paris, France		https://ClinicalTrials.gov/show/NCT04341415
184	NCT04330144	Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)		Not yet recruiting	No Results Available	Contact Person From COVID-19 Confirmed Patient	Drug: Hydroxychloroquine as post exposure prophylaxis|Other: Others(No intervention)	The rate of COVID-19	Gangnam Severance Hospital	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 3	2486	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	3-2020-0036	April 1, 2020	March 30, 2021	March 30, 2022	April 1, 2020		April 1, 2020			https://ClinicalTrials.gov/show/NCT04330144
185	NCT04318015	Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial)	PHYDRA	Not yet recruiting	No Results Available	COVID-19|Severe Acute Respiratory Syndrome	Drug: Hydroxychloroquine|Drug: Placebo oral tablet	Symptomatic COVID-19 infection rate|Symptomatic non-COVID viral infection rate|Days of labor absenteeism|Rate of labor absenteeism|Rate of severe respiratory COVID-19 disease in healthcare personnel	National Institute of Respiratory Diseases, Mexico|Sanofi	All	18 Years and older   (Adult, Older Adult)	Phase 3	400	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	ProfilaxisCOVID	April 1, 2020	December 31, 2020	March 31, 2021	March 23, 2020		March 23, 2020			https://ClinicalTrials.gov/show/NCT04318015
186	NCT04341038	Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury	TACROVID	Recruiting	No Results Available	COVID-19|Lung Injury	Drug: Tacrolimus|Drug: Methylprednisolone	Time to reach clinical stability|Time to reach an afebrile state for 48 hours.|Time to reach PaO2 / FiO2> 400 and / or SatO2 / FiO2> 300|Time to reach FR ≤ 24 rpm for 48 hours|Time to normalization of D-dimer (<250 ug / L)|Time until PCR normalization (<5mg / L).|Time until normalization of ferritin (<400ug / L)|Study the impact of immunosuppressive treatment on viral load using quantitative PCR|Time until hospital discharge|Need for ventilatory support devices|Duration that it is necessary to maintain ventilatory support.|COVID-19 mortality|all-cause mortality|Analyze the expanded cytokine profile before the start of treatment and their evolution every 7 days after admission|Describe the side effects and their severity attributed to tacrolimus and / or methylprednisolone.	Hospital Universitari de Bellvitge|Institut d'Investigació Biomèdica de Bellvitge	All	18 Years and older   (Adult, Older Adult)	Phase 3	84	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	TACRO-BELL-COVID|2020-001445-39	April 1, 2020	June 1, 2020	July 1, 2020	April 10, 2020		April 10, 2020	Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain		https://ClinicalTrials.gov/show/NCT04341038
187	NCT04341766	Evolution of Pulmonary Ultrasound in Patients Hospitalized for Covid (Coronavirus Disease) 19		Recruiting	No Results Available	Pneumonia, Viral|COVID-19	Other: No special intervention	Characteristics of pulmonary ultrasound for Covid-19 patients|Charateristics of pulmonary CT-scan for Covid-19 patients	Centre Hospitalier Intercommunal Creteil	All	18 Years to 105 Years   (Adult, Older Adult)		200	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	COVID-ECHO	March 31, 2020	May 1, 2020	September 30, 2020	April 10, 2020		April 10, 2020	CHG de Chambery, Chambéry, France|Centre Hospitalier Intercommunal de Créteil, Créteil, France|CHU de Limoges, Limoges, France|APHM - Hopital Nord, Marseille, France|CHU de Nancy, Nancy, France|Hopital privé de la Loire, Saint-Étienne, France|CHU de Tours, Tours, France		https://ClinicalTrials.gov/show/NCT04341766
188	NCT04251767	Washed Microbiota Transplantation for Patients With 2019-nCoV Infection		Withdrawn	No Results Available	COVID-19 Complicated With Refractory Intestinal Infections	Other: washed microbiota transplantation|Other: placebo	Number of participants with improvement from severe type to common type	The Second Hospital of Nanjing Medical University	All	14 Years to 70 Years   (Child, Adult, Older Adult)	Not Applicable	0	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	WMT-YJ-202001	February 5, 2020	April 30, 2020	April 30, 2020	February 5, 2020		March 17, 2020	Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China		https://ClinicalTrials.gov/show/NCT04251767
189	NCT04338568	Screening COVID-19 by Point-of-care Lung Ultrasound: a Validation Study	SCOUT	Not yet recruiting	No Results Available	COVID-19 Pneumonia|Lung Ultrasound	Diagnostic Test: Lung ultrasound	Accuracy of the diagnosis of interstitial syndrome by lung ultrasound|Inter-observer variability	Hasselt University|Ziekenhuis Oost-Limburg	All	18 Years and older   (Adult, Older Adult)	Not Applicable	50	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	CTU2020032	April 13, 2020	April 30, 2020	April 30, 2020	April 8, 2020		April 10, 2020	Ziekenhuis Oost Limburg, Genk, Limburg, Belgium		https://ClinicalTrials.gov/show/NCT04338568
190	NCT04304690	COVID-19 Seroconversion Among Front Line Medical and Paramedical Staff in Emergency, Intensive Care Units and Infectious Disease Departments During the 2020 Epidemic	SEROCOV	Recruiting	No Results Available	Sars-CoV2	Other: blood sample	Quantify the proportion of patients with documented Sars-CoV2 infection among medical and paramedical staff|Identification of risk factors for seroconversion|Quantify the proportion of asymptomatic infections among staff who have seroconverted|" Describe symptomatic infections for personnel developing acute clinical (respiratory or digestive) viral syndrome "	Assistance Publique - Hôpitaux de Paris	All	Child, Adult, Older Adult	Not Applicable	1000	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	APHP200310	March 16, 2020	July 16, 2020	October 16, 2020	March 11, 2020		April 13, 2020	Hopital Pitié Salpetrière, Paris, France		https://ClinicalTrials.gov/show/NCT04304690
191	NCT04335630	Cardiovascular Manifestations of COVID-19		Recruiting	No Results Available	Cardiovascular Diseases|COVID	Diagnostic Test: Electrocardiogram, telemetry, echocardiogram, laboratory values	Prevalence of cardiomyopathy, myocardial infarction, heart failure, clinically significant arrhythmias, cardiogenic shock or cardiac arrest.|Prevalence of pericarditis, pericardial effusion, valvular disease.|Identification of characteristic electrocardiographic patterns related to COVID-19|Role of active cardiovascular disease in clinical outcomes of patients with COVID-19 including length of ICU stay, length of hospitalization and mortality.|Role of pre-existing cardiovascular comorbidities in clinical course of COVID-19|Role of treatment with ACE inhibitors or ARBs in the clinical course of COVID-19|Role of insurance type on clinical outcomes of patients with COVID-19|Effect of age, gender and race on clinical course of COVID-19 and prevalence of cardiovascular complications|Role of active smoking on clinical course of COVID-19 and prevalence of cardiovascular complications	Memorial Hermann Health System	All	18 Years and older   (Adult, Older Adult)		500	Other	Observational	Observational Model: Case-Control|Time Perspective: Retrospective	HSC-MS-20-0286	March 30, 2020	March 2021	March 2022	April 6, 2020		April 7, 2020	Memorial Hermann Hospital-Texas Medical Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT04335630
192	NCT04335552	Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection		Not yet recruiting	No Results Available	SARS-CoV-2	Other: Standard of care|Drug: Hydroxychloroquine|Drug: Azithromycin	World Health Organization (WHO) ordinal scale measured at 14 days after enrollment|Rates of death during the index hospitalization|Number of days on mechanical ventilation for patients who were on mechanical ventilation at baseline|Proportion of patients not receiving mechanical ventilation at baseline who progress to requiring mechanical ventilation during the index hospitalization|WHO ordinal scale measured at 28 days after enrollment|Hospital length of stay in days for the index hospitalization|Rates of all-cause study medication discontinuation|Rates of severe adverse events	Duke University	All	12 Years and older   (Child, Adult, Older Adult)	Phase 2	500	Other	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PRO00105339	April 2020	August 1, 2020	August 1, 2020	April 6, 2020		April 13, 2020	Duke Regional Hospital, Durham, North Carolina, United States|Duke University Hospital, Durham, North Carolina, United States|Durham VA Medical Center, Durham, North Carolina, United States|Duke Raleigh Hospital, Raleigh, North Carolina, United States		https://ClinicalTrials.gov/show/NCT04335552
193	NCT04336761	Prevalence of Covid-19 in Children Admitted to Paediatric Emergency Departments During the Pandemic Period in France	INCOVPED	Not yet recruiting	No Results Available	Coronavirus|COVID|Infection Viral	Diagnostic Test: nasopharyngeal swab	Prevalence of positivity of COVID-19 virus measured by rt-PCR|Prevalence of positivity of COVID-19 virus measured by rt-PCR in the following subpopulations of emergency patients|Respiratory signs of children tested within 28 day|Percentage of children hospitalized tested within 28 day|Contact frequency|Prevalence of positivity of other respiratory viruses measured by rt-PCR	University Hospital, Lille	All	up to 18 Years   (Child, Adult)		914	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	2020_21|2020-A00811-38	April 2020	December 2020	December 2020	April 7, 2020		April 7, 2020	CH Louis MOURIER, Colombes, France|Hôpital Mère Enfant CHU, Nantes, France|Hôpitaux Pédiatriques de Nice CHU-Lenval, Nice, France|Hôpital des enfants - CHU, Toulouse, France|CHU de Tours, Tours, France		https://ClinicalTrials.gov/show/NCT04336761
194	NCT04336657	Corona-Like Illness: Did we Got it Before WHO Announcement of the Disease?		Recruiting	No Results Available	COVID-19	Other: Questionnaire|Diagnostic Test: IgG	Measure frequency of people suffered from unusual flu-like symptoms before December 2019|Measure remote immunity for COVID-19 in subject with past history of severe flu before WHO announcement date- if possible	Assiut University	All	8 Years to 80 Years   (Child, Adult, Older Adult)		100	Other	Observational	Observational Model: Ecologic or Community|Time Perspective: Prospective	AssiutU11	April 2020	May 2020	May 2020	April 7, 2020		April 7, 2020	AssiutU, Assiut, Egypt		https://ClinicalTrials.gov/show/NCT04336657
195	NCT04343781	National Survey of Symptoms of People Aged 70 and Overs Diagnosed With COVID-19	COVID19PUGG2	Completed	No Results Available	SARS-CoV-2	Other: observation	symptoms of COVID-19 in older patients	University Hospital, Angers	All	70 Years and older   (Older Adult)		353	Other	Observational	Observational Model: Cohort|Time Perspective: Cross-Sectional	ar20-0031v1	March 22, 2020	April 5, 2020	April 5, 2020	April 13, 2020		April 13, 2020	Angers University Hospital, Angers, France		https://ClinicalTrials.gov/show/NCT04343781
196	NCT04335019	Interest of the Use of Pulmonary Ultrasound in the Referral of Patients With or Suspected COVID-19 +	eChoVid	Not yet recruiting	No Results Available	2019-nCoV (COVID-19)|Interstitial Pneumonia	Other: Pulmonary ultrasound	Association of pulmonary lesions on ultrasound on D0 classified according to three stages of severity|Assessment of the agreement between a newly trained operator and an experienced operator of classification in one of the three stages of ultrasound gravity, by Cohen's kappa coefficient.|Estimate in patients who had a CT-scan on D0, the agreement in the evaluation of the severity of lung lesions via ultrasound vs. CT-scan, by Cohen's kappa coefficient|Measurement of the cumulative incidence of invasive mechanical ventilation and measurement of survival	Assistance Publique - Hôpitaux de Paris	All	18 Years and older   (Adult, Older Adult)		300	Other	Observational	Observational Model: Other|Time Perspective: Prospective	APHP200390|2020-A00768-31	April 2020	April 2020	May 2020	April 6, 2020		April 6, 2020			https://ClinicalTrials.gov/show/NCT04335019
197	NCT04340921	The Role of Adaptive Immunity in COVID-19 Associated Myocardial Injury		Not yet recruiting	No Results Available	Cardiovascular Disease Acute|Cardiomyopathies|COVID	Biological: COVID-19 exposure	T-cell immunophenotype|Mortality|ITU admission|Myocardial injury	Barts & The London NHS Trust|Queen Mary University of London	All	18 Years and older   (Adult, Older Adult)		140	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	282289	April 10, 2020	April 10, 2020	June 10, 2020	April 10, 2020		April 10, 2020			https://ClinicalTrials.gov/show/NCT04340921
198	NCT04322188	An Observational Case-control Study of the Use of Siltuximab in ARDS Patients Diagnosed With COVID-19 Infection	SISCO	Recruiting	No Results Available	Severe Acute Respiratory Syndrome (ARDS) Secondary to SARS-COV-2 Infection		Cohort A: reduction of the need of invasive ventilation or 30-day mortality|Cohort B: reduction of mortality|Cohort A Reduction of the need of time of ventilatory support|Cohort B Percentage of patients that undergo to tracheostomy|Cohort B Improvement of the lung function assessed by radiologic findings	A.O. Ospedale Papa Giovanni XXIII	All	18 Years and older   (Adult, Older Adult)		50	Other	Observational	Observational Model: Case-Control|Time Perspective: Retrospective	v 0.9 16th March 2020	March 19, 2020	May 19, 2020	May 19, 2020	March 26, 2020		March 31, 2020	ASST - Papa Giovanni XXIII, Bergamo, Italy		https://ClinicalTrials.gov/show/NCT04322188
199	NCT04334460	Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects		Not yet recruiting	No Results Available	Sars-CoV2	Drug: BLD-2660	Antiviral Activity|Improvement of oxygenation|Safety & Tolerability: incidence of TEAEs and serious adverse events (SAEs)	Blade Therapeutics	All	18 Years to 65 Years   (Adult, Older Adult)	Phase 2	120	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	B-2660-204	May 2020	August 2020	September 2020	April 6, 2020		April 6, 2020			https://ClinicalTrials.gov/show/NCT04334460
200	NCT04303507	Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting	COPCOV	Not yet recruiting	No Results Available	COVID19|Coronavirus|Acute Respiratory Illnesses	Drug: Chloroquine or Hydroxychloroquine|Drug: Placebo	Number of symptomatic COVID-19 infections|Symptoms severity of COVID-19|Number of asymptomatic cases of COVID-19|Number of symptomatic acute respiratory illnesses|Severity of symptomatic acute respiratory illnesses	University of Oxford	All	16 Years and older   (Child, Adult, Older Adult)	Not Applicable	40000	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention	VIR20001	April 2020	April 2021	April 2021	March 11, 2020		March 27, 2020			https://ClinicalTrials.gov/show/NCT04303507
201	NCT04333914	Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection	IMMUNONCOVID	Recruiting	No Results Available	SARS-CoV-2 (COVID-19) Infection|Advanced or Metastatic Hematological or Solid Tumor	Drug: Chloroquine analog (GNS651)|Drug: Nivolumab|Drug: Tocilizumab|Other: Standard of care	28-day survival rate|Time to clinical improvement|Clinical status|Mean change in clinical status from baseline to days|Overall survival|Length of stay in Intensive Care Unit|Duration of mechanical ventilation or high flow oxygen devices|Duration of hospitalization|Rate of throat swab negativation|Quantitative SARS-CoV-2 virus in throat swab and blood samples|Rate of secondary infection by other documented pathogens|Biological parameters|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Cost-Effectiveness Analyses (CEA)	Centre Leon Berard	All	18 Years and older   (Adult, Older Adult)	Phase 2	273	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ET20-076 - IMMUNONCOVID-20|2020-001373-70	April 2020	June 2020	August 2020	April 3, 2020		April 7, 2020	Centre Léon Bérard, Lyon, Rhône, France		https://ClinicalTrials.gov/show/NCT04333914
202	NCT04323644	Outcomes of Surgery in COVID-19 Infection: International Cohort Study (CovidSurg)	CovidSurg	Not yet recruiting	No Results Available	COVID-19|Coronavirus|Surgery	Procedure: Surgery	30-day mortality|7-day mortality|30-day reoperation|Postoperative ICU admission|Postoperative respiratory failure|Postoperative acute respiratory distress syndrome (ARDS)|Postoperative sepsis	University of Birmingham	All	Child, Adult, Older Adult		1000	Other	Observational	Observational Model: Cohort|Time Perspective: Other	CS-20200324	March 31, 2020	September 30, 2020	September 30, 2020	March 26, 2020		March 26, 2020			https://ClinicalTrials.gov/show/NCT04323644
203	NCT04329546	Understanding COVID-19		Recruiting	No Results Available	SARS-CoV-2 Viral Kinetics and Host Immune Responses	Other: NA (no intervention)	Immunogenicity primary outcome: Geometric mean antibody concentration of total IgG antibodies to SARS-CoV-2 assessed by ELISA at 28 days|Virologic primary outcome: Peak viral load in the 56 days following diagnosis/suspected diagnosis	University Hospital, Geneva|University of Geneva, Switzerland	All	Child, Adult, Older Adult		250	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	2020-00516	March 27, 2020	January 31, 2022	March 31, 2022	April 1, 2020		April 13, 2020	University Hospitals of Geneva, Geneva, Switzerland		https://ClinicalTrials.gov/show/NCT04329546
204	NCT04320511	Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2		Not yet recruiting	No Results Available	SARS-COV2|Severe Acute Respiratory Syndrome|COVID-19	Device: CT-V	Predictive association between CT-V, PBM score and disease progression	William Beaumont Hospitals	All	18 Years and older   (Adult, Older Adult)		25	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	2020-087	April 2020	March 2021	March 2022	March 25, 2020		March 31, 2020	Beaumont Health, Royal Oak, Michigan, United States		https://ClinicalTrials.gov/show/NCT04320511
205	NCT04261517	Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19		Completed	No Results Available	Pneumonia, Pneumocystis|Coronavirus|COVID-19	Drug: Hydroxychloroquine	The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7|The mortality rate of subjects at weeks 2|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|The critical illness rate of subjects at weeks 2	Shanghai Public Health Clinical Center	All	18 Years and older   (Adult, Older Adult)	Phase 3	30	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HC-COVID-19	February 6, 2020	February 25, 2020	February 25, 2020	February 7, 2020		April 13, 2020	Shanghai Public Health Clinical Center, Shanghai, Shanghai, China|Shanghai Public Health Clinical Center, Shanghai, Shanghai, China		https://ClinicalTrials.gov/show/NCT04261517
206	NCT04331574	Renin-Angiotensin System Inhibitors and COVID-19	SARS-RAS	Recruiting	No Results Available	COVID-19|Hypertension|Cardiovascular Diseases		Numbers of COVID-19 patients enrolled that use ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents|Numbers of COVID-19 patients enrolled with no symptoms, with moderate symptoms or with severe symptoms of pneumoni based on the WHO specification for ARDS that also used ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents|Number and type of anthropometric and clinical parameters that associate with COVID19 and COVID-19 severity	Societa Italiana dell'Ipertensione Arteriosa	All	18 Years to 120 Years   (Adult, Older Adult)		2000	Other	Observational	Observational Model: Case-Only|Time Perspective: Cross-Sectional	SARS-RAS	March 10, 2020	April 10, 2020	April 30, 2020	April 2, 2020		April 2, 2020	Spedali Civili di Brescia, Brescia, Italy		https://ClinicalTrials.gov/show/NCT04331574
207	NCT04333953	COVID-19 in Patients With HIV		Recruiting	No Results Available	HIV/AIDS|COVID-19|SARS-CoV-2	Other: No intervention	Mortality|Frequency of patients requiring hospital admissions|Frequency of patients requiring ICU admissions|Frequency of respiratory support use|Frequency of kidney injury|Frequency of liver injury	University of Missouri-Columbia	All	Child, Adult, Older Adult		500	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	262095	April 1, 2020	October 1, 2020	October 1, 2020	April 3, 2020		April 7, 2020	University of Missouri-Columbia, Columbia, Missouri, United States		https://ClinicalTrials.gov/show/NCT04333953
208	NCT04339998	Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS)		Not yet recruiting	No Results Available	Coronavirus Infection|COVID|Covid-19|SARS-CoV-2	Diagnostic Test: Point-of-Care Ultrasonography (POCUS)	POCUS Score - Lungs|POCUS Score - Heart	University of Minnesota	All	18 Years and older   (Adult, Older Adult)		500	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	STUDY00009429	April 15, 2020	October 2020	October 2020	April 9, 2020		April 9, 2020	University of Minnesota Medical Center (UMMC), Minneapolis, Minnesota, United States|M Health Fairview Bethesda Hospital, Saint Paul, Minnesota, United States		https://ClinicalTrials.gov/show/NCT04339998
209	NCT04323345	Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus		Not yet recruiting	No Results Available	COVID-19	Dietary Supplement: Natural Honey|Other: Standard Care	Rate of recovery from positive to negative swaps|Fever to normal temperature in days|Resolution of lung inflammation in CT or X ray|30 days mortality rate|Number of days till reaching negative swab results	Misr University for Science and Technology	All	5 Years to 75 Years   (Child, Adult, Older Adult)	Phase 3	1000	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment	MUST23032020	March 25, 2020	April 25, 2020	May 10, 2020	March 26, 2020		March 26, 2020	Mahmoud Tantawy, Cairo, Egypt		https://ClinicalTrials.gov/show/NCT04323345
210	NCT04270383	Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children		Not yet recruiting	No Results Available	2019-nCoV		The cure rate of 2019-nCoV.|The improvement rate of 2019-nCoV.|The incidence of long-term adverse outcomes.|Duration of fever|Duration of respiratory symptoms|Duration of hospitalization|Number of participant(s) need intensive care|Number of participant(s) with acute respiratory distress syndrome|Number of participant(s) with extra-pulmonary complications, including shock, renal failure, multiple organ failure, hemophagocytosis syndrome, et al.|Number of participant(s) who died during the trial	Beijing Children's Hospital|Capital Institute of Pediatrics, China|The First Affiliated Hospital of Anhui Medical University|China-Japan Friendship Hospital|The First Affiliated Hospital of Xiamen University|Guangzhou Women and Children's Medical Center|Shenzhen Children's Hospital|First Affiliated Hospital of Guangxi Medical University|The Affiliated Hospital Of Guizhou Medical University|Hainan People's Hospital|Children's Hospital of Hebei Province|Wuhan Women and Children's Medical Center|Changchun Children's Hospital|Children’s Hospital of Nanjing Medical University|Jiangxi Province Children's Hospital|Shengjing Hospital|Shanxi Provincial Maternity and Children's Hospital|Xian Children's Hospital|Children's Hospital of Chongqing Medical University|Tianjin Children's Hospital|Tianjin Medical University Second Hospital|Kunming Children's Hospital|Second Affiliated Hospital of Wenzhou Medical University	All	up to 18 Years   (Child, Adult)		500	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	BCH Lung 012	February 15, 2020	December 31, 2020	December 31, 2020	February 17, 2020		February 17, 2020	Beijing Children's Hospital,, Beijing, China		https://ClinicalTrials.gov/show/NCT04270383
211	NCT04272710	Prognositc Factors in COVID-19 Patients Complicated With Hypertension		Withdrawn	No Results Available	2019-nCoV		Occupancy rate in the intensive care unit (ICU)|Mechanical Ventilation|Death|All cause mortality|Time from onset of symptoms to main outcome and its components|Time to Clinical Recovery	Chongqing Medical University	All	18 Years to 100 Years   (Adult, Older Adult)		0	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	2020-02	January 25, 2020	March 31, 2020	April 30, 2020	February 17, 2020		March 17, 2020	The First Affiliated Hospital of Chongqing Medical University, Chongqing, China		https://ClinicalTrials.gov/show/NCT04272710
212	NCT04341792	Predictive Biomarkers of Secondary Aggravation in Covid-19 Suspect Patient	BIOCOVU	Not yet recruiting	No Results Available	Infection Viral|Coronavirus|COVID-19		Rate of secondary aggravation|Change of standart biological parameters|Change of Von willebrand factor (vWF) changes over time|Change of the Factor VIII (FVIII)|Prevalence of positivity of COVID-19 virus measured by PCR or serology	University Hospital, Lille	All	18 Years and older   (Adult, Older Adult)		1000	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	2020_33|2020-A00906-33	April 2020	August 2020	August 2020	April 10, 2020		April 10, 2020			https://ClinicalTrials.gov/show/NCT04341792
213	NCT04335032	EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2)		Not yet recruiting	No Results Available	SARS-CoV-2	Drug: Eicosapentaenoic acid gastro-resistant capsules	Evaluation of EPA-FFA efficacy compared to standard of care|Increase in oxygen saturation|PaO2/FiO2 >300mmHg increase|Reduction of IL-6|Mortality rate reduction|Reduction in ICU stays|Reducing hospitalisation days|reduction in need for mechanical ventilation|Fever reduction	S.L.A. Pharma AG	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 3	240	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EPA-COV-001	April 13, 2020	July 13, 2020	July 31, 2020	April 6, 2020		April 13, 2020			https://ClinicalTrials.gov/show/NCT04335032
214	NCT04324190	DIgital Online SuPport for COVID-19 StrEss	DISPOSE	Not yet recruiting	No Results Available	COVID-19|Psychosocial Stress|Mental Health	Behavioral: Guided online support program|Behavioral: WHO recommendations (waiting condition)	Change in Short-Form-36 (SF-36) Health Survey - Mental Health Component Summary score|Short-Form-36 (SF-36) Health Survey - Mental Health Component Summary score|Chronic stress items (9 items)|Generalized Anxiety Disorder Scale (GAD-7)|Patient Health Questionnaire (PHQ8)|Somatic Symptom Disorder (SSD-12)|Somatic Symptom Scale (SSS-8)|Allgemeine Selbstwirksamkeit Kurzskala (ASKU)|Screening Tool for Psychological Distress (STOP-D) - selected items	Gunther Meinlschmidt|Selfapy GmbH|International Psychoanalytic University Berlin	All	18 Years and older   (Adult, Older Adult)	Not Applicable	600	Other	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment	IPUB_2020_01	April 2020	June 2020	December 2021	March 27, 2020		April 10, 2020	Selfapy GmbH, Berlin, Germany		https://ClinicalTrials.gov/show/NCT04324190
215	NCT04333693	Outcomes of Vascular Surgery in COVID-19 Infection: National Cohort Study	Covid-VAS	Not yet recruiting	No Results Available	Vascular Surgical Procedures|COVID-19|Postoperative Complications	Procedure: Vascular surgery	30-days mortality|7-days mortality|30-days reoperation|Postoperative ICU admission|Postoperative respiratory failure|Postoperative acute respiratory distress syndrome (ARDS)|Postoperative sepsis	Vascular Investigation Network Spanish Society for Angiology and Vascular Surgery	All	18 Years and older   (Adult, Older Adult)		50	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	RIV-2020-1	April 1, 2020	October 1, 2020	November 1, 2020	April 3, 2020		April 3, 2020	Spanish Society for Angiology and Vascular Surgery, Madrid, Spain		https://ClinicalTrials.gov/show/NCT04333693
216	NCT04341142	Assessment of Serological Techniques for Screening Patients Regarding COVID-19-COVID-SER	COVID-SER	Not yet recruiting	No Results Available	Suspicion of Infection With SARS-CoV-2	Diagnostic Test: Serological tests will be applied on patients blood sampling	The positivity (Yes/No) of the serological test.	Hospices Civils de Lyon	All	18 Years and older   (Adult, Older Adult)	Not Applicable	400	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	69HCL20_0329	April 9, 2020	September 9, 2020	September 9, 2020	April 10, 2020		April 10, 2020			https://ClinicalTrials.gov/show/NCT04341142
217	NCT04338802	Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19		Not yet recruiting	No Results Available	COVID-19|Nintedanib|Safety|Effect of Drugs	Drug: Nintedanib 150 MG|Other: Placebo	Changes in forced vital capacity (FVC)|Changes in carbon monoxide dispersion (DLco%)|Changes in the six-minute walk test (6MWT)|Changes in High resolution CT score	Huilan Zhang|Tongji Hospital	All	18 Years to 70 Years   (Adult, Older Adult)	Phase 2	96	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	huilanz Zhang	April 2, 2020	May 4, 2020	August 1, 2020	April 8, 2020		April 8, 2020			https://ClinicalTrials.gov/show/NCT04338802
218	NCT04334954	SARS-COV2 Pandemic Serosurvey and Blood Sampling		Recruiting	No Results Available	SARS-COV2 Virus		Number of people with detectable antibodies to SARS-COV2	National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)	All	18 Years and older   (Adult, Older Adult)		1000	NIH	Observational	Observational Model: Case-Only|Time Perspective: Cross-Sectional	200083|20-I-0083	April 16, 2020	March 31, 2022	March 31, 2022	April 6, 2020		April 13, 2020	National Institutes of Health Clinical Center, Bethesda, Maryland, United States		https://ClinicalTrials.gov/show/NCT04334954
219	NCT04324021	Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.		Recruiting	No Results Available	SARS-CoV-2	Biological: Emapalumab|Biological: Anakinra	Treatment success|Time to mechanical ventilation|Change from baseline in Modified Early Warning system score|Change from baseline in resting peripheral capillary oxygen saturation (SpO2)|Change from baseline in partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2)|Change of pH in hemogasanalysis from baseline|Change of carbon dioxide tension (pCO2) in hemogasanalysis from baseline|Change of oxygen tension (pO2) in hemogasanalysis from baseline|Change of potassium in hemogasanalysis from baseline|Change of sodium in hemogasanalysis from baseline|Change of chloride in hemogasanalysis from baseline|Change of lactic acid in hemogasanalysis from baseline|Change of hemoglobin in hemogasanalysis from baseline|Change from baseline in oxygen supplementation|Change of findings of high-resolution computed tomography (CT) scan of the chest|Change from baseline in Ferritin|Change from baseline in lactate dehydrogenase (LDH)|Change from baseline in D-dimers|Change from baseline in White Blood Cells with differential counts|Change from baseline in Red Blood Counts|Change from baseline in Hemoglobin|Change from baseline in Platelet count|Change from baseline in Fibrinogen|Change from baseline in Complement factors C3/C4|Change from baseline in Prothrombin time|Change from baseline in Cardiac troponin|Change from baseline in aspartate aminotransferase (AST)|Change from baseline in alanine aminotransferase (ALT)|Change from baseline in total bilirubin levels|Change from baseline in C-Reactive Protein|Change from baseline in Creatinine|Overall survival|Time to hospital discharge	Swedish Orphan Biovitrum	All	30 Years to 79 Years   (Adult, Older Adult)	Phase 2|Phase 3	54	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Sobi.IMMUNO-101|2020-001167-93	April 2, 2020	July 2020	September 2020	March 27, 2020		April 9, 2020	ASST Spedali Civili di Brescia Dipartimento di Reumatologia e Immunologia Clinica, Brescia, Italy|Ospedale Maggiore Policlinico, Dipartimento di Anestesia-Rianimazione e Medicina di Urgenza, Milano, Italy|Azienda Ospedaliero-Universitaria di Parma, Dipartimento di Malattie infettive ed epatologia, Parma, Italy|Ospedale Lazzaro Spallanzani, Dipartimento di Malattie Infettive ad alta Intensità di cura ed altamente contagiose,Ospedale Lazzaro Spallanzani, Roma, Italy		https://ClinicalTrials.gov/show/NCT04324021
220	NCT04325048	Clinical Evaluation of Cordio Application in Adult COVID19 Virus Positive Patients		Not yet recruiting	No Results Available	Coronavirus Infection	Device: Cordio App	Voice anaysis	Cordio Medical	All	18 Years and older   (Adult, Older Adult)		5000	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	COV001	April 2020	June 2021	September 2021	March 27, 2020		March 27, 2020			https://ClinicalTrials.gov/show/NCT04325048
221	NCT04336787	Physical Activity Level, Stress Level, Sleep Quality in Pregnant Women During Covid-19 Quarantine		Not yet recruiting	No Results Available	Covid-19|Coronavirus Infection|Pregnancy Related	Other: Survey	International Physical Activity Questionnaire|Pittsburgh Sleep Quality Index|Perceived Stress Scale|Numerical Pain Rating Scale	Istanbul Kültür University|Istanbul University-Cerrahpasa	Female	18 Years to 45 Years   (Adult)		100	Other	Observational	Observational Model: Ecologic or Community|Time Perspective: Prospective	FADP-2	April 12, 2020	May 10, 2020	June 10, 2020	April 7, 2020		April 13, 2020	Istanbul University - Cerrahpaşa, Istanbul, Turkey		https://ClinicalTrials.gov/show/NCT04336787
222	NCT04292964	Prognostic Factors of Patients With COVID-19		Completed	No Results Available	SARS-CoV-2|Outcome, Fatal		all-cause mortality|Severe state	Chongqing Medical University	All	18 Years and older   (Adult, Older Adult)		201	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	02/02/2020	March 1, 2020	March 13, 2020	March 13, 2020	March 3, 2020		March 17, 2020	The First Affiliated Hospital of Chongqing Medical University, Chongqing, China		https://ClinicalTrials.gov/show/NCT04292964
223	NCT04328961	Hydroxychloroquine for COVID-19 PEP		Not yet recruiting	No Results Available	COVID-19|Corona Virus Infection|SARS (Severe Acute Respiratory Syndrome)	Drug: Hydroxychloroquine Sulfate|Drug: Ascorbic Acid	Polymerase chain reaction (PCR) confirmed SARS-CoV-2 infection|Rate of participant-reported adverse events|Incidence rates of COVID-19 through study completion	University of Washington|New York University|Bill and Melinda Gates Foundation	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 1	2000	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention	STUDY00009750	March 2020	September 30, 2020	October 31, 2020	April 1, 2020		April 1, 2020	NYU Langone Health, New York, New York, United States|University of Washington, Coordinating Center, Seattle, Washington, United States|UW Virology Research Clinic, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT04328961
224	NCT04342195	Acquiring Convalescent Specimens for COVID-19 Antibodies		Recruiting	No Results Available	COVID-19|Coronavirus Infection|Corona Virus Infection	Procedure: Blood draw	Number of antibodies against coronaviruses isolated and identified from patient samples	Columbia University	All	18 Years to 65 Years   (Adult, Older Adult)		12	Other	Observational	Observational Model: Case-Only|Time Perspective: Cross-Sectional	AAAS9517	March 25, 2020	March 2021	March 2021	April 10, 2020		April 13, 2020	Columbia University Irving Medical Center/NYP, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04342195
225	NCT04341441	Will Hydroxychloroquine Impede or Prevent COVID-19	WHIP COVID-19	Recruiting	No Results Available	COVID-19|Coronavirus|Coronavirus Infections|SARS-CoV 2	Drug: Hydroxychloroquine - Daily Dosing|Drug: Hydroxychloroquine - Weekly Dosing|Other: Placebo oral tablet|Diagnostic Test: Monitoring Visit - Baseline|Diagnostic Test: Monitoring Visit - Week 4|Diagnostic Test: Monitoring Visit - Week 8|Other: Weekly Assessment	Reduction in the number of COVID-19 infections in healthcare workers.	Henry Ford Health System	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 3	3000	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention	1410401	April 7, 2020	June 30, 2020	April 30, 2021	April 10, 2020		April 13, 2020	Henry Ford Hospital, Detroit, Michigan, United States|Detroit Department of Transportation (DDOT), Detroit, Michigan, United States|Detroit Fire Department & Detroit EMS, Detroit, Michigan, United States|Detroit Police Department, Detroit, Michigan, United States	Study Protocol, https://ClinicalTrials.gov/ProvidedDocs/41/NCT04341441/Prot_000.pdf	https://ClinicalTrials.gov/show/NCT04341441
226	NCT04268537	Immunoregulatory Therapy for 2019-nCoV		Not yet recruiting	No Results Available	2019 nCoV, PD-1	Drug: PD-1 blocking antibody+standard treatment|Drug: Thymosin+standard treatment|Other: standard treatment	lung injury score|absolute lymphocyte counts|serum level of CRP, PCT and IL-6|SOFA score|all cause mortality rate|ventilation free days|ICU free days	Southeast University, China	All	18 Years and older   (Adult, Older Adult)	Phase 2	120	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	2020YFC0841300-03	February 10, 2020	April 30, 2020	October 31, 2020	February 13, 2020		February 13, 2020			https://ClinicalTrials.gov/show/NCT04268537
227	NCT04316299	Acute Kidney Injury in Patients Hospitalized With COVID-19		Completed	No Results Available	COVID-19|Acute Kidney Injury|Kidney Function		Rate of Acute Kidney Injury|Rate of Death|the length of hospital stay	Zhenhua Zen|Nanfang Hospital of Southern Medical University	All	18 Years and older   (Adult, Older Adult)		287	Other	Observational	Observational Model: Case-Control|Time Perspective: Retrospective	hkyy2020-005 AKI	February 26, 2020	February 28, 2020	March 8, 2020	March 20, 2020		March 30, 2020	Hankou Hospital, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04316299
228	NCT04310865	Yinhu Qingwen Granula for the Treatment of Severe CoVID-19		Not yet recruiting	No Results Available	COVID-19|Severe Pneumonia|Chinese Medicine	Drug: Yinhu Qingwen Granula|Drug: Yin Hu Qing Wen Granula(low does)|Other: standard medical treatment	changes in the ratio of PaO2 to FiO2 from baseline|PaO2|blood oxygen saturation (SpO2)|clinical status rating on the 7-point ordinal scale|Time to Clinical Improvement (TTCI)|Duration (hours) of non-invasive mechanical ventilation or high-flow nasal catheter oxygen inhalation use|Duration (hours) of invasive mechanical ventilation use|Duration (hours) of extracorporeal membrane oxygenation (ECMO) use|Duration (days) of Oxygen use|The proportion of the patients reporting 2019-nCoV RT-PCR negativity at Day 10 after treatment|The counts/percentage of Lymphocyte|Time to hospital discharge with clinical recovery from the randomisation|The incidence of critical status conversion in 30 days|All-cause mortality within 30 days|Frequency of severe adverse drug events	Zhong Wang|Wuhan Leishenshan Hospital|The First Affiliated Hospital of Dalian Medical University|Tanshan People's Hospital|North China University of Science and Technology Affiliated Hospital|Jizhong Energy Fengfeng Group Hospital|China Academy of Chinese Medical Sciences	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	116	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	YHQW-Severe-V2.0	March 20, 2020	March 30, 2021	June 30, 2021	March 17, 2020		March 17, 2020	Wuhan No.7 Hospital/Jizhong Energy Fengfeng Group Hospital, Wuhan, Hubei, China|Wuhan No.7 Hospital/North China University of Science and Technology Affiliated Hospital, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University/Tanshan People's Hospital, Wuhan, Hubei, China|Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04310865
229	NCT04336345	Outcomes of Patients With COVID-19 in the Intensive Care Unit	MexCOVID-19	Not yet recruiting	No Results Available	Coronavirus Infections|COVID-19|Viral Pneumonia Human Coronavirus		Hospital mortality|Length of stay in the intensive care unit	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran	All	18 Years and older   (Adult, Older Adult)		150	Other	Observational	Observational Model: Cohort|Time Perspective: Cross-Sectional	TEI-3336-20-20-1	April 1, 2020	April 30, 2020	May 30, 2020	April 7, 2020		April 7, 2020	Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico|All centres from Mexico willing to contribute are Welcome., Mexico, Mexico		https://ClinicalTrials.gov/show/NCT04336345
230	NCT04339634	Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy		Active, not recruiting	No Results Available	COVID|Drug Effect|Drug Interaction|Adverse Drug Event	Other: Simulation of Repurposed Drugs for COVID-19	To determine the Medication Risk Score of de-identified PACE's participants using their current drug regimen.|To simulate the Medication Risk Score following the addition of different repurposed drugs against COVID-19 to their current drug regimen.|To compare the impact on Medication Risk Score before and after the addition of repurposed drugs for COVID-19.|To assess and compare the effects of various repurposed drugs for COVID-19 on each of the 5 factors computed by algorithms to derive the Medication Risk Score.|To investigate the effects of various covariables on the Medication Risk Score in the presence of repurposed drugs for COVID-19.|To explore the effects on Medication Risk Score of various repurposed drugs for COVID-19 within subgroups of patients classified by specific diseases or drugs used.	Tabula Rasa HealthCare	All	55 Years and older   (Adult, Older Adult)		12123	Industry	Observational	Observational Model: Cohort|Time Perspective: Retrospective	COVID-PACE-2020-001	April 7, 2020	July 7, 2020	April 6, 2021	April 9, 2020		April 9, 2020	Tabula Rasa HealthCare Precision Pharmacotherapy Research and Development Institute, Orlando, Florida, United States		https://ClinicalTrials.gov/show/NCT04339634
231	NCT04339881	NOsocomial Dissemination Risk of SARS-Cov2	NODS-Cov2	Not yet recruiting	No Results Available	Sars-CoV2		Understanding the dissemination of SARS Cov2 in hospital|Optimizing hospital strategies to prevent transmission to caregivers and not infected hospitalized patients with SARSCov2	Assistance Publique - Hôpitaux de Paris	All	Child, Adult, Older Adult		100	Other	Observational	Observational Model: Other|Time Perspective: Prospective	APHP200417	April 13, 2020	May 15, 2020	June 15, 2020	April 9, 2020		April 9, 2020			https://ClinicalTrials.gov/show/NCT04339881
232	NCT04325646	Sero-epidemiological Study of the SARS-CoV-2 Virus in France: Constitution of a Collection of Human Biological Samples	CORSER	Recruiting	No Results Available	SARS (Severe Acute Respiratory Syndrome)|COVID-19	Other: Human Biological samples	Presence of specific anti-SARS-CoV-2 antibodies in the different study groups.|Percentage of asymptomatic forms in individuals with anti-SARS-CoV-2 antibodies	Institut Pasteur	All	5 Years and older   (Child, Adult, Older Adult)		1000	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	2020-007	March 13, 2020	February 28, 2021	February 28, 2023	March 27, 2020		March 31, 2020	CHU Amiens-Picardie, Amiens, France|CHU François Mitterand, Dijon, France|CHU Limoges, Limoges, France|Hôpital de la Croix Rousse, Lyon, France|Hôpitaux de Brabois, Nancy, France|CHR Orléans, Orléans, France|Institut Pasteur, Paris, France|CHU Poitiers, Poitiers, France|Hôpital Pontchaillou, Rennes, France|CHU Saint-Etienne, Saint-Étienne, France|CH de Tourcoing, Tourcoing, France|Hôpital Bretonneau, Tours, France		https://ClinicalTrials.gov/show/NCT04325646
233	NCT04334876	Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers	COVID-Antibody	Not yet recruiting	No Results Available	SARS-CoV-2	Diagnostic Test: SARS-CoV-2 IgG Antibody Testing Kit	Validation of SARS-CoV-2 IgG Antibody Test|Incidence of Seroconversion|Identify Candidacy	Indiana University	All	18 Years and older   (Adult, Older Adult)		340	Other	Observational	Observational Model: Ecologic or Community|Time Perspective: Prospective	2003973826	April 1, 2020	November 1, 2020	January 1, 2021	April 6, 2020		April 6, 2020			https://ClinicalTrials.gov/show/NCT04334876
234	NCT04320017	Joint Use of Electrocardiogram and Transthoracic Echocardiography in an Observational Study to Monitor Cardio-vascular Events in Patients Diagnosed With COVID-19	JOCOVID	Recruiting	No Results Available	COVID-19|Myocardial Injury|Myocarditis	Diagnostic Test: Electrocardiogram and transthoracic echocardiography	Incidence of acute myocardial events in COVID-19 population at baseline and during hospital stay|Description of cardiovascular outcomes in the cohort|Prognosis role of baseline cardio-vascular caracteristics on patients survival|Prediction of cardio-vascular events with baseline characteristics|Characterization of inflammation on cardio-vascular outcomes	Groupe Hospitalier Pitie-Salpetriere	All	16 Years and older   (Child, Adult, Older Adult)		500	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	CIC1421-20-05	March 20, 2020	May 20, 2020	May 20, 2020	March 24, 2020		March 24, 2020	Clinical Investigation Center Pitié-Salpêtrière, Paris, France		https://ClinicalTrials.gov/show/NCT04320017
235	NCT04273763	Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)		Enrolling by invitation	No Results Available	Novel Coronavirus Pneumonia|2019-nCoV	Drug: Bromhexine Hydrochloride Tablets|Drug: Arbidol Hydrochloride Granules|Drug: Recombinant Human Interferon α2b Spray	Time to clinical recovery after treatment|Rate of aggravation|Clinical remission rate|Dynamic changes of oxygenation index|Time to cure|rate to cure|Time to defervescence|Time to cough remission|Time to dyspnea remission|Days of supplemental oxygenation|Rate of patients with requring supplemental oxygen|Rate of patients with mechanical ventilation|Time of negative COVID-19 nucleic acid results|Rate of negative COVID-19 nucleic acid results|Rate of ICU admission|28-day mortality	Second Affiliated Hospital of Wenzhou Medical University|WanBangDe Pharmaceutical Group Co.,Ltd.	All	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	60	Other	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2019NCP1.0	February 16, 2020	April 15, 2020	April 30, 2020	February 18, 2020		March 23, 2020	The Second AffIliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China		https://ClinicalTrials.gov/show/NCT04273763
236	NCT04337424	Evaluation of Quickly Diagnostic Saliva Tests for SARS-CoV-2	EasyCoV	Not yet recruiting	No Results Available	SARS-CoV-2	Diagnostic Test: Sampling salivary	Specific detection of SARS-CoV-2 specific RNA|Analytical sensitivity of the LAMP test.|The correlation between the measurement of the assayed viral load (CT value) by the standard method and by the LAMP developed by SYS2DIAG / SKILLCELL.|Evaluation of the use of saliva samples compared to nasopharyngeal samples	University Hospital, Montpellier|SkillCell|Sys2Diag (CNRS-Alcediag UMR9005)	All	18 Years to 90 Years   (Adult, Older Adult)		180	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	RECHMPL20_0170	April 7, 2020	April 17, 2020	April 17, 2020	April 7, 2020		April 7, 2020			https://ClinicalTrials.gov/show/NCT04337424
237	NCT04252664	Mild/Moderate 2019-nCoV Remdesivir RCT		Recruiting	No Results Available	2019-nCoV	Drug: Remdesivir|Drug: Remdesivir placebo	Time to Clinical recoveryTime to Clinical Recovery (TTCR)|All cause mortality|Frequency of respiratory progression|Time to defervescence (in those with fever at enrolment)|Time to cough reported as mild or absent (in those with cough at enrolment rated severe or moderate)|Time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnoea at enrolment rated as severe or moderate,)|Frequency of requirement for supplemental oxygen or non-invasive ventilation|Time to 2019-nCoV RT-PCR negative in upper respiratory tract specimen|Change (reduction) in 2019-nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve.|Frequency of requirement for mechanical ventilation|Frequency of serious adverse events	Capital Medical University|Chinese Academy of Medical Sciences	All	18 Years and older   (Adult, Older Adult)	Phase 3	308	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CAP-China remdesivir 1	February 12, 2020	April 10, 2020	April 27, 2020	February 5, 2020		February 24, 2020	Jin Yin-tan hospital, Wu Han, Hubei, China		https://ClinicalTrials.gov/show/NCT04252664
238	NCT04252118	Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus		Recruiting	No Results Available	2019 Novel Coronavirus Pneumonia	Biological: MSCs	Size of lesion area by chest radiograph or CT|Side effects in the MSCs treatment group|Improvement of Clinical symptoms including duration of fever and respiratory|Time of nucleic acid turning negative|Rate of mortality within 28-days|CD4+ and CD8+ T celll count|Alanine aminotransferase|C-reactive protein|Creatine kinase	Beijing 302 Hospital|Innovative Precision Medicine Group (IPM), Hangzhou, China.|Huoshenshan Hospital|Tianjin Haihe Hospital|VCANBIO CELL & GENE ENGINEERING CORP.,LTD, China|Shenzhen Third People's Hospital|Fifth Affiliated Hospital, Sun Yat-Sen University	All	18 Years to 70 Years   (Adult, Older Adult)	Phase 1	20	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020003D	January 27, 2020	December 2020	December 2021	February 5, 2020		February 26, 2020	Beijing 302 Military Hospital of China, Beijing, China		https://ClinicalTrials.gov/show/NCT04252118
239	NCT04261426	The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia		Not yet recruiting	No Results Available	2019-nCoV	Drug: Intravenous Immunoglobulin|Other: Standard care	Clinical improvement based on the 7-point scale|Lower Murray lung injury score|28-day mortality|Duration of mechanical ventilation|Duration of hospitalization|Proportion of patients with negative RT-PCR results|Proportion of patients in each category of the 7-point scale|Proportion of patients with normalized inflammation factors|Frequency of Adverse Drug Events|Frequency of Serious Adverse Drug Events	Peking Union Medical College Hospital|Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	80	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IVIG-001	February 10, 2020	April 30, 2020	June 30, 2020	February 7, 2020		February 7, 2020			https://ClinicalTrials.gov/show/NCT04261426
240	NCT04255017	A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia		Recruiting	No Results Available	2019-nCoV	Drug: Abidol hydrochloride|Drug: Oseltamivir|Drug: Lopinavir/ritonavir	Rate of disease remission|Time for lung recovery|Rate of no fever|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of CRP,ES,Biochemical criterion(CK,ALT,Mb) recovery|Rate of undetectable viral RNA	Tongji Hospital	All	18 Years and older   (Adult, Older Adult)	Phase 4	400	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	TJ20200128	February 1, 2020	June 1, 2020	July 1, 2020	February 5, 2020		March 17, 2020	Department and Institute of Infectious Disease, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04255017
241	NCT04336215	Rutgers COVID-19 Cohort Study		Recruiting	No Results Available	Coronavirus|SARS-CoV-2	Other: Non-Interventional	Prevalence|Incidence	Rutgers, The State University of New Jersey	All	20 Years and older   (Adult, Older Adult)		750	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	2020000679	March 28, 2020	September 1, 2020	October 21, 2021	April 7, 2020		April 7, 2020	Clinical Research Center Rutgers-Robert Wood Johnson Medical School RWJUH East Tower -, New Brunswick, New Jersey, United States|Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Clinical Research Unit Rutgers New Jersey Medical School, Newark, New Jersey, United States|Rutgers School of Dental Medicine, Newark, New Jersey, United States|University Hospital, Newark, New Jersey, United States|Environmental and Occupational Health Sciences Institute, Piscataway, New Jersey, United States|RUCDR Infinite Biologics, Piscataway, New Jersey, United States		https://ClinicalTrials.gov/show/NCT04336215
242	NCT04254874	A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia		Recruiting	No Results Available	2019-nCoV	Drug: Abidol hydrochloride|Drug: Abidol Hydrochloride combined with Interferon atomization	Rate of disease remission|Time for lung recovery|Rate of no fever|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of CRP,ES,Biochemical criterion (CK,ALT,Mb)recovery|Rate of undetectable viral RNA	Tongji Hospital	All	18 Years and older   (Adult, Older Adult)	Phase 4	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	TJ20200131	February 1, 2020	June 1, 2020	July 1, 2020	February 5, 2020		March 17, 2020	Department and Institute of Infectious Disease, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04254874
243	NCT04321265	Outcomes and Prognostic Factors in COVID-19	COVIP	Recruiting	No Results Available	COVID-19|Elderly Patients|Critical Illness|Survival|Old Age		Survival|Fragilty	Heinrich-Heine University, Duesseldorf	All	70 Years and older   (Older Adult)		4000	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	20-004	March 19, 2020	September 2020	December 2020	March 25, 2020		April 8, 2020	Department of Intensive Care, Aarhus University Hospital, Aarhus, Denmark|Hôpitaux de Paris, Hôpital Saint-Antoine, service de réanimation médicale, Paris, France|INSERM, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France|Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France|Division of Cardiology, Pulmonary Disease and Vascular Medicine, Duesseldorf, Germany|Department of Anaestesia and Intensive Care, Haukeland University Hospital, Bergen, Norway|Department of Clinical Medecine,University of Bergen, Bergen, Norway		https://ClinicalTrials.gov/show/NCT04321265
244	NCT04323787	Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID19 Registry	VIRUS	Recruiting	No Results Available	Coronavirus	Other: observational	ICU and hospital mortality of COVID-19 patients|30 days mortality	Mayo Clinic	All	Child, Adult, Older Adult		50000	Other	Observational	Observational Model: Cohort|Time Perspective: Other	20-002610	March 30, 2020	April 30, 2021	April 30, 2021	March 27, 2020		April 3, 2020	Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Society of Critical Care Medicine (150+ sites), Chicago, Illinois, United States|Rahul Kashyap, Rochester, Minnesota, United States		https://ClinicalTrials.gov/show/NCT04323787
245	NCT04327206	BCG Vaccination to Protect Healthcare Workers Against COVID-19	BRACE	Recruiting	No Results Available	Coronavirus Disease 2019 (COVID-19)|Febrile Respiratory Illness|Corona Virus Infection|COVID-19	Drug: BCG Vaccine	COVID-19 disease incidence|Severe COVID-19 disease incidence|COVID-19 incidence by 12 months|Severe COVID-19 incidence by 12 months|Time to first symptom of COVID-19|Episodes of COVID-19|Asymptomatic SARS-CoV-2 infection|Work absenteeism due to COVID-19|Bed confinement due to COVID-19|Symptom duration of COVID-19|SARS-CoV-2 pneumonia|Oxygen therapy with SARS-CoV-2|Critical care admissions with SARS-CoV-2|Critical care admission duration with SARS-CoV-2|Mechanical ventilation with SARS-CoV-2|Mechanical ventilation duration with SARS-CoV-2|Hospitalisation duration with COVID-19|Mortality with SARS-CoV-2|Febrile respiratory illness|Episodes of febrile respiratory illness|Work absenteeism due to febrile respiratory illness|Bed confinement due to febrile respiratory illness|Symptom duration of febrile respiratory illness|Pneumonia|Oxygen therapy|Critical care admissions|Mechanical ventilation|Mortality|Hospitalisation duration with febrile respiratory illness|Unplanned work absenteeism|Hospitalisation cost to treat COVID-19|Local and systemic adverse events to BCG vaccination in healthcare workers	Murdoch Childrens Research Institute|Royal Children's Hospital	All	18 Years and older   (Adult, Older Adult)	Phase 3	4170	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	62586	March 30, 2020	October 30, 2020	March 30, 2022	March 31, 2020		April 7, 2020	Epworth Victoria Parade, Melbourne, Victoria, Australia|Royal Children's Hospital, Melbourne, Victoria, Australia|Epworth Richmond, Melbourne, Victoria, Australia|Epworth Eastern, Melbourne, Victoria, Australia|Monash Health- Monash Medical Centre, Melbourne, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Perth Children's Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia		https://ClinicalTrials.gov/show/NCT04327206
246	NCT04316949	Predictors of Respiratory Failure in SARS-Cov-2 Infection		Recruiting	No Results Available	SARS-CoV-2 Pneumonia		Respiratory failure|Occurence of bacterial superinfection	University of Bologna	All	18 Years to 99 Years   (Adult, Older Adult)		350	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	PREDI-CO	March 20, 2020	April 30, 2020	May 31, 2020	March 20, 2020		April 7, 2020	University of Bologna - Department of Medical and Surgical Sciences, Bologna, Italy		https://ClinicalTrials.gov/show/NCT04316949
247	NCT04321616	The Efficacy of Different Anti-viral Drugs in (Severe Acute Respiratory Syndrome-Corona Virus-2) SARS-CoV-2		Not yet recruiting	No Results Available	SARS-CoV Infection|COVID 19|Acute Respiratory Distress Syndrome ARDS	Drug: Hydroxychloroquine|Drug: Remdesivir|Other: (Standard of Care) SoC	In-hospital mortality|Occurrence and duration of mechanical ventilation|Occurrence and duration of intensive care unit (ICU) treatment|Duration of hospital admittance|28 Day mortality|Viral clearance as assessed by SARS-CoV-2 PCR in peripheral blood and nasopharyngeal airway speciemen|Occurrence of co-infections|Occurrence of organ dysfunction	Oslo University Hospital	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	700	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	118684	March 26, 2020	August 2020	November 2020	March 25, 2020		April 3, 2020			https://ClinicalTrials.gov/show/NCT04321616
248	NCT04339712	Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction	ESCAPE	Not yet recruiting	No Results Available	COVID-19|Virus Diseases|Macrophage Activation Syndrome|Corona Virus Infection	Drug: Anakinra|Drug: Tocilizumab	Change of baseline total sequential organ failure assessment (SOFA) score|Improvement of lung involvement measurements|Increase of pO2/FiO2 ratio|Comparison of change of baseline total sequential organ failure assessment (SOFA) score in enrolled subjects towards historical comparators|Comparison of change of lung involvement measurements in enrolled subjects towards historical comparators|Comparison of pO2/FiO2 ratio in enrolled subjects towards historical comparators|Change of sequential organ failure assessment (SOFA) score|Rate of Mortality|Cytokine stimulation|Gene expression|Serum/plasma proteins|Classification of the immune function	Hellenic Institute for the Study of Sepsis	All	18 Years and older   (Adult, Older Adult)	Phase 2	20	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ESCAPE|2020-001039-29	April 6, 2020	April 1, 2022	April 1, 2022	April 9, 2020		April 13, 2020	2nd Department of Critical Care Medicine, ATTIKON University Hospital, Athens, Haidari, Greece|Intensive Care Unit, Ioannina University Hospital, Ioánnina, Ioannina, Greece|Department of Internal Medicine, Patras University Hospital, Patras, Rion, Greece|Department of Internal Medicine, I PAMMAKARISTOS Hospital, Athens, Greece|Intensive Care Unit, General Hospital of Athens KORGIALENIO-BENAKIO E.E.S., Athens, Greece|1st Department of Pulmonary Medicine and Intensive Care Unit, Athens, Greece|Intensive Care Unit, General Hospital of Athens IPPOKRATEIO, Athens, Greece|4th Department of Internal Medicine, Attikon University Hospital, Athens, Greece|Intensive Care Unit, General Hospital ASKLEPIEIO Voulas, Athens, Greece|Intensive Care Unit, "Latsio", Thriasio Elefsis General Hospital, Elefsína, Greece|Intensive Care Unit, "Koutlimbaneio & Triantafylleio" Larissa General Hospital, Larissa, Greece|Department of Internal Medicine, Larissa University Hospital, Larissa, Greece|Intensive Care Unit, AGIOS DIMITRIOS General Hospital of Thessaloniki, Thessaloniki, Greece|Intensive Care Unit, G. GENNIMATAS General Hospital of Thessaloniki, Thessaloniki, Greece|Intensive Care Unit, Theageneio Oncological Hospital of Thessaloniki, Thessaloniki, Greece|Intensive Care Unit, General Hospital of Thessaloniki IPPOKRATEIO, Thessaloniki, Greece|Department of Anesthesiology and Intensive Care Medicine, University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece		https://ClinicalTrials.gov/show/NCT04339712
249	NCT04323761	Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection		Available	No Results Available	SARS-CoV2 Infection	Drug: Remdesivir		Gilead Sciences	All	18 Years and older   (Adult, Older Adult)			Industry	Expanded Access:Treatment IND/Protocol		GS-US-540-5821|2020-001453-49				March 27, 2020		April 9, 2020	Huntington Hospital, Pasadena, California, United States|California Pacific Medical Center, San Francisco, California, United States|Regional Medical Center, San Jose, California, United States|Lawnwood Regional Medical Center, Fort Pierce, Florida, United States|Sarasota Memorial Hospital Clinical Research Center, Sarasota, Florida, United States|Piedmont Fayette Hospital, Fayetteville, Georgia, United States|Touro Infirmary, New Orleans, Louisiana, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|St. Joseph Mercy Hospital Health System, Ann Arbor, Michigan, United States|Hackensack Meridian Health - JFK Medical Center, Edison, New Jersey, United States|Hunterdon Medical Center, Flemington, New Jersey, United States|St. Michael's Medical Center, Newark, New Jersey, United States|The Valley Hospital, Ridgewood, New Jersey, United States|Holy Name Medical Center, Teaneck, New Jersey, United States|Maimonides Medical Center, Brooklyn, New York, United States|New York Presbyterian Hospital, Flushing, New York, United States|Mount Sinai South Nassau, Oceanside, New York, United States|Ellis Hospital, Schenectady, New York, United States|Texas Health Presbyterian Hospital Dallas, Dallas, Texas, United States|Centre Hospitalier Universitaire de Poitiers, Poitiers, France|Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy|Southampton University Hospital, Southampton, United Kingdom		https://ClinicalTrials.gov/show/NCT04323761
250	NCT04343053	Pro-thrombotic Status in Patients With SARS-Cov-2 Infection	ATTAC-Co	Recruiting	No Results Available	Severe Acute Respiratory Syndrome Coronavirus 2	Other: SARS-Cov-2 infection	on-treatment platelet reactivity|apoptosis rate in human umbilical vein endothelial cells (HUVEC)|Nitric oxide (NO) intracellular levels|reactive oxygen species (ROS) levels|coagulation factors levels|respiratory function|cardiac function|clinical outcome	University Hospital of Ferrara	All	18 Years and older   (Adult, Older Adult)	Not Applicable	60	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	250320	April 8, 2020	June 30, 2020	June 30, 2021	April 13, 2020		April 13, 2020	Azienda Ospedaliera Universitaria di Ferrara, Ferrara, Italy		https://ClinicalTrials.gov/show/NCT04343053
251	NCT04261270	A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia		Recruiting	No Results Available	2019-nCoV Pneumonia	Drug: ASC09F+Oseltamivir|Drug: Ritonavir+Oseltamivir|Drug: Oseltamivir	Rate of comprehensive adverse outcome|Time of clinical remission|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no need for oxygen inhalation|Rate of undetectable viral RNA|Rate of mechanical ventilation|Rate of ICU admission|Rate and time of CRP,ES,Biochemical criterion(CK,ALT,Mb)recovery	Tongji Hospital	All	18 Years to 55 Years   (Adult)	Phase 3	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	ASC09F-CTP-TJ-01	February 1, 2020	May 1, 2020	July 1, 2020	February 7, 2020		March 17, 2020	Department and Institute of Infectious Disease, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04261270
252	NCT04330300	Coronavirus (COVID-19) ACEi/ARB Investigation	CORONACION	Recruiting	No Results Available	Hypertension|COVID-19	Drug: Thiazide or Thiazide-like diuretics|Drug: Calcium Channel Blockers|Drug: ACE inhibitor|Drug: Angiotensin receptor blocker	Number of Covid-19 positive participants who die, require intubation in ICU, or require hospitalization for non-invasive ventilation (NIV)|Number of Covid-19 positive participants who die|Number of Covid-19 positive participants who require intubation in intensive care unit (ICU)|Number of Covid-19 positive participants who require hospitalization for non-invasive ventilation (NIV)|Number of SARS-CoV-2 positive participants|Maximum troponin T value (ng/L) among Covid-19 positive participants who require acute hospitalization|24 hour mean systolic BP (mmHg) on ambulatory BP monitoring|All-cause mortality	National University of Ireland, Galway, Ireland	All	60 Years and older   (Adult, Older Adult)	Phase 4	2414	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	C.A. 2348	March 30, 2020	January 31, 2021	March 1, 2021	April 1, 2020		April 13, 2020	University Hospital Galway, Galway, Ireland		https://ClinicalTrials.gov/show/NCT04330300
253	NCT04332042	TOFAcitinib in SARS-CoV2 Pneumonia		Not yet recruiting	No Results Available	SARS-COv2 Related Interstitial Pneumonia	Drug: Tofacitinib	need of mechanical ventilation|need of admission in intensive care unit|death|rate of adverse events	Università Politecnica delle Marche	All	18 Years to 65 Years   (Adult, Older Adult)	Phase 2	50	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TOFACoV	April 10, 2020	June 20, 2020	July 10, 2020	April 2, 2020		April 2, 2020	Ospedali Riuniti di Ancona, Ancona, Marche, Italy		https://ClinicalTrials.gov/show/NCT04332042
254	NCT04320472	Acute Encephalopathy in Critically Ill Patients With COVID-19	NeuroCOVID19	Recruiting	No Results Available	COVID-19|Encephalopathy|Critically Ill	Other: Follow up	prevalence|Favorable outcome	Ictal Group	All	18 Years and older   (Adult, Older Adult)		250	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	Neuro-COVID-19	March 23, 2020	December 2020	December 2020	March 25, 2020		April 13, 2020	Centre Hospitalier de Versailles, Le Chesnay, France		https://ClinicalTrials.gov/show/NCT04320472
255	NCT04329195	ACE Inhibitors or ARBs Discontinuation in Context of SARS-CoV-2 Pandemic	ACORES-2	Not yet recruiting	No Results Available	History of Cardiovascular Disease Treated With RAS Blockers and With SARS-CoV-2 Infection	Drug: 1: discontinuation of RAS blocker therapy|Drug: 2: continuation of RAS blocker therapy	Time to clinical improvement from day 0 to day 28 (improvement of two points on a seven-category ordinal scale, or live discharge from the hospital, whichever comes first)|Primary safety endpoint: major adverse cardiac events defined as the composite of cardiovascular death, myocardial infarction, stroke or acute heart failure at day 28|Clinical status as assessed with the seven-category ordinal scale on days 7, 14 and 28.|Number of days alive free of oxygen.|Number of days alive outside hospital until day28|Number of days alive free of intensive-care unit (ICU) admission or mechanical ventilation (invasive or non-invasive) until day28|Number of days alive free of mechanical ventilation (invasive or non-invasive) until day28|Number of days alive free of ICU admission until day28|Rate of all-cause mortality at day 28|Rate of cardiovascular death at day 28|Number of days alive free of acute kidney injury until hospital discharge	Assistance Publique - Hôpitaux de Paris|Groupe Hospitalier Pitié-Salpêtrière	All	18 Years and older   (Adult, Older Adult)	Phase 3	554	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	APHP200409	April 2020	May 2020	May 2020	April 1, 2020		April 6, 2020			https://ClinicalTrials.gov/show/NCT04329195
256	NCT04263402	The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia		Recruiting	No Results Available	2019-nCoV Severe Pneumonia	Drug: Methylprednisolone	Rate of disease remission|Rate and time of entering the critical stage|Rate of normal tempreture|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of laboratory indicator recovery|Rate of undetectable viral RNA	Tongji Hospital	All	18 Years and older   (Adult, Older Adult)	Phase 4	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	TJ20200201	February 1, 2020	June 1, 2020	July 1, 2020	February 10, 2020		March 17, 2020	Department and Institute of Infectious Disease, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04263402
257	NCT04341389	A Phase II Clinical Trial to Evaluate the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector)	CTII-nCoV	Not yet recruiting	No Results Available	COVID-19	Biological: Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)|Other: Placebo	Occurrence of adverse reactions|Anti SARS-CoV-2 S antibody response(ELISA)|Neutralizing antibody response to SARS-CoV-2|Occurrence of adverse events|Occurrence of serious adverse reaction|Neutralizing antibody response to Ad5-vector	Insitute of Biotechnology, Academy of Military Medical Sciences, PLA of China|CanSino Biologics Inc.|Jiangsu Province Centers for Disease Control and Prevention|Hubei Provincial Center for Disease Control and Prevention	All	18 Years and older   (Adult, Older Adult)	Phase 2	500	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention	JSVCT089	April 12, 2020	January 31, 2021	January 31, 2021	April 10, 2020		April 10, 2020			https://ClinicalTrials.gov/show/NCT04341389
258	NCT04340050	COVID-19 Convalescent Plasma		Not yet recruiting	No Results Available	Coronavirus	Biological: anti-SARS-CoV-2 convalescent plasma	Feasibility of performing study pathway consisting of consenting convalescent donors, harvesting convalescent plasma, application for FDA eIND and administering convalescent plasma to the patients|Type of respiratory support|Cardiac arrest|Transfer to ICU|ICU mortality|ICU length of stay|Hospital mortality|Hospital length of stay|Ventilator-free days|Overall survival (28-day mortality)	University of Chicago	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	10	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB20-0523	April 30, 2020	December 31, 2020	December 31, 2021	April 9, 2020		April 9, 2020	University of Chicago Medicine, Chicago, Illinois, United States		https://ClinicalTrials.gov/show/NCT04340050
259	NCT04342806	Healthcare Worker Exposure Response and Outcomes (HERO) Registry Study, COVID-19		Recruiting	No Results Available	Health Care Worker (HCW)|COVID-19		Number and percent of participants who enroll in the HERO Registry Study by geographic region, age, COVID-19 risk factors, and past COVID-19 diagnosis|Distribution of COVID-19 risk factors by participant characteristics|Proportion of participants undergoing changes in health status (e.g. new diagnosis of COVID-19, ER visits, hospitalization)|Proportion of all participants enrolled in the HERO Registry who participate in an ancillary research study|Proportion of participants who continue to supple information about their health to the HERO Registry at various time points after their enrollment	Duke University|Patient-Centered Outcomes Research Institute	All	18 Years to 89 Years   (Adult, Older Adult)		100000	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	Pro00105284	April 10, 2020	December 31, 2099	December 31, 2099	April 13, 2020		April 13, 2020	Duke Clinical Research Institute, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT04342806
260	NCT04333368	Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS	STROMA-CoV2	Not yet recruiting	No Results Available	Severe Acute Respiratory Syndrome Coronavirus 2|Severe Acute Respiratory Distress Syndrome	Biological: Umbilical cord Wharton's jelly-derived human|Other: NaCl 0.9%	Respiratory efficacy evaluated by the increase in PaO2/FiO2 ratio from baseline to day 7 in the experimental group compared with the placebo group|Lung injury score|Oxygenation index|In-hospital mortality|Mortality|Ventilator-free days|Number of days between randomization and the first day the patient meets weaning criteria o Number of days between randomization and the first day the patient meets PaO2/FiO2 > 200 (out of a prone positioning session)|Cumulative use of sedatives|Cumulative duration of use of sedatives|Cumulative duration of use of neuromuscular blocking agents (other than used for intubation)|Cumulative use of neuromuscular blocking agents (other than used for intubation)|ICU-acquired weakness and delirium|Treatment-induced toxicity rate and adverse events up to day 28|Quality of life at one year (EQ5D-3L quality of life questionnaire)|Measurements of plasmatic cytokines (IL1, IL6, IL8, TNF-alpha, IL10, TGF-beta, sRAGE, Ang2) level|Anti-HLA antibodies plasmatic dosage	Assistance Publique - Hôpitaux de Paris	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	APHP200395|2020-001287-28	April 1, 2020	June 30, 2020	May 31, 2021	April 3, 2020		April 3, 2020	Hôpital Pitié-Salpêtrière - APHP, Paris, France|Hôpital Européen Georges Pompidou - APHP, Paris, France		https://ClinicalTrials.gov/show/NCT04333368
261	NCT04279197	Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu		Recruiting	No Results Available	Pulmonary Fibrosis Due to 2019-nCoV	Drug: N-acetylcysteine+ Fuzheng Huayu Tablet|Drug: N-acetylcysteine+Placebo	High-resolution computed tomography (HRCT) score|Lung function including FVC, FVC as a percentage of projected value and DLco|Times of acute exacerbation|Six-minute walk distance|Dyspnea Scores|Composite physiological index	ShuGuang Hospital|Hubei Hospital of Traditional Chinese Medicine|Jingmen No.1 People’s Hospital|Tongji Hospital	All	18 Years to 65 Years   (Adult, Older Adult)	Phase 2	136	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	Fzhy-ncp-2	February 15, 2020	December 2022	December 2022	February 21, 2020		February 21, 2020	Shuguang Hospital, Shanghai, Shanghai, China		https://ClinicalTrials.gov/show/NCT04279197
262	NCT04284046	CT Scores Predict Mortality in 2019-nCoV Pneumonia		Completed	No Results Available	CT Scores Predict Mortality in 2019-nCoV Pneumonia	Other: CT score	7-day mortality	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	All	Child, Adult, Older Adult		39	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	CT2019-nCoV	January 31, 2020	February 18, 2020	February 18, 2020	February 25, 2020		February 25, 2020	Wuhan third hospital, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04284046
263	NCT04331613	Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS		Recruiting	No Results Available	COVID-19|Acute Respiratory Distress Syndrome|Virus; Pneumonia|Acute Lung Injury	Biological: CAStem	Adverse reaction (AE) and severe adverse reaction (SAE)|Changes of lung imaging examinations|Time to SARS-CoV-2 RT-PCR negative|Duration of fever (Celsius)|Changes of blood oxygen (%)|Rate of all-cause mortality within 28 days|Lymphocyte count (*10^9/L)|Alanine aminotransferase (U/L)|Creatinine (umol/L)|Creatine kinase (U/L)|C-reactive protein (mg/L)|Procalcitonin (ng/L)|Lactate (mmol/L)|IL-1beta (pg/mL)|IL-2 (pg/mL)|IL-6 (pg/mL)|IL-8 (pg/mL)	Chinese Academy of Sciences|Beijing YouAn Hospital	All	18 Years to 70 Years   (Adult, Older Adult)	Phase 1|Phase 2	9	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ChineseASZQ-006	January 27, 2020	December 2020	December 2020	April 2, 2020		April 2, 2020	Beijing YouAn Hospital, Capital Medical University, Beijing, Beijing, China, China		https://ClinicalTrials.gov/show/NCT04331613
264	NCT04321928	Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary	PROACTIVE-19	Not yet recruiting	No Results Available	SARS-CoV-2|Coronavirus|COVID-19|2019-nCoV|2019nCoV	Behavioral: Personalized health education|Behavioral: General health education	Primary composite rate of intensive care unit (ICU) admission, 48 hours of hospital admission, death in COVID-19 positive cases|The number of general practitioner visits|The number of emergency, hospital admission and intensive care admission|Length of hospitalization and intensive care unit stay|Organ dysfunction|Lifestyle changes|The cost of care	University of Pecs	All	60 Years and older   (Adult, Older Adult)	Not Applicable	7576	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention	IV/2428- 2 /2020/EKU	April 1, 2020	April 21, 2021	August 21, 2021	March 25, 2020		March 27, 2020			https://ClinicalTrials.gov/show/NCT04321928
265	NCT04334967	Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care		Enrolling by invitation	No Results Available	COVID-19|Corona Virus Infection|SARS-CoV-2|2019-nCoV|2019 Novel Coronavirus	Drug: Hydroxychloroquine|Dietary Supplement: Vitamin C	Total Hospitalization|Total Mechanical Ventilation|Fever intensity measure|Shortness of breath measure|Changes in daytime cough measure|Changes in nighttime cough measure|Total mortality	Providence Health & Services|Center for Outcomes Research and Education|Providence Cancer Center, Earle A. Chiles Research Institute	All	45 Years and older   (Adult, Older Adult)	Phase 4	1250	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	2020000186	March 30, 2020	September 30, 2021	September 30, 2023	April 6, 2020		April 6, 2020	Portland Providence Medical Center, Portland, Oregon, United States		https://ClinicalTrials.gov/show/NCT04334967
266	NCT04290858	Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection	NoCovid	Withdrawn	No Results Available	Coronavirus Infections|Pneumonia, Viral|Dyspnea	Drug: Nitric Oxide	Reduction in the incidence of intubation and mechanical ventilation|Mortality|Negative conversion of COVID-19 RT-PCR from upper respiratory tract|Time to clinical recovery	Xijing Hospital|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico	All	18 Years and older   (Adult, Older Adult)	Phase 2	0	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	COVID19 NOgas mild	March 1, 2020	March 1, 2021	February 1, 2022	March 2, 2020		March 24, 2020			https://ClinicalTrials.gov/show/NCT04290858
267	NCT04319445	Mindfulness During COVID-19		Recruiting	No Results Available	Migraine Disorders|Stress|Anxiety	Behavioral: Mindfulness session(s)	Helpfulness of the session|Platform effectiveness|Change in Anxiety Level|Change in Stress Level|Value of the session|Satisfaction with the session|Percentage of participants that showed interest in a future session|Percentage of participants that would recommend this session to a family member|Percentage of participants by session frequency preference	Wake Forest University Health Sciences	All	Child, Adult, Older Adult	Not Applicable	200	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	IRB00064587	March 22, 2020	December 2020	December 2020	March 24, 2020		April 8, 2020	Wake Forest Health Sciences, Winston-Salem, North Carolina, United States		https://ClinicalTrials.gov/show/NCT04319445
268	NCT04264858	Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients		Not yet recruiting	No Results Available	2019-nCoV|Immunoglobulin of Cured Patients	Drug: Immunoglobulin of cured patients|Drug: γ-Globulin	Time to Clinical Improvement (TTCI)|Clinical status assessed by the ordinal scale|The differences in oxygen intake methods|Duration (days) of supplemental oxygenation|Duration (days) of mechanical ventilation|The mean PaO2/FiO2|The lesions of the pulmonary segment numbers involved in pulmonary CT [ every 7 days]|Time to 2019-nCoV RT-PCR negativity in respiratory tract specimens [every 3 days]|Dynamic changes of 2019-nCoV antibody titer in blood|Length of hospital stay (days)|All cause mortality	Wuhan Union Hospital, China	All	18 Years and older   (Adult, Older Adult)	Not Applicable	10	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	WuhanUH-2019 nCoV-Ig	March 17, 2020	April 30, 2020	May 31, 2020	February 11, 2020		March 17, 2020	Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04264858
269	NCT04336748	HCQ for Primary Prophylaxis Against COVID19 in Health-care Workers		Not yet recruiting	No Results Available	Sars-CoV2|Infection Viral|Healthcare Worker|Prophylaxis	Drug: Hydroxychloroquine	Symptomatic or asymptomatic SARS-CoV-2 infection confirmed by PCR|Viral load during SARS-CoV-2 infection|Seroconversion during the study period|Incidence of any acute respiratory infection|Days of sick leave	Medical University of Vienna	All	18 Years and older   (Adult, Older Adult)	Phase 3	440	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention	HCQ prophylaxis for COVID19	April 2020	July 2020	August 2020	April 7, 2020		April 7, 2020			https://ClinicalTrials.gov/show/NCT04336748
270	NCT04341012	Breath Analysis Based Disease Biomarkers of COVID-19 and Other Diseases		Recruiting	No Results Available	Liver Diseases|Liver Cancer|COVID19	Diagnostic Test: Collection of breath sample	Breath volatile organic compound profiles|Utility of breath profiles for disease diagnosis or prognosis	Mayo Clinic	All	18 Years and older   (Adult, Older Adult)		120	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	19-001971	September 10, 2019	December 31, 2021	December 31, 2021	April 10, 2020		April 13, 2020	Mayo Clinic Florida, Jacksonville, Florida, United States		https://ClinicalTrials.gov/show/NCT04341012
271	NCT04313127	A Phase I Clinical Trial in 18-60 Adults	APICTH	Active, not recruiting	No Results Available	COVID-19	Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)	Safety indexes of adverse reactions|Safety indexes of adverse events|Safety indexes of SAE|Safety indexes of lab measures|Immunogencity indexes of GMT(ELISA)|Immunogencity indexes of GMT(pseudoviral neutralization test method)|Immunogencity indexes of seropositivity rates(ELISA)|Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method)|Immunogencity indexes of GMI(ELISA)|Immunogencity indexes of GMI(pseudoviral neutralization test method)|Immunogencity indexes of GMC(Ad5 vector)|Immunogencity indexes of GMI(Ad5 vector)|Immunogencity indexes of cellular immune	CanSino Biologics Inc.|Institute of Biotechnology, Academy of Military Medical Sciences. PLA of China|Jiangsu Province Centers for Disease Control and Prevention|Hubei Provincial Center for Disease Control and Prevention|Tongji Hospital	All	18 Years to 60 Years   (Adult)	Phase 1	108	Industry|Other	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	JSVCT088	March 16, 2020	December 30, 2020	December 20, 2022	March 18, 2020		March 31, 2020	Hubei Provincial Center for Disease Control and Prevention, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04313127
272	NCT04332666	Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial	ATCO	Not yet recruiting	No Results Available	Coronavirus|Respiratory Failure|Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere|SARS-CoV-2	Drug: Angiotensin 1-7|Drug: Placebos	ventilator free days|ICU free days|Hospital length of stay|Time to wean from mechanical ventilation|PaO2/FiO2 changes during drug administration|Deep vein thrombosis incidence|Changes in inflammatory markers|RAS effectors levels|Radiological findings	Erasme University Hospital|Fonds Erasme pour la Recherche Médicale	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	P2020/201	March 31, 2020	May 30, 2020	June 15, 2020	April 3, 2020		April 6, 2020			https://ClinicalTrials.gov/show/NCT04332666
273	NCT04320238	Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff		Recruiting	No Results Available	2019 Novel Coronavirus Infection	Drug: recombinant human interferon Alpha-1b|Drug: thymosin alpha 1	new-onset COVID-19|Number of Participants with coronavirus related symptoms|Number of Participants with adverse effect	Shanghai Jiao Tong University School of Medicine	All	18 Years to 65 Years   (Adult, Older Adult)	Phase 3	2944	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	Interferon_prophylaxis	January 21, 2020	May 2020	June 2020	March 24, 2020		March 31, 2020	Taihe Hospital, Shiyan, Hubei, China		https://ClinicalTrials.gov/show/NCT04320238
274	NCT04332991	Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease	ORCHID	Recruiting	No Results Available	Coronavirus|Acute Respiratory Infection|SARS-CoV Infection	Drug: Hydroxychloroquine|Drug: Placebo	COVID Ordinal Outcomes Scale on Day 15|all-location, all-cause mortality assessed on day 15|all-location, all-cause mortality assessed on day 29|COVID Ordinal Outcomes Scale on Study Day 3|COVID Ordinal Outcomes Scale on Study Day 8|COVID Ordinal Outcomes Scale on Study Day 29|Number of patients dead or with receipt of ECMO between enrollment and Day 28|Oxygen-free days through Day 28|Ventilator-free days through Day 28|Vasopressor-free days through Day 28|ICU-free days to Day 28|Hospital-free days to Day 28	Massachusetts General Hospital|National Heart, Lung, and Blood Institute (NHLBI)	All	18 Years and older   (Adult, Older Adult)	Phase 3	510	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	PETAL 05 Orchid	April 2, 2020	April 2021	July 2021	April 3, 2020		April 7, 2020	University of Arizona, Tucson, Arizona, United States|UCSF Fresno, Fresno, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|UC Davis Medical Center, Sacramento, California, United States|UCSF Medical Center, San Francisco, California, United States|Stanford University, Stanford, California, United States|Medical Center of Aurora, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|St. Joseph Hospital, Denver, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Kentucky, Lexington, Kentucky, United States|University Medical Center, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|St. Vincent's Hospital, Worcester, Massachusetts, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|Henry Ford Medical Center, Detroit, Michigan, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Montefiore Medical Center-Weiler, Bronx, New York, United States|Montefiore Medical Center-Moses, Bronx, New York, United States|Mt. Sinai Hospital, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|UPMC Presbyterian/Mercy/Shadyside, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Health Science Center, Houston, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|University of Utah Hospital, Salt Lake City, Utah, United States|University of Virginia Health System, Charlottesville, Virginia, United States|VCU Medical Center, Richmond, Virginia, United States|Harborview Medical Center, Seattle, Washington, United States|Swedish Hospital First Hill, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT04332991
275	NCT04324528	Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation	CYCOV	Recruiting	No Results Available	Coronavirus|COVID-19|SARS-CoV Infection|Respiratory Failure|Cytokine Storm	Device: vv-ECMO + cytokine adsorption (Cytosorb adsorber)|Device: vv-ECMO only (no cytokine adsorption)	interleukin-6 (IL-6) level after 72 hours|30-day-survival|vasopressor dosage|fluid balance|lactate	Dr. Alexander Supady|University Hospital Freiburg	All	18 Years to 100 Years   (Adult, Older Adult)	Not Applicable	30	Other	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CYCOV	March 27, 2020	September 26, 2020	November 26, 2020	March 27, 2020		March 31, 2020	University Clinic Freiburg, Freiburg, Germany		https://ClinicalTrials.gov/show/NCT04324528
276	NCT04298060	DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)	STOP-Flu	Not yet recruiting	No Results Available	Influenza Infection|SAD-RV Infection and COVID-19	Drug: DAS181|Drug: Placebo	Percent of subjects who have returned to room air|Percent change of subjects return to baseline oxygen requirement	Ansun Biopharma, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 2	280	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	DAS181-2-07	April 2020	March 2021	September 2022	March 6, 2020		April 2, 2020	Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China		https://ClinicalTrials.gov/show/NCT04298060
277	NCT04338009	Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019	REPLACECOVID	Not yet recruiting	No Results Available	COVID-19	Other: Discontinuation of ARB/ACEI|Other: Continuation of ARB/ACEI	Hierarchical composite endpoint|All-Cause Death|Length of Hospital Stay|Length of ICU Stay, invasive mechanical ventilation or extracorporeal membrane oxygenation|AUC SOFA	University of Pennsylvania|Jordana B. Cohen, MD, MSCE|Thomas C. Hanff, MD, MPH|Vicente Corrales-Medina, MD, PhD|James Brian Byrd, MD|Roberto Viau Colindres	All	18 Years and older   (Adult, Older Adult)	Not Applicable	152	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	842810	March 31, 2020	December 31, 2020	December 31, 2020	April 8, 2020		April 8, 2020			https://ClinicalTrials.gov/show/NCT04338009
278	NCT04334265	Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019		Not yet recruiting	No Results Available	COVID-19	Drug: Anluohuaxian	Changes in high-resolution computer tomography of the lung|Change in 6-minute walking distance|Changes in compound physiological index|Changes in the scores of the St. George's Hospital Respiratory Questionnaire|Changes in modified British Medical Research Council Dyspnea Scale (mMRC) scores|Changes in vital capacity of the lung	Peking University First Hospital	All	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	750	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020 research 110	April 1, 2020	June 1, 2020	December 1, 2020	April 6, 2020		April 6, 2020	The Second People's Hospital of Fuyang, Fuyang, Anhui, China|Ezhou Central Hospital, Wuhan, Hubei, China|Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China|Jinyintan Hospital of Wuhan, Wuhan, Hubei, China|Tongji Hospital of Huazhong University of Science and Technology, Wuhan, Hubei, China|West Hospital Union Hospital Huazhong University of Science and Technology, Wuhan, Hubei, China|Wuhan Pulmonary Hospital, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China|Wenzhou Medical University Affiliated First Hospital, Wenzhou, Zhejiang, China		https://ClinicalTrials.gov/show/NCT04334265
279	NCT04334148	Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine	HERO-HCQ	Not yet recruiting	No Results Available	COVID-19	Drug: Hydroxychloroquine|Drug: Placebo oral tablet	Number of participants testing positive for COVID-19 infection|Number of participants with COVID-19 viral shedding|Safety as measured by number of adverse events	Duke University|Patient-Centered Outcomes Research Institute	All	18 Years and older   (Adult, Older Adult)	Phase 3	15000	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention	Pro00105274	April 2020	July 2020	July 2020	April 6, 2020		April 6, 2020			https://ClinicalTrials.gov/show/NCT04334148
280	NCT04333589	Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive		Not yet recruiting	No Results Available	COVID-19	Drug: Favipiravir	Viral nucleic acid test negative conversion rate|Clinical cure rate	Peking University First Hospital	All	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	210	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020 research 112	April 1, 2020	June 1, 2020	September 15, 2020	April 3, 2020		April 10, 2020	The Second People's Hospital of Fuyang, Fuyang, Anhui, China|Ezhou Hospital of Traditional Chinese Medicine, Ezhou, Hubei, China|Ezhou Central Hospital, Wuhan, Hubei, China|Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China|Jinyintan Hospital of Wuhan, Wuhan, Hubei, China|Wuhan Pulmonary Hospital, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China|Wenzhou Medical University Affiliated First Hospital, Wenzhou, Zhejiang, China		https://ClinicalTrials.gov/show/NCT04333589
281	NCT04330599	Longitudinal Population-based Observational Study of Coronavirus Disease in the UK Population	COVIDENCE	Not yet recruiting	No Results Available	COVID-19		Incidence of suspected, probable or confirmed COVID-19|Incidence of confirmed COVID-19|Incidence of COVID-19 requiring hospitalisation|Incidence of COVID-19 requiring ventilatory support|Incidence of fatal COVID-19|Symptom duration per COVID-19 episode|Symptom severity per COVID-19 episode|Incidence of seroconversion to SARS-CoV-2|Incidence of recurrent COVID-19|EQ-5D-3L health-related quality of life score|Health care costs associated with incident COVID-19|Impact of COVID-19 on participants' financial status|Incidence of physical complications of COVID-19|Impact of COVID-19 on participants' mental well-being	Queen Mary University of London|King's College London|London School of Hygiene and Tropical Medicine	All	16 Years and older   (Child, Adult, Older Adult)		12000	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	COVIDENCE	April 2, 2020	April 1, 2025	April 1, 2025	April 1, 2020		April 1, 2020			https://ClinicalTrials.gov/show/NCT04330599
282	NCT04328480	The ECLA PHRI COLCOVID Trial	COLCOVID	Not yet recruiting	No Results Available	COVID-19	Drug: Colchicine|Other: Local standard of care	All-cause mortality|Composite outcome:composite of intubation for mechanical ventilation or death.	Estudios Clínicos Latino América|Population Health Research Institute	All	18 Years and older   (Adult, Older Adult)	Phase 3	2500	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	COLCOVID version1.2	March 2020	May 30, 2020	June 30, 2020	March 31, 2020		March 31, 2020			https://ClinicalTrials.gov/show/NCT04328480
283	NCT04311398	Development and Verification of a New Coronavirus Multiplex Nucleic Acid Detection System		Not yet recruiting	No Results Available	COVID-19	Diagnostic Test: New QIAstat-Dx fully automatic multiple PCR detection platform	Sensitivity， spectivity turnaround time of the New QIAstat-Dx fully automatic multiple PCR detection platform	Huashan Hospital	All	16 Years to 100 Years   (Child, Adult, Older Adult)		100	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	KY2020-COVID-19	March 14, 2020	June 1, 2020	December 1, 2020	March 17, 2020		March 17, 2020	Huashan Hospital of Fudan University, Shanghai, Shanghai, China		https://ClinicalTrials.gov/show/NCT04311398
284	NCT04310228	Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019		Recruiting	No Results Available	COVID-19	Drug: Favipiravir Combined With Tocilizumab|Drug: Favipiravir|Drug: Tocilizumab	Clinical cure rate|Viral nucleic acid test negative conversion rate and days from positive to negative|Duration of fever|Lung imaging improvement time|Mortality rate because of Corona Virus Disease 2019|Rate of non-invasive or invasive mechanical ventilation when respiratory failure occurs|Mean in-hospital time	Peking University First Hospital	All	18 Years to 65 Years   (Adult, Older Adult)	Not Applicable	150	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020YFC0844100	March 8, 2020	May 2020	May 2020	March 17, 2020		April 10, 2020	Guiqiang Wang, Beijing, Beijing, China|Peking University First Hospital, Beijing, Beijing, China|Ezhou Central Hospital, Wuhan, Hubei, China|Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China|Jinyintan Hospital of Wuhan, Wuhan, Hubei, China|Wuhan Pulmonary Hospital, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04310228
285	NCT04343651	Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19		Recruiting	No Results Available	Coronavirus Disease 2019	Drug: Placebos|Drug: Leronlimab (700mg)	Clinical Improvement as assessed by change in total symptom score (for fever, myalgia, dyspnea and cough)|Time to clinical resolution (TTCR)|Change from baseline in National Early Warning Score 2 (NEWS2)|Change from baseline in pulse oxygen saturation (SpO2)|Change from baseline in the patient's health status on a 7-category ordinal scale|Incidence of hospitalization|Duration (days) of hospitalization|Incidence of mechanical ventilation supply|Duration (days) of mechanical ventilation supply|Incidence of oxygen use|Duration (days) of oxygen use|Mortality rate|Time to return to normal activity	CytoDyn, Inc.	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 2	75	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CD10_COVID-19	April 1, 2020	December 4, 2020	April 4, 2021	April 13, 2020		April 13, 2020	Montefiore Medical Center, Bronx, New York, United States		https://ClinicalTrials.gov/show/NCT04343651
286	NCT04302519	Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells		Not yet recruiting	No Results Available	COVID-19	Biological: Dental pulp mesenchymal stem cells	Disppear time of ground-glass shadow in the lungs|Absorption of Lung shadow absorption by CT Scan-Chest|Changes of blood oxygen	CAR-T (Shanghai) Biotechnology Co., Ltd.	All	18 Years to 75 Years   (Adult, Older Adult)	Early Phase 1	24	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	KT005HB001	March 5, 2020	June 30, 2021	July 30, 2021	March 10, 2020		March 10, 2020			https://ClinicalTrials.gov/show/NCT04302519
287	NCT04295551	Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)		Not yet recruiting	No Results Available	COVID-19	Drug: Lopinavir / ritonavir tablets combined with Xiyanping injection|Drug: Lopinavir/ritonavir treatment	Clinical recovery time	Jiangxi Qingfeng Pharmaceutical Co. Ltd.	All	18 Years to 100 Years   (Adult, Older Adult)	Not Applicable	80	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	QF-XYP1990-1	March 14, 2020	July 14, 2020	April 14, 2021	March 4, 2020		March 4, 2020			https://ClinicalTrials.gov/show/NCT04295551
288	NCT04306705	Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19	TACOS	Recruiting	No Results Available	Covid-19|SARS|Cytokine Storm|Cytokine Release Syndrome|Tocilizumab	Drug: Tocilizumab|Other: Standard of care|Procedure: Continuous renal replacement therapy	Proportion of Participants With Normalization of Fever and Oxygen Saturation Through Day 14|Duration of hospitalization|Proportion of Participants With Normalization of Fever Through Day 14|Change from baseline in white blood cell and differential count|Time to first negative in 2019 novel Corona virus RT-PCR test|All-cause mortality|Change from baseline in hsCRP|Change from baseline in cytokines IL-1β, IL-10, sIL-2R, IL-6, IL-8 and TNF-α|Change from baseline in proportion of CD4+CD3/CD8+CD3 T cells	Tongji Hospital|Hubei Xinhua Hospital|Wuhan No.1 Hospital|Wuhan central hospital	All	18 Years to 80 Years   (Adult, Older Adult)		120	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	WHTJCOVID-19	February 20, 2020	May 30, 2020	June 20, 2020	March 13, 2020		March 17, 2020	Tongji Hospital, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04306705
289	NCT04342650	Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection	CloroCOVID19II	Not yet recruiting	No Results Available	COVID-19|SARS-CoV Infection|Severe Acute Respiratory Syndrome (SARS) Pneumonia|Clinical Trial	Drug: Chloroquine Diphosphate|Drug: Placebo oral tablet	Proportion of patients with onset of severe acute respiratory syndrome (SARS)|Mortality rate|Number of participants in need of intensive care support|Viral concentration|Cumulative incidence of serious adverse events|Cumulative incidence of grade 3 and 4 adverse events|Proportion of patients with discontinued treatment|Incidence of cardiac lesions|Incidence of cardiac disfunctions|Change in respiratory capacity	Fundação de Medicina Tropical Dr. Heitor Vieira Dourado	All	18 Years and older   (Adult, Older Adult)	Phase 2	210	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CAAE: 30504220.5.0000.0005	April 2020	September 2020	September 2020	April 13, 2020		April 13, 2020	Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Amazonas, Brazil		https://ClinicalTrials.gov/show/NCT04342650
290	NCT04285190	The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19		Not yet recruiting	No Results Available	Coronavirus Disease 2019|Novel Coronavirus Pneumonia	Drug: T89	The time to oxygen saturation recovery to normal level (≥97%)|The proportion of patients with normal level of oxygen saturation(≥97%)|The degree of remission of symptoms of patients, including: fatigue, nausea, vomiting, chest tightness, shortness of breath, etc.|The time to the myocardial enzyme spectrum recovery to normal after treatment|The proportion of the patients with normal myocardial enzyme spectrum after treatment|The time to the electrocardiogram recovery to normal level after treatment|The proportion of the patients with normal electrocardiogram after treatment|The time to the hemodynamics recovery to normal after treatment|The proportion of the patients with normal hemodynamics after treatment|The time to exacerbation or remission of the disease after treatment;|The proportion of the patients with exacerbation or remission of disease after treatment|The proportion of patients who need other treatment (e.g. heparin, anticoagulants) due to microcirculation disorders|The all-cause mortality rate|The proportion of patients with acidosis|The total duration of the patients in-hospital|The total duration of oxygen inhalation during treatment|The oxygen flow rate during treatment|The oxygen concentration during treatment	Tasly Pharmaceuticals, Inc.	All	18 Years to 85 Years   (Adult, Older Adult)	Not Applicable	120	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	T89-NCP-01	February 26, 2020	June 15, 2020	September 15, 2020	February 26, 2020		February 26, 2020			https://ClinicalTrials.gov/show/NCT04285190
291	NCT04324606	A Study of a Candidate COVID-19 Vaccine (COV001)		Not yet recruiting	No Results Available	Coronavirus	Biological: ChAdOx1 nCoV-19|Biological: MenACWY Placebo	Assess efficacy of the candidate ChAdOx1 nCoV-19 against COVID-19: Number of virologically confirmed (PCR positive) symptomatic cases|Assess the safety of the candidate vaccine ChAdOx1 nCoV: Occurrence of serious adverse events (SAEs)|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of solicited local reactogenicity signs and symptoms|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of solicited systemic reactogenicity signs and symptoms|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of unsolicited adverse events (AEs)|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV through standard blood tests|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV by measuring the number of disease enhancement episodes|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by measuring seroconversion rates|Assess cellular and humoral immunogenicity of ChAdOx1 nCoV-19 through ELISpot assays|Assess cellular and humoral immunogenicity of ChAdOx1 nCoV-19	University of Oxford	All	18 Years to 55 Years   (Adult)	Phase 1|Phase 2	510	Other	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	COV001	April 2020	May 2021	May 2021	March 27, 2020		April 6, 2020	NIHR WTCRF, University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom|CCVTM, University of Oxford, Churchill Hospital, Oxford, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom		https://ClinicalTrials.gov/show/NCT04324606
292	NCT04321096	The Impact of Camostat Mesilate on COVID-19 Infection	CamoCO-19	Recruiting	No Results Available	Corona Virus Infection	Drug: Camostat Mesilate|Drug: Placebo oral tablet	Days to clinical improvement from study enrolment|Safety evaluation, as measured by AEs, Adverse Reactions (ARs), SAEs, Serious ARs (SARs)|Clinical status as assessed by the 7-point ordinal scale at day 7, 14 and 30|Day 30 mortality|Change in NEW(2) score from baseline to day 30|Admission to ICU|Use of invasive mechanical ventilation or ECMO|Duration of supplemental oxygen (days)|Days to self-reported recovery (e.g. limitations in daily life activities) during telephone interviews conducted at day 30	University of Aarhus	All	18 Years to 110 Years   (Adult, Older Adult)	Phase 1|Phase 2	180	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	2020-001200-42	March 31, 2020	December 31, 2020	May 1, 2021	March 25, 2020		April 6, 2020	Department of Infectious Diseases, Aalborg, Denmark|Department for Infectious Diseases, Aarhus University Hospital, Aarhus N, Denmark|Herning Regional Hospital, Herning, Denmark|Northzealands hospital - Hillerød, Hillerød, Denmark|Horsens Regional Hospital, Horsens, Denmark|Bispebjerg hospital, København, Denmark|Dept. of Infectious Diseases, Odense University Hospital, Odense, Denmark|Randers Regional Hospital, Randers, Denmark|Silkeborg Hospital, Silkeborg, Denmark		https://ClinicalTrials.gov/show/NCT04321096
293	NCT04323800	Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19	CSSC-001	Not yet recruiting	No Results Available	Coronavirus|Convalescence	Biological: Anti- SARS-CoV-2 Plasma|Biological: SARS-CoV-2 non-immune Plasma	Cumulative incidence of composite outcome of disease severity|Anti-SARS-CoV-2 titers|Rates of SARS-CoV-2 PCR positivity|Duration of SARS-CoV-2 PCR positivity|Peak quantity levels of SARS-CoV-2 RNA|Cumulative incidence of disease severity	Johns Hopkins University	All	18 Years and older   (Adult, Older Adult)	Phase 2	150	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	IRB00245634	May 1, 2020	December 31, 2022	January 2023	March 27, 2020		April 8, 2020			https://ClinicalTrials.gov/show/NCT04323800
294	NCT04335162	Cardiovascular Complications and COVID-19 (CovCardioVasc)	CovCardioVasc	Recruiting	No Results Available	COVID|Acute Coronary Syndrome|Myocardial Infarction|Myocarditis|Venous Thromboembolism|Deep Vein Thrombosis|Pulmonary Embolism		Determine the incidence of cardiomyopathies and venous thromboembolism|Mortality|Duration of mechanical ventilation|shock at day 28|length of stay in the intensive care unit	Centre Hospitalier Universitaire de Nice	All	18 Years and older   (Adult, Older Adult)		100	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	20reamedcovid19	February 28, 2020	August 28, 2020	August 28, 2020	April 6, 2020		April 6, 2020	CHU de Nice, Nice, France|Hôpitaux Universitaires Paris Centre - Hôpital Cochin, Paris, France		https://ClinicalTrials.gov/show/NCT04335162
295	NCT04337788	Gerontological Telemonitoring of Older Adults Living in Nursing Homes With COVID-19 Disease	COVIDeHPAD	Not yet recruiting	No Results Available	Coronavirus Infection	Other: telehealth applications	Impact of Gerontological telemonitoring on healthcare management for older adults living in Nursing Homes with symptoms of confirmed or probable COVID-19 disease (Death within 30 days).	University Hospital, Limoges	All	75 Years and older   (Older Adult)	Not Applicable	200	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	87RI20_0013	April 2020	July 2020	September 2020	April 8, 2020		April 8, 2020			https://ClinicalTrials.gov/show/NCT04337788
296	NCT04343664	Mental Health Assessment Among Community Member During the Covid-19 Pandemic in Indonesia	New	Not yet recruiting	No Results Available	Mental Stress|Mental Health Wellness 1|Depression|Anxiety|Behavior Problem|Emotional Problem		Depression|Anxiety symptoms|Stress related problems|Behavior and emotional problem among children and adolescents	Tjhin Wiguna|Fakultas Kedokteran Universitas Indonesia|Dr Cipto Mangunkusumo General Hospital	All	4 Years and older   (Child, Adult, Older Adult)		10000	Other	Observational	Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional	MH-Covid19	April 12, 2020	June 30, 2020	December 31, 2020	April 13, 2020		April 13, 2020	dr. Cipto Mangunkusumo General Hospital, Jakarta Pusat, DKI Jakarta, Indonesia		https://ClinicalTrials.gov/show/NCT04343664
297	NCT04332380	Convalescent Plasma for Patients With COVID-19: A Pilot Study	CP-COVID-19	Not yet recruiting	No Results Available	Coronavirus|Coronavirus Infection	Drug: Plasma	Change in Viral Load|Change in Immunoglobulin M COVID-19 antibodies Titers|Change in Immunoglobulin G COVID-19 antibodies Titers|Intensive Care Unit Admission|Length of Intensive Care Unit stay|Length of hospital stay (days)|Requirement of mechanical ventilation|Duration (days) of mechanical ventilation|Clinical status assessed according to the World Health Organization guideline|Mortality	Universidad del Rosario|CES University|Instituto Distrital de Ciencia Biotecnologia e Innovacion en salud|Fundación Universitaria de Ciencias de la Salud	All	18 Years to 60 Years   (Adult)	Phase 2	10	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ABN011-1	April 1, 2020	August 31, 2020	December 31, 2020	April 2, 2020		April 2, 2020	Universidad del Rosario, Bogota, Cundinamarca, Colombia		https://ClinicalTrials.gov/show/NCT04332380
298	NCT04334928	Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel	EPICOS	Active, not recruiting	No Results Available	Coronavirus Infection	Drug: Emtricitabine/tenofovir disoproxil|Drug: Hydroxychloroquine|Drug: Placebo: Emtricitabine/tenofovir disoproxil Placebo|Drug: Placebo: Hydroxychloroquine	Number of confirmed symptomatic infections of SARS-CoV-2 (COVID-19)|Severity of disease in confirmed infected participants of SARS-CoV-2 (COVID-19)|Duration of symptoms in confirmed infected participants of SARS-CoV-2 (COVID-19) measured in days	Plan Nacional sobre el Sida (PNS)|Effice Servicios Para la Investigacion S.L.	All	18 Years to 65 Years   (Adult, Older Adult)	Phase 3	4000	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention	PrEP COVID-19	April 1, 2020	June 30, 2020	July 31, 2020	April 6, 2020		April 9, 2020	Hospital Universitario Ramón y Cajal, Madrid, Spain		https://ClinicalTrials.gov/show/NCT04334928
299	NCT04316884	Mechanisms for Organ Dysfunction in Covid-19	UMODCOVID19	Recruiting	No Results Available	COVID-19|Organ Dysfunction Syndrome Sepsis|Organ Dysfunction Syndrome, Multiple|Septic Shock|Acute Kidney Injury|Acute Respiratory Distress Syndrome		Acute Kidney Injury|ARDS|30 day mortality|1 year mortality|Chronic Kidney Disease|SOFA-score	Uppsala University	All	18 Years and older   (Adult, Older Adult)		100	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	EPN 2017/043 Covid19	March 12, 2020	December 31, 2020	December 31, 2021	March 20, 2020		March 20, 2020	Uppsala University Hospital, Uppsala, Sweden		https://ClinicalTrials.gov/show/NCT04316884
300	NCT04329533	Effects of Using Mobile App on Perceived Stress During COVID-19 Pandemic		Not yet recruiting	No Results Available	Perceived Stress|Anxiety|Sleep Disturbance	Other: "Calm" is a mindfulness meditation mobile app	Perceived Stress Scale|Hospital Anxiety and Depression Scale|PROMIS Sleep Disturbance Short Form Survey|Adherence|Participant Satisfaction|Coronavirus Questionnaire	University of Arizona	Female	18 Years to 99 Years   (Adult, Older Adult)	Not Applicable	150	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	Pending UA IRB Approval	April 1, 2020	June 30, 2020	July 30, 2020	April 1, 2020		April 13, 2020			https://ClinicalTrials.gov/show/NCT04329533
301	NCT04319172	Multicentric Study of Coronavirus Disease 2019 (COVID-2019) in Solid Organ Transplant Recipients	COVIDSOT	Not yet recruiting	No Results Available	Transplant Recipient|Infections, Coronavirus		Incidence of coronavirus infection in Solid Organ Transplant Recipients|Clinical manifestations of coronavirus infection in Solid Organ Transplant Recipients|Presence of other risk factors|Establish the frequency and type of complications related to the net state of the patient immunosuppression|Frequency of co-infections|Mortality|Laboratory characteristics|Determination of coronavirus viral load|Microbiological testing	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla|Spanish Network for Research in Infectious Diseases|GESITRA-IC	All	16 Years and older   (Child, Adult, Older Adult)		50	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	COVIDSOT	March 2020	March 2022	April 2022	March 24, 2020		March 24, 2020			https://ClinicalTrials.gov/show/NCT04319172
302	NCT04332835	Convalescent Plasma for Patients With COVID-19: A Randomized, Open Label, Parallel, Controlled Clinical Study	CP-COVID-19	Not yet recruiting	No Results Available	Coronavirus|Coronavirus Infection	Drug: Plasma|Drug: Hydroxychloroquine|Drug: Azithromycin	Change in Viral Load|Change in Immunoglobulin M COVID-19 Titers|Change in Immunoglobulin G COVID-19 Titers|Intensive Care Unit Admission|Length of Intensive Care Unit stay|Length of hospital stay (days)|Requirement of mechanical ventilation|Duration (days) of mechanical ventilation|Clinical status assessed according to the World Health Organization guideline|Mortality	Universidad del Rosario|Fundación Universitaria de Ciencias de la Salud|CES University|Instituto Distrital de Ciencia Biotecnología e Innovacion en Salud	All	18 Years to 60 Years   (Adult)	Phase 2|Phase 3	80	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ABN011-2	April 1, 2020	August 31, 2020	December 31, 2020	April 3, 2020		April 3, 2020	Universidad del Rosario, Bogota, Cundinamarca, Colombia		https://ClinicalTrials.gov/show/NCT04332835
303	NCT04312100	Sequential Oxygen Therapy Strategy for Patients With COVID-19	SOTSPC	Recruiting	No Results Available	Coronavirus Disease-2019	Other: oxygen treatment	Incidence of respiratory failure|28 day mortality rate	Henan Provincial People's Hospital	All	18 Years to 75 Years   (Adult, Older Adult)		30	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	SOT-C	February 1, 2020	October 2020	February 2021	March 18, 2020		March 18, 2020	Henan Provincial People's Hospital, Zhengzhou, Henan, China		https://ClinicalTrials.gov/show/NCT04312100
304	NCT04312009	Losartan for Patients With COVID-19 Requiring Hospitalization		Not yet recruiting	No Results Available	Corona Virus Infection|Acute Respiratory Distress Syndrome|SARS-CoV Infection	Drug: Losartan|Other: Placebo	Sequential Organ Failure Assessment (SOFA) Respiratory Score|28-Day Mortality|90-Day Mortality|Respiratory Failure Requiring Mechanical Ventilation|Number of 28-Day Ventilator-Free Days|Length of Hospital Stay|ICU Admission|ICU Length of Stay|Acute Kidney Injury|Hypotension Requiring Vasopressors|Sequential Organ Failure Assessment (SOFA) Total Score|Severity Assessment|Incidence of Respiratory Failure|Oxygen Saturation / Fractional Inhaled Oxygen (F/S)	University of Minnesota	All	18 Years and older   (Adult, Older Adult)	Phase 2	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	SURG-2020-28675	April 2, 2020	April 1, 2021	April 1, 2021	March 17, 2020		April 3, 2020	Hennepin County Medical Center, Minneapolis, Minnesota, United States|M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States		https://ClinicalTrials.gov/show/NCT04312009
305	NCT04315948	Trial of Treatments for COVID-19 in Hospitalized Adults	DisCoVeRy	Recruiting	No Results Available	Corona Virus Infection	Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care	Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)	Institut National de la Santé Et de la Recherche Médicale, France	All	18 Years and older   (Adult, Older Adult)	Phase 3	3100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	C20-15	March 22, 2020	March 2023	March 2023	March 20, 2020		March 25, 2020	CHRU Lille, Lille, France|CHU Nantes, Nantes, France|APHP - Bichat Claude Bernard, Paris, France		https://ClinicalTrials.gov/show/NCT04315948
306	NCT04311177	Losartan for Patients With COVID-19 Not Requiring Hospitalization		Recruiting	No Results Available	Corona Virus Infection|Acute Respiratory Distress Syndrome|SARS-CoV Infection	Drug: Losartan|Other: Placebo	Hospital Admission|Change in PROMIS Dyspnea Functional Limitations|Change in PROMIS Dyspnea Severity|Daily Maximum Temperature|Emergency Department/Clinic Presentations|Disease Severity Rating Day 7|Disease Severity Rating Day 15|Disease Severity Rating Day 28|Viral Load by Oropharyngeal Swab Day 9|Viral Load by Oropharyngeal Swab Day 15|Ventilator-Free Days|Therapeutic Oxygen-Free Days|Need for Hospital Admission at 15 Days|Need for Oxygen Therapy at 15 Days	University of Minnesota	All	18 Years and older   (Adult, Older Adult)	Phase 2	580	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	SURG-2020-28683	April 9, 2020	April 1, 2021	April 1, 2021	March 17, 2020		April 13, 2020	Hennepin County Medical Center, Minneapolis, Minnesota, United States|M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic Health System, Rochester, Minnesota, United States		https://ClinicalTrials.gov/show/NCT04311177
307	NCT04327388	Sarilumab COVID-19		Recruiting	No Results Available	Corona Virus Infection	Drug: Sarilumab SAR153191|Drug: Placebo	Phase 2: Time to resolution of fever for at least 48 hours without antipyretics or until discharge, whichever is sooner|Phase 3: The percentage of patients reporting each severity rating on the 7-point ordinal scale|Phase 2: The time to improvement in oxygenation|Phase 2: Mean change in 7-point ordinal scale from baseline to Day 15|Phase 2: Clinical status using the 7-point ordinal scale at Day 15|Phase 2: Time to improvement of two categories from admission using the 7-point ordinal scale|Phase 2 and 3 : Time to resolution of fever|Phase 2 and 3 : Time to improvement in oxygenation|Phase 2 and 3: Time to resolution of fever and improvement in oxygenation|Phase 2 and 3:Time to change in NEWS2 from baseline|Phase 2 and 3: Time to NEWS2 of <2 and maintained for 24 hours|Phase 2 and 3: Mean change from baseline to days 3, 5, 8, 11, 15, and 29 in NEWS2|Phase 2 and 3:Days with fever|Phase 2 and 3: Alive off supplemental oxygen at day 29|Phase 2 and 3: Days of resting respiratory rate >24 breaths/min|Phase 2 and 3:Days of hypoxemia|Phase 2 and 3: Days of supplemental oxygen use|Phase 2 and 3: Time to saturation ≥94% on room air|Phase 2 and 3: Ventilator free days in the first 28 days (to day 29)|Phase 2 and 3: The number of patients with Initiation of mechanical ventilation, non-invasive ventilation, or use of high flow nasal cannula|Phase 2 and 3: Proportion of patients requiring rescue medication during the 28-day period|Phase 2 and 3: The number of patients transferred to the ICU or the need to transfer to the ICU (if the ICU is not available)|Phase 2 and 3: Days of hospitalization among survivors|Phase 2 and 3: Incidence of death|Phase 3: Mean change in the 7-point ordinal scale from baseline to days 3, 5, 8, 11, 15, and 29 (or until discharge)|Phase 3: Clinical status using the 7-point ordinal scale at days 3, 5, 8, 11,15, and 29|Phase 3: Time to improvement of two categories from admission using the 7-point ordinal scale|Phase 2 and 3: Incidence of serious adverse events|Phase 2 and 3: The incidence of major or opportunistic bacterial or fungal infections|Phase 2 and 3: The incidence of major or opportunistic bacterial or fungal infections in patients with grade 4 neutropenia|Phase 2 and 3: The incidence of hypersensitivity reactions, infusion reactions, gastrointestinal perforation|The number of patients with clinically significant laboratory abnormalities	Sanofi|Regeneron Pharmaceuticals	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	300	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	EFC16844|U1111-1249-6021	March 29, 2020	July 2020	June 2021	March 31, 2020		April 9, 2020	Investigational Site Number 1240001, Montreal, Canada|Investigational Site Number 2500001, Bordeaux Cedex, France|Investigational Site Number 2500003, Strasbourg, France|Investigational Site Number 3800001, Milano, Italy|Investigational Site Number 7240003, Barcelona, Spain|Investigational Site Number 7240004, Barcelona, Spain|Investigational Site Number 7240002, Madrid, Spain|Investigational Site Number 7240005, Madrid, Spain|Investigational Site Number 7240001, Madrid, Spain		https://ClinicalTrials.gov/show/NCT04327388
308	NCT04313946	Artificial Intelligence Algorithms for Discriminating Between COVID-19 and Influenza Pneumonitis Using Chest X-Rays	AI-COVID-Xr	Recruiting	No Results Available	COVID-19|Pneumonia, Viral|Influenza With Pneumonia|Flu Symptom|Flu Like Illness|Pneumonia, Interstitial|Pneumonia, Ventilator-Associated|Pneumonia Atypical	Diagnostic Test: Scanning Chest X-rays and performing AI algorithms on images	COVID-19 positive X-Rays|COVID-19 negative X-Rays	Professor Adrian Covic|Falcon Trading Iasi|Grigore T. Popa University of Medicine and Pharmacy	All	Child, Adult, Older Adult		200	Other	Observational	Observational Model: Ecologic or Community|Time Perspective: Prospective	110	March 18, 2020	August 16, 2020	August 18, 2020	March 18, 2020		April 2, 2020	U.O. Multidisciplinare di Patologia Mammaria e Ricerca Traslazionale; Dipartimento Universitario Clinico di Scienze Mediche, Chirurgiche e della Salute Università degli Studi di Trieste, Cremona, Italy|University of Medicine and Pharmacy Gr T Popa, Iaşi, Romania|Department of Cardiology at Chelsea and Westminster NHS hospital, London, United Kingdom		https://ClinicalTrials.gov/show/NCT04313946
309	NCT04321811	Behavior, Environment And Treatments for Covid-19	BEAT19	Recruiting	No Results Available	Coronavirus	Other: Observation of patients with known, suspected, or at risk for COVID-19 infection	Define Natural Symptom Course|Time to Hospitalization|Time to Symptomatic Recovery	xCures|Genetic Alliance|LunaDNA|Cancer Commons|REDCap Cloud	All	18 Years and older   (Adult, Older Adult)		100000	Industry|Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	XC-PCOR-COVID19	March 21, 2020	March 20, 2021	March 20, 2022	March 25, 2020		April 2, 2020	BEAT19.org, San Francisco, California, United States	Study Protocol and Informed Consent Form, https://ClinicalTrials.gov/ProvidedDocs/11/NCT04321811/Prot_ICF_000.pdf	https://ClinicalTrials.gov/show/NCT04321811
310	NCT04340466	French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management Study	FRENCH CORONA	Recruiting	No Results Available	Pneumonia, Viral|Critically Ill|Corona Virus Infection	Other: No intervention	Mortality at day 28|severe complications|Imaging|Microbiological diagnosis|Antiviral therapy|Antibiotic therapy|Covid-19 treatments|Patients receiving renal replacement therapy|Patients receiving mechanical ventilation|Vital status	Centre Hospitalier Universitaire de Nīmes	All	18 Years and older   (Adult, Older Adult)		220	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	2020-A00797-32	April 3, 2020	June 30, 2020	April 30, 2021	April 9, 2020		April 9, 2020	CHU Nimes, Nîmes, France		https://ClinicalTrials.gov/show/NCT04340466
311	NCT04260594	Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus		Not yet recruiting	No Results Available	2019-nCoV	Drug: Arbidol|Other: basic treatment	Virus negative conversion rate in the first week|Virus negative conversion rate|Antipyretic rate|Symptom relief time|Finger oxygen improvement rate|Disease progression rate|Mortality rate|Incidence of severe adverse reactions|Change curve of peripheral blood lymphocyte count	Jieming QU|Ruijin Hospital	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 4	380	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Abdrcspc202001	February 7, 2020	July 1, 2020	December 30, 2020	February 7, 2020		February 7, 2020			https://ClinicalTrials.gov/show/NCT04260594
312	NCT04332016	COVID-19 Biological Samples Collection	COLCOV19-BX	Recruiting	No Results Available	Infection Viral	Other: biological samples collection	COVID-19 desease description	University Hospital, Bordeaux	All	up to 100 Years   (Child, Adult, Older Adult)		2000	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	CHUBX 2020/11	April 2, 2020	March 2023	March 2023	April 2, 2020		April 3, 2020	Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France		https://ClinicalTrials.gov/show/NCT04332016
313	NCT04314232	Mechanisms to Morbidity and Mortality for Covid-19	COVID MECH	Not yet recruiting	No Results Available	Coronavirus|SARS		Change in viral expression in association to organspecific biomarkers	University Hospital, Akershus	All	18 Years and older   (Adult, Older Adult)		200	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	117589	March 23, 2020	December 31, 2021	December 31, 2021	March 19, 2020		March 19, 2020			https://ClinicalTrials.gov/show/NCT04314232
314	NCT04327570	In-depth Immunological Investigation of COVID-19.	COntAGIouS	Not yet recruiting	No Results Available	Coronavirus Infections	Other: Patient sampling	Clinical Features|Immune host response at systemic level|Immune host response at local level|Host genetic variation|Comparison severe and non-severe COVID-19 hospitalised patients|Correlation of findings with outcome|Correlation of immune profiling - microbiome	Universitaire Ziekenhuizen Leuven	All	18 Years and older   (Adult, Older Adult)		100	Other	Observational	Observational Model: Other|Time Perspective: Prospective	COntAGIouS	March 27, 2020	September 30, 2020	September 30, 2020	March 31, 2020		March 31, 2020			https://ClinicalTrials.gov/show/NCT04327570
315	NCT04341935	Effects of DPP4 Inhibition on COVID-19		Not yet recruiting	No Results Available	Coronavirus Infection|Type 2 Diabetes	Drug: Linagliptin|Drug: Insulin regimen	Changes in Glucose Llevels|Changes in SpO2 levels|Changes in Interleukin 6 (IL6)|Changes in chest structures	University of Miami	All	18 Years and older   (Adult, Older Adult)	Phase 4	20	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20200384	April 30, 2020	June 30, 2020	September 30, 2020	April 10, 2020		April 10, 2020	University of Miami, Miami, Florida, United States		https://ClinicalTrials.gov/show/NCT04341935
316	NCT04273646	Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia		Not yet recruiting	No Results Available	2019 Novel Coronavirus Pneumonia|COVID-19	Biological: UC-MSCs|Drug: Placebo	Pneumonia severity index|Oxygenation index (PaO2/FiO2)|Side effects in the UC-MSCs treatment group|28-days survival|Sequential organ failure assessment|C-reactive protein|Procalcitonin|Lymphocyte count|CD3+, CD4+ and CD8+ T celll count|CD4+/CD8+ratio	Wuhan Union Hospital, China|Wuhan Hamilton Bio-technology Co., Ltd, China.	All	18 Years to 65 Years   (Adult, Older Adult)	Not Applicable	48	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	202001	February 16, 2020	June 30, 2020	February 15, 2022	February 18, 2020		February 21, 2020	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04273646
317	NCT04323839	COVID-19 PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY)	PRIORITY	Recruiting	No Results Available	Pregnancy|Coronavirus|COVID-19	Other: Pregnant women under investigation for Coronavirus or diagnosed with COVID-19|Other: Postpartum women under investigation for Coronavirus or diagnosed with COVID-19	Clinical presentation|Disease prognosis outcomes|Pregnancy outcomes|Obstetric outcomes|Neonatal outcomes|Modes of transmission of COVID-19	University of California, San Francisco|University of California, Los Angeles	Female	18 Years and older   (Adult, Older Adult)		1000	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	20-30410	March 20, 2020	March 31, 2024	March 31, 2024	March 27, 2020		April 7, 2020	University of California, San Francisco, San Francisco, California, United States		https://ClinicalTrials.gov/show/NCT04323839
318	NCT04275414	Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia	BEST-CP	Recruiting	No Results Available	Coronavirus Infections	Drug: Bevacizumab Injection	Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio|Degree of dyspnea (Liker scale)|Degree of dyspnea (VAS)|The area of lung lesions on Chest CT|The degree of lung exudation on Chest CT|SpO2|PaO2|CRP|hs-CRP|All-cause mortality	Qilu Hospital of Shandong University|Renmin Hospital of Wuhan University|Moriggia-Pelascini Gravedona Hospital	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 2|Phase 3	20	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	QLEmer20200214	February 15, 2020	April 2020	May 2020	February 19, 2020		April 3, 2020	Renmin Hospital of Wuhan University, Wuhan, Hubei, China|Qilu Hospital of Shandong University, Jinan, Shandong, China|Moriggia-Pelascini Gravedona Hospital, Gravedona, Italy		https://ClinicalTrials.gov/show/NCT04275414
319	NCT04325919	Coronavirus Disease 2019 (COVID-19) Study of Hospitalized Patients in Hong Kong		Recruiting	No Results Available	Coronavirus Infections	Other: No intervention	Clinical|Virological|Microbiological	Chinese University of Hong Kong	All	18 Years and older   (Adult, Older Adult)		170	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	COVID-19 study 2020.076	February 24, 2020	February 28, 2021	June 17, 2021	March 30, 2020		March 30, 2020	Prince of Wales Hospital, Sha Tin, Hong Kong		https://ClinicalTrials.gov/show/NCT04325919
320	NCT04324866	Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy		Not yet recruiting	No Results Available	Coronavirus Infection	Diagnostic Test: Nasopharyngeal swab	Point prevalence of COVID-19 infection|Incidence of COVID-19 infection|Percentage of subjects presenting fever or respiratory symptoms|Evaluate the relationship between COVID-19 infection and chronic pharmacological treatments|Evaluate the relationship between COVID-19 infection and comorbid medical conditions	Universita di Verona|Azienda Ospedaliera Universitaria Integrata Verona	All	18 Years to 75 Years   (Adult, Older Adult)		300	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	Gisondi 4	April 1, 2020	November 2020	December 2020	March 27, 2020		March 27, 2020			https://ClinicalTrials.gov/show/NCT04324866
321	NCT04327349	Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial		Enrolling by invitation	No Results Available	Coronavirus Infections	Biological: Convalescent Plasma	Mortality changes in day 10|Mortality changes in day 30|Changes of C-reactive protein|Changes of Interleukin 6|Changes of tumor necrosis factor-α|Changes of PaO2/FiO2 Ratio|Changes of CD3|Changes of CD4|Changes of CD8|Changes of CD4/CD8 ratio|Changes of lymphocyte count|Changes of leukocyte count|Changes of alanine transaminase (ALT)|Changes of aspartate transaminase (AST)|Changes of alkaline phosphatase (ALP)|Changes of lactate dehydrogenase (LDH)|Changes of creatine phosphokinase (CPK)|Changes of Creatine kinase-MB (CK-MB)|Changes of Specific IgG|Radiological findings|Number of days ventilated|Length of hospitalization	Mazandaran University of Medical Sciences	All	30 Years to 70 Years   (Adult, Older Adult)	Not Applicable	30	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IR.MAZUMS.REC.1399.7330|IRCT20181104041551N1	March 28, 2020	May 20, 2020	September 30, 2020	March 31, 2020		March 31, 2020	Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Mazandaran, Iran, Islamic Republic of		https://ClinicalTrials.gov/show/NCT04327349
322	NCT04328129	Household Transmission Investigation Study for COVID-19 in French Guiana	EPI-COVID-19	Recruiting	No Results Available	Coronavirus Infections|Severe Acute Respiratory Syndrome|SARS-CoV Infection	Procedure: Human biological samples	Evaluation of the extent of the virus transmission within households|Characterization of the secondary cases	Institut Pasteur|Institut Pasteur de la Guyane|Centre Hospitalier Andrée Rosemon de Cayenne	All	Child, Adult, Older Adult	Not Applicable	450	Industry|Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening	2020-009	March 23, 2020	March 23, 2022	March 23, 2022	March 31, 2020		March 31, 2020	Centre Hospitalier Andrée Rosemon, Cayenne, French Guiana|Institut Pasteur de la Guyane, Cayenne, French Guiana		https://ClinicalTrials.gov/show/NCT04328129
323	NCT04342169	University of Utah COVID-19 Hydrochloroquine Trial		Not yet recruiting	No Results Available	Coronavirus Infection|Coronavirus|Infectious Disease	Drug: Hydroxychloroquine|Drug: Placebo oral tablet	Duration of viral shedding|Duration of COVID-19-attributable symptoms|Hospitalization|Adult household contact viral acquisition	University of Utah	All	18 Years and older   (Adult, Older Adult)	Phase 2	400	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB_00131893	April 14, 2020	April 2022	April 2023	April 10, 2020		April 10, 2020	University of Utah, Salt Lake City, Utah, United States		https://ClinicalTrials.gov/show/NCT04342169
324	NCT04341922	A Online-delivered Cognitive-behavioral Intervention for Dysfunctional Worry Related to the Covid-19 Pandemic		Not yet recruiting	No Results Available	Dysfunctional Worry	Behavioral: Internet-delivered cognitive behavior therapy (ICBT) for dysfunctional worry related to the Covid-19 pandemic	The self-rated Generalized Anxiety Disorder Scale-7 (GAD-7)|Montgomery Åsberg Depression Rating Scale - Self report (MADRS-S)|Adapted Covid-19 version of the Work and Social Adjustment Scale (WSAS)|Insomnia Severity Index (ISI)|Adapted Swedish version of the CoRonavIruS Health Impact Survey (CRISIS)|Intolerance of uncertainty Scale (IUS)|Patient Satisfaction Questionnaire (PSQ)|Adverse events (AE)	Karolinska Institutet	All	16 Years and older   (Child, Adult, Older Adult)	Not Applicable	670	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Put in EPN	April 10, 2020	June 10, 2021	June 10, 2021	April 10, 2020		April 10, 2020	Karolinska Institutet, Stockholm, Sweden		https://ClinicalTrials.gov/show/NCT04341922
325	NCT04337489	Remote Monitoring Use In Cases Of Suspected COVID-19 (Coronavirus)	REMOTE-COVID	Not yet recruiting	No Results Available	Coronavirus	Device: SensiumVitals wearable sensor	Deterioration resulting in healthcare review|Hospitalisation|Participant anxiety|Participant depression	Imperial College London|CW+ Charity	All	18 Years to 95 Years   (Adult, Older Adult)		200	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	REMOTE-COVID	April 1, 2020	April 1, 2021	April 1, 2021	April 7, 2020		April 7, 2020			https://ClinicalTrials.gov/show/NCT04337489
326	NCT04316728	Clinical Performance of the VivaDiag ™ COVID-19 lgM / IgG Rapid Test in Early Detecting the Infection of COVID-19		Not yet recruiting	No Results Available	Coronavirus Infections	Device: VivaDiag™ COVID-19 lgM/IgG Rapid Test	Number of patients with constant negative results|Number of patients with positive test with a positive PCR for COVID-19|Overall Number of patients positive for COVID-19|Overall Number of patients negative for COVID-19|Number of patients with contrasting results|Reliability of the test|Positive HCW|Number of Chronic Patients	Centro Studi Internazionali, Italy|VivaChek Laboratories, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	200	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	VivaDiag-2020	March 2020	September 2020	November 2020	March 20, 2020		March 20, 2020	Unità' Complesse di cure primarie (UCCP), ASP Catanzaro, Catanzaro, Italy		https://ClinicalTrials.gov/show/NCT04316728
327	NCT04334434	Telerehabilitation in Individuals Over 65 Years of Age Having Social Isolation Due to Coronavirus (Covid-19)		Not yet recruiting	No Results Available	Telerehabilitation	Other: Telerehabilitation	Physical Activity Scale for the Elderly|Nottingham Health Profile|Loneliness Scale for the Elderly	Kubra Koce, MSc PT|Istanbul University-Cerrahpasa	All	65 Years and older   (Older Adult)	Not Applicable	30	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention	2	April 1, 2020	June 1, 2020	July 31, 2020	April 6, 2020		April 7, 2020			https://ClinicalTrials.gov/show/NCT04334434
328	NCT04311697	Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress	COVID-AIV	Not yet recruiting	No Results Available	Acute Respiratory Distress Syndrome|Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)|Corona Virus Infection	Drug: Aviptadil by intravenous infusion + maximal intensive care|Drug: Normal Saline Infusion + Maximal intensive care	Mortality|PaO2:FiO2 ratio|TNF alpha|Multi-system organ failure free days	NeuroRx, Inc.|Relief Therapeutics Holding SA|Target Health Inc.|Lavin Consulting, LLC	All	18 Years to 100 Years   (Adult, Older Adult)	Phase 2	120	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	COVID-AIV	April 2020	August 2020	September 2020	March 17, 2020		April 10, 2020	Miller School of Medicine / University of Miami Medical Center, Miami, Florida, United States|Robert I Grossman School of Medicine / NYU Langone Medical Center, New York, New York, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Rambam Health Care Campus, Haifa, Israel		https://ClinicalTrials.gov/show/NCT04311697
329	NCT04325867	Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19	eCardioCovid19	Recruiting	No Results Available	Angina Pectoris|Acute Coronary Syndrome|Coronary Syndrome|Coronary Artery Disease|Angioplasty|Stent Restenosis|Hypertension|Heart Failure, Systolic|Depression, Anxiety|Covid-19|Isolation, Social	Other: Tele-medicine platform	Providing a special electronic platform (e-health) for remote managing cardiovascular outpatients|Number of patients included in this platform|Number of consultations/sessions given	Professor Adrian Covic|Medical Sciences Academy - Romania|Victor Babes Clinical Hospital of Infectious Diseases - Bucharest|Grigore T. Popa University of Medicine and Pharmacy	All	Child, Adult, Older Adult	Not Applicable	200	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	GTP0032	March 31, 2020	October 1, 2020	October 1, 2020	March 30, 2020		April 1, 2020	Medical Sciences Academy, Bucharest, Romania|University of Medicine and Pharmacy Gr T Popa, Iasi, Romania		https://ClinicalTrials.gov/show/NCT04325867
330	NCT04341480	The Safety of Chemotherapy for Patients With Gynecological Malignancy in High-risk Region of COVID-19		Not yet recruiting	No Results Available	Gynecological Cancer	Drug: Chemotherapy	SARS-CoV-2 infection|Tumor response|Safety and tolerability|Patient-reported outcomes	Tongji Hospital	Female	18 Years to 80 Years   (Adult, Older Adult)		207	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	2020-TJ-COVID-19	April 10, 2020	July 10, 2020	July 10, 2020	April 10, 2020		April 10, 2020	Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04341480
331	NCT04340349	Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals	HCQINRLGII	Not yet recruiting	No Results Available	Hydroxychloroquine|Antimalarials|Enzyme Inhibitors|Antirheumatic Agents	Drug: Hydroxychloroquine Sulfate|Drug: Bromhexine 8 MG	Polymerase chain reaction assay (PCR) negative at day 0 plus negative serological panel for COVID-19 antibodies at enrolment.|Polymerase chain reaction assay (PCR) negative at day 30.|Polymerase chain reaction assay (PCR) negative at day 60.	Instituto Nacional de Rehabilitacion	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention	20/20	April 10, 2020	June 9, 2020	July 10, 2020	April 9, 2020		April 9, 2020	National Institute of Rehabilitation, Mexico City, Cdmx, Mexico		https://ClinicalTrials.gov/show/NCT04340349
332	NCT04339322	Characteristics and Outcome of Coronavirus Disease 2019 (COVID-19) in Egypt	COVID-19	Not yet recruiting	No Results Available	Characteristics Diseases|Outcome, Fatal	Other: Follow up	Demographics of Coronavirus Disease 2019 (COVID-19) in the cohort group|Clinical manifestations of Coronavirus Disease 2019 (COVID-19)|Laboratory data of included Coronavirus Disease 2019 (COVID-19) cohort|Radiological features of Coronavirus Disease 2019 (COVID-19) cohort|outcomes of Coronavirus Disease 2019 (COVID-19) infection in the cohort group	Assiut University	All	Child, Adult, Older Adult		200	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	COVID-19 in Egypt	May 1, 2020	July 30, 2020	July 30, 2020	April 9, 2020		April 9, 2020			https://ClinicalTrials.gov/show/NCT04339322
333	NCT04327505	Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19	COVID-19-HBO	Not yet recruiting	No Results Available	Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)|Cytokine Storm|Infection Viral	Drug: Hyperbaric oxygen	PO2/FiO2 (Safety)|PO2/FiO2 (Efficacy)|Early Warning Score (NEWS) (Safety)|Early Warning Score (NEWS) (Efficacy)|Immunological response (Efficacy)|Mechanical ventilation (Efficacy)|SAE|Serious ADR|AE|Oxygen dose|Pulmonary CT (low-dose CT)|Chest X-ray|Chest ultrasound|Secondary infections|Mortality|ICU free days|ICU mortality|Hospital mortality|Micro RNA plasma (Biomarker)|MicroRNA/RNA PBMC (Explanatory)|Immunological response (Explanatory)|Viral load	Karolinska University Hospital|Karolinska Institutet|University of California, San Diego|Blekinge County Council Hospital	All	18 Years to 90 Years   (Adult, Older Adult)	Phase 2|Phase 3	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	K-2020-2611|2020-001349-37|4-1199/2020	April 25, 2020	October 31, 2021	December 31, 2022	March 31, 2020		March 31, 2020			https://ClinicalTrials.gov/show/NCT04327505
334	NCT04339387	COVID-19 Risk Stratification		Recruiting	No Results Available	Coronavirus|Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere		Suitable for discharge	Brigham and Women's Hospital	All	18 Years and older   (Adult, Older Adult)		1500	Other	Observational	Observational Model: Cohort|Time Perspective: Other	2020P000944	March 1, 2020	April 15, 2020	April 15, 2020	April 9, 2020		April 9, 2020	Brigham and Women's Hospital, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT04339387
335	NCT04318314	COVID-19: Healthcare Worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2	COVID19-HCW	Recruiting	No Results Available	Health Care Worker Patient Transmission|Coronavirus|Coronavirus Infections|Immunological Abnormality	Diagnostic Test: COPAN swabbing and blood sample collection	Seroconversion to SARS-CoV-2 positivity	University College, London|St. Bartholomew's Hospital|Royal Free Hospital NHS Foundation Trust|UCLH	All	18 Years and older   (Adult, Older Adult)		400	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	130852	March 18, 2020	December 31, 2020	December 31, 2021	March 23, 2020		March 26, 2020	Barts Heart Center, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom		https://ClinicalTrials.gov/show/NCT04318314
336	NCT04256395	Efficacy of a Self-test and Self-alert Mobile Applet in Detecting Susceptible Infection of COVID-19	COVID-19	Recruiting	No Results Available	Susceptibility to Viral and Mycobacterial Infection	Other: mobile internet survey on self-test	positive number diagnosed by national guideline in the evaluated population|distribution map of evaluated people|Effect of medical guidance by designated feedback questionnaire|mental scale of relief the mental anxiety and avoid unnecessary outpatient	Beijing Tsinghua Chang Gung Hospital|Institute for precision medicine of Tsinghua University|Institute for artificial intelligent of Tsinghua University|Chinese Medical Doctor Association|Institute for network behavior of Tsinghua University|school of clinical medicine of Tsinghua University	All	Child, Adult, Older Adult		300000	Other	Observational	Observational Model: Other|Time Perspective: Prospective	RWS-BTCH-002	February 1, 2020	July 31, 2020	July 31, 2020	February 5, 2020		February 20, 2020	Beijing Tsinghua Changgung Hospital, Beijing, Beijing, China		https://ClinicalTrials.gov/show/NCT04256395
337	NCT04252274	Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19	DC-COVID-19	Recruiting	No Results Available	Pneumonia, Pneumocystis|Coronavirus	Drug: Darunavir and Cobicistat	The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|The critical illness rate of subjects at weeks 2|The mortality rate of subjects at weeks 2	Shanghai Public Health Clinical Center	All	Child, Adult, Older Adult	Phase 3	30	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DC-COVID-19	January 30, 2020	August 31, 2020	December 31, 2020	February 5, 2020		April 13, 2020	Shanghai Public Health Clinical Center, Shanghai, Shanghai, China|Shanghai Public Health Clinical Center, Shanghai, Shanghai, China		https://ClinicalTrials.gov/show/NCT04252274
338	NCT04305457	Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19	NoCovid	Recruiting	No Results Available	Coronavirus Infections|Pneumonia, Viral|Acute Respiratory Distress Syndrome	Drug: Nitric Oxide	Reduction in the incidence of patients with mild/moderate COVID-19 requiring intubation and mechanical ventilation|Mortality|Time to clinical recovery	Massachusetts General Hospital|Xijing Hospital|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico	All	18 Years and older   (Adult, Older Adult)	Phase 2	240	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NOgas mildCOVID-19	March 21, 2020	April 1, 2021	April 1, 2022	March 12, 2020		April 9, 2020	Massachusetts General Hospital, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT04305457
339	NCT04324463	Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial	ACT COVID19	Not yet recruiting	No Results Available	Coronavirus|Severe Acute Respiratory Syndrome	Drug: Azithromycin|Drug: Chloroquine	Outpatients: Hospital Admission or Death|Inpatients: Invasive mechanical ventilation or mortality	Population Health Research Institute	All	18 Years and older   (Adult, Older Adult)	Phase 3	1500	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PHRI.ACT.COVID19	April 1, 2020	September 30, 2020	December 31, 2020	March 27, 2020		March 27, 2020	Hamilton Health Sciences, Hamilton, Ontario, Canada		https://ClinicalTrials.gov/show/NCT04324463
340	NCT04325412	Cardiac complicAtions in Patients With SARS Corona vIrus 2 regisTrY	CAPACITY-COVID	Recruiting	No Results Available	COVID-19; Cardiovascular Diseases		The incidence of cardiovascular complications in patients with COVID-19	UMC Utrecht	All	18 Years and older   (Adult, Older Adult)		1000	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	20-161/C	March 23, 2020	March 23, 2021	June 23, 2021	March 27, 2020		March 27, 2020	University Medical Center Utrecht, Utrecht, Netherlands		https://ClinicalTrials.gov/show/NCT04325412
341	NCT04320277	Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.	BARI-COVID	Recruiting	No Results Available	Pharmacological Action	Drug: Baricitinib	The percentage of patients requiring transfer to ICU as compared with the rate of transfers observed in controls.|The percentage of patients achieving the remission; CRP, IL-6 and TNFα values at baseline and during the treatment course; the number of AEs.	Hospital of Prato	All	18 Years to 85 Years   (Adult, Older Adult)	Phase 3	60	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HPrato-3	March 16, 2020	April 30, 2020	April 30, 2020	March 24, 2020		March 24, 2020	Fabrizio Cantini, Prato, Tuscany, Italy		https://ClinicalTrials.gov/show/NCT04320277
342	NCT04322396	Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalized Patients With COVID-19	ProPAC-COVID	Recruiting	No Results Available	Virus Diseases|Infection Viral|Corona Virus Infection	Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Placebo oral tablet	Number of days alive and discharged from hospital within 14 days|Categorization of hospitalization status|Admitted to intensive care unit, if admitted to ICU then length of stay|Have used Non-invasive ventilation (NIV) during hospitalization|Mortality|Length of hospitalization|Days alive and discharged from hospital|Number of readmissions (all causes)|Number of days using non-invasive ventilation (NIV)|Change in patient's oxygen partial pressure|Change in patient's carbondioxid partial pressure|Level of pH in blood|Time for no oxygen supplement (or regular oxygen supplement "LTOT")	Chronic Obstructive Pulmonary Disease Trial Network, Denmark	All	Child, Adult, Older Adult	Phase 2	226	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	KronLungesyg_COVID_19_protokol	April 6, 2020	October 31, 2020	March 31, 2021	March 26, 2020		April 13, 2020	Aalborg Sygehus, Aalborg, Denmark|Bispebjerg Hospital, Copenhagen, Denmark|Herlev-Gentofte Hospital, Copenhagen, Denmark|Hvidovre Hospital, Copenhagen, Denmark|Nordsjællands Hospital, Hillerød, Denmark|Odense Universitetshospital, Odense, Denmark|Roskilde Sygehus, Roskilde, Denmark|Slagelse Sygehus, Slagelse, Denmark		https://ClinicalTrials.gov/show/NCT04322396
343	NCT04327401	COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III	CODEX	Not yet recruiting	No Results Available	Coronavirus Infection|Pneumonia, Viral|Acute Respiratory Distress Syndrome	Drug: Dexamethasone	Ventilator-free days|Evaluation of the clinical status|All-cause mortality|Mechanical ventilation duration|Sequential Organ Failure Assessment (SOFA) Score	Luiz F. L. Reis, Ph.D.|Hospital Israelita Albert Einstein|Hospital do Coracao|Brazilian Research In Intensive Care Network|Ache Laboratorios Farmaceuticos S.A.|Hospital Sirio-Libanes	All	18 Years and older   (Adult, Older Adult)	Phase 3	290	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	codex_v1.1	April 1, 2020	August 30, 2020	August 30, 2020	March 31, 2020		April 1, 2020	Hospital Ana Nery, Salvador, Bahia, Brazil|Instituto de Cardiologia do Distrito Federal, Brasília, Distrito Federal, Brazil|Fundação Social Rural de Colatina, Colatina, Esoírito Santo, Brazil|Hospital Vera Cruz AS, Belo Horizonte, Minas Gerais, Brazil|Hospital Maternidade E Pronto Socorro Santa Lucia Ltda, Poços De Caldas, Minas Gerais, Brazil|Universidade Estadual de Londrina, Londrina, Paraná, Brazil|Eurolatino Natal Pesquisas Médicas Ltda, Natal, Rio Grande Do Norte, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Maestri E Kormann Consultoria Medico-Cientifica, Blumenau, Santa Catarina, Brazil|Sociedade Literaria e Caritativa Santo Agostinho, Criciúma, Santa Catarina, Brazil|Fundação Pio XII, Barretos, São Paulo, Brazil|Santa Casa de Misericordia de Votuporanga, Votuporanga, São Paulo, Brazil|Associacao Beneficente Siria, São Paulo, Brazil|Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da USP - HCFMRP, São Paulo, Brazil|Hospital Israelita Albert Einstein, São Paulo, Brazil|Prevent Senior Private Operadora de Saude Ltda, São Paulo, Brazil|Real e Benemérita Associação Portuguesa de Beneficência/SP, São Paulo, Brazil|Santa Casa de Misericórdia, São Paulo, Brazil|Secretaria de Saúde do Estado de São Paulo, São Paulo, Brazil|Sociedade Beneficente de Senhoras Hospital Sírio-Libanês, São Paulo, Brazil|Universidade Federal de São Paulo, São Paulo, Brazil		https://ClinicalTrials.gov/show/NCT04327401
344	NCT04342156	Safety And Efficacy Of Hydroxychloroquine As COVID-19 Prophylaxis For At-Risk Population (SHARP): A Cluster Randomized Controlled Trial	SHARP COVID-19	Not yet recruiting	No Results Available	Coronavirus Infection|Hydroxychloroquine Adverse Reaction	Drug: Hydroxychloroquine Sulfate 200 milligram (mg) Tab	positive serology or reverse transcriptase (RT-PCR) for COVID-19 up until day 28.	Tan Tock Seng Hospital|National Center for Infectious Diseases|Singapore Clinical Research Institute|Singapore Eye Research Institute|Saw Swee Hock School of Public Health|Duke-NUS Graduate Medical School|Netherlands: Ministry of Health, Welfare and Sports	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 3	3000	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	2020/00402	April 2020	August 2020	October 2020	April 10, 2020		April 10, 2020			https://ClinicalTrials.gov/show/NCT04342156
345	NCT04339790	Mental Health Impact of COVID-19 Pandemic on NIMH Research Participants and Volunteers		Recruiting	No Results Available	Healthy Volunteer|Mood Disorder|Anxiety Disorder|Preexisting Medical Condition		NIMH COVID Study survey - adult responses|DSM XC and KS survey	National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)	All	18 Years and older   (Adult, Older Adult)		5000	NIH	Observational	Observational Model: Cohort|Time Perspective: Prospective	999920085|20-M-N085	April 16, 2020	March 1, 2022	April 1, 2022	April 9, 2020		April 13, 2020	National Institute of Mental Health (NIMH), Bethesda, Maryland, United States		https://ClinicalTrials.gov/show/NCT04339790
346	NCT04280705	Adaptive COVID-19 Treatment Trial (ACTT)		Recruiting	No Results Available	Corona Virus Infection	Other: Placebo|Drug: Remdesivir	Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of infusions|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Number of non-invasive ventilation/high flow oxygen free days|Number of oxygenation free days|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first|Ventilator/extracorporeal membrane oxygenation (ECMO) free days	National Institute of Allergy and Infectious Diseases (NIAID)	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 3	440	NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	20-0006	February 21, 2020	April 1, 2023	April 1, 2023	February 21, 2020		April 6, 2020	University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States|University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States|University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States|University of California Irvine Medical Center - Infectious Disease, Orange, California, United States|VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States|University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States|Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States|University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States|Cedars Sinai Medical Center, West Hollywood, California, United States|Rocky Mountain Regional Veteran Affairs Medical Center - Department of Infectious Diseases, Aurora, Colorado, United States|Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States|University of Florida Health Sciences Center, College of Public Health- Epidemiology, Gainesville, Florida, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States|University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States|Southeast Louisiana Veterans Health Care System (SLVHCS) - Section of Infectious Diseases, New Orleans, Louisiana, United States|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Annapolis, Maryland, United States|Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States|Walter Reed Army Institute of Research - Clinical Trials Center, Silver Spring, Maryland, United States|Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States|University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States|Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States|New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States|University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States|Hospital of the University of Pennsylvania - Infectious Diseases, Philadelphia, Pennsylvania, United States|University of Pennsylvania Perelman School of Medicine - Penn Institute for Immunology, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center - Infectious Diseases, Nashville, Tennessee, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States|Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States|University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States|University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States|Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States|EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States|The University of Washington - Virology Research Clinic, Seattle, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States|University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases, Copenhagen, Denmark|Universitatsklinikum Bonn, Medizinische Klinik I - Bereich Infektiologie/HIV der Medizinischen Klinik, Bonn, Nordrhein-Westfalen, Germany|Universitätsklinikum Frankfurt -Medizinische Klinik II - Infektiologie, Frankfurt, Germany|National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan|Seoul National University Bundang Hospital - Division of Infectious Diseases, Bundang-gu Seongnam-si, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of|Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cosío Villegas, Mexico City, Mexico|National Centre for Infectious Diseases (NCID), Singapore, Singapore|Saint Thomas' Hospital - Directorate of Infection, London, London, City Of, United Kingdom|Royal Victoria Infirmary - Department of Infectious Diseases, Level 6, Ward 19, Newcastle Upon Tyne, United Kingdom		https://ClinicalTrials.gov/show/NCT04280705
347	NCT04321278	Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)		Recruiting	No Results Available	Coronavirus Infections|Pneumonia, Viral	Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine	Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death	Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|Cristália Produtos Químicos Farmacêuticos Ltda.	All	18 Years and older   (Adult, Older Adult)	Phase 3	440	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	30155020.5.1001.0071	March 28, 2020	August 30, 2020	August 30, 2020	March 25, 2020		April 1, 2020	Instituto de Cardiologia do Distrito Federal, Brasília, Distrito Federal, Brazil|Fundação Social Rural de Colatina, Colatina, Espirito Santo, Brazil|Hospital Vera Cruz AS, Belo Horizonte, Minas Gerais, Brazil|Hospital Maternidade E Pronto Socorro Santa Lucia Ltda, Poços De Caldas, Minas Gerais, Brazil|Universidade Estadual de Londrina, Londrina, Paraná, Brazil|Hospital Universitário Onofre Lopes, Natal, Rio Grande Do Norte, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Maestri E Kormann Consultoria Medico-Cientifica, Blumenau, Santa Catarina, Brazil|Sociedade Literaria e Caritativa Santo Agostinho, Criciúma, Santa Catarina, Brazil|Fundação Pio XII, Barretos, São Paulo, Brazil|Santa Casa de Misericordia de Votuporanga, Votuporanga, São Paulo, Brazil|Hospital Israelita Albert Einstein, São Paulo, Brazil|AMICO Saude LTDA, São Paulo, Brazil|Associacao Beneficente Siria, São Paulo, Brazil|Prevent Senior Private Operadora de Saude Ltda, São Paulo, Brazil|Real e Benemérita Associação Portuguesa de Beneficência/SP, São Paulo, Brazil|Real e Benemérita Associação Portuguesa de Beneficência/SP, São Paulo, Brazil|Santa Casa de Misericórdia, São Paulo, Brazil|Secretaria de Saúde do Estado de São Paulo, São Paulo, Brazil|Serv Social da Industria do papel, papelão e cortiça do estado de SP, São Paulo, Brazil|Sociedade Beneficente de Senhoras Hospital Sírio-Libanês, São Paulo, Brazil|Universidade Federal de São Paulo, São Paulo, Brazil		https://ClinicalTrials.gov/show/NCT04321278
348	NCT04323592	Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome	MP-C19	Recruiting	No Results Available	Severe Acute Respiratory Syndrome (SARS) Pneumonia|Coronavirus Infections|ARDS, Human	Drug: Methylprednisolone|Other: standard care	Composite primary end-point|death|Admission to ICU|Endotracheal intubation (invasive mechanical ventilation)|reduction of C-reactive protein or CRP|Reduction of mechanical ventilation	University of Trieste	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 2|Phase 3	104	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MP-19 023_2020	March 23, 2020	May 20, 2020	May 30, 2020	March 26, 2020		March 27, 2020	Marco Confalonieri, Trieste, TS, Italy	Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/92/NCT04323592/Prot_SAP_000.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/92/NCT04323592/ICF_001.pdf	https://ClinicalTrials.gov/show/NCT04323592
349	NCT04322487	Simple, Safe, Same: Lung Ultrasound for COVID-19	LUSCOVID19	Not yet recruiting	No Results Available	Coronavirus|Epidemic Disease|Pneumonia, Viral	Diagnostic Test: Lung ultrasound	Lung ultrasound grading system for COVID-19 pneumonia	Catholic University of the Sacred Heart|Valle del Serchio General Hospital, Lucca, Italy|University of Trento, Trento, Italy|Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy|Bresciamed, Brescia, Italy|118 USL Nordovest Toscana, Lucca, Italy|General Hospital, Voghera, Italy|Lodi General Hospital, Lodi, Italy	All	Child, Adult, Older Adult		100	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	0013226/20	April 1, 2020	December 31, 2020	January 15, 2021	March 26, 2020		March 27, 2020	Bresciamed, Brescia, Italy|Pulmonary Medicine Unit, Lodi General Hospital, Lodi, Italy|118 USL Nordovest Toscana, Lucca, Italy|Diagnostic and Interventional Ultrasound Unit, Valle del Serchio General Hospital, Lucca, Italy|Emergency Department, Fondazione IRCCS Policlinico San Matteo, and Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy|Department of woman and child health and public health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy|Pulmonary Medicine Unit, Dept. Medical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy|Department of Information Engineering and Computer Science, Ultrasound Laboratory Trento, University of Trento, Trento, Italy|Emergency Medicine Unit, General Hospital, Voghera, Italy		https://ClinicalTrials.gov/show/NCT04322487
350	NCT04257656	Severe 2019-nCoV Remdesivir RCT		Recruiting	No Results Available	2019-nCov|Remdesivir	Drug: Remdesivir|Drug: Remdesivir placebo	Time to Clinical Improvement (TTCI) [Censored at Day 28]|Clinical status|Time to Hospital Discharge OR NEWS2 (National Early Warning Score 2) of ≤ 2 maintained for 24 hours.|All cause mortality|Duration (days) of mechanical ventilation|Duration (days) of extracorporeal membrane oxygenation|Duration (days) of supplemental oxygenation|Length of hospital stay (days)|Time to 2019-nCoV RT-PCR negativity in upper and lower respiratory tract specimens|Change (reduction) in 2019-nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve.|Frequency of serious adverse drug events	Capital Medical University	All	18 Years and older   (Adult, Older Adult)	Phase 3	453	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CAP-China remdesivir 2	February 6, 2020	April 3, 2020	May 1, 2020	February 6, 2020		February 24, 2020	Bin Cao, Beijing, Beijing, China		https://ClinicalTrials.gov/show/NCT04257656
351	NCT04321174	COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir	CORIPREV-LR	Not yet recruiting	No Results Available	Coronavirus Infections|Post-exposure Prophylaxis	Drug: Lopinavir/ritonavir	Microbiologic evidence of infection|Adverse events|Symptomatic COVID-19 disease|Seropositivity|Days of hospitalization attributable to COVID-19 disease|Respiratory failure requiring ventilatory support attributable to COVID-19 disease|Mortality|Short-term psychological impact of exposure to COVID-19 disease|Long-term psychological impact of exposure to COVID-19 disease|Health-related quality of life	Darrell Tan|St. Michael's Hospital, Toronto	All	18 Months and older   (Child, Adult, Older Adult)	Phase 3	1220	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	CORIPREV-1	March 30, 2020	March 31, 2021	March 31, 2022	March 25, 2020		March 25, 2020	Sunnybrook Hospital, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT04321174
352	NCT04288713	Eculizumab (Soliris) in Covid-19 Infected Patients	SOLID-C19	Available	No Results Available	Coronavirus	Drug: Eculizumab		Hudson Medical	All	18 Years and older   (Adult, Older Adult)			Other	Expanded Access:Individual Patients|Treatment IND/Protocol		COVID19				February 28, 2020		March 30, 2020			https://ClinicalTrials.gov/show/NCT04288713
353	NCT04326387	Evaluation of Novel Diagnostic Tests for COVID-19	COVIDx	Recruiting	No Results Available	Acute Disease|Coronavirus|Respiratory Viral Infection	Diagnostic Test: SAMBA II (Diagnostic for the Real World)|Diagnostic Test: Public Health England Gold Standard|Diagnostic Test: Cambridge Validated Viral Detection Method|Diagnostic Test: Radiological Detection	SAMBA COVID-19 POC PCR Test|Patient acceptability|Immune Response Positivity	CCTU- Cancer Theme|Cambridge University Hospitals NHS Foundation Trust	All	16 Years and older   (Child, Adult, Older Adult)		200	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	COVIDx	April 6, 2020	April 7, 2021	October 7, 2021	March 30, 2020		April 10, 2020	Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom		https://ClinicalTrials.gov/show/NCT04326387
354	NCT02735707	Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia	REMAP-CAP	Recruiting	No Results Available	Community-acquired Pneumonia, Influenza, COVID-19	Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra	All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization	MJM Bonten|Berry Consultants|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|UMC Utrecht	All	18 Years and older   (Adult, Older Adult)	Phase 4	6800	Other	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584	April 11, 2016	December 2021	June 2022	April 13, 2016		March 30, 2020	Wollongong Hospital, Sidney, New South Wales, Australia|St Vincent's Hospital Sydney, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|Royal Darwin Hospital,, Darwin, Northern Territory, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Logan Hospital, Brisbane, Queensland, Australia|Toowoomba Hospital, Toowoomba, Queensland, Australia|The Queen Elizabeth Hospital, Adelaide, South Australia, Australia|Bendigo Hospital, Bendigo, Victoria, Australia|University Hosptial Geelong, Geelong, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia|St John of God Hospital Midland, Perth, Western Australia, Australia|Fiona Stanley Hospital, Perth, Western Australia, Australia|St John of God Hospital Murdoch, Perth, Western Australia, Australia|AZ Sint-Jan, Brugge, Belgium|CHU de Charleroi - Hôpital Civil Marie Curie, Charleroi, Belgium|Universitair Ziekenhuis Antwerp, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|St. Joseph's Healthcare Hamilton, Hamilton, Canada|Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Canada|St. Michael's Hospital Unity Health Toronto, Toronto, Canada|General County Hospital Požega, Požega, Croatia|University Hospital Centre Zagreb, Zagreb, Croatia|University Hospital for Infectious Diseases, Zagreb, Croatia|Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie, Berlin, Germany|Charité - Universitätsmedizin Berlin - Nephrologie, Berlin, Germany|Vivantes Klinikum Neukölln, Berlin, Germany|Universitätsklinikum Köln, Cologne, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Jena, Jena, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitäts Klinikum Tübingen, Tübingen, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Jósa András County Hospital, Nyíregyháza, Hungary|Csolnoky Ferenc Kórház - Veszprem County Hospital, Veszprém, Hungary|Almási Balogh Pál Kórház, Ózd, Hungary|Beaumont Hospital, Dublin, Ireland|St. Vincent's University Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|Meander Medisch Centrum, Amersfoort, Netherlands|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands|Martini Hospital Groningen, Groningen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|North Shore Hospital, Auckland, New Zealand|CVICU, Auckland City Hospital, Auckland, New Zealand|DCCM, Auckland City Hospital, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|Rotorua Hospital, Rotorua, New Zealand|Tauranga Hospital, Tauranga, New Zealand|Wellington Regional Hospital, Wellington, New Zealand|Whangarei Hospital, Whangarei, New Zealand|Centro Hospitalar do Medio Tejo, Abrantes, Portugal|Hospital Lusíadas Lisbon, Lisboa, Portugal|Clinical Hospital of Infectious and Tropical Diseases "Dr. Victor Babes", Bucharest, Romania|Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom|Southmead Hospital, Bristol, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Darlington Memorial Hospital, Darlington, United Kingdom|University Hospital of North Durham, Durham, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom|The James Cook University Hospital, Middlesbrough, United Kingdom|Milton Keynes University Hospital, Milton Keynes, United Kingdom|Northampton General Hospital, Northampton, United Kingdom|Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Poole Hospital NHS Foundation Trust, Poole, United Kingdom|Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom|Royal Berkshire Hospital, Reading, United Kingdom|University Hospital of North Tees, Stockton-on-Tees, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom|Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, United Kingdom|York Hospital, York, United Kingdom		https://ClinicalTrials.gov/show/NCT02735707
355	NCT04335747	COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases		Not yet recruiting	No Results Available	Rheumatoid Arthritis|Psoriatic Arthritis|Axial Spondyloarthritis|Systemic Lupus Erythematosus|Giant Cell Arteritis	Other: COVID-19 infection	Disease activity|Immune modulating treatments|Biomarkers	Salome Kristensen|Aalborg University Hospital	All	18 Years and older   (Adult, Older Adult)		333	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	20200401	April 8, 2020	August 1, 2021	September 1, 2021	April 6, 2020		April 7, 2020	Aalborg University Hospital, Aalborg, Denmark		https://ClinicalTrials.gov/show/NCT04335747
356	NCT04340219	Oncology-patient-reported Anxiety, Mood, and QoL During the COVID-19 Pandemic	ONCOVID	Recruiting	No Results Available	Cancer	Other: Survey administration	Distress at baseline measured by the COVID-19 Peritraumatic Distress Index (CPDI); in terms of proportions (0-28 vs ≥ 29).|Depression at baseline measured by the 7-item depression subscale of the 21-item Depression, Anxiety, and Stress Scale (DASS-21) (DASS-21—Depression); in terms of proportions (0-4 vs ≥ 5).|Anxiety at baseline measured by the 7-item anxiety subscale of the DASS-21 (DASS-21—Anxiety); in terms of proportions (0-3 vs ≥ 4).|Stress at baseline measured by the 7-item stress subscale of the DASS-21 (DASS-21—Stress); in terms of proportions (0-7 vs ≥ 8).|Distress measured at baseline by the CPDI; in terms of continuous values.|Depression at baseline measured by the DASS-21—Depression; in terms of continuous values.|Anxiety at baseline measured by the DASS-21—Anxiety; in terms of continuous values.|Stress at baseline measured by the DASS-21—Stress; in terms of continuous values.|Domain-specific quality of life at baseline measured by the 7-item physical health domain of the World Health Organization Quality of Life-BREF (WHOQOL-BREF) questionnaire (WHOQOL-BREF—Physical health); in terms of continuous values.|Domain-specific quality of life at baseline measured by the 6-item psychological health domain of the WHOQOL-BREF questionnaire (WHOQOL-BREF—Psychological health); in terms of continuous values.|Domain-specific quality of life at baseline measured by the 3-item social relationships domain of the WHOQOL-BREF questionnaire (WHOQOL-BREF—Social relationships); in terms of continuous values.|Domain-specific quality of life at baseline measured by the 8-item environment domain of the WHOQOL-BREF questionnaire (WHOQOL-BREF—Environment); in terms of continuous values.|Overall perception of quality of life and overall perception of health at baseline measured by the two items from the Overall QOL and General Health in the WHOQOL-BREF questionnaire—in terms of continuous values.|Change from baseline in distress measured by CDPI; in terms of continuous values.|Change from baseline in depression measured by the DASS-21—Depression; in terms of continuous values.|Change from baseline in anxiety measured by the DASS-21—Anxiety; in terms of continues values.|Change from baseline in stress measured by the DASS-21—Stress; in terms of continuous values.|Change from baseline in domain-specific quality of life at baseline measured by the WHOQOL-BREF—Physical health; in terms of continuous values.|Change from baseline in domain-specific quality of life at baseline measured by the WHOQOL-BREF—Psychological health; in terms of continuous values.|Change from baseline in domain-specific quality of life measured by the WHOQOL-BREF—Social relationship; in terms of continuous values.|Change from baseline in domain-specific quality of life measured by the WHOQOL-BREF—Environment; in terms of continuous values.|Change from baseline in overall perception of quality of life and overall perception of health measured by the 2 items from the Overall QOL and General Health in the WHOQOL-BREF questionnaire; in terms of continuous values.|The real-life impact of COVID-19 on systemic treatment administration will be assessed using descriptive statistics	University Hospital, Ghent	All	18 Years and older   (Adult, Older Adult)		180	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	BC-07505-LGE	March 30, 2020	April 2020	September 2020	April 9, 2020		April 9, 2020	University Hospital Gent, Gent, Belgium		https://ClinicalTrials.gov/show/NCT04340219
357	NCT04320953	Non-contact Endoscopy at Covid-19 Outbreak		Completed	No Results Available	Gastrointestinal Disease|Infectious Disease	Device: Non-contact MCE system	Technical success|Clinical success|Adverse events	Changhai Hospital	All	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	1	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	ncMCE1	March 16, 2020	March 16, 2020	March 16, 2020	March 25, 2020		March 25, 2020	Changhai Hospital, Shanghai, China		https://ClinicalTrials.gov/show/NCT04320953
358	NCT04334629	LIBA Trial in COVID-19	LIBA	Not yet recruiting	No Results Available	Coronavirus|Respiratory Distress Syndrome|SARS-CoV Infection	Drug: Ibuprofen	Disease progression|Time to mechanical ventilation|Overall survival|Reduction in proportion of patients who require ventilation|Reduction in length of Critical Care stay|Reduction in length of Hospital stay|Modulation of serum pro- and anti-inflammatory cytokines|Reduction in duration of ventilation|Increase in ventilator-free days	King's College London|Guy's & St Thomas NHS Foundation Trust	All	18 Years and older   (Adult, Older Adult)	Phase 4	230	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment	282009	April 6, 2020	August 5, 2020	November 5, 2020	April 6, 2020		April 6, 2020			https://ClinicalTrials.gov/show/NCT04334629
359	NCT04322565	Colchicine Efficacy in COVID-19 Pneumonia		Not yet recruiting	No Results Available	Coronavirus Infections|Pneumonia, Viral	Drug: Colchicine	Clinical improvement|Hospital discharge|Death|Clinical status|Mechanical venhtilation|Hospitalization|Time from death|Negativization COVID 19|Fever	Lucio Manenti|Azienda Ospedaliero-Universitaria di Parma	All	18 Years to 85 Years   (Adult, Older Adult)	Phase 2	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	COLCOVID01	April 1, 2020	May 30, 2020	June 30, 2020	March 26, 2020		March 26, 2020			https://ClinicalTrials.gov/show/NCT04322565
360	NCT04308187	Influence of the COvid-19 Epidemic on STRESS	COVISTRESS	Not yet recruiting	No Results Available	Stress, Psychological		Stress|Perception and knowledge of the epidemic|Feeling of information on the part of companies / establishments / governments|Means of protection|Feelings of fear generated and its impact on feelings of stigmatization towards ethnic groups or categories of patients|Sociodemographic factors and lifestyle habits	University Hospital, Clermont-Ferrand|Faculty of Medicine, Clermont-Ferrand, France|UMR CNRS 6024 LaPSCo, Clermont-Ferrand, France|Wittyfit, Paris, France	All	Child, Adult, Older Adult		50000	Other	Observational	Observational Model: Cohort|Time Perspective: Cross-Sectional	2020 COVISTRESS	March 11, 2020	March 2022	March 2022	March 13, 2020		March 13, 2020	University Hospital, Clermont-Ferrand, Clermont-Ferrand, France		https://ClinicalTrials.gov/show/NCT04308187
361	NCT04326452	Treating COVID-19 With a Bidirectional Oxygenation Valve		Recruiting	No Results Available	Coronavirus Infection	Device: bidirectional oxygenation mouthpiece	Pulse oximetry level|Respiratory rate|Heart rate|Blood pressure|Systemic carbon dioxide	TMC HealthCare|PEEP Medical, LLC	All	18 Years and older   (Adult, Older Adult)	Not Applicable	15	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	COVID19PEEP2020|GO2 PEEP Study	March 27, 2020	May 1, 2020	June 1, 2020	March 30, 2020		April 1, 2020	TMC HealthCare, Tucson, Arizona, United States|Stanford University, Stanford, California, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States		https://ClinicalTrials.gov/show/NCT04326452
362	NCT04327180	PREdiction of DIagnosed Covid-19 infecTion in IUC Patients	PREDICT	Recruiting	No Results Available	Infection Viral|Coronavirus|ARDS|Pneumonia		Correlation between nasal and deep PCR positivity for Covid-19 patients performed and all predictors for Covid-19 patients performed within 24 hours of admission to ICU|Coinfections|Respiratory dysfunction requiring mechanical ventilation|Sequential Organ Failure Assessment (SOFA) Score|SAPS II score|Disseminated Intravascular Coagulation (DIC) score|Number of days on vasopressive amines|Occurrence of an event of venous or arterial thromboembolic disease|Number of days with extra renal treatment (ERA)|Number of patients alive after ICU stay less than 28 days will be tracked|Short Form 36|Hospital anxiety and depression scale (HADS)|Impact of Event Scale - revised (IES-R)|Post-traumatic stress disorder Checklist version DSM-5 (PSL-5)|Modified Medical Research Council (MMRC) Dyspnea Scale|Correlation between number of patient deaths and all predictors for Covid-19 including anamnestic, clinical, biological, radiological parameters|Viral clearance	University Hospital, Lille	All	18 Years and older   (Adult, Older Adult)		500	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	2020_20|2020-A00763-36	March 30, 2020	September 2021	September 2021	March 30, 2020		April 6, 2020	Hôpital Roger Salengro, ICU, CHU Lille, Lille, France		https://ClinicalTrials.gov/show/NCT04327180
363	NCT04322344	Escin in Patients With Covid-19 Infection	add-on-COV2	Recruiting	No Results Available	Coronavirus Infections	Drug: Escin|Drug: standard therapy	Mortality rate|Clinical status evaluated in agreement with guidelines|The differences in oxygen intake methods|Time of hospitalization (days)|Time of hospitalization in intensive care units|Pulmonary function	University of Catanzaro|Azienda Ospedaliera Pugliese Ciaccio|Azienda Ospedaliera Policlinico "Mater Domini"	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 2|Phase 3	120	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care	covid-19 add-on therapy	March 23, 2020	June 30, 2020	August 30, 2020	March 26, 2020		March 27, 2020	Luca Gallelli, Catanzaro, Italy		https://ClinicalTrials.gov/show/NCT04322344
364	NCT04335279	Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together Program	SPIN-CHAT	Not yet recruiting	No Results Available	Scleroderma|Scleroderma, Systemic|Systemic Sclerosis	Other: SPIN-CHAT Program	Anxiety: Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety 4a v1.0|Depression symptoms: Patient Health Questionnaire (PHQ-8)|Stress: Perceived Stress Scale (PSS)|Loneliness: University of California, Los Angeles (UCLA) Loneliness Scale (ULS-6)|Boredom: Multidimensional State Boredom Scale (MSBS-8)|Physical activity: International Physical Activity Questionnaire - modified for the elderly (IPAQ-E)|Frequency of social interactions|Adverse Effects	Lady Davis Institute	All	18 Years and older   (Adult, Older Adult)	Not Applicable	162	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	SPIN-CHAT-001	April 15, 2020	June 3, 2020	June 3, 2020	April 6, 2020		April 6, 2020			https://ClinicalTrials.gov/show/NCT04335279
365	NCT04312243	NO Prevention of COVID-19 for Healthcare Providers	NOpreventCOVID	Not yet recruiting	No Results Available	Coronavirus Infections|Healthcare Associated Infection	Drug: Inhaled nitric oxide gas	COVID-19 diagnosis|Positive SARS-CoV-2 rt-PCR test	Massachusetts General Hospital	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 2	470	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	NOpreCOVID-19	April 2, 2020	March 20, 2021	March 20, 2022	March 18, 2020		April 3, 2020			https://ClinicalTrials.gov/show/NCT04312243
366	NCT04337502	Clinical and Radiomic Model of COVID-19		Completed	No Results Available	Coronavirus|Machine Learning	Diagnostic Test: Machine learning model	Predictive performance	Maastricht University|The Central Hospital of Wuhan	All	Child, Adult, Older Adult		300	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	UM_2020_GY_COVID-19	December 23, 2019	January 20, 2020	March 3, 2020	April 7, 2020		April 7, 2020	The central hospital of Wuhan, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04337502
367	NCT04324684	Prognostic Factors Keeping Track for Covid-19 Pneumonia	NIKE_C19	Recruiting	No Results Available	Pneumonia, Viral|Hypertension|Diabetes Mellitus|Obesity|Cardiovascular Diseases|Obstructive Lung Disease		rate of recovery|time to improvement|efficacy of treatments|organ failure	Catholic University of the Sacred Heart	All	18 Years to 100 Years   (Adult, Older Adult)		198	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	20202503	March 31, 2020	May 5, 2020	May 30, 2020	March 27, 2020		April 13, 2020	Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy		https://ClinicalTrials.gov/show/NCT04324684
368	NCT04337047	Assessment of Distress in Crisis Situations During COVID-19		Enrolling by invitation	No Results Available	Stress, Psychological	Other: questionnaire assesment	quantify and qualify distress over a large population in times of pandemic crisis.|qualify demographic data vs distress over a large population in times of pandemic crisis.	Wefight	All	18 Years and older   (Adult, Older Adult)		2000	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	WefightDistress20	March 31, 2020	April 30, 2020	May 31, 2020	April 7, 2020		April 7, 2020	Wefight, Montpellier, France		https://ClinicalTrials.gov/show/NCT04337047
369	NCT04306055	Blood Donor Recruitment During Epidemic of COVID-19		Completed	No Results Available	Blood Donation	Other: Questionnaire with precaution information|Other: Experimental: Questionnaire without precaution information	Differences of attitude about blood donation towards different questionnaires|Rates of blood donation during 3 weeks	Guangzhou Blood Center	All	18 Years to 60 Years   (Adult)	Not Applicable	19491	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	Blood donor recruitment	March 13, 2020	March 13, 2020	April 3, 2020	March 12, 2020		April 13, 2020	Guangzhou Blood Center, Guangzhou, Guangdong, China		https://ClinicalTrials.gov/show/NCT04306055
370	NCT03808922	Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study		Recruiting	No Results Available	Lower Respiratory Tract Infection|Parainfluenza|Immunocompromised|COVID-19	Drug: DAS181|Drug: Placebo|Drug: DAS181 COVID-19|Drug: DAS181 OL	Percent of subjects who Return to Room Air (RTRA) (main study)|Percent of subjects with improved COVID-19 Clinical Status Scale (sub-study)|All-cause mortality rate (main study)|Time (in days) to RTRA (main study)|Percent of subjects who achieve clinical stability (main study)|Percent of subjects discharged (without mortality and hospice) (main study)|Time (in days) to first hospital discharge (without hospice) (main study)|Total number of inpatient days (main study)|Baseline SAD-RV infection-related mortality rate (main study)|Change in pulmonary function (FEV1% predicted) (main study)|Time to improved COVID19 clinical status (Sub-study)|Time to RTRA|Time to Clinical stability|Time to SARS-CoV-2 RNA in the respiratory specimens being undetectable|Time to Clinical deterioration|Time to Discharge from hospital (without readmission before Day 28).|Time to Death (all causes)	Ansun Biopharma, Inc.	All	Child, Adult, Older Adult	Phase 3	250	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	DAS181-3-01|2018-004318-16	May 23, 2019	April 30, 2021	December 28, 2021	January 18, 2019		April 2, 2020	City of Hope cancer Center, Duarte, California, United States|UCLA, Los Angeles, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|University of Kansas Medical Center, Fairway, Kansas, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Washington University, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center Health System, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Cook Children's, Fort Worth, Texas, United States|MD Anderson, Houston, Texas, United States|VCU Health System, Richmond, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Westmead Hospital, Sydney, New South Wales, Australia|The Wesley Hospital, Brisbane, Queensland, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|Seoul National University Bundang Hospital, Seongnam-si, Guenoggi-do, Korea, Republic of|Samsung Medical Center, Gangnam-gu, Seoul, Korea, Republic of|Seoul National University Hospital, Jongno-gu, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seocho-gu, Seoul, Korea, Republic of|Asan Medical Center, Songpa-gu, Seoul, Korea, Republic of|National Taiwan University Hospital, Zhongzheng Dist., Taipei City, Taiwan		https://ClinicalTrials.gov/show/NCT03808922
371	NCT04320732	Risk Factors for Community- and Workplace Transmission of COVID-19		Recruiting	No Results Available	Coronavirus	Behavioral: Observation of behavior and COVID-19 infection will be conducted.	Rate of COVID-19 infection	Oslo University Hospital|Age Labs AS	All	18 Years and older   (Adult, Older Adult)		50000	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	REK-124170	March 27, 2020	March 27, 2022	March 20, 2030	March 25, 2020		March 31, 2020	Oslo University Hospital, Oslo, Norway		https://ClinicalTrials.gov/show/NCT04320732
372	NCT04322786	The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective?		Active, not recruiting	No Results Available	Covid-19, Coronavirus, Angiotensin Converting Enzyme Inhibitors, Influenza, Electronic Health Records, Epidemiology, Comorbidity, Incidence, United Kingdom	Drug: ACE inhibitor	Incidence of influenza	University College, London	All	18 Years and older   (Adult, Older Adult)		1302508	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	ISAC17_205R	January 1, 1998	May 31, 2016	March 31, 2020	March 26, 2020		March 26, 2020			https://ClinicalTrials.gov/show/NCT04322786
373	NCT04296643	Medical Masks vs N95 Respirators for COVID-19		Not yet recruiting	No Results Available	Coronavirus|N95|Medical Mask	Device: Medical Mask|Device: N95 respirator	RT-PCR confirmed COVID-19 infection|Acute respiratory illness|Absenteeism|Lower respiratory infection|Pneumonia|ICU admission|Mechanical ventilation|Death	McMaster University|Vancouver Coastal Health|University of Alberta|Dalhousie University	All	18 Years and older   (Adult, Older Adult)	Not Applicable	576	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	20006014	April 1, 2020	December 1, 2020	January 1, 2021	March 5, 2020		March 5, 2020			https://ClinicalTrials.gov/show/NCT04296643
374	NCT04343898	Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19	STOP-COVID	Recruiting	No Results Available	Coronavirus Infection	Other: No intervention	14-Day Mortality|21-Day Mortality|28-Day Mortality|60-Day Mortality|90-Day Mortality|1-Year Mortality	Brigham and Women's Hospital	All	18 Years and older   (Adult, Older Adult)		2000	Other	Observational	Observational Model: Cohort|Time Perspective: Other	2007P000003	April 1, 2020	April 15, 2020	June 1, 2022	April 13, 2020		April 13, 2020	Brigham and Women's Hospital, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT04343898
375	NCT04319016	Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy	COVID-preg	Recruiting	No Results Available	Infection Viral	Other: pregnant women with laboratory-confirmed 2019-n-CoV	Maternal and perinatal outcomes	Federico II University	Female	Child, Adult, Older Adult		20	Other	Observational	Observational Model: Cohort|Time Perspective: Other	145/20	January 1, 2020	April 30, 2020	May 1, 2020	March 24, 2020		April 10, 2020	Gabriele Saccone, Napoli, Italy		https://ClinicalTrials.gov/show/NCT04319016
376	NCT04333654	Hydroxychloroquine in Outpatient Adults With COVID-19		Recruiting	No Results Available	Coronavirus Infection	Drug: Hydroxychloroquine SAR321068|Drug: Placebo	Change from baseline to Day 3 in nasopharyngeal SARS-CoV-2 viral load (if quantitative PCR is available)|Number of participants by PCR result status (positive or negative) (if quantitative PCR is not available)|Change from baseline to Day 5 in nasopharyngeal SARS-CoV-2 viral load|Number of participants by PCR result status (positive or negative)|Number of participants with COVID-19 symptoms by severity|Time to resolution of COVID-19 Symptoms|Time to resolution of fever|Percentage of participants with resolution of fever|Percentage of participants hospitalized|Number of participants with Adverse Events	Sanofi	All	18 Years and older   (Adult, Older Adult)	Phase 1	210	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	EFC16855|2020-001269-35|U1111-1249-6168	March 31, 2020	May 2020	May 2020	April 3, 2020		April 13, 2020	Investigational Site Number 8400001, Boston, Massachusetts, United States|Investigational Site Number 2501001, Bordeaux Cedex, France		https://ClinicalTrials.gov/show/NCT04333654
377	NCT04302688	Accurate Classification System for Patients With COVID-19 Pneumonitis		Completed	No Results Available	Pneumonitis		survival status	Renmin Hospital of Wuhan University	All	Child, Adult, Older Adult		669	Other	Observational	Observational Model: Other|Time Perspective: Retrospective	COVID-19 WU1	December 10, 2019	February 10, 2020	March 4, 2020	March 10, 2020		March 10, 2020	Renmin Hospital of Wuhan University, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04302688
378	NCT04333849	Telephony Or Videophony for Isolated elDerly in Maine-Et-Loire 49 During COVID-19	TOVID-49	Recruiting	No Results Available	Coronavirus		Preferred means of communication for elderly people in isolation, hospitalized in the acute care geriatric unit or residing at St Nicolas nursing home (Angers UH).|proportion of elderly people with loss of functional independence to communicate with their relatives.|level of satisfaction of patients who have benefited from a telephone call.|level of satisfaction of patients who have benefited from a videophone call.|satisfaction level of older people according to the means of communication used.|impact of age on the preferred means of communication.	University Hospital, Angers	All	70 Years and older   (Older Adult)		100	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	2020/29	March 27, 2020	September 2020	September 2020	April 3, 2020		April 8, 2020	Angers University Hospital, Angers, France		https://ClinicalTrials.gov/show/NCT04333849
379	NCT04279899	The Investigation of the Neonates With or With Risk of COVID-19		Recruiting	No Results Available	Neonatal Infection|Perinatal Problems|Infectious Disease		The death of newborns with COVID-19|The SARS-CoV-2 infection of neonates born to mothers with COVID-19|The Chinese standardized Denver Developmental Screening Test (DDST) in neonates with or with risk of COVID-19|The small for gestational age newborns in the neonates born to mothers with COVID-19|The preterm delivery of neonates born to mothers with COVID-19|The disease severity of neonates with COVID-19	Children's Hospital of Fudan University	All	up to 28 Days   (Child)		100	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	CHFudanU_NNICU14	February 1, 2020	November 30, 2020	December 31, 2020	February 21, 2020		February 21, 2020	Maternal and Child Health Hospital of Hubei Province, Wuhan, Hubei, China|Children Hospital of Fudan University, Shanghai, Shanghai, China		https://ClinicalTrials.gov/show/NCT04279899
380	NCT04290871	Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.	NOSARSCOVID	Withdrawn	No Results Available	Coronavirus|SARS (Severe Acute Respiratory Syndrome)	Drug: Nitric Oxide Gas	SARS-free patients at 14 days|Survival at 28 days|Survival at 90 days|SARS-free days at 28 days|SARS -free days at 90 days|Renal Replacement Therapy|Liver Failure|Mechanical Support of Circulation|PaO2/FiO2 ratio in ambient air	Xijing Hospital|Massachusetts General Hospital|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico	All	18 Years and older   (Adult, Older Adult)	Phase 2	0	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	NO-SARS-COVID-19	March 23, 2020	March 1, 2021	March 1, 2022	March 2, 2020		March 24, 2020			https://ClinicalTrials.gov/show/NCT04290871
381	NCT04337151	Blood Titanium Analysis of Patients With MAGEC Spine Rods in the COVID-19 Environment		Recruiting	No Results Available	MAGEC Rod	Device: MAGEC Spine Rod|Diagnostic Test: Titanium blood test	Titanium level	Royal National Orthopaedic Hospital NHS Trust	All	Child, Adult, Older Adult		100	Other	Observational	Observational Model: Case-Control|Time Perspective: Retrospective	RNOH MAGEC	April 2020	January 2021	March 2021	April 7, 2020		April 7, 2020	Royal National Orthopaedic Hospital, Stanmore, United Kingdom		https://ClinicalTrials.gov/show/NCT04337151
382	NCT04341493	Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19		Recruiting	No Results Available	Coronavirus Infection	Drug: Nitazoxanide 500 MG|Drug: Hydroxychloroquine	Mechanical ventilation requirement	Hugo Mendieta Zeron|Materno-Perinatal Hospital of the State of Mexico	All	5 Years and older   (Child, Adult, Older Adult)	Phase 4	86	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	2020-03-681	April 6, 2020	August 30, 2020	December 30, 2020	April 10, 2020		April 10, 2020	Materno-Perinatal Hospital "Mónica Pretelini", Toluca, Mexico		https://ClinicalTrials.gov/show/NCT04341493
383	NCT04315480	Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis		Active, not recruiting	No Results Available	SARS Pneumonia	Drug: Tocilizumab	arrest in deterioration of pulmonary function|improving in pulmonary function|need of oro-tracheal intubation|death	Università Politecnica delle Marche|Azienda Ospedaliera Ospedali Riuniti Marche Nord	All	18 Years to 90 Years   (Adult, Older Adult)	Phase 2	38	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TOCICOV-1	March 12, 2020	April 9, 2020	May 2020	March 19, 2020		April 13, 2020	Università Politecnica delle Marche, Ancona, AN, Italy	Study Protocol, https://ClinicalTrials.gov/ProvidedDocs/80/NCT04315480/Prot_000.pdf	https://ClinicalTrials.gov/show/NCT04315480
384	NCT04328454	Clinical Characteristics and Prognostic Factors of Patients With COVID-19		Recruiting	No Results Available	Coronavirus	Other: retrospective analysis	Time to negative conversion of severe acute respiratory syndrome coronavirus 2|Length of stay in hospital|Survival|Intubation	Shanghai 10th People's Hospital|Chibi People's Hospital, Hubei Province	All	18 Years and older   (Adult, Older Adult)		120	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	HBCBH-IEC-2020-101	January 30, 2020	April 2, 2020	April 15, 2020	March 31, 2020		March 31, 2020	Shanghai 10th People's Hospital, Shanghai, Shanghai, China		https://ClinicalTrials.gov/show/NCT04328454
385	NCT04342208	Evaluate the Working Environments of Individuals Working From Home During Covid-19 Outbreak		Not yet recruiting	No Results Available	Musculoskeletal Pain		The Rapid Office Strain Assessment (ROSA)|The Standardised Nordic Questionnaries (NMQ)	Istanbul University-Cerrahpasa	All	18 Years to 65 Years   (Adult, Older Adult)		500	Other	Observational	Observational Model: Case-Only|Time Perspective: Other	GPA1347	April 10, 2020	June 1, 2020	July 1, 2020	April 10, 2020		April 10, 2020			https://ClinicalTrials.gov/show/NCT04342208
386	NCT04325906	Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS		Not yet recruiting	No Results Available	Prone Positioning|High Flow Nasal Cannula|Acute Respiratory Distress Syndrome|Corona Virus Infection	Device: high flow nasal cannula (HFNC)|Procedure: Prone positioning (PP)	Treatment failure|Intubation rate|Efficacy of PP	Rush University Medical Center|Medical College of Wisconsin	All	18 Years and older   (Adult, Older Adult)	Not Applicable	346	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	COVID-19-HFNC+PP	April 6, 2020	May 31, 2020	June 30, 2020	March 30, 2020		April 3, 2020	Rush University Medical Center, Chicago, Illinois, United States|Medical College of Wisconsin, Wauwatosa, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT04325906
387	NCT04338672	The Impact of the Covid-19 Outbreak on Emergency Room Attendances of Surgical Patients		Not yet recruiting	No Results Available	Emergency Service, Hospital|General Surgery	Other: COVID-19 Pandemic	Rates of emergency visits needing surgical consult|The ratio of severe presentations to non-severe presentations|The impact of age on ED attendance rates|Differences in ED surgical visits (in terms of capacity and severity) of surgical patients depending on the presentation and the co morbidity	Sheba Medical Center	All	18 Years and older   (Adult, Older Adult)		1000000	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	SMC-20-7078-YZ-CTIL	April 5, 2020	April 1, 2021	April 1, 2022	April 8, 2020		April 8, 2020	Sheba Medical Center, Ramat Gan, Israel		https://ClinicalTrials.gov/show/NCT04338672
388	NCT04325893	Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease	HYCOVID	Recruiting	No Results Available	Coronavirus	Drug: Hydroxychloroquine|Drug: Placebo	Number of death from any cause, or the need for intubation and mechanical ventilation during the 14 days following inclusion and start of treatment.|Number of death from any cause, or the need for intubation and mechanical ventilation during the 28 days following inclusion and start of treatment.|Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 between day 0 and day 14|Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 between day 0 and day 28.|Number of all-cause mortality at day 14|Number of all-cause mortality at day 28|Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal samples at day 5|Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal samples at day 10|The rate of venous thromboembolic events at day 28, documented and confirmed by an adjudication committee.|Number of all-cause mortality at day 28 in patients aged 75 and older|Clinical evolution on the WHO OSCI scale for COVID-19 between day 0 and day 28 for patients aged 75 or older|Rate of severe adverse events at day 28|Number of all-cause mortality at day 14 in patients aged 75 and older	University Hospital, Angers	All	18 Years and older   (Adult, Older Adult)	Phase 3	1300	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	49RC20_0071	April 2020	September 2020	September 2020	March 30, 2020		April 8, 2020	CH Agen, Agen, France|CHU Amiens, Amiens, France|CHU Angers, Angers, France|APHP Avicenne, Bobigny, France|CHU Brest, Brest, France|CHU Caen, Caen, France|CH Cherbroug, Cherbourg, France|CH Cholet, Cholet, France|CH Colmar, Colmar, France|APHP Henri Mondor, Créteil, France|CHU Dijon, Dijon, France|CHD Vendée, La Roche-sur-Yon, France|CH Laval, Laval, France|CH Le Mans, Le Mans, France|CHU Limoges, Limoges, France|CH Lorient, Lorient, France|CH Melun, Melun, France|CHU Nantes, Nantes, France|Hôpital Privé du Confluent, Nantes, France|CH Niort, Niort, France|CHR Orléans, Orléans, France|APHP Saint-Antoine, Paris, France|La Pitié-Salpétrière, Paris, France|CHU Poitiers, Poitiers, France|CH Pointoise, Pontoise, France|CH Quimper, Quimper, France|CH Saint-Brieuc, Saint-Brieuc, France|CH Saint-Nazaire, Saint-Nazaire, France|CHU Saint-Etienne, Saint-Étienne, France|CHU Toulouse, Toulouse, France|CH Tourcoing, Tourcoing, France|CHU Tours, Tours, France|CH Valenciennes, Valenciennes, France|Clinique Tessier Valenciennes, Valenciennes, France|CH Vannes, Vannes, France|CH Versailles, Versailles, France|CH Princesse Grace, Monaco, Monaco		https://ClinicalTrials.gov/show/NCT04325893
389	NCT04341714	Efficiency and Satisfaction With Telephone Consultation in Neuro-urology: Experience of the COVID-19 Pandemic		Recruiting	No Results Available	Efficacy, Self|Satisfaction, Patient|Telemedicine	Other: Satisfaction evaluation	Efficiency of the telephone consultation|Satisfaction of the telephone consultation	Pierre and Marie Curie University	All	18 Years and older   (Adult, Older Adult)		400	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	GREEN GRC01	March 16, 2020	May 30, 2020	June 15, 2020	April 10, 2020		April 10, 2020	Department of Neuro- Urology, Hôpital Tenon, Paris, France		https://ClinicalTrials.gov/show/NCT04341714
390	NCT04326725	Proflaxis Using Hydroxychloroquine Plus Vitamins-Zinc During COVID-19 Pandemia		Recruiting	No Results Available	Pneumonitis|Coronavirus Infection	Drug: Plaquenil 200Mg Tablet	Protection against COVID-19	Istinye University	All	20 Years to 90 Years   (Adult, Older Adult)		80	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	01/02/2020	March 20, 2020	July 1, 2020	September 1, 2020	March 30, 2020		April 10, 2020	Istinye University Medical School, Istanbul, Turkey		https://ClinicalTrials.gov/show/NCT04326725
391	NCT04321369	Impact of Swab Site and Sample Collector on Testing Sensitivity for COVID-19 Virus in Symptomatic Individuals		Completed	No Results Available	Infections, Respiratory|Fever|Cough	Diagnostic Test: Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals	Accuracy of patient administered tests	Dr. Deneen Vojta|Quest Diagnostics|Bill and Melinda Gates Foundation|UnitedHealth Group	All	Child, Adult, Older Adult		533	Industry|Other	Observational	Observational Model: Case-Only|Time Perspective: Retrospective	20-001	March 9, 2020	March 23, 2020	March 23, 2020	March 25, 2020		April 13, 2020	Everett Clinic, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT04321369
392	NCT04292340	Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19		Recruiting	No Results Available	Coronavirus		The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 1|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7|Numbers of participants with different Clinical outcomes|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0	Shanghai Public Health Clinical Center	All	Child, Adult, Older Adult		15	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	Anti-SARS-CoV-2	February 1, 2020	July 31, 2020	December 31, 2020	March 3, 2020		March 3, 2020	Shanghai Public Health Clinical Center, Shanghai, Shanghai, China		https://ClinicalTrials.gov/show/NCT04292340
393	NCT04326114	Effectiveness and Safety of Respiratory Training in the Prevention and Severity of COVID-19		Not yet recruiting	No Results Available	Disease, Infectious|Respiratory Disease|Safety Issues|Effectiveness	Device: Inspiratory training device|Device: Expiratory training device	COVID-19 disease diagnosis|COVID-19 disease symptoms severity|Adverse effects	Universidad Complutense de Madrid	All	18 Years and older   (Adult, Older Adult)	Not Applicable	240	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	Covid_ISCIII 20/265-E_BS	April 26, 2020	September 26, 2020	October 12, 2020	March 30, 2020		March 30, 2020			https://ClinicalTrials.gov/show/NCT04326114
394	NCT04327479	Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection		Recruiting	No Results Available	Cardiovascular Diseases|Cardiovascular Risk Factor|SARS	Diagnostic Test: Assessment of cardiovascular diseases and cardiovascular risk factors	All-cause mortality|30-day mortality|Major adverse cardiovascular events	University Hospital, Essen	All	18 Years and older   (Adult, Older Adult)		6000	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	20-9213-BO	March 26, 2020	March 25, 2026	March 25, 2026	March 31, 2020		March 31, 2020	University Hospital Essen, Essen, NRW, Germany		https://ClinicalTrials.gov/show/NCT04327479
395	NCT04322123	Safety and Efficacy of Hydroxychloroquine Associated With Azythromycin in SARS-Cov-2 Virus (COVID-19)	Coalition-I	Recruiting	No Results Available	Coronavirus Infections	Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin	Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Presence of virus at day 10 in subset of 180 patients	Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS	All	18 Years and older   (Adult, Older Adult)	Phase 3	630	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Brazil COVID Coalition I Trial	April 1, 2020	August 30, 2020	August 30, 2020	March 26, 2020		April 13, 2020	Hospital Geral Clériston Andrade, Feira De Santana, BA, Brazil|Hospital Ana Nery - HAN/SESAB, Salvador, BA, Brazil|HHospital SAMUR, Vitória Da Conquista, BA, Brazil|Hospital Geral de Vitória da Conquista, Vitória Da Conquista, BA, Brazil|Hospital de Brasília, Brasilia, DF, Brazil|Instituto de Cardiologia do Distrito Federal, Brasília, DF, Brazil|Hospital Maternidade São José - UNESC - Fundação Social Rural de Colatina, Colatina, ES, Brazil|Hospital Vila da Serra, Nova Lima, MG, Brazil|Santa Casa de Misericórdia de São João Del Rei, São João Del Rei, MG, Brazil|Associação Evangélica Beneficente de Londrina - Hospital Evangélico de Londrina, Londrina, PR, Brazil|Instituto Estadual do Cérebro Paulo Niemeyer, Rio De Janeiro, RJ, Brazil|Hospital Geral de Caxias do Sul, Caxias do Sul, RS, Brazil|Hospital Santa Rita - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil|Hospital São Francisco - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil|Hospital São José, Criciuma, SC, Brazil|Hospital Baía Sul - Baía Sul Medical Center, Florianópolis, SC, Brazil|Hospital Nereu Ramos, Florianópolis, Sc, Brazil|Centro Hospitalar Unimed, Joinville, SC, Brazil|Hospital de Amor - Unidade Barretos (Fundação PIO XII), Barretos, SP, Brazil|Casa de Saúde Santa Marcelina, São Paulo, SP, Brazil|Hospital Albert Einstein, São Paulo, SP, Brazil|Hospital Beneficência Portuguesa - Real e Benemérita Associação Portuguesa de Beneficência, São Paulo, SP, Brazil|Hospital BP Mirante - Real e Benemérita, São Paulo, SP, Brazil|Hospital das Clínicas da FMUSP, São Paulo, SP, Brazil|Hospital do Servidor Público Estadual - HSPE - IAMSPE, São Paulo, SP, Brazil|Hospital São Paulo - UNIFESP, São Paulo, SP, Brazil|Hospital Sírio-Libanês, São Paulo, SP, Brazil|Hospital SEPACO, São Paulo, S, Brazil		https://ClinicalTrials.gov/show/NCT04322123
396	NCT04324047	Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients	CORIMUNO-19	Recruiting	No Results Available	Corona Virus Infection		Survival|WHO progression scale COVID 19	Assistance Publique - Hôpitaux de Paris	All	18 Years and older   (Adult, Older Adult)		1000	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	APHP200375|2020-001246-18	March 27, 2020	March 27, 2021	December 31, 2021	March 27, 2020		April 1, 2020	Kremlin Bictre APHP, Le Kremlin-Bicêtre, Ile De France, France|Cochin Aphp, Paris, Ile De France, France|Hegp Aphp, Paris, Ile De France, France		https://ClinicalTrials.gov/show/NCT04324047
397	NCT04315870	Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy: The Italian Registry on Coronavirus in Pregnancy.	I-COVID	Recruiting	No Results Available	Infection Viral	Other: pregnant women with laboratory-confirmed 2019-n-CoV	Maternal and perinatal outcomes	Federico II University	Female	18 Years to 50 Years   (Adult)		20	Other	Observational	Observational Model: Cohort|Time Perspective: Other	mai-20	January 1, 2020	April 20, 2020	April 30, 2020	March 20, 2020		March 20, 2020	University of Naples Federico II, Napoli, Italy		https://ClinicalTrials.gov/show/NCT04315870
398	NCT04337918	Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection	NOCOVID	Not yet recruiting	No Results Available	Corona Virus Infection	Drug: NORS (Nitric Oxide Releasing Solution)	Prevention Study: Measure the effect of NORS on the prevention of COVID-19 infection among health care professionals at risk of exposure to COVID-19|Treatment Sub Study: Measure the efficacy of NORS at reducing the progression of COVID- 19|Prevention Study: Measure the effect of NORS on the prevention of progression of COVID- 19|Prevention Study: Measure the tolerability of NORS treatments|Treatment Sub Study: Measure the virucidal effect of NORS Treatments|Treatment Sub Study: Determine effect of NORS on the speed of clinical recovery|Treatment Sub Study: Determine the reduction in clinical symptoms	Sanotize Research and Development corp.|The Emmes Company, LLC	All	19 Years and older   (Adult, Older Adult)	Phase 2	200	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	COVID-CTP-01	April 6, 2020	July 31, 2020	September 30, 2020	April 8, 2020		April 9, 2020			https://ClinicalTrials.gov/show/NCT04337918
399	NCT04326036	Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection	GARM-COVID19	Enrolling by invitation	No Results Available	Pulmonary Alveolar Proteinosis|COPD|Idiopathic Pulmonary Fibrosis|Viral Pneumonia|Coronavirus Infection|Interstitial Lung Disease	Procedure: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF)|Device: Centricyte 1000|Procedure: IV Deployment Of cSVF In Sterile Normal Saline IV Solution|Drug: Liberase Enzyme (Roche)|Drug: Sterile Normal Saline for Intravenous Use	Incidence of Treatment-Emergent Adverse Events|Pulmonary Function Analysis|Digital Oximetry	Healeon Medical Inc|Robert W. Alexander, MD	All	18 Years to 90 Years   (Adult, Older Adult)	Early Phase 1	10	Industry|Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GARM COVID19	March 25, 2020	November 1, 2021	December 31, 2021	March 30, 2020		March 31, 2020	Robert W. Alexander, MD, FICS, LLC, Stevensville, Montana, United States		https://ClinicalTrials.gov/show/NCT04326036
400	NCT04341610	ASC Therapy for Patients With Severe Respiratory COVID-19	ASC COVID-19	Not yet recruiting	No Results Available	Respiratory Tract Diseases	Drug: Stem Cell Product	Changes in clinical critical treatment index|Days of respirator treatment|Improvement of clinical symptoms including duration of fever and respiratory need|Mortality|Marker of Immunological function -CD4+ and CD8+ T cell count|C-reactive protein and leucocyte|Cytokine profile|Glomerular Filtration Rate|Duration of hospitalization	Rigshospitalet, Denmark	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 1|Phase 2	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	EudraCT number: 2020-001330-36	April 20, 2020	January 30, 2021	April 30, 2021	April 10, 2020		April 10, 2020	2014 Department of Cardiology, The Heart Centre, University Hospital Rigshospitalet, Copenhagen, Denmark		https://ClinicalTrials.gov/show/NCT04341610
401	NCT04341519	Psychological Burden in ICU Survivors of Severe COVID-19 Pneumonia, Their Relatives and Their Healthcare Providers	BURDENCOV	Not yet recruiting	No Results Available	Corona Virus Infection|Post-traumatic Stress Disorder	Behavioral: PTSD|Behavioral: Burnout	PTSD Family members sup 22|PTSD Family members|PTSD Patients|PTSD healthcare providers|HADS Family members|HADS Patients|SF36 Patients|Questionnaire Family members|Questionnaire Patients|Questionnaire healthcare providers|MBI healthcare providers|Karasec instrument healthcare providers	Assistance Publique - Hôpitaux de Paris	All	18 Years and older   (Adult, Older Adult)		1464	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	APHP200389	April 9, 2020	November 30, 2020	December 31, 2021	April 10, 2020		April 10, 2020	Saint-Louis Hospital, Paris, Ile De France, France		https://ClinicalTrials.gov/show/NCT04341519
402	NCT04274322	Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool		Active, not recruiting	No Results Available	Critically Ill|Coronavirus Infections	Other: Nutrition support	28-day all cause mortality|All cause infection|The rate of complications|Length of ICU stay|Duration of mechanical ventilation	Peking University Third Hospital|School of Pharmaceutical Sciences, Peking University, Beijing, China|Department of Medicine, Queen's University, Kingston, Ontario, Canada	All	18 Years and older   (Adult, Older Adult)		117	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	COV_NUTRIC	February 19, 2020	April 4, 2020	July 2020	February 18, 2020		April 8, 2020	Peking University Third Hospital, Beijing, China		https://ClinicalTrials.gov/show/NCT04274322
403	NCT04324073	Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI	CORIMUNO-SARI	Recruiting	No Results Available	Corona Virus Infection	Drug: Sarilumab	Survival without needs of ventilator utilization at day 14.|WHO progression scale <=5 at day 4|Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) at day 14|WHO progression scale <=7 at day 4|WHO progression scale|Survival|28-day ventilator free-days|respiratory acidosis at day 4|PaO2/FiO2 ratio|time to oxygen supply independency|duration of hospitalization|time to negative viral excretion|time to ICU discharge|time to hospital discharge	Assistance Publique - Hôpitaux de Paris	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	240	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	APHP200375-2	March 27, 2020	March 27, 2021	December 31, 2021	March 27, 2020		April 1, 2020	Kremlin Bicetre hospital APHP, Le Kremlin-Bicêtre, Ile De France, France|Cochin Aphp, Paris, Ile De France, France|HEGP, Paris, Ile De France, France|NECKER Hospital, Paris, France		https://ClinicalTrials.gov/show/NCT04324073
404	NCT04342702	A Study on the Prospective Cohort Library of COVID-19 in Southeran		Active, not recruiting	No Results Available	Follow-up|COVID-19|Infectious Diseases|Respiratory		days to cure|Days of turning negative on RT-PCR test|36-Item Short Form Survey Instrument (SF-36)|C-reactive protein|number of cases returning to positive result in RT-PCR test|Number of positive outcome of IgG for antibody of COVID-19	Second Affiliated Hospital of Wenzhou Medical University|Wenzhou Medical University|First Affiliated Hospital of Wenzhou Medical University|Wenzhou Central Hospital And Sixth People's Hospital of Wenzhou Medical University|Yueqing Hospital of Wenzhou Medical University|Ruian Hospital of Wenzhou Medical University|Cangnan Hospital of Wenzhou Medical University|Pingyang Hospital of Wenzhou Medical University|Yongjia People's Hospital	All	Child, Adult, Older Adult		504	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	SAHoWMU-CR2020-NCP-202	March 16, 2020	March 2021	March 2021	April 13, 2020		April 13, 2020	Wenzhou Medical University, Wenzhou, Zhejiang, China|The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China		https://ClinicalTrials.gov/show/NCT04342702
405	NCT04337983	Hemodynamic Characteristics of Patients With SARS-CoV-2	PiCCOVID	Not yet recruiting	No Results Available	Coronavirus|SARS-CoV-2|COVID-19|Acute Respiratory Distress Syndrome|Shock|Acute Circulatory Failure|Left Ventricular Dysfunction|Fluid Overload	Device: Transpulmonary thermodilution|Device: Echocardiography	Body temperature|Blood pressure|Pulse (heart rate)|Respiratory rate|Data provided by transpulmonary thermodilution-CI|Data provided by transpulmonary thermodilution-GEDV|Data provided by transpulmonary thermodilution-EVLW|Data provided by transpulmonary thermodilution-PVPI|Incidence of abnormal laboratory test results|Incidence of new-onset or reversible systolic left ventricular dysfunction|Changes of extravascular lung water measured by transpulmonary thermodilution|Changes of pulmonary vascular permeability index measured by transpulmonary thermodilution|Correlation between the hemodynamic characteristics and 90-day mortality	Bicetre Hospital	All	Child, Adult, Older Adult		200	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	2020-A00793-36	April 15, 2020	October 2020	April 2021	April 8, 2020		April 8, 2020	Bicetre Hospital, Paris, Val-de-Marne, France		https://ClinicalTrials.gov/show/NCT04337983
406	NCT04343404	PLACE OF VENOVENOUS ECMO IN THE MANAGEMENT OF SEVERE REFRACTORY ARDS ASSOCIATED WITH SARS-COV-2	ECMO-COVID-19	Recruiting	No Results Available	Respiratory Distress Syndrome		Retrospective description of COVID-19 patients receiving respiratory ECMO-VV supplementation and what happens to them	University Hospital, Strasbourg, France	All	18 Years and older   (Adult, Older Adult)		100	Other	Observational	Observational Model: Case-Only|Time Perspective: Retrospective	7772	April 1, 2020	April 15, 2020	April 15, 2020	April 13, 2020		April 13, 2020	Service de Chirurgie Thoracique Nouvel Hôpital Civil Hôpitaux Universitaires de Strasbourg, Strasbourg, France		https://ClinicalTrials.gov/show/NCT04343404
407	NCT04279795	Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship With Clinical Manifestations		Recruiting	No Results Available	Coronavirus		Positive rate of 2019 Novel Coronavirus RNA|Survival rate	Third Affiliated Hospital, Sun Yat-Sen University	All	Child, Adult, Older Adult		20	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	PL11	January 20, 2020	January 31, 2021	February 28, 2021	February 21, 2020		February 21, 2020	The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China		https://ClinicalTrials.gov/show/NCT04279795
408	NCT04279782	Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection		Recruiting	No Results Available	Coronavirus	Other: Comprehensive treatment	Survival rate|Chest computed tomography|Recovery Time|Depression evaluation	Third Affiliated Hospital, Sun Yat-Sen University	All	Child, Adult, Older Adult		100	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	XWX3	January 20, 2020	January 31, 2021	February 28, 2021	February 21, 2020		February 24, 2020	The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China		https://ClinicalTrials.gov/show/NCT04279782
409	NCT04283461	Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection (COVID-19)		Recruiting	No Results Available	Corona Virus Infection|Immunisations	Biological: mRNA-1273	Frequency of solicited local reactogenicity adverse events (AEs)|Frequency of any medically-attended adverse events (MAAEs)|Frequency of any new-onset chronic medical conditions (NOCMCs)|Frequency of any serious adverse events (SAEs)|Frequency of any unsolicited adverse events (AEs)|Frequency of solicited systemic reactogenicity adverse events (AEs)|Grade of any unsolicited adverse events (AEs)|Grade of solicited local reactogenicity adverse events (AEs)|Grade of solicited systemic reactogenicity adverse events (AEs)|Geometric mean fold rise (GMFR) in IgG titer from baseline|Geometric mean titer (GMT) of antibody|Percentage of subjects who seroconverted	National Institute of Allergy and Infectious Diseases (NIAID)	All	18 Years to 55 Years   (Adult)	Phase 1	45	NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	20-0003|1UM1AI148373-01	March 3, 2020	June 1, 2021	June 1, 2021	February 25, 2020		April 13, 2020	Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|National Institutes of Health - Clinical Center - Vaccine Research Center Clinical Trials Program, Bethesda, Maryland, United States|Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT04283461
410	NCT04340414	Safety and Effectiveness of Low-flow ECMO Driving by CVVH Machine in Severe NCP		Recruiting	No Results Available	COVID-19|ECMO	Device: Low flow ECMO driving by CVVH machine	PaCO2|Driving Pressure|Tidal volume	Peking Union Medical College Hospital	All	14 Years and older   (Child, Adult, Older Adult)	Not Applicable	10	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Low flow-ECMO by CVVH in NCP	March 3, 2020	August 15, 2020	October 15, 2020	April 9, 2020		April 9, 2020	Yun Long, Beijing, Beijing, China		https://ClinicalTrials.gov/show/NCT04340414
411	NCT04331886	An Observational Study of Patients With Coronavirus Disease 2019	COVID-19	Not yet recruiting	No Results Available	COVID-19|Coronavirus		Natural history of COVID-19: Characteristics of COVID-19|Natural history of COVID-19: Participant demographics|Natural history of COVID-19: Treatment use|Time point of clinical response	Target PharmaSolutions, Inc.	All	18 Years and older   (Adult, Older Adult)		5000	Industry	Observational	Observational Model: Cohort|Time Perspective: Other	TARGET-COVID-19	April 2020	March 2021	March 2021	April 2, 2020		April 9, 2020			https://ClinicalTrials.gov/show/NCT04331886
412	NCT04293887	Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients		Not yet recruiting	No Results Available	COVID-19|Recombinant Human Interferon α1β	Drug: Recombinant human interferon α1β	The incidence of side effects|Time from patient enrollment to clinical remission|Proportion of patients with normal body|Proportion of patients without dyspnea|Proportion of patients without cough|Proportion|The negative conversion rate of new coronavirus nucleic acid|Frequency of serious adverse drug events.	Tongji Hospital	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	328	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Zhaojp	March 1, 2020	May 30, 2020	June 30, 2020	March 3, 2020		March 3, 2020			https://ClinicalTrials.gov/show/NCT04293887
413	NCT04330261	Clinical Characteristics and Outcomes of Pediatric COVID-19	PERN-COVID-19	Recruiting	No Results Available	COVID-19|SARS-CoV-2 Infection|Pediatric ALL|Pneumonia, Viral|Pandemic Response	Other: Exposure (not intervention) - SARS-CoV-2 infection	Clinical characteristics of children with SARS-CoV-2|Factors associated with severe COVID-19 outcomes|Health care resource utilization for COVID-19 patient management|Sensitivity and specificity of COVID-19 case screening policies	University of Calgary	All	up to 18 Years   (Child, Adult)		12500	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	REB18-0107_MOD9	March 18, 2020	March 17, 2021	March 17, 2022	April 1, 2020		April 1, 2020	University of Calgary/Alberta Children's Hospital, Calgary, Alberta, Canada		https://ClinicalTrials.gov/show/NCT04330261
414	NCT04341584	CORIMUNO-ANA: TRIAL EVALUATING EFFICACY OF ANAKINRA IN PATIENTS WITH COVID-19 INFECTION, NESTED IN THE CORIMUNO-19 COHORT	CORIMUNO-ANA	Not yet recruiting	No Results Available	Corona Virus Infection	Drug: Anakinra	Survival without needs of ventilator utilization at day 14|WHO progression scale ≤ 5|Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) or withdrawal of NIV or high flow (for > 48h), at day 14|Decrease of at least one point in WHO progression scale score|WHO progression scale|Survival|28-day ventilator free-days|Respiratory acidosis|PaO2/FiO2 ratio|Time to oxygen supply independency|Duration of hospitalization|Time to negative viral excretion|Time to ICU discharge|Time to hospital discharge	Assistance Publique - Hôpitaux de Paris	All	18 Years and older   (Adult, Older Adult)	Phase 2	240	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	APHP200375-5	April 2020	May 2020	December 31, 2020	April 10, 2020		April 10, 2020			https://ClinicalTrials.gov/show/NCT04341584
415	NCT04326426	ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection		Not yet recruiting	No Results Available	Coronavirus Infection	Drug: Tradipitant|Drug: Placebo	Proportion of participants with normalization of fever and oxygen saturation by day 14|Treatment and prevention of inflammatory lung injury as measured by change in baseline of interleukin-6 (IL-6)|Rate of Decline of COVID-19 viral load assessed by RT-PCR from nasopharyngeal samples|In-hospital mortality|Mean change in NEWS2 score from baseline|Understand the effect of genetics for treatment response through whole genome sequence of the participant and the COVID-19 virus|Reduction from baseline of NRS for cough	Vanda Pharmaceuticals	All	18 Years to 90 Years   (Adult, Older Adult)	Phase 3	300	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	VLY-686-3501	April 1, 2020	August 1, 2020	August 31, 2020	March 30, 2020		April 6, 2020			https://ClinicalTrials.gov/show/NCT04326426
416	NCT04290780	COVID-19 - Multicenter Study on Nosocomial Transmission of SARS-CoV-2 Virus	NOSO-COR	Recruiting	No Results Available	Infection Viral	Other: nosocomial infection/hospital acquired infection	nosocomial infection	Hospices Civils de Lyon	All	Child, Adult, Older Adult		300	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	69HCL20_0214	March 9, 2020	October 10, 2020	October 30, 2020	March 2, 2020		April 13, 2020	Service Hygiène, Epidémiologie et Prévention, Lyon, France|Service Hygiène, Epidémiologie et Prévention, Lyon, France		https://ClinicalTrials.gov/show/NCT04290780
417	NCT04292327	Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus	2019-nCoV	Active, not recruiting	No Results Available	Pneumonia Caused by Human Coronavirus		Mortality|The time interval of Nucleic acid detection become negative	Fujian Provincial Hospital	All	18 Years to 75 Years   (Adult, Older Adult)		400	Other	Observational	Observational Model: Other|Time Perspective: Retrospective	KY-2020-24.01	January 1, 2020	April 30, 2020	July 31, 2020	March 3, 2020		March 3, 2020	Fujian Provincial Hospital, Fuzhou, Fujian, China		https://ClinicalTrials.gov/show/NCT04292327
418	NCT04322513	Biomarkers for Identification of COVID-19 Infection	B-DT-COV2	Recruiting	No Results Available	Coronavirus	Diagnostic Test: Biomarkers expression	Biomarkers expression|Liver Biomarkers expression|biomarkers expression (microRNAs, oxidative stress, IL-2, IL-6, TNF-alfa, leukocytes, subtypes lymphocytes) after treatment	University of Catanzaro|Azienda Ospedaliera Pugliese Ciaccio|Azienda Ospedaliera Policlinico "Mater Domini"	All	14 Years to 75 Years   (Child, Adult, Older Adult)		110	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	covid-19 biomarkers	March 24, 2020	June 30, 2020	August 30, 2020	March 26, 2020		April 13, 2020	Luca Gallelli, Catanzaro, Italy		https://ClinicalTrials.gov/show/NCT04322513
419	NCT04318366	COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor	COVID-BioB	Recruiting	No Results Available	Coronavirus Infections	Other: Observational Study	Characterize Patients With SARS-Cov-2 Infection and to Create a Biobank to Identify Predictors of Disease Severity, Mortality and Treatment Response	Università Vita-Salute San Raffaele	All	18 Years and older   (Adult, Older Adult)		1000	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	COVID-BioB/OSR	March 19, 2020	March 19, 2022	March 19, 2022	March 24, 2020		March 31, 2020	Autoimmunity and Vascular Inflammation Unit, Division of Regenerative Medicine, Stem Cells and Gene Therapy - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|AIDS Immunopathogenesis Unit - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Department of Infection Diseases - IRCCS San Raffaele Scientific Institute -, Milan, Lombardy, Italy|Department of Internal Medicine - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Diabetes Research Institute -IRCCS San Raffaele Scientific Istitute, Milan, Lombardy, Italy|Division of Immunology, Transplantation and Infectious Diseases - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Division of Research of Regenerative Medicine, Cell and Gene Therapy - IRCCS San Raffaele Scientific Istitute, Milan, Lombardy, Italy|Laboratory of Microbiology and Virology - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Nephrology Unit - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Strategic Program in Nephrology and Dialysis - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Viral pathogens and biosafety Unit - IRCCS San Raffaele Scietific Institute, Milan, Lombardy, Italy|Unit of Immunology, Rheumatology, Allergy and Rare Diseases - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Università Vita-Salute San Raffaele, Milano, Mi, Italy		https://ClinicalTrials.gov/show/NCT04318366
420	NCT04269525	Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia		Recruiting	No Results Available	Pneumonia, Viral|Pneumonia, Ventilator-Associated	Biological: UC-MSCs	Oxygenation index|28 day mortality|Hospital stay|2019-nCoV nucleic acid test|Improvement of lung imaging examinations|White blood cell count|Lymphocyte count|Lymphocyte percentage|Procalcitonin|interleukin(IL)-2|IL-4|IL-6|IL-8|IL-10|tumor necrosis factor(TNF)-α|γ-interferon(IFN)	ZhiYong Peng|Tuohua Biological Technology Co. Ltd|Zhongnan Hospital	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 2	10	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	2020002	February 6, 2020	April 30, 2020	September 30, 2020	February 13, 2020		February 17, 2020	Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04269525
421	NCT04320862	COVID-19 Pandemic Response Network		Recruiting	No Results Available	COVID-19|SARS-CoV-2|Coronavirus|Influenza -Like Illness|Lower Resp Tract Infection|Upper Resp Tract Infection		Number of participants who experience inpatient admission|Number of participants admitted to the intensive care unit|Number of participants requiring mechanical ventilation|Number of deceased participants	Duke University	All	Child, Adult, Older Adult		200000	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	Pro00105189	April 3, 2020	December 31, 2021	December 31, 2021	March 25, 2020		April 13, 2020	Duke University Medical Center, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT04320862
422	NCT04261907	Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection		Not yet recruiting	No Results Available	2019-nCoV	Drug: ASC09/ritonavir group|Drug: lopinavir/ritonavir group	The incidence of composite adverse outcome|Time to recovery|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no requring supplemental oxygen|Rate of undectable viral RNA|Rate of mechanical ventilation|Rate of ICU admission|Time and rate of laboratory indicators related to disease improvement to return to normal	First Affiliated Hospital of Zhejiang University|Ascletis Pharmaceuticals Co., Ltd.	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	160	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ASC09F-CTP-ZY-01	February 7, 2020	May 31, 2020	June 30, 2020	February 10, 2020		February 10, 2020			https://ClinicalTrials.gov/show/NCT04261907
423	NCT04306393	Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19	NOSARSCOVID	Recruiting	No Results Available	SARS (Severe Acute Respiratory Syndrome)|Coronavirus	Drug: Nitric Oxide Gas	Change of arterial oxygenation at 48 hours from enrollment|Time to reach normoxemia during the first 28 days after enrollment|Proportion of SARS-nCoV-2 free patients during the first 28 days after enrollment|Survival at 28 days from enrollment|Survival at 90 days from enrollment	Massachusetts General Hospital|Xijing Hospital|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Niguarda Hospital	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 2	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	NO-SARS-COVID-19	March 21, 2020	March 21, 2021	March 21, 2022	March 12, 2020		April 7, 2020	University of Alabama, Birmingham, Alabama, United States|Louisiana State University Health Shreveport, Shreveport, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT04306393
424	NCT04322773	Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure	TOCIVID	Recruiting	No Results Available	Corona Virus Disease	Drug: RoActemra iv|Drug: RoActemra sc|Drug: Kevzara sc|Other: Standard medical care	Time to independence from supplementary oxygen therapy|Number of deaths|Days out of hospital and alive|Ventilator free days alive and out of hospital|C-reactive protein (CRP) level|Number of participants with serious adverse events	Marius Henriksen|Lars Erik Kristensen|Frederiksberg University Hospital	All	18 Years and older   (Adult, Older Adult)	Phase 2	200	Other	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	APPI2-CV-2020-01	April 5, 2020	June 1, 2021	June 1, 2021	March 26, 2020		April 7, 2020	Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark|Hillerød Hospital, Hillerød, Denmark		https://ClinicalTrials.gov/show/NCT04322773
425	NCT04336410	Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers		Recruiting	No Results Available	Coronavirus Infection	Drug: INO-4800|Device: CELLECTRA® 2000	Percentage of Participants with Adverse Events (AEs)|Percentage of Participants with Administration (Injection) Site Reactions|Percentage of Participants with Adverse Events of Special Interest (AESIs)|Change from Baseline in Antigen-Specific Binding Antibody Titers|Change from Baseline in Antigen-Specific Interferon-Gamma (IFN-γ) Cellular Immune Response	Inovio Pharmaceuticals|Coalition for Epidemic Preparedness Innovations (CEPI)	All	18 Years to 50 Years   (Adult)	Phase 1	40	Industry|Other	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	COVID19-001	April 3, 2020	November 2020	November 2020	April 7, 2020		April 9, 2020	Center for Pharmaceutical Research, Kansas City, Missouri, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT04336410
426	NCT04340557	Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection		Recruiting	No Results Available	SARS-CoV Infection	Drug: Losartan	Mechanical ventilation|ICU transfer|Oxygen therapy	Sharp HealthCare	All	18 Years and older   (Adult, Older Adult)	Phase 4	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	COVID-ARB|2003902	March 27, 2020	October 6, 2020	December 31, 2020	April 9, 2020		April 9, 2020	Sharp Grossmont Hospital, La Mesa, California, United States|Sharp Chula Vista Medical Center, San Diego, California, United States|Sharp Coronado Hospital, San Diego, California, United States|Sharp Memorial Hospital, San Diego, California, United States		https://ClinicalTrials.gov/show/NCT04340557
427	NCT04264533	Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia		Recruiting	No Results Available	Vitamin C|Pneumonia, Viral|Pneumonia, Ventilator-Associated	Drug: VC|Drug: Sterile Water for Injection	Ventilation-free days|28-days mortality|ICU length of stay|Demand for first aid measuments|Vasopressor days|Respiratory indexes|Ventilator parameters|APACHE II scores|SOFA scores	ZhiYong Peng|Zhongnan Hospital	All	18 Years and older   (Adult, Older Adult)	Phase 2	140	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	2020001	February 14, 2020	September 30, 2020	September 30, 2020	February 11, 2020		March 10, 2020	Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04264533
428	NCT04338841	HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With a SARS-CoV-2 Infection	HOME-CoV	Recruiting	No Results Available	Coronavirus Infection	Other: HOME-CoV rule implementation	the composite rate of adverse outcomes|The rate of hospitalization	University Hospital, Angers	All	18 Years and older   (Adult, Older Adult)	Not Applicable	4000	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-A00831-38	April 9, 2020	June 1, 2020	June 1, 2020	April 8, 2020		April 13, 2020	Clinique Universitaire Saint-Luc, Bruxelles, Belgium|CHU de Liège, Liege, Belgium|Ch Argenteuil, Argenteuil, France|CHU Brest, Brest, France|CH Cholet, Cholet, France|CHU Clermont Ferrand, Clermont Ferrand, France|Ch Colmar, Colmar, France|CH Alpes Lemant, Contamine-sur-Arve, France|CHU Dijon, Dijon, France|CH Le Mans, Le Mans, France|CH Libourne, Libourne, France|CH Limoges, Limoges, France|Ch Longjumeau, Longjumeau, France|Hospices Civils de Lyon (University Hospital of Lyon), Lyon, France|Chu Montpellier, Montpellier, France|Centre Hospitalier Universitaire de Nantes, Nantes, France|CH Niort, Niort, France|Hopital Paris Saint Joseph, Paris, France|Hopital Saint Antoine, Paris, France|Hôpital Bichat, Paris, France|Hôpital Lariboisière, Paris, France|CHU de Poitiers, Poitiers, France|CH Reims, Reims, France|Ch Remiremont, Remiremont, France|Chu Rennes, Rennes, France|CHU de Rouen, Rouen, France|CHU de St Etienne, Saint Etienne, France|CH de Saint-Brieuc, Saint-Brieuc, France|Ch Troyes, Troyes, France|CH VICHY, Vichy, France|CH Princesse Grace, Monaco, Monaco		https://ClinicalTrials.gov/show/NCT04338841
429	NCT04275388	Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia		Not yet recruiting	No Results Available	2019 Novel Coronavirus Pneumonia	Drug: Xiyanping injection|Drug: Lopinavir / ritonavir, alpha-interferon nebulization	Clinical recovery time|Complete fever time|Cough relief time|Virus negative time|Incidence of severe or critical neocoronavirus pneumonia	Jiangxi Qingfeng Pharmaceutical Co. Ltd.	All	18 Years to 70 Years   (Adult, Older Adult)	Not Applicable	348	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	QF-XYP2001-1	February 14, 2020	May 14, 2020	December 14, 2021	February 19, 2020		February 19, 2020			https://ClinicalTrials.gov/show/NCT04275388
430	NCT04323527	Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2	CloroCOVID19	Recruiting	No Results Available	SARS-CoV Infection|Severe Acute Respiratory Syndrome (SARS) Pneumonia	Drug: Chloroquine diphosphate	Absolute mortality at day 28|Absolute mortality on days 7 and 14|Improvement in overall subject's clinical status assessed in standardized clinical questionnaires on days 14 and 28|Improvement in daily clinical status assessed in standardized clinical questionnaires during hospitalization|Duration of supplemental oxygen (if applicable)|Duration of mechanical ventilation (if applicable)|Absolute duration of hospital stay in days|Prevalence of grade 3 and 4 adverse events|Prevalence of serious adverse events|Change in serum creatinine level|Change in serum troponin I level|Change in serum aspartate aminotransferase level|Change in serum CK-MB level|Change in detectable viral load in respiratory tract swabs|Viral concentration in blood samples|Absolute number of causes leading to participant death (if applicable)	Fundação de Medicina Tropical Dr. Heitor Vieira Dourado|Marcus Vinícius Guimarães de Lacerda|Mayla Gabriela Silva Borba|Wuelton Marcelo Monteiro|Gisely Cardoso de Melo|Fernando Fonseca de Almeida e Val|Felipe Gomes Naveca|Maria Paula Gomes Mourão|Ludmila Abrahão Hajjar|Jorge Souza Mendonça	All	18 Years to 100 Years   (Adult, Older Adult)	Phase 2	440	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CAAE: 30152620.1.0000.0005	March 23, 2020	August 31, 2020	August 31, 2020	March 26, 2020		March 30, 2020	Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Amazonas, Brazil		https://ClinicalTrials.gov/show/NCT04323527
431	NCT04245631	Development of a Simple, Fast and Portable Recombinase Aided Amplification Assay for 2019-nCoV		Recruiting	No Results Available	New Coronavirus	Diagnostic Test: Recombinase aided amplification (RAA) assay	Detection sensitivity is greater than 95%|Detection specificity is greater than 95%|Consistent with existing universal reagent detection rates greater than 95%	Beijing Ditan Hospital	All	1 Year to 90 Years   (Child, Adult, Older Adult)		50	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	DTXY022	January 1, 2020	December 31, 2020	December 31, 2020	January 29, 2020		April 10, 2020	Department of Hepatology Division 2, Beijing Ditan Hospital, Beijing, Beijing, China		https://ClinicalTrials.gov/show/NCT04245631
432	NCT04343729	Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in SARS-CoV2: a Randomized, Double-blind, Placebo-controlled Clinical Trial	MetCOVID	Not yet recruiting	No Results Available	SARS-CoV Infection|Severe Acute Respiratory Syndrome (SARS) Pneumonia	Drug: Methylprednisolone Sodium Succinate|Drug: Placebo solution	Mortality rate at day 28|Proportion of patients with SARS|Mortality rate on days 7, 14 and 28|Incidence of orotracheal intubation|Change in oxygenation index	Fundação de Medicina Tropical Dr. Heitor Vieira Dourado	All	18 Years and older   (Adult, Older Adult)	Phase 2	420	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CAEE: 30615920.2.0000.0005	April 2020	September 2020	September 2020	April 13, 2020		April 13, 2020	Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Amazonas, Brazil		https://ClinicalTrials.gov/show/NCT04343729
433	NCT04324736	Coronavirus SARS-CoV2 and Diabetes Outcomes	CORONADO	Recruiting	No Results Available	Coronavirus|Diabetes	Other: no interventional study	Assess the prevalence of severe forms among hospitalized patients with diabètes and COVID-19|describe the clinical and biological characteristics of hospitalized subjects with diabetes and COVID-19|describe the prognosis of hospitalized subjects with diabetes and COVID-19|describe the care management of hospitalized subjects with diabetes and COVID-19	Nantes University Hospital	All	Child, Adult, Older Adult		1000	Other	Observational	Observational Model: Cohort|Time Perspective: Other	RC20_0148	March 10, 2020	April 10, 2020	May 8, 2020	March 27, 2020		April 8, 2020	CHU Nantes, Nantes, France		https://ClinicalTrials.gov/show/NCT04324736
434	NCT04322682	Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)	COVID-19	Recruiting	No Results Available	Corona Virus Infection	Drug: Colchicine|Drug: Placebo oral tablet	Number of participants who die or require hospitalization due to COVID-19 infection|Number of participants who die|Number of participants requiring hospitalization due to COVID-19 infection|Number of participants requiring mechanical ventilation	Montreal Heart Institute|DACIMA Software	All	40 Years and older   (Adult, Older Adult)	Phase 3	6000	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	MHIPS-2020-001	March 23, 2020	September 2020	September 2020	March 26, 2020		April 9, 2020	New York University School of Medecine, New York, New York, United States|Montreal Heart Institute, Montreal, Quebec, Canada		https://ClinicalTrials.gov/show/NCT04322682
435	NCT04255940	2019-nCoV Outbreak and Cardiovascular Diseases		Recruiting	No Results Available	Cardiovascular Death; Major Adverse Cardiovascular Events		Cardiovascular Death|Major Adverse Cardiovascular Events|Times From symptom onset to hospital arrival|Anxiety	Qilu Hospital of Shandong University	All	Child, Adult, Older Adult		12000	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	2019nCoV-CVD	January 20, 2020	April 30, 2020	April 30, 2020	February 5, 2020		February 5, 2020	Affiliated Hospital of Binzhou Medical Universty, Binzhou, Shandong, China|Heze Municipal Hospital, Heze, Shandong, China|Shandong University Qilu Hospital, Jinan, Shandong, China|Jinan Central Hospital, Shandong University, Jinan, Shandong, China|First Hospital Affiliated with Shandong First Medical University, Jinan, Shandong, China|Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China|The Second Hospital of Shandong University, Jinan, Shandong, China|Jining Hospital of Traditional Chinese Medicine, Jining, Shandong, China|Qihe People's Hospital, Qihe, Shandong, China|Affiliated Hospital of Qingdao University Medical College, Qingdao, Shandong, China|Weihai Municipal Hospital, Weihai, Shandong, China|Central Hospital of Zibo, Zibo, Shandong, China		https://ClinicalTrials.gov/show/NCT04255940
436	NCT04305574	Social Media Use During COVID-19		Recruiting	No Results Available	Coronavirus|Depression|Anxiety|Stress	Behavioral: Use of social media during COVID-19	Assessment of COVID-19 situation|Depression, Anxiety and Stress Scale|Familiarity and trust in COVID-related rumours|Availability heuristic	Jean Liu|Yale-NUS College	All	21 Years and older   (Adult, Older Adult)		5000	Other	Observational	Observational Model: Cohort|Time Perspective: Cross-Sectional	2020-CERC-001	March 8, 2020	May 31, 2020	May 31, 2020	March 12, 2020		March 17, 2020	Yale-NUS College, Singapore, Singapore		https://ClinicalTrials.gov/show/NCT04305574
437	NCT04281693	A New Screening Strategy for 2019 Novel Coronavirus Infection		Not yet recruiting	No Results Available	Novel Coronavirus Infection Pneumonia	Diagnostic Test: Standard screening strategy|Diagnostic Test: New screening strategy	Screening accuracy|Cost-effectiveness analysis	Affiliated Hospital to Academy of Military Medical Sciences|The Fifth Medical Center of Chinese PLA General Hospital	All	Child, Adult, Older Adult	Not Applicable	230	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening	307-nCoV	February 2020	March 2020	March 2020	February 24, 2020		February 24, 2020	the Fifth Medical Center of Chinese PLA General Hospital, Beijing, Beijing, China		https://ClinicalTrials.gov/show/NCT04281693
438	NCT04280913	Clinical Outcomes of Patients With COVID19		Withdrawn	No Results Available	Coronavirus Disease 2019	Other: retrospective analysis	Time to negative conversion of severe acute respiratory syndrome coronavirus 2|Length of stay in hospital|Survival|Intubation	Guangzhou Institute of Respiratory Disease|Huizhou Municipal Central Hospital	All	Child, Adult, Older Adult		0	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	GZHZ-COVID19	February 22, 2020	March 31, 2020	March 31, 2020	February 21, 2020		March 19, 2020	HuiZhou Municipal Central Hospital, Huizhou, Guangdong, China		https://ClinicalTrials.gov/show/NCT04280913
439	NCT04259892	Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection	Cov-CONTACT	Recruiting	No Results Available	Coronavirus	Biological: 2019-nCoV PCR	Number of Participants with presence of 2019-nCoV in at least one of nasopharyngeal swab|For each participant, time (days) between the last contact with the laboratory-confirmed 2019-nCoV case and the first positive PCR|For each participant, time (days) between the first positive PCR and the first negative PCR|Number of Participants with presence of at least one of the following symptoms: fever > 38°C, asthenia/fatigue/malaise, headache, thrills/sweating, myalgia/aches, cough, dyspnea, Acute Respiratory Distress Syndrome, diarrhe|Number of Participants with positive serology in the 90 days following last contact	Institut National de la Santé Et de la Recherche Médicale, France	All	Child, Adult, Older Adult		300	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	C20-06|2020-A00280-39	February 4, 2020	October 4, 2020	February 4, 2021	February 7, 2020		February 17, 2020	CIC 1425, Paris, France		https://ClinicalTrials.gov/show/NCT04259892
440	NCT04327804	A Longitudinal Study of SARS-CoV-2 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research		Recruiting	No Results Available	SARS-CoV Infection	Diagnostic Test: Odd/Even birth year intervention groups	Detection of SARS-CoV-2 virus|Trajectory of COVID-19 and antibody development	Dr. Deneen Vojta|PATH|Mayo Clinic|Bill and Melinda Gates Foundation|UnitedHealth Group	All	Child, Adult, Older Adult		120	Industry|Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	20-002	March 25, 2020	April 3, 2020	April 10, 2020	March 31, 2020		March 31, 2020	Everett Clinic, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT04327804
441	NCT04251871	Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection		Recruiting	No Results Available	Pneumonia Caused by Human Coronavirus (Disorder)	Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules|Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)	Time to complete remission of 2019-nCoV infection-associated symptoms|The incidence of dyspnea with low oxygen saturation level and high respiratory rate|Number of subjects who develop complications of 2019-nCoV infection|Time to virus shedding|Time to improvement of abnormalities in Chest radiology|The evaluation of Traditional Chinese Medicine (TCM) symptoms before and after treatment	Beijing 302 Hospital	All	14 Years to 80 Years   (Child, Adult, Older Adult)	Not Applicable	150	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020001D	January 22, 2020	January 22, 2021	January 22, 2021	February 5, 2020		February 5, 2020	The Fifth Medical Center, General Hospital of PLA, Beijing, Beijing, China		https://ClinicalTrials.gov/show/NCT04251871
442	NCT04260308	A Survey of Psychological Status of Medical Workers and Residents in the Context of 2019 Novel Coronavirus Pneumonia		Recruiting	No Results Available	Virus; Pneumonia		GHQ-12(general health questionnaire-12)|IES-R(Impact of Event Scale-Revised)	Huazhong University of Science and Technology	All	Child, Adult, Older Adult		30000	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	IRBID:TJ-C 20200107	February 3, 2020	April 15, 2020	April 20, 2020	February 7, 2020		February 7, 2020	Tongji Hospital，Tongji Medical College Affiliated，Huazhong University of Science ＆ Technology, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT04260308
443	NCT04275245	Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia		Recruiting	No Results Available	2019-nCoVs Infection Pneumonia	Drug: Meplazumab for Injection	2019 nCoV nucleic acid detection|Recovery of body temperature|Recovery of resting respiratory rate|Recovery of SPO2|Chest CT / chest film changes|PaO2 / FiO2|Time to reach the isolation release standard|Changes of inflammatory immune status	Tang-Du Hospital	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 1|Phase 2	20	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20200101	February 3, 2020	December 31, 2020	December 31, 2020	February 19, 2020		February 19, 2020	Tangdu Hospital, Xi'an, Shaanxi, China		https://ClinicalTrials.gov/show/NCT04275245
444	NCT04307459	Acute Respiratory Failure and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Real Life		Not yet recruiting	No Results Available	Coronavirus Infections|Respiratory Failure|Ventilator Lung	Other: standard operating procedures	Real life data of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection|in-hospital mortality|30 days mortality|6 months mortality|Intubation rate|Time to Intubation|Time to ventilation|Non invasive to Invasive time|Recovery rate|Recurrence rate|Risk factor for COVID19|Blood tests and outcome|Antiviral therapy|Coinfections|Radiological findings|Ultrasound findings|Myocardial injury|Medical management	University of Milan	All	18 Years and older   (Adult, Older Adult)		50	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	02-PNSNP-2020	March 19, 2020	April 19, 2020	December 31, 2020	March 13, 2020		March 17, 2020	Luigi Sacco University Hospital, Milan, Lombardia, Italy		https://ClinicalTrials.gov/show/NCT04307459
445	NCT04299152	Stem Cell Educator Therapy Treat the Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2		Not yet recruiting	No Results Available	Severe Acute Respiratory Syndrome (SARS) Pneumonia	Combination Product: Stem Cell Educator-Treated Mononuclear Cells Apheresis	Determine the number of Covid-19 patients who were unable to complete SCE Therapy|Examine the percentage of activated T cells after SCE therapy by flow cytometry|Assess the percentage of Th17 cells after SCE therapy by flow cytometry|Chest imaging changes by computed tomography (CT) scan of the chest|Quantification of the SARS-CoV-2 viral load by real time RT-PCR	Tianhe Stem Cell Biotechnologies Inc.	All	18 Years to 60 Years   (Adult)	Phase 2	20	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment	2020-TH-001	April 10, 2020	October 9, 2020	November 10, 2020	March 6, 2020		March 30, 2020			https://ClinicalTrials.gov/show/NCT04299152
446	NCT04322279	Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection (CoV-CONTACT-SERO)		Recruiting	No Results Available	Coronavirus	Diagnostic Test: Serology|Genetic: Sequencing	Number of Participants with positive serology in the 90 days following last contact|fever > 38°C, asthenia/fatigue/malaise, headache, thrills/sweating, myalgia/aches, cough, dyspnea, Acute Respiratory Distress Syndrome, diarrhea	Institut National de la Santé Et de la Recherche Médicale, France	All	Child, Adult, Older Adult		300	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	C20-16|2020-A00609-30	March 9, 2020	May 1, 2020	May 1, 2020	March 26, 2020		March 26, 2020	CIC 1425, Paris, France		https://ClinicalTrials.gov/show/NCT04322279
447	NCT04341727	Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection	WU352	Recruiting	No Results Available	Coronavirus Infection	Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin|Drug: Chloroquine Sulfate	Hours to recovery|Time fever resolution	Washington University School of Medicine	All	18 Years and older   (Adult, Older Adult)	Phase 3	500	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	202003188	April 4, 2020	April 1, 2021	August 1, 2021	April 10, 2020		April 10, 2020	Washington University School of Medicine Infectious Disease Clinical Research Unit, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States		https://ClinicalTrials.gov/show/NCT04341727
448	NCT04325672	Convalescent Plasma to Limit Coronavirus Associated Complications		Withdrawn	No Results Available	Coronavirus	Biological: Convalescent Plasma	RNA in SARS-CoV-2|ICU Admissions|Hospital Mortality|Hospital Length of Stay (LOS)|Type of respiratory support|Duration of respiratory support	Mayo Clinic	All	18 Years and older   (Adult, Older Adult)	Phase 2	0	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	20-002864	April 1, 2020	December 31, 2022	December 31, 2022	March 27, 2020		April 8, 2020			https://ClinicalTrials.gov/show/NCT04325672
449	NCT04302766	Expanded Access Remdesivir (RDV; GS-5734™)		Available	No Results Available	Coronavirus Disease 2019	Drug: Remdesivir		U.S. Army Medical Research and Development Command	All	Child, Adult, Older Adult			U.S. Fed	Expanded Access:Intermediate-size Population|Treatment IND/Protocol		S-20-01				March 10, 2020		April 10, 2020			https://ClinicalTrials.gov/show/NCT04302766
450	NCT04061382	Sero-epidemiological Survey of England in 2019/2020	STORY	Recruiting	No Results Available	Serogroup C Meningococcal Meningitis|Diphtheria|COVID-19	Procedure: venepuncture	Feasibility of developing a UK based sero-epidemiological programme in 0-24 year olds|Feasibility of developing a UK based sero epidemiological survey in 0-24 year olds|Recruitment rate|Cost|To assess, in relevant age groups, immunity against infections and vaccine preventable diseases|Sera collection	University of Oxford	All	up to 24 Years   (Child, Adult)		2300	Other	Observational	Observational Model: Other|Time Perspective: Prospective	ID 263097	October 15, 2019	April 30, 2020	November 30, 2020	August 19, 2019		March 24, 2020	Centre for Clinical Vaccinology & Tropical Medicine (CCVTM), Oxford, Oxfordshire, United Kingdom		https://ClinicalTrials.gov/show/NCT04061382
451	NCT03331445	Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections	NONTM	Active, not recruiting	No Results Available	Respiratory Tract Infections|Corona Virus Infection	Drug: Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation	Measure the safety of 160ppm inhaled nitric oxide delivery in NTM subjects|Measure the effect of 160ppm inhaled nitric oxide delivery on lung spirometry in NTM subjects|Measure the antimicrobial effect of 160ppm inhaled nitric oxide on lung NTM bacterial load in the sputum|Measure the effect of 160ppm inhaled nitric oxide on Quality of Life (CRISS) Score	University of British Columbia|Mallinckrodt	All	14 Years and older   (Child, Adult, Older Adult)	Phase 2	20	Other|Industry	Interventional	Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NTM-CTP-01: H17-02107	October 24, 2017	December 31, 2020	March 31, 2021	November 6, 2017		March 31, 2020	Diamond Centre, Vancouver, British Columbia, Canada		https://ClinicalTrials.gov/show/NCT03331445
452	NCT04320056	Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decrease During Pneumonia		Not yet recruiting	No Results Available	Coronavirus|Pneumonia|Oxygen Toxicity	Other: Standard administration of oxygen flow|Device: Automated oxygen administration - FreeO2	The number of interventions|Duration of interventions|Mean oxygen flow|Time within theSpO2 target|Time with hypoxemia|Time with hyperoxemia|Rate of ICU admission|Rate of needed non invasive respiratory support|Rate of intubation|NEWS 2 score evolution|EWSO2 score evolution|Cost-effectiveness|length of stay	Laval University	All	18 Years and older   (Adult, Older Adult)	Not Applicable	216	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	21909	April 6, 2020	April 30, 2021	October 31, 2021	March 24, 2020		March 27, 2020			https://ClinicalTrials.gov/show/NCT04320056
453	NCT04335851	Video-Based Exercises and Well-Being During Social Isolation		Not yet recruiting	No Results Available	Social Isolation|Physical Inactivity|Well-Being	Other: Video based aerobic exercise	World Health Organization Quality of Life Questionnaire Bref|Rapid Assessment of Physical Activity|Global Rating of Change Scale	Biruni University|Istanbul University-Cerrahpasa	All	18 Years to 35 Years   (Adult)	Not Applicable	30	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention	Physical Activity Project	April 6, 2020	May 13, 2020	June 30, 2020	April 6, 2020		April 6, 2020	Biruni University, Istanbul, Turkey|Istanbul University Cerrahpasa, Istanbul, Turkey		https://ClinicalTrials.gov/show/NCT04335851
454	NCT04319211	Effects of Social Isolation From Coronavirus; on Physical Activity, Quality of Life and Stress	COVID-19	Not yet recruiting	No Results Available	Healthy People	Other: Determination of physical activity, quality of life, stress levels of isolated people at home with the danger of coronavirus.	International Physical Activity Questionnaire (IPAQ)|Health-Related Quality of Life SF-12 Scale|Beck Depression Scale	Istanbul University-Cerrahpasa	All	18 Years to 55 Years   (Adult)		200	Other	Observational	Observational Model: Case-Only|Time Perspective: Cross-Sectional	EAvcil|İpek Yeldan	March 25, 2020	May 15, 2020	July 20, 2020	March 24, 2020		March 24, 2020	Istanbul University Cerrahpasa, Istanbul, Turkey		https://ClinicalTrials.gov/show/NCT04319211
455	NCT04331808	CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)	CORIMUNO-TOC	Not yet recruiting	No Results Available	Corona Virus Infection	Drug: Tocilizumab	Survival without needs of ventilator utilization at day 14.|WHO progression scale <=5 at day 4|Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) at day 14|WHO progression scale at day 4|WHO progression scale|Survival|28-day ventilator free-days|respiratory acidosis at day 4|PaO2/FiO2 ratio|time to oxygen supply independency|duration of hospitalization|time to negative viral excretion|time to ICU discharge|time to hospital discharge	Assistance Publique - Hôpitaux de Paris	All	18 Years and older   (Adult, Older Adult)	Phase 2	240	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	APHP200375-1	March 31, 2020	March 31, 2021	December 31, 2021	April 2, 2020		April 8, 2020			https://ClinicalTrials.gov/show/NCT04331808
456	NCT04328467	Pre-exposure Prophylaxis for SARS-Coronavirus-2		Recruiting	No Results Available	COVID-19|Corona Virus Infection|ARDS|Acute Respiratory Distress Syndrome	Drug: Hydroxychloroquine|Other: Placebo	COVID-19-free survival|Incidence of confirmed SARS-CoV-2 detection|Incidence of possible COVID-19 symptoms|Incidence of all-cause study medicine discontinuation|Ordinal Scale of COVID-19 Disease maximum severity if COVID-19 diagnosed at study end|Incidence of Hospitalization for COVID-19 or death|Incidence of study medication-related side effects	University of Minnesota	All	18 Years and older   (Adult, Older Adult)	Phase 3	3500	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	STUDY00009414	April 6, 2020	August 2020	August 2020	March 31, 2020		April 10, 2020	Nationwide Enrollment via Internet, please email: covid19@umn.edu, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States		https://ClinicalTrials.gov/show/NCT04328467
457	NCT04333251	Study Testing Convalescent Plasma vs Best Supportive Care		Not yet recruiting	No Results Available	Pneumonia, Interstitial	Biological: high-titer anti-Sars-CoV-2 plasma|Other: oxygen therapy	reduction in oxygen and ventilation support	Baylor Research Institute	All	18 Years and older   (Adult, Older Adult)	Phase 1	115	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	020-123	April 1, 2020	December 31, 2022	December 31, 2022	April 3, 2020		April 6, 2020			https://ClinicalTrials.gov/show/NCT04333251
458	NCT04280224	NK Cells Treatment for Novel Coronavirus Pneumonia		Recruiting	No Results Available	Novel Coronavirus Pneumonia	Biological: NK Cells	Improvement of clinical symptoms including duration of fever|Improvement of clinical symptoms including respiratory frequency|Number of participants with treatment-related adverse events evaluated with CTCAE,version 4.0|Time of virus nucleic acid test negative|CD4+ and CD8+ T cell count|Rate of mortality within 28-days|Size of lesion area by thoracic imaging	Xinxiang medical university|First Affiliated Hospital of Xinjiang Medical University	All	18 Years to 65 Years   (Adult, Older Adult)	Phase 1	30	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	xinxiangM	February 20, 2020	September 30, 2020	December 30, 2020	February 21, 2020		February 21, 2020	The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China		https://ClinicalTrials.gov/show/NCT04280224
459	NCT04333875	Morbidity and Mortality Due to Deferral of Aortic Valve Replacement in Patients With Severe Aortic Stenosis	AS DEFER	Recruiting	No Results Available	Aortic Valve Stenosis	Device: TAVR or SAVR	Composite of all-cause mortality, disabling and non-disabling stroke, and hospitalization for heart failure	University Hospital Inselspital, Berne	All	18 Years and older   (Adult, Older Adult)		100	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	2020-00672	March 20, 2020	December 2020	December 2020	April 3, 2020		April 7, 2020	Department of Cardiology, Bern University Hospital, Bern, Switzerland		https://ClinicalTrials.gov/show/NCT04333875
460	NCT04244591	Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With Severe Acute Respiratory Failure	Steroids-SARI	Recruiting	No Results Available	Coronavirus Infections|Respiratory Infection Virus	Drug: methylprednisolone therapy|Other: Standard care	Lower Murray lung injury score|The difference of PaO2/FiO2 between two groups|Lower Sequential Organ Failure Assessment (SOFA) score|Mechanical ventilation support|Clearance of noval coronavirus|All-cause mortality	Peking Union Medical College Hospital|Zhongda Hospital|Zhongnan Hospital|Renmin Hospital of Wuhan University	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	80	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Glucocorticoid nCoV	January 26, 2020	April 25, 2020	December 25, 2020	January 28, 2020		February 13, 2020	Medical ICU,Peking Union Medical College Hospital, Beijing, Beijing, China		https://ClinicalTrials.gov/show/NCT04244591
461	NCT04316377	Norwegian Coronavirus Disease 2019 Study	NO COVID-19	Recruiting	No Results Available	Corona Virus Infection	Drug: Hydroxychloroquine Sulfate	Rate of decline in SARS-CoV-2 viral load|Change in National Early Warning Score score|Admission to intensive care unit|In-hospital mortality|Duration of hospital admission|Mortality at 30 and 90 days|Clinical status	University Hospital, Akershus	All	18 Years and older   (Adult, Older Adult)	Phase 4	202	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	REC 121446	March 25, 2020	April 1, 2021	March 3, 2025	March 20, 2020		April 3, 2020	Akershus University Hospital, Lørenskog, Norway		https://ClinicalTrials.gov/show/NCT04316377
462	NCT04276688	Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment		Recruiting	No Results Available	Novel Coronavirus Infection	Drug: Lopinavir/ritonavir|Drug: Ribavirin|Drug: Interferon Beta-1B	Time to negative NPS|Time to negative saliva|Time to clinical improvement|Hospitalisation|Mortality|Immune reaction|Adverse events|Time to negative all clinical specimens	The University of Hong Kong|Hospital Authority, Hong Kong	All	18 Years and older   (Adult, Older Adult)	Phase 2	70	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UW-20-074	February 10, 2020	January 31, 2022	July 31, 2022	February 19, 2020		February 28, 2020	University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong		https://ClinicalTrials.gov/show/NCT04276688
463	NCT03680274	Lessening Organ Dysfunction With VITamin C	LOVIT	Recruiting	No Results Available	Sepsis|Vitamin C|Intensive Care Unit|COVID-19|Pandemic|Coronavirus	Drug: Vitamin C|Other: Control	Number of deceased participants or with persistent organ dysfunction|Number of participants with persistent organ dysfunction-free days in intensive care unit|Number of participants deceased at 6 months|Score of health related quality of life in 6-month survivors|Global tissue dysoxia|Organ function (including renal function)|Rate of inflammation|Rate of infection|Rate of endothelial injury|Occurrence of stage 3 acute kidney injury|Acute hemolysis|Hypoglycemia|Vitamin C volume of distribution|Vitamin C clearance|Vitamin C plasma concentration	Université de Sherbrooke|Lotte & John Hecht Memorial Foundation	All	18 Years and older   (Adult, Older Adult)	Phase 3	800	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	MP-31-2019-2945	November 8, 2018	December 31, 2021	December 31, 2022	September 21, 2018		April 10, 2020	Research Center of the CHUS, Sherbrooke, Quebec, Canada		https://ClinicalTrials.gov/show/NCT03680274
464	NCT04326309	Audio Data Collection for Identification and Classification of Coughing		Recruiting	No Results Available	COVID-19|Coronavirus Infections|Hay Fever|Asthma|Chronic Obstructive Pulmonary Disease|Influenza|Common Cold|Respiratory Tract Infections|Healthy		Dataset size|Cough sound identification|Improvement of the existing model|Evaluate the usability of the application	HealthMode Inc.	All	18 Years and older   (Adult, Older Adult)		1000	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	HM070102	March 25, 2020	September 25, 2022	September 25, 2022	March 30, 2020		March 30, 2020	Virtual Facility, Bronx, New York, United States		https://ClinicalTrials.gov/show/NCT04326309
465	NCT04262921	Clinical Characterisation Protocol for Severe Emerging Infections	CCP-nCoV	Recruiting	No Results Available	Coronavirus Infections		Clinical features|Response to treatment|Pathogen replication, excretion and evolution, within the host|Immune host responses to infection and therapy|Host genetic variants	Institut National de la Santé Et de la Recherche Médicale, France	All	Child, Adult, Older Adult		500	Other	Observational	Observational Model: Other|Time Perspective: Prospective	C20-05|2020-A00256-33	February 7, 2020	August 7, 2020	August 7, 2023	February 10, 2020		February 11, 2020	CHU Pellegrin, service des Maladies Infectieuses et Tropicales, Bordeaux, France|APHP La Pitié Salpêtrière, service des Maladies Infectieuses et Tropicales, Paris, France|APHP Bichat, Service de réanimation médicale et infectieuse, Paris, France|APHP Bichat, Service des Maladies Infectieuses et Tropicales, Paris, France		https://ClinicalTrials.gov/show/NCT04262921
466	NCT04308668	Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2	COVID-19 PEP	Recruiting	No Results Available	Corona Virus Infection|Acute Respiratory Distress Syndrome|SARS-CoV Infection|Coronavirus|Coronavirus Infections	Drug: Hydroxychloroquine|Other: Placebo	Incidence of COVID19 Disease among those who are asymptomatic at trial entry|Ordinal Scale of COVID19 Disease Severity at 14 days among those who are symptomatic at trial entry|Incidence of Hospitalization|Incidence of Death|Incidence of Confirmed SARS-CoV-2 Detection|Incidence of Symptoms Compatible with COVID19 (possible disease)|Incidence of All-Cause Study Medicine Discontinuation or Withdrawal|Overall symptom severity at 5 and 14 day	University of Minnesota|McGill University Health Centre/Research Institute of the McGill University Health Centre|University of Manitoba|University of Alberta	All	18 Years and older   (Adult, Older Adult)	Phase 3	3000	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	STUDY00009267	March 17, 2020	April 21, 2020	May 12, 2020	March 16, 2020		April 8, 2020	Nationwide Enrollment via Internet, please email: covid19@umn.edu, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Internet, New York, New York, United States|University of Alberta, Edmonton, Alberta, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|Research Institute of the McGill University Heath Centre, Montréal, Quebec, Canada		https://ClinicalTrials.gov/show/NCT04308668
467	NCT04329897	Acceptance and Commitment Therapy Delivered by Automated Software Messaging		Enrolling by invitation	No Results Available	Hip Osteoarthritis|Knee Osteoarthritis|Mental Stress|Coronavirus	Behavioral: Software Messaging	Change in reported pain intensity score (PROMIS Pain Intensity 3A) Patient-reported outcomes measurement information system Pain Intensity (PROMIS) 3A short form scores collected from all participating subjects.|Change in reported pain intensity score (PROMIS Pain Intensity 1A) Patient-reported outcomes measurement information system Pain Intensity (PROMIS) 1A short form scores collected from all participating subjects.|Change in reported pain interference score Patient-reported outcomes measurement information system (PROMIS) Pain Interference 8A short form scores collected from all participating subjects.|Change in reported emotional distress (anxiety) score. Patient-reported outcomes measurement information system (PROMIS) Emotional Distress-Anxiety 8A short form scores collected from all participating subjects.	University of Iowa	All	18 Years and older   (Adult, Older Adult)	Not Applicable	82	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	201412701-1	April 5, 2020	May 30, 2020	June 30, 2020	April 1, 2020		April 8, 2020	University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States		https://ClinicalTrials.gov/show/NCT04329897
468	NCT04276987	A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia		Not yet recruiting	No Results Available	Coronavirus	Biological: MSCs-derived exosomes	Adverse reaction (AE) and severe adverse reaction (SAE)|Time to clinical improvement (TTIC)|Number of patients weaning from mechanical ventilation|Duration (days) of ICU monitoring|Duration (days) of vasoactive agents usage|Duration (days) of mechanical ventilation supply|Number of patients with improved organ failure|Rate of mortality	Ruijin Hospital|Shanghai Public Health Clinical Center|Wuhan Jinyintan Hospital, Wuhan, China|Cellular Biomedicine Group Ltd.	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 1	30	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MEXCOVID	February 15, 2020	May 31, 2020	July 31, 2020	February 19, 2020		February 25, 2020			https://ClinicalTrials.gov/show/NCT04276987
469	NCT04339842	Eating Habits of Adults During the Quarantine		Not yet recruiting	No Results Available	Health Behavior|Eating Behavior	Other: Assessment of Dietary Changes in Adults in the Quarantine	Changes in the Eating Habits of Adults during the Quarantine	Eliz Arter|Cyprus Science University|Eastern Mediterranean University	All	18 Years to 80 Years   (Adult, Older Adult)		400	Other	Observational	Observational Model: Case-Only|Time Perspective: Cross-Sectional	Nutr2020	April 10, 2020	May 31, 2020	May 31, 2020	April 9, 2020		April 10, 2020	Online, Nicosia, Cyprus	Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/42/NCT04339842/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT04339842